WorldWideScience

Sample records for radiopharmaceutical 99m tc-hynic-lys3-bn

  1. Preparation of the radiopharmaceutical 99m Tc-HYNIC-[Lys3]-BN

    International Nuclear Information System (INIS)

    Conde S, E.

    2007-01-01

    In accordance with their design, the radiopharmaceuticals can be divided in three generations. The radiopharmaceuticals of third generation are used in nuclear medicine to obtain images of specific molecular targets, and they are only in their capacity to detect in vivo such specific biochemical places as receivers and enzymes. The receivers of regulator peptides are over expressed in numerous carcinogenic cells. Those receivers have been used as molecular targets of radiolabelled peptides to locate cancerous tumors. The small peptide bombesin (BN, 14 amino acids) it was isolated of the frog skin and it belongs to a wide neuropeptides group with many biological functions. The equivalent human is the liberator peptide of the gastrin (GRP, 27 amino acids) and his receivers (r-GRP) that are on expressed in the membranes of the tumor cells. The receiving subtype 2 of bombesin (receiving GRP) it is on expressed in several human tumors including breast, prostate, lung cells and pancreatic cancer. Some radiopharmaceuticals similar of BN has been developed that were prepared to be used in nuclear medicine for the detection of wicked tumors and to evidence prostate cancers, breast and of lymphatic nodules. A technique was developed to allow the conjugation of HYNIC-[Lys3]-BN that allowed to obtain this product with a high purity. The identity was determined by HPLC chromatography. It was necessary the validation of the method and the HPLC system, to assure that the results were reliable. Linearity, specificity, accuracy and precision parameters were analyzed, that are those required by the Mexican pharmacopoeia for chromatographic methods. With this conjugated a formulation for lyophilized kits were analyzed, with the purpose of obtaining a radiochemical purity, after the labelled one with 99m Tc, bigger to 95%; the components used in the nucleus-equipment should favor the conjugation of the 99m Tc by means of a ligands exchange between the tricine and the

  2. Radiation decomposition of technetium-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Billinghurst, M.W.; Rempel, S.; Westendorf, B.A.

    1979-01-01

    Technetium-99m radiopharmaceuticals are shown to be subject to autoradiation-induced decomposition, which results in increasing abundance of pertechnetate in the preparation. This autodecomposition is catalyzed by the presence of oxygen, although the removal of oxygen does not prevent its occurrence. The initial appearance of pertechnetate in the radiopharmaceutical is shown to be a function of the amount of radioactivity, the quantity of stannous ion used, and the ratio of /sup 99m/Tc to total technetium in the preparation

  3. Radiopharmaceuticals to 99mTc

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    Studies about 99m Tc had demonstrated that have favorable properties for support diagnostic proceedings in nuclear medicine. This physical and chemical properties used for obtain another radiopharmaceuticals have been employed through re actives kits labelled with Tc 99m . A brief description was given about 99m utilities in diagnostic techniques such as endothelium reticular system,renal and hepatic studies,bone scintillators,cardiac diagnostic and cerebral perfusion

  4. The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy

    International Nuclear Information System (INIS)

    Bodenant, V.

    1998-01-01

    In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

  5. Quality control in 99m technetium radiopharmaceuticals

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    This work means about the quality control in Tc radiopharmaceuticals preparation at hospitalary levels. Several steps must be used in a Nuclear Medicine Laboratory, such as proceeding,radiopharmaceuticals kits preparation, and dispensation materials,glasses,stopper,physical aspects,identification,ph control,storage,and reactif kits

  6. Preparation and quality control of technetium-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Samuels, D.L.

    1978-11-01

    Appropriate procedures for the production and quality control of technetium-99m based radiopharmaceuticals in hospital radiopharmacy consistent with the recently published Australian Code of Good Manufacturing Practice are discussed

  7. To the radiotoxicity of {sup 99m}Tc radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Ftacnikova, S [Inst. of Preventive and Clinical Medicine, 83301 Bratislava (Slovakia)

    1996-12-31

    In this paper the radiotoxicity and RBE values of Auger electrons for {sup 99m}Tc radiopharmaceuticals were discussed. Expression for the expected RBE for {sup 99m}Tc compounds is given. For the Auger electrons emitted in the decay of {sup 99m}Tc the RBE(Auger) = 10 and a value of 20 for the radiation weighing factor were recommended. (J.K.) 4 refs.

  8. Synthesis and formulation of 99m Tc-ECD radiopharmaceutical

    International Nuclear Information System (INIS)

    Ocampo G, B.E.

    1998-01-01

    Nuclear medicine is a medical specialty which uses radioactive compounds (radionuclides) for diagnostic and therapeutic purposes. 99m Tc is the more common radionuclide used in many studies in nuclear medicine because its advantages: it has a photopeak of 140 KeV and a half-life of 6 hours; it can be eluted from a Molybdenum 99 generator, so radiopharmaceuticals can be prepared on site. Ethyl cysteine dimer (ECD) labelled with reduced Technetium 99m has been purposed recently as a promising radiopharmaceutical for brain perfusion imaging 99m Tc-ECD is a lipophilic neutral complex which cross the brain blood barrier and show high brain uptake. The objective of this work was synthesize and to design a freeze dried formulation for the instant preparation of 99m Tc-ECD complex useful for brain perfusion imaging. We obtained a freeze dried stable formulation for the preparation of 99m Tc-ECD kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytic techniques for the determination of the different chemical compounds into the lyophilized kit. (Author)

  9. Interaction between some disinfectants and Tcsup(99m)-radiopharmaceuticals

    International Nuclear Information System (INIS)

    Verbruggen, A.; Cleynhens, B.; Hoogmartens, M.; De Roo, M.

    1985-01-01

    Contamination of Tcsup(99m) sulphur colloid with small amounts of iodinated antiseptics has been described to result in the formation of free pertechnetate and excessive blood-pool activity upon injection. As far as we know similar or other interactions have not been reported for disinfectants that are effective by another mechanism than oxidizing activity. The present study has been set up to investigate the effect of small amounts of a wide variety of commonly available antiseptics on the radiochemical and biological behaviour of different Tcsup(99m) labelled radiopharmaceuticals. (Auth.)

  10. The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy; Les radiopharmaceutiques marques au technetium-99m et la radiopharmacie

    Energy Technology Data Exchange (ETDEWEB)

    Bodenant, V

    1998-10-01

    In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

  11. Technical artifacts in chromatographic analysis of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kowalsky, R.J.; Creekmore, J.R.

    1982-01-01

    Technical artifacts produced during chromatographic analysis of technetium radiopharmaceuticals were investigated. Such artifacts are, we found, caused by improper spotting and drying techniques; these in turn produce spuriously high impurities in Tc-99m complexes of DTPA, MDP, PPi, and GH. The ITLC-SG/acetone system produces considerable streaking of Tc-complex if the applied spot is large and not dried before development. This results in activity in the solvent front portion of the chromatographic strip indicating falsely high levels of pertechnetate impurity. Proper drying of the applied spot eliminates the artifact. The ITLC-SG/saline system yields falsely high, hydrolyzed-reduced technetium impurities if the spot is allowed to enter the solvent during development. Correct spot placement and size eliminate this problem. Strips that are allowed to dry in room air for several minutes may indicate considerable pertechnetate impurity on the chromatogram; yet this may not actually be present in the radiopharmaceutical vial. Drying spots rapidly with hot air or in a nitrogen atmosphere before development eliminates this problem

  12. In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals.

    Science.gov (United States)

    Martini, Petra; Boschi, Alessandra; Cicoria, Gianfranco; Zagni, Federico; Corazza, Andrea; Uccelli, Licia; Pasquali, Micòl; Pupillo, Gaia; Marengo, Mario; Loriggiola, Massimo; Skliarova, Hanna; Mou, Liliana; Cisternino, Sara; Carturan, Sara; Melendez-Alafort, Laura; Uzunov, Nikolay M; Bello, Michele; Alvarez, Carlos Rossi; Esposito, Juan; Duatti, Adriano

    2018-05-30

    In the last years, the technology for producing the important medical radionuclide technetium-99m by cyclotrons has become sufficiently mature to justify its introduction as an alternative source of the starting precursor [ 99m Tc][TcO 4 ] - ubiquitously employed for the production of 99m Tc-radiopharmaceuticals in hospitals. These technologies make use almost exclusively of the nuclear reaction 100 Mo(p,2n) 99m Tc that allows direct production of Tc-99m. In this study, it is conjectured that this alternative production route will not replace the current supply chain based on the distribution of 99 Mo/ 99m Tc generators, but could become a convenient emergency source of Tc-99m only for in-house hospitals equipped with a conventional, low-energy, medical cyclotron. On this ground, an outline of the essential steps that should be implemented for setting up a hospital radiopharmacy aimed at the occasional production of Tc-99m by a small cyclotron is discussed. These include (1) target production, (2) irradiation conditions, (3) separation/purification procedures, (4) terminal sterilization, (5) quality control, and (6) Mo-100 recovery. To address these issues, a comprehensive technology for cyclotron-production of Tc-99m, developed at the Legnaro National Laboratories of the Italian National Institute of Nuclear Physics (LNL-INFN), will be used as a reference example. Copyright © 2018 Elsevier Ltd. All rights reserved.

  13. Tumor affinity of technetium-99m labeled radiopharmaceuticals. II. Sup(99m)Tc-Sn-diphosphonate (sup(99m)Tc-EHDP), sup(99m)Tc-Sn-dimercaptosuccinic acid (sup(99m)Tc-DMSA), sup(99m)Tc-Sn-diethyl stilbestrol diphosphate (sup(99m)Tc-DSDP)

    Energy Technology Data Exchange (ETDEWEB)

    Itoh, K; Kobayashi, S; Hisada, K; Tonami, N [Kanazawa Univ. (Japan). School of Medicine; Ando, A

    1976-10-01

    The authors have examined the tumor affinity of various sup(99m)Tc-labelled radiopharmaceuticals to Ehrlich's tumor for the purpose of delineating human malignant neoplasm positively. The biologic distributions of sup(99m)Tc-Sn-diphosphonate (sup(99m)Tc-EHDP), sup(99m)Tc-Sn-dimercaptosuccinic acid (sup(99m)Tc-DMSA) and sup(99m)Tc-Sn-diethyl stilbestrol diphosphate (sup(99m)Tc-DSDP, sup(99m)Tc-Honvan) are included as the second report on the tumor affinity of Ehrlich-bearing mice. Tumor concentration of sup(99m)Tc-EHDP was lowest and the positive delineation of implanted tumor with sup(99m)Tc-EHDP was poorest in sequential images, though active accumulation in some soft tissues malignant neoplasms, breast cancer, and thyroid cancer, has been reported. Tumor concentration and the tumor-to-blood ratio of sup(99m)Tc-DMSA were not so high, contrary to our expectation that /sup 197/Hg-DMSA might show high tumor concentration and high tumor-to-blood ratio the same as /sup 197/Hg chlormerodrin of the renal scanning radiopharmaceuticals. Tumor concentration of sup(99m)Tc-DSDP was highest. The tumor-to-blood concentration ratio was lower than that of the above mentioned radiopharmaceuticals but the tumor-to-liver ratio and/or tumor-to-lung ratio was over 1.0 at the earlier time. Biologic distribution of sup(99m)Tc-DSDP was similar to that of /sup 32/P labeled DSDP. It is presumed that sup(99m)Tc is labeled at the phosphate ester of DSDP which is dephospholytated immediately by phospholylase in vivo following intravenous injection. Although it is not known precisely it may be assumed that the mechanism of accumulating sup(99m)Tc-DSDP in Ehrlich's tumor is related to the phospholylase activity in neoplasms.

  14. The quality control of technetium-99m radiopharmaceuticals produced at the AAEC Research Establishment

    International Nuclear Information System (INIS)

    Farrington, K.J.

    1983-08-01

    The methods of quality control used for technetium-99m radiopharmaceuticals produced at the AAEC Research Establishment are described for both non-fission and fission derived sources of sodium pertechnetate, technetium-99m labelled radipopharmaceuticals, and reagent kits produced for technetium-99m labelling

  15. Quantitative HPLC determination of [99mTc]-pertechnetate in radiopharmaceuticals and biological samples: Pt. 1

    International Nuclear Information System (INIS)

    Tianze Zhou; Hirth, W.W.; Heineman, W.R.; Deutsch, Edward

    1988-01-01

    Techniques have been developed which allow HPLC (high performance liquid chromatography) to be used for the quantitative determination of [ 99m Tc]pertechnetate in radiopharmaceuticals and biological samples. An instrumental technique accounts for 99m Tc species which do not elute from the HPLC column, while a chemical technique obviates interferences caused by Sn(II). These two techniques are incorporated into an anion exchange HPLC procedure which is applied to the determination of [ 99m Tc]pertechnetate in 99m Tc-diphosphonate radiopharmaceuticals and biological samples. (author)

  16. Stannous ion determination in99mTc - radiopharmaceutical kits

    International Nuclear Information System (INIS)

    Almeida, M.A.T.M. de; Silva, C.P.G. da.

    1989-10-01

    Two simple and selective methods for determination of stannous ion in radiopharmaceutical kits are proposed. One of this permits the estimation of stannic ion. The first method used is a potentiometric tiration of Sn +2 in HCl medium using KIO 3 solution under nitrogen gas and a redox platinum electrode. The second method consist of a compleximetric tiration of tin (Sn +2 and Sn +4 ) using EDTA standart solution at pH 5.5-5.6 without use of nitrogen gas. The employed procedures indicates that both the methods can be used for routine quantitative determination of tin in most labeled radiopharmaceuticals. (author) [pt

  17. Influence of Storage Temperature on Radiochemical Purity of 99mTc-Radiopharmaceuticals.

    Science.gov (United States)

    Uccelli, Licia; Boschi, Alessandra; Martini, Petra; Cittanti, Corrado; Bertelli, Stefania; Bortolotti, Doretta; Govoni, Elena; Lodi, Luca; Romani, Simona; Zaccaria, Samanta; Zappaterra, Elisa; Farina, Donatella; Rizzo, Carlotta; Giganti, Melchiore; Bartolomei, Mirco

    2018-03-15

    The influence of effective room temperature on the radiochemical purity of 99m Tc-radiopharmaceuticals was reported. This study was born from the observation that in the isolators used for the preparation of the 99m Tc-radiopharmaceuticals the temperatures can be higher than those reported in the commercial illustrative leaflets of the kits. This is due, in particular, to the small size of the work area, the presence of instruments for heating, the continuous activation of air filtration, in addition to the fact that the environment of the isolator used for the 99m Tc-radiopharmaceuticals preparation and storage is completely isolated and not conditioned. A total of 244 99m Tc-radiopharmaceutical preparations (seven different types) have been tested and the radiochemical purity was checked at the end of preparation and until the expiry time. Moreover, we found that the mean temperature into the isolator was significantly higher than 25 °C, the temperature, in general, required for the preparation and storage of 99m Tc-radiopharmaceuticals. Results confirmed the radiochemical stability of radiopharmaceutical products. However, as required in the field of quality assurance, the impact that different conditions than those required by the manufacturer on the radiopharmaceuticals quality have to be verified before human administration.

  18. Analysis of 99mTc-labeled radiopharmaceuticals by high-performance liquid chromatography

    International Nuclear Information System (INIS)

    Muto, Toshio

    1990-01-01

    High-performance liquid chromatography (HPLC) equiped with on line radiometric and optical detectors (i.e. radio-HPLC) have been applied to the radiochemical analysis of commonly-used 99m Tc-radio pharma ceuticals with a view point to check the radiochemical purities of the compounds. Chromatographic conditions were determined by examination of the types of column, mobile phase and pH. An aqueous size-exclusion (Shim-pack Diol-300) and reversed-phase column (Zorbax-ODS) were found to be suitable for 99m Tc-HSA and the other 99m Tc-agents, respectively. The analysis of low molecular weight 99m Tc-agents (e.g. 99m Tc-DTPA, 99m Tc-DMSA, 99m Tc-pyrophosphate, 99m Tc-phytic acid, 99m Tc-MDS, 99m Tc-HMDP) were done by reversed-phaseion pairing chromatography using a optimized mobile phase consisted on a mixture of 50 mM phosphate buffer (pH 7.0) and 2 mM TBA (tetra nbutyl) ammonium hydroxide) in 30 % methanol. The mobile phases for analysis of medium molecular weight 99m Tc-HSA were consisted of a mixture of 50 mM phosphate buffer (ph 7.0) in 30 % methanol, and a mixtures of 1 % SDS (sodium dodecyl sulfonate) in Tris buffer (pH. 7.0), respectively. It was apparent from the radio-chromatograms obtained from these chromatographic conditions, that impurity of 99m TcO 4 was observed in 99m Tc-pyrophosphate, 99m Tc-phytic acid, 99m Tc-MDP, 99m Tc-HMDP, and impurities of 99m Tc-labeled species and 99m TcO 4 , were observed in 99m Tc-HIDA, 99m Tc-HIDA, 99m Tc-HSA. The radiochemical impurities of the 99m Tc-radiopharmaceuticals were ranged between 90 and 100 %. From these results, radio-HPLC has been shown to be suitable method for analysis of 99m Tc-radiopharmaceuticals, with rapidity and excellent precision. (author)

  19. /sup 99m/Tc-labelled hepatobiliary radiopharmaceuticals

    International Nuclear Information System (INIS)

    Galli, G.; Maini, C.L.

    1986-01-01

    During the last 15 years many compounds labelled with /sup 99m/Tc have been proposed for use in cholescintigraphy. A short chronological list includes: toluidine blue, penicillamine, tetracycline, dihydrothioctic acid, mercaptoisubutyric acid, pyridoxals, pyridoxylideneaminates, carboxyl-hydroxyquinoline, substituted acetanilide iminodiacetates (so called IDAs), ethylenediamine-N, N-diacetate derivatives (such as sulfonyl-EDDA and benzoyl-EDDA), and orthoiodohippurate analogues. Among all these compounds the IDAs have been those most extensively used for basic and clinical research. A large series of IDA derivatives has been developed, and the properties of 33 of them have recently been tested

  20. Radiopharmacokinetic data for 99mTc-ABP - A new radiopharmaceutical for bone scanning: Comparison with 99mTc-MDP

    International Nuclear Information System (INIS)

    Murphy, Consuelo Arteaga de; Melendez-Alafort, Laura; Montoya-Molina, Carlos E.; Sepulveda-Mendez, Jesus

    1997-01-01

    Technetium-99m-labeled alendronate is a new radiopharmaceutical for bone scanning developed under strict quality control at the INNSZ. The purpose of this work was to compare the radiopharmacokinetic data and the dosimetry of 99m Tc-ABP and 99m Tc-MDP in 10 volunteers, after it was tested in laboratory animals. 99m Tc-ABP has shorter mean residence time (MRT) and t (1(2)) β; is less protein bound; has a higher renal clearance; smaller Vdss, and similar bone uptake at 1 and 2 h. 99m Tc-ABP gives less radiation exposure to the patient with a 740 MBq dose, and the quality of the bone scan is excellent. 99m Tc-ABP is a better radiopharmaceutical than 99m Tc-MDP for bone scanning

  1. labelling and quality control of some 99m Tc-radiopharmaceuticals of expected biological activity

    International Nuclear Information System (INIS)

    Abdallah, A.B.I.

    2009-01-01

    this thesis addresses the labelling and quality control of some 99m Tc-radiopharmaceuticals which could be used for infection imaging. this study focuses on the labelling of sarafloxation, gatifloxation and cefepine with technetium-99m and biological evaluation of these labeled complexes and biodistribution in both normal and inflamed mice. the thesis is organized into two chapters: chapter I :labelling of some antibiotics chapter II :biological evaluation.

  2. Biological evaluation of 99m Tc-N-(3-bromo-trimethyl-acetanilide)-iminodiacetic acid (99mTc mebrofenin) as hepatobiliary radiopharmaceutical

    International Nuclear Information System (INIS)

    Hamada, E.S.

    1994-01-01

    Technetium-99 m-N-(3-bromo-2,4,6-trimethyl acetanilide) iminodiacetic acid ( 99m Tc-Mebrofenin) has been described as having optimal properties as hepatobiliary radiopharmaceutical. This paper describes the synthesis, radiopharmaceutical preparation and biological distribution of new labeled compound. The biodistribution study of 99m Tc-Mebrofenin- was carried out in normal mice. The specificity for hepatobiliary excretion blood clearance and cumulative biliary excretion were evaluated in normal and cirrhotic rats. (author). 5 refs, 3 figs, 3 tabs

  3. Stannous ion quantitation in sup(99m)Tc-radiopharmaceutical kits

    International Nuclear Information System (INIS)

    Chervu, L.R.; Vallabhajosyula, B.; Mani, J.; Chun, S.B.; Blaufox, M.D.

    1982-01-01

    A simple and inexpensive method for the estimation of stannous ion, Sn(II), in radiopharmaceutical kits is described. The method used is a potentiometric titration of Sn(II) in 1 N HCl medium, using potassium iodate as the oxidizing agent in an atmosphere of nitrogen. The apparatus includes a pH meter, a platinum electrode, and a simple titration cell. Several commonly used radiopharmaceutical kits were analyzed for their Sn(II) content using this method. These studies indicate that the procedure can be used, as a routine quantitative test for the Sn(II) content of various sup(99m)Tc-labeled radiopharmaceuticals. (orig.)

  4. Physicochemical and Biological Analysis of 99mTc-Glutathione Radiopharmaceuticals

    International Nuclear Information System (INIS)

    ME- Sriyani; N- Zainuddin

    2013-01-01

    99m Tc-glutathion ( 99m Tc-GSH) radiopharmaceutical is available in the GSH lyophilized-kit in which ready to use directly after adding 99m Tc radionuclide. In nuclear medicine, 99m Tc-GSH diagnostic kit is a radiopharmaceutical commonly utilized for cancer diagnoses using imaging method. This paper described the physicochemical and biological characteristics as well as the quality of 99m Tc-GSH diagnostic kit prepared from the GSH lyophilized-kit. The radiochemical purity was determined with thin layer chromatography (TLC) method, performed on a TLC-SG stationary phase with a mobile phase of a dried acetone and 0,9% of NaCl solution. Studies on the effect of volume and radioactivity of Na 99m TcO 4 solution to the radiochemical purity of 99m Tc-GSH were carried out. The sterility of GSH-lyophilized kit and toxicity of 99m Tc-GSH were also investigated. The stability test on GSH lyophilized kit and 99m Tc-GSH in several storage conditions, as well as the plasma stability of 99m Tc-GSH was performed. The analysis result showed that the GSH lyophilized-kit was sterile; the 99m Tc-GSH was non toxic with 99.54 ± 0.01% of radiochemical purity and remained stable 5 hours either at room temperature or 4℃. The volume more than 4 mL of Na 99m TcO 4 solution on the labeling of GSH could decreased the 99m Tc-GSH radiochemical purity, while the radioactivity more than 20 mCi in 7 mL of volume extended the incubation time. In-vitro stability test of 99m Tc-GSH in plasma showed that in the two hours of storage, the radiochemical purity decreased to 51.84 ± 2.52%, and until 5 hours of storage it did not change significantly. From the result, it can be concluded that the GSH lyophilized-kit was remained stable after 13 month of storage either at room temperature or 4℃ with 99% of 99m Tc-GSH radiochemical purity. (author)

  5. Radiolabeling of human platelets using four radiopharmaceuticals with Tc-99m

    International Nuclear Information System (INIS)

    Portillo L, M.C.; Godoy, C.

    1991-01-01

    The present investigation work has been done in an evaluation of four different radiopharmaceuticals with Tin II (Glucoheptonate, Pyrophosphate, Citrate and DTPA), with the purpose of determining which one of the four would be obtained a higher rate of radiolabeling of platelets with Tc-99m. In order to evaluate the four radiopharmaceuticals it was procede to the separation and labeling of the human platelets. It was worked with samples of blood from five pacients, and the platelets from each one of them were labeled with the radiopharmaceuticals-Tc-99m. Then was observed a significant difference among the four radiopharmaceuticals studied, with a reliable level of 0.05 being the Glucoheptonate-Tc-99m the best to label platelets, obtaining with the same 50.23% of labeling efficiency, while for DTPA, Pyrophosphate and Citrate, It was obtained 33.42%, 29.82% and |2.62% respectively. Also, it was studied the biodistribution of the labeled platelets, using Glucoheptonate-Tc-99m as a radiopharamceutical. The biodistribution was studied in white mice at different times and it was founded that the place of biodistribution of the labeled platelets is given in greater percentage in the liver, spleen, lungs and kydneis. (Author)

  6. Radiochemical purity and in vitro stability of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Vucina, J.

    2001-01-01

    The increased contents of long lived 99 Tc, oxygen and cupric ions could affect the labeling yield of eight radiopharmaceuticals. Oxygen and in leaser extend copper were found to affect the radiochemical purity of the preparations. In vitro stability of radiopharmaceuticals, examined on 99m Tc(Sn)-pyrosphoshate solutions, was extended when ascorbic acid was added as the chemical stabilizer. The quantity of 5x10 -7 mol/dm 3 of ascorbic acid was found to be sufficient to keep the content of 99m Tc-pertechnetate below 1 % six hours after labeling even in the cases when 99m Tc was present in high radioactive concentrations (740-814 GBq/dm 3 ). The results led to the development of the kits in which ascorbic or gentisic acid are the standards component in the kit composition (author)

  7. Validation of an ergonomic method to withdraw [99mTc] radiopharmaceuticals.

    Science.gov (United States)

    Blondeel-Gomes, Sandy; Marie, Solène; Fouque, Julien; Loyeau, Sabrina; Madar, Olivier; Lokiec, François

    2017-11-10

    The main objective of the present work was to ensure quality of radiopharmaceuticals syringes withdrawn with a "Spinal needle/obturator In-Stopper" system. Methods: Visual examinations and physicochemical tests are performed at T0 and T+4h for [ 99m Tc]albumin nanocolloid and T+7h for [ 99m Tc]eluate, [ 99m Tc] HydroxyMethylene DiPhosphonate and [ 99m Tc]Human Serum Albumin. Microbiological validation was performed according to European pharmacopoeia. Fingertip radiation exposure was evaluated to confirm the safety of the system. Results: Results show stable visual and physicochemical properties. The integrity of the connector was not affected after 30 punctures (no cores). No microbiological contamination was found on tested syringes. Conclusion: The system could be used 30 times. The stability of syringes drawing with this method is guaranteed up to 4 hours for [ 99m Tc]albumin nanocolloid and 7 hours for [ 99m Tc]eluate, [ 99m Tc]HydroxyMethylene DisPhosphonate and [ 99m Tc]Human serum albumin. Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

  8. The quality of 99mTc-radiopharmaceuticals - a basic requirement in the diagnostic nuclear medicine

    International Nuclear Information System (INIS)

    Ivanova, S.; Popsavova, H.; Kostadinova, I.

    2011-01-01

    Development and application of new high quality radiopharmaceuticals (RP) are of a great significance for the development in nuclear medicine. The high quality of the radiopharmaceuticals has a major influence on the accuracy of nuclear medical examinations. Therefore, a good knowledge and application if various control methods, is essential. Radiochemical impurities affect the quality of RP most significantly and they can appear at every stage of the preparation. The aim of this review is to present the literature information concerning the quality of the most commonly used radiopharmaceuticals, labeled with 99m Tc, and all requirements for them, i.e. radiochemical, radionuclide and chemical purity. This is well-known fact that metastable isotope of Technetium is golden standard for diagnostics in nuclear medicine. Research shows that about 80% of approx. 25 million nuclear medical studies a year are performed with this radionuclide. According to the European Pharmacopoeia and to the leaflets provided with the kits, radiochemical purity must exceed 95%. The main radiochemical impurities in 99m Tc-radiopharmaceuticals are free pertechnetate ( 99m TcO 4 - ), whose presence causes accumulation of RP in the thyroid gland, stomach, gastrointestinal tract, or the salivary glands, leading to a wrong diagnosis, and reduced hydrolyzed technetium, which causes visualization of the reticulo-endothelial system. This paper contains information about the authors' experience with analyses of the radiochemical purity of the two most commonly used radiopharmaceuticals in Bulgaria - for bone and renal scintigraphy (MDA and DTPA). An Instant Thin-Layer Chromatography (ITLC) is used for this purpose. It is concluded that the high quality of the applied 99m Tc-radiopharmaceuticals can be guaranteed only with both selection of renowned manufactures, recognized by EU, and a routine daily control of the labeling and generator eluate, meeting all requirements of the manufacturer and

  9. Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons.

    Science.gov (United States)

    Boschi, Alessandra; Martini, Petra; Pasquali, Micol; Uccelli, Licia

    2017-09-01

    99m Tc is the most commonly used radionuclide in the field of diagnostic imaging, a noninvasive method intended to diagnose a disease, assess the disease state and monitor the effects of treatments. Annually, the use of 99m Tc, covers about 85% of nuclear medicine applications. This isotope releases gamma rays at about the same wavelength as conventional X-ray diagnostic equipment, and owing to its short half-life (t ½  = 6 h) is ideal for diagnostic nuclear imaging. A patient can be injected with a small amount of 99m Tc and within 24 h almost 94% of the injected radionuclide would have decayed and left the body, limiting the patient's radiation exposure. 99m Tc is usually supplied to hospitals through a 99 Mo/ 99m Tc radionuclide generator system where it is produced from the β decay of the parent nuclide 99 Mo (t ½  = 66 h), which is produced in nuclear reactors via neutron fission. Recently, the interruption of the global supply chain of reactor-produced 99 Mo, has forced the scientific community to investigate alternative production routes for 99m Tc. One solution was to consider cyclotron-based methods as potential replacement of reactor-based technology and the nuclear reaction 100 Mo(p,2n) 99m Tc emerged as the most worthwhile approach. This review reports some achievements about 99m Tc produced by medical cyclotrons. In particular, the available technologies for target design, the most efficient extraction and separation procedure developed for the purification of 99m Tc from the irradiated targets, the preparation of high purity 99m Tc radiopharmaceuticals and the first clinical studies carried out with cyclotron produced 99m Tc are described.

  10. Determination of Sn in 99mTc Radiopharmaceutical Kits by Polarographic Methods

    International Nuclear Information System (INIS)

    Castro, M.; Cruz, J.; Sanchez, M.

    2009-01-01

    Kits of 99 m Tc radiopharmaceuticals are used in nuclear medicine for diagnosis of different diseases. Sn (II) is one of the essential components in their formulations, which is used for reduction 99 m Tc-pertechnetate in cold kits for on-site preparation 99 m Tc-pertechnetate radiopharmaceuticals. Usually, these cold kits contain different additives (complexing agents, antioxidants, buffers, etc.) and the amount of Sn (II) varies from kit to kit. The determination of Sn in these products is essential in assessing their quality. We report here the development of a new polarographic method for the determination of Sn (II) and total Sn in representative radiopharmaceuticals kits (for the content of Sn and chemical composition) produced at the Center of Isotopes of Cuba (CENTIS). These methods were validated by analysis of variance and recovery techniques. From the results of the validation, the characteristic functions of uncertainties and fits are considered for the established methods, which give the necessary evidences to demonstrate the usefulness of these methods according to the current trends in Analytical Chemistry. This work provides practical results of great importance for CENTIS. After the speciation of Sn in the MAG3 radiopharmaceuticals kit is inferred that the production process is affected by uncontrolled factors that influence in the product stability, which demonstrates the necessity for analytical tools for the characterization of products and processes. (Author) 57 refs.

  11. Recent developments in 99mTc and 123I-radiopharmaceuticals for SPECT imaging

    International Nuclear Information System (INIS)

    Kulkarni, P.V.

    1991-01-01

    Availability of 123 I of high radionuclidic purity has encouraged the development of 123 I-based radiopharmaceuticals for the assessment of myocardial fatty acid metabolism, myocardial neuronal activity, and for receptor and antibody imaging. Advances in the chemistry of technetium have resulted in the development of novel agents for myocardial and cerebral perfusion and renal function studies. Monoclonal antibodies labeled with 99m Tc show promise for imaging neoplastic lesions, myocardial infarcts, and thrombus localization. Recent developments in 123 I and 99m Tc agents for myocardial and brain imaging studies are discussed. (author)

  12. Internal dosimetry of technetium-99m-labelled radiopharmaceuticals used in clinical nuclear medicine

    Energy Technology Data Exchange (ETDEWEB)

    Roedler, H D [Freie Univ. Berlin (Germany, F.R.). Klinikum Steglitz

    1977-01-01

    For radiopharmaceuticals labelled with /sup 99m/Tc, which is the most common short-lived radionuclide used in nuclear medicine, the possible dose reduction in comparison to other radionuclides for equal administered activities is deduced from the formalism of absorbed dose calculation and compared to the actually achieved decrease of absorbed dose for the most important radiopharmaceuticals. Absorbed doses per ..mu..Ci of administered activity are tabulated for the gonads, red bone marrow, and critical organs of the adult human, the newborn, and the child of 1, 5, 10, and 15 years.

  13. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose

    Science.gov (United States)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.

    2016-08-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25 MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 min. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D-glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio-D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  14. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis

    Science.gov (United States)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Bragina, O.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.; Dergilev, A.

    2016-06-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 minutes at room temperature. After centrifugation of the vials with cells, the supernatant was removed. Radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B 1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 minutes. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D- glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3±0.15MBq and 1.07±0.6MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio- D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  15. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose

    Energy Technology Data Exchange (ETDEWEB)

    Zeltchan, R., E-mail: r.zelchan@yandex.ru; Medvedeva, A.; Sinilkin, I.; Chernov, V. [Tomsk Cancer Research Institute, Tomsk, 634050 (Russian Federation); Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Stasyuk, E.; Rogov, A.; Il’ina, E.; Larionova, L.; Skuridin, V. [Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation)

    2016-08-02

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with {sup 99m}Tc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of {sup 99m}Tc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with {sup 99m}Tc was added to the vials with 3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25 MBq of {sup 99m}Tc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 min. Results: when measuring the radioactivity of normal and malignant cells after incubation with {sup 99m}Tc-1-thio-D-glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased accumulation of {sup 99m}Tc-1-thio-D-glucose at the tumor site. The accumulation of {sup 99m}Tc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that {sup 99m}Tc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of {sup 99m}Tc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  16. Alternative chromatographic system for the quality control of lipophilic technetium-99m radiopharmaceuticals such as [{sup 99m}Tc(MIBI){sub 6}]{sup +}

    Energy Technology Data Exchange (ETDEWEB)

    Faria, D.P.; Buchpiguel, C.A.; Marques, F.L.N., E-mail: danielefaria1@gmail.com [Universidade de Sao Paulo (USP), Sao Paulo, SP (Brazil). Faculdade de Medicina. Departamento de Radiologia. Servico de Medicina Nuclear

    2015-10-15

    Knowledge of the radiochemical purity of radiopharmaceuticals is mandatory and can be evaluated by several methods and techniques. Planar chromatography is the technique normally employed in nuclear medicine since it is simple, rapid and usually of low cost. There is no standard system for the chromatographic technique, but price, separation efficiency and short time for execution must be considered. We have studied an alternative system using common chromatographic stationary phase and alcohol or alcohol:chloroform mixtures as the mobile phase, using the lipophilic radiopharmaceutical [{sup 99m}Tc(MIBI){sub 6}]{sup +} as a model. Whatman 1 modified phase paper and absolute ethanol, Whatman 1 paper and methanol: chloroform (25:75), Whatman 3MM paper and ethanol:chloroform (25:75), and the more expensive ITLC-SG and 1-propanol: chloroform (10:90) were suitable systems for the direct determination of radiochemical purity of [{sup 99m}Tc(MIBI){sub 6}]{sup +} since impurities such as {sup 99m}Tc-reduced-hydrolyzed (RH), {sup 99m}TcO4{sup -} and [{sup 99m}Tc(cysteine){sub 2}]{sup -} complex were completely separated from the radiopharmaceutical, which moved toward the front of chromatographic systems while impurities were retained at the origin. The time required for analysis was 4 to 15 min, which is appropriate for nuclear medicine routines. (author)

  17. Synthesis and formulation of {sup 99m} Tc-ECD radiopharmaceutical; Sintesis y formulacion del radiofarmaco {sup 99m} Tc-ECD

    Energy Technology Data Exchange (ETDEWEB)

    Ocampo G, B E

    1998-06-01

    Nuclear medicine is a medical specialty which uses radioactive compounds (radionuclides) for diagnostic and therapeutic purposes. {sup 99m} Tc is the more common radionuclide used in many studies in nuclear medicine because its advantages: it has a photopeak of 140 KeV and a half-life of 6 hours; it can be eluted from a Molybdenum 99 generator, so radiopharmaceuticals can be prepared on site. Ethyl cysteine dimer (ECD) labelled with reduced Technetium 99m has been purposed recently as a promising radiopharmaceutical for brain perfusion imaging {sup 99m} Tc-ECD is a lipophilic neutral complex which cross the brain blood barrier and show high brain uptake. The objective of this work was synthesize and to design a freeze dried formulation for the instant preparation of {sup 99m} Tc-ECD complex useful for brain perfusion imaging. We obtained a freeze dried stable formulation for the preparation of {sup 99m} Tc-ECD kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytic techniques for the determination of the different chemical compounds into the lyophilized kit. (Author).

  18. Alternative chromatographic system for the quality control of lipophilic technetium-99m radiopharmaceuticals such as [99mTc(MIBI6]+

    Directory of Open Access Journals (Sweden)

    D.P. Faria

    2015-01-01

    Full Text Available Knowledge of the radiochemical purity of radiopharmaceuticals is mandatory and can be evaluated by several methods and techniques. Planar chromatography is the technique normally employed in nuclear medicine since it is simple, rapid and usually of low cost. There is no standard system for the chromatographic technique, but price, separation efficiency and short time for execution must be considered. We have studied an alternative system using common chromatographic stationary phase and alcohol or alcohol:chloroform mixtures as the mobile phase, using the lipophilic radiopharmaceutical [99mTc(MIBI6]+ as a model. Whatman 1 modified phase paper and absolute ethanol, Whatman 1 paper and methanol:chloroform (25:75, Whatman 3MM paper and ethanol:chloroform (25:75, and the more expensive ITLC-SG and 1-propanol:chloroform (10:90 were suitable systems for the direct determination of radiochemical purity of [99mTc(MIBI6]+ since impurities such as 99mTc-reduced-hydrolyzed (RH, 99mTcO4 - and [99mTc(cysteine2]- complex were completely separated from the radiopharmaceutical, which moved toward the front of chromatographic systems while impurities were retained at the origin. The time required for analysis was 4 to 15 min, which is appropriate for nuclear medicine routines.

  19. Development and validation of methodology for technetium-99m radiopharmaceuticals using high performance liquid chromatography (HPLC)

    International Nuclear Information System (INIS)

    Almeida, Erika Vieira de

    2009-01-01

    Radiopharmaceuticals are compounds, with no pharmacological action, which have a radioisotope in their composition and are used in Nuclear Medicine for diagnosis and therapy of several diseases. In this work, the development and validation of an analytical method for 99 mTc-HSA, 99 mTc-EC, 99 mTc-ECD and 99 mTc-Sestamibi radiopharmaceuticals and for some raw materials were carried out by high performance liquid chromatography (HPLC). The analyses were performed in a Shimadzu HPLC equipment, LC-20AT Prominence model. Some impurities were identified by the addition of a reference standard substance. Validation of the method was carried out according to the criteria defined in RE n. 899/2003 of the National Sanitary Agency (ANVISA). The results for robustness of the method showed that it is necessary to control flow rate conditions, sample volume, pH of the mobile phase and temperature of the oven. The analytical curves were linear in the concentration ranges, with linear correlation coefficients (r 2 ) above 0.9995. The results for precision, accuracy and recovery showed values in the range of 0.07-4.78%, 95.38-106.50% and 94.40-100.95%, respectively. The detection limits and quantification limits varied from 0.27 to 5.77 μg mL -1 and 0.90 to 19.23 μg mL -1 , respectively. The values for HAS, EC, ECD and MIBI in the lyophilized reagents were 8.95; 0.485; 0.986 and 0.974 mg L-1, respectively. The mean radiochemical purity for 99 mTc-HSA, 99 mTc-EC, 99 mTc-ECD and 99 mTc-Sestamibi was (97.28 ± 0.09)%, (98.96 ± 0.03)%, (98.96 ± 0.03)% and (98.07 ± 0.01)%, respectively. All the parameters recommended by ANVISA were evaluated and the results are below the established limits. (author)

  20. Development, preparation and control of sup(99m)Tc or sup(113m)In labelled stannous hydroxide radiopharmaceuticals. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Alvarez Cervera, J.

    1975-01-01

    The preparation of different sup(99m)Tc and sup(113m)In radiopharmaceuticals using stannous chloride was investigated. Chemical and radiochemical procedures for the quality control of these preparations were studied. Toxicity and biological controls of the preparation were carried out. Procedures for the preparation and control of the following radiopharmaceuticals have been standardized by the authors; albumin macroaggregates labelled with sup(99m)Tc, sup(113m)In and other isotopes for lung scanning; albumin microspheres labelled with sup(99m)Tc for lung scanning; sup(99m)Tc or sup(113m)In-labelled stannous hydroxide colloid for liver scanning; sup(99m)Tc-stannous phytate for liver scanning; sup(99m)Tc-Sn-dextrose, a new radiopharmaceutical which has been proposed by the authors and is now used in Mexico for renal and cerebral scanning and sup(99m)Tc-Sn pyrophosphate and diphosphonate for bone scanning

  1. Biodistribution of the radiopharmaceutical technetium-99m-sodium phytate in rats after splenectomy

    International Nuclear Information System (INIS)

    Pereira, Kercia Regina Santos Gomes; Acucena, Maria Kadja Meneses Torres; Villarim Neto, Arthur; Rego, Amalia Cinthia Meneses; Bernardo-Filho, Mario; Azevedo, Italo Medeiros; Araujo Filho, Irami; Medeiros, Aldo Cunha

    2008-01-01

    Drugs and surgery can interfere with the biodistribution of radiopharmaceuticals and data about the effect of splenectomy on the metabolism of phytate-Tc-99m are scarce. This study aimed at evaluating the interference of splenectomy on phytate-Tc-99m biodistribution and liver function in rats. The SP group rats (n=6) underwent splenectomy. In group C (control) the animals were not operated on. After 15 days, all rats were injected with 0.1 mL of Tc-99m-phytate via orbital plexus (0.66 MBq). After 30 minutes, liver samples were harvested, weighed and the percentage of radioactivity per gram (%ATI/g) was determined by a Wizard Perkin-Elme gamma counter. The ATI%/g in splenectomized rats (0.99±0.02) was significantly higher than in controls (0.4±0.02), (p=0.034). ALT, AST and HDL were significantly lower in SP rats (p= 0.001) and leucocytosis was observed in SP rats. In conclusion, splenectomy in rats changed the hepatic biodistribution of Tc-99m-phytate and liver enzymatic activity. (author)

  2. Biodistribution of the radiopharmaceutical technetium-99m-sodium phytate in rats after splenectomy

    Energy Technology Data Exchange (ETDEWEB)

    Pereira, Kercia Regina Santos Gomes; Acucena, Maria Kadja Meneses Torres; Villarim Neto, Arthur; Rego, Amalia Cinthia Meneses [Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN (Brazil). Centro de Ciencias da Saude; Bernardo-Filho, Mario [Universidade do Estado do Rio de Janeiro (UERJ), RJ (Brazil). Inst. de Biologia Roberto Alcantara Gomes. Dept. de Biofisica e Biometria; Azevedo, Italo Medeiros; Araujo Filho, Irami; Medeiros, Aldo Cunha [Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN (Brazil). Dept. de Cirurgia]. E-mail: aldo@ufrnet.br

    2008-12-15

    Drugs and surgery can interfere with the biodistribution of radiopharmaceuticals and data about the effect of splenectomy on the metabolism of phytate-Tc-99m are scarce. This study aimed at evaluating the interference of splenectomy on phytate-Tc-99m biodistribution and liver function in rats. The SP group rats (n=6) underwent splenectomy. In group C (control) the animals were not operated on. After 15 days, all rats were injected with 0.1 mL of Tc-99m-phytate via orbital plexus (0.66 MBq). After 30 minutes, liver samples were harvested, weighed and the percentage of radioactivity per gram (%ATI/g) was determined by a Wizard Perkin-Elme gamma counter. The ATI%/g in splenectomized rats (0.99{+-}0.02) was significantly higher than in controls (0.4{+-}0.02), (p=0.034). ALT, AST and HDL were significantly lower in SP rats (p= 0.001) and leucocytosis was observed in SP rats. In conclusion, splenectomy in rats changed the hepatic biodistribution of Tc-99m-phytate and liver enzymatic activity. (author)

  3. Synthesis, chemical controls and radiopharmaceuticals of 'mebrofenin-Tc-99m'

    International Nuclear Information System (INIS)

    Arguelles, Maria; Canellas, Carlos; Arciprete, Carlos; Mitta, Aldo; Gros, Eduardo; Ceriani, Juan; Caneda, Graciela

    1988-01-01

    The chemical and radiopharmacological studies carried out with 'mebrofenin-Tc-99m' and its use in human beings is presented. The purpose of this work was to determine the potential use of this radiopharmaceutical in humans, who were carriers of different clinic and pathological diseases. 'Mebrofenin-Tc-99mc' was synthesized by the method of Callery modified (in its second stage) so as to raise the yield from 70 % to 90 %. Plasma kinetics was determined by extracorporal circulation in wistar rats and hepatic and renal circulation were determined in all the results analized in a processor and thus plasmatic half lives and maximum uptake times were obtained. (Author) [es

  4. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits

    International Nuclear Information System (INIS)

    McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    1978-01-01

    This report summarizes the results of quality control studies of Tc 99m labelled normal serum albumin and macro-aggregated albumin radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed since the inception of the program in 1976 until the end of 1977. The results presented herein were obtained through the application of various in vitro tests and animal (mouse) bio-distribution studies. It is hoped that a similar report will be published annually for the benefit of hospital nuclear medicine departments and kit manufacturers. (auth)

  5. Study of the properties of sup(99m)Tc-DTPA-ferroascorbinate and sup(99m)Tc-dextrose as radiopharmaceuticals for renal scintiscanning

    International Nuclear Information System (INIS)

    Salambashev, L.; Konstantinov, P.; Ketskarova, S.; Kovacheva, S.; Babeva, S.

    1979-01-01

    Description is made of an own method for labelling of the complex DTPA-ferroascorbinate and dextrose with sup(99m)Tc for the purpose of renal scintiscanning. Experimental investigations on rabbits were carried out, and afterwards conventional scintiscanning and follow-up of the intake into the renal parenchyma by means of gamma camera were performed on 15 patients. The observations revealed that sup(99m)Tc-DTPA-ferroascorbinate was more rapidly excreted (40 min to 2 h following the intravenous administration). For this reason it is more convenient for gamma camera examination, while sup(99m)Tc-dextrose is fixing more lastingly in the parenchyma and respons to all requirements with respect to radiopharmaceuticals for conventional renal scintiscanning. (author)

  6. In vitro effect of cyclophosphamide on the binding of radiopharmaceuticals (99m Tc O4- and 99m Tc-MDP) to blood elements

    International Nuclear Information System (INIS)

    Ripoll-Hamer, E.; Paula, E.F. de; Bernardo Filho, M.; Freitas, L.C.; Fonseca, L.M.; Gutfilen, B.

    1995-01-01

    Using an in vitro model, it was evaluated the effect of cyclophosphamide on percent radioactivity of 99m Tc O - 4 and methylene diphosphonic acid ( 99m Tc-MDP) bound to isolated blood elements. Blood samples were incubated with the two radiopharmaceuticals, plasma and blood cells were separated and precipitated, and soluble and insoluble fractions were separated. To evaluate the effect of cyclophosphamide, blood was incubated with this drug 1 h prior to the addition of the radiopharmaceuticals. The fraction of 99m Tc O - 4 radioactivity was slightly higher in plasma (61.2 to 53.8%) than in blood cells (38.8 to 46.2%) up to 6 h. The amount of 99m Tc - MDP radioactivity was higher in plasma (91.1 to 87.2%) than in blood cells (8.9 to 12.8%) up to 24 h. The binding of 99m Tc O - 4 to the insoluble fraction of plasma (4.9 to 6.1%) was low. But a small blockade (9.8 to 4.8%) was observed at 24 h. From 3 h on, cyclophosphamide slightly inhibited 99m Tc O - 4 binding to blood cells (23.1 to 16.6%) and increased it at 24 h (31.2 to 14.3%). The effect of cyclophosphamide was strongest at 24 h, with decreased radioactivity binding to the insoluble fraction of plasma (47.6 to 27.0%) and blood cells (51.2 to 23.2%). The fact that cyclophosphamide can bind to plasma proteins and/or cross the cell membrane explains in part the results obtained. (author). 20 refs., 2 tabs

  7. Effect of experimental conditions on the stability of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Vucina, J.

    2002-01-01

    The stability of three 99m Tc radiopharmaceuticals in dependence on the experimental conditions and on the presence of some chemical stabiliser was tested. Examined were dimercapto succinate (DMS), pyrophosphate (PyP) and 2,3-dicarboxypropane-1,1-diphosphonate (DPD). The reliability and applicability of the preparation of the three radiopharmaceuticals from the inactive (technetium-cold) kit solutions were tested. Each kit was dissolved in saline (0.9% NaCl). The storage conditions of the inactive kit solutions before labelling were determined. The main problem is the stability of the reductant stannous ions which is very difficult to predict. Ascorbic or gentisic acid was added in order to stabilise the labelled radiopharmaceuticals and ensure their good quality. The best results were obtained by keeping the samples at -20 deg C. Although either stabiliser can be used, much lower concentrations of ascorbic acid are sufficient for an effective protection. Its concentrations of 12-60 μg/ml of the kit stabilise DMS and PyP for about 7-8 days. The solution of DPD was stable even without any stabiliser, presumably dut to the chemical nature of this complex. In routine practice, however, the procedure requires caution, and the staff should be very experienced in radiopharmacy procedures

  8. Preparation and stability of the 99m Tc-HNE2 radiopharmaceutical

    International Nuclear Information System (INIS)

    Estrada T, J.

    2002-01-01

    A radiopharmaceutical is all substance containing a radioactive atom inside of its structure and what because of its pharmaceutical form, quantity and quality of radiation can be administered in the human beings with diagnostic or therapeutic aims. With the purpose to developing effective radiopharmaceuticals it is necessary to pick carefully the appropriate radionuclide in combination with the In vivo localization and the pharmacon kinetic properties of the carrier molecule. The peptides are designed by the nature to stimulate, regulate or inhibit numerous life functions, they act mainly as information transmitters and activity coordinators of several tissues in the body; it has been found that such substances are present in cells and in the body fluids in quantities extremely small, therefore the peptides have been considered as ideal agents for therapeutic applications. Elastase of human neutrophylls is a 29 kDa protease which is produced in high levels inside the neutrophyll and it is released as response for an inflammatory stimulus in infection/inflammation places. Once it liberated is quickly inhibited by the anti elastase α tripsine (HNE-2) peptide. Therefore, the neutrophylls elastase is considered as a target to obtain In vivo images of inflammatory/infectious processes by the intravenous application of 99m Tc-HNE-2. The objective of this work was to develop a labelling method with 99m Tc for the inhibitor peptide of the human neutrophyll elastase (HNE-2). Likewise, for evaluating its In vivo and In vitro stabilities. The methodology which was followed as first step to conjugate the (HNE-2) peptide with the bi chelating agents HYNIC and DTPA capable to chelate the 99m Tc metal. Therefore the attachment reactions to the peptide were realized starting from the NHS and HYNIC and the DTPA anhydride in buffer of 0.1 M, pH= 9.0/DMF (10:1) bicarbonates with a molar relation peptide/bi chelating agent 1:5. For the purification of the conjugate the solid phase

  9. Testing the radiochemical purity of radiopharmaceuticals: application to 99mTc-HMPAO

    International Nuclear Information System (INIS)

    Ait Ben Ali, S.; Darsin, D.; Rizzo, N.; Lours, S.; De Beco, V.; Dumont, A.; Goudou-Sinha, C.; Izembart, M.; Jourdain, J.R.; Lemercier, V.; Linsker, S.; Moati, F.; Piketty, M.L.; Schlageter, M.H.; Moretti, J.L.

    1997-01-01

    The low stability of 99m Tc-HMPAO imposes to carry out the quality testing within the 15 minutes following the preparation. This study has the aim of comparing different methods of radiochemical purity determination (RP) of this radiopharmaceutical in order to validate a fast, reproducible, feasible technique, capable of separating the primary lipophilic 99m Tc-HMPAO (I) of impurities: hydrophilic secondary complex (II), TcO 4 - , reduced and halyards Tc. The reference technique associating two thin-layer chromatographies (TLC), 'C1' and 'C2', has been compared with a TLC 'W' technique and with liquid-liquid extraction 'E' technique: C1 - stationary phase, ITLC Silica gel/mobile phase, Butanone-2; C2 - stationary phase, ITLC Silica gel/mobile phase, 0.9% NaCl; W - stationary phase, Papier Whatman n o 1/mobile phase, Ether; E - extraction with ethyls acetate /0.9% NaCl (1/1 v/v). The 'C1' chromatography allows isolating the reduced Tc and the complex II, the 'C2' chromatography does the same with TcO 4 - but it requires too long techniques (20 min.). The 'W' and 'E' techniques are rapid, reproducible and allow to separate the complex I from the other impurities without discrimination. However, as their results depend upon the deposited quantity of sampling, an optimization and standardization of the techniques are necessary. A forth technique by chromatography on Sep-Pak column is to be evaluated

  10. Technetium-99m-labeled N-(2,6-dimethylphenylcarbamoylmethyl) iminodiacetic acid (/sup 99m/Tc HIDA): a new radiopharmaceutical for hepatobiliary imaging studies

    International Nuclear Information System (INIS)

    Ryan, J.; Cooper, M.; Loberg, M.; Harvey, E.; Sikorski, S.

    1977-01-01

    An easily formulated, stable kit preparation of technetium-99m HIDA, suitable for use in humans, was developed and tested in mice and dogs. The tracer was cleared rapidly from the blood and excreted predominantly by the liver in both species. In dogs, the hepatobiliary clearance of Tc-99m HIDA was significantly greater than that of C-14 HIDA and Sn-113 HIDA. The LD 50 for HIDA in mice, 168 mg/kg, exceeded the average human dose by a factor of 1000 on a per-weight basis. Blood clearance curves for Tc-99m HIDA in 12 normal subjects were biexponential with half-times of 4.6 +- 1.0 min and 31.5 +- 7.0 min, and cumulative 90-min urine samples contained 14.2 +- 1.8% of the injected dose. Images in normal subjects and nonjaundiced patients showed rapid concentration of tracer by the liver and activity was present within the biliary system in 10 to 20 min. In jaundiced patients, the tracer blood clearance was delayed and urinary excretion increased, but intestinal activity, indicating biliary patency, was imaged in those patients without complete focal obstruction of the common duct. Technetium-99m HIDA is a nontoxic radiopharmaceutical useful for clinical evaluation of hepatobiliary disorders in humans

  11. Comparison of four technetium-99m radiopharmaceuticals for detection and localization of gastrointestinal bleeding in a sheep model

    International Nuclear Information System (INIS)

    Owunwanne, A.; Al-Wafai, I.; Vallgren, S.; Sadek, S.; Abdel-Dayem, H.M.; Yacoub, T.

    1988-01-01

    Four Tc-99 radiopharmaceuticals, Tc-99m sulphur colloid, Tc-99m red blood cells (RBCs), Tc-99m mercaptoacetyltriglycine (MAG3), and Tc-99m DTPA, were studied in an experimental animal model for detection and localization of gastrointestinal (GI) bleeding site in both the upper and lower abdomen. With Tc-99m sulphur colloid and Tc-99m RBCs, it was possible to detect and localize the GI bleeding site in the lower abdomen. With Tc-99m MAG3, it was possible to visualize the bleeding site in both the upper and lower abdomen. However, Tc-99m MAG3 is partially excreted by the liver into the bile, hence it will be difficult to use Tc-99m MAG3 to localize the GI bleeding site in the lower abdomen. With Tc-99m DTPA, it was possible to detect and localize the GI bleeding site simultaneously in both upper and lower abdomen. The overall background radioactivity was reduced considerably by diuresis with frusemide and catheterization of the urinary bladder

  12. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits (1980-81)

    International Nuclear Information System (INIS)

    1983-01-01

    This report summarized the results of quality control studies of Tc 99m labelled human serum albumin, macroaggregated albumin, bone imaging and reticuloendothelial system imaging radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed from January 1980 to December 1981 by the radiopharmaceutical quality control section of the Radiation Protection Bureau. These results were obtained by the application of various in vitro and animal (mouse) biodistribution studies

  13. Synthesis, labeling with 99mTc and biokinetics of brains scintigraphy diaminodithiol perfusion radiopharmaceuticals

    International Nuclear Information System (INIS)

    Goncalves, Marcos Moises

    1999-01-01

    The recent tomography status using radiopharmaceuticals have been contributing greatly with the 'age of certainty' in the diagnosis examination of syndromes, pathologies and clinical signs, because they can evidence some phenomena occurring in a molecular manner. The purpose of this work have had the development of new diaminodithiol (DADT) perfusion radiopharmaceuticals to be used in brain diagnosis using S.P.E.T. (Single Photon Emission Tomography). Initially, the rational planning had been performed with the new DADT molecular structures as radiopharmaceutical candidates. Using of Q.S.A.R. (Quantitative Structure Activity Relationship) techniques, the molecular descriptors such as partition coefficient and effective polarizability, have been studied in order to increase the blood brain barrier transport and the brain uptake respectively. Applying the Q.S.P.R. (Quantitative Structure Property Relationship) concepts to perform drug latentiation, based on bio-labile functional groups, the congener DADT derivative has been transformed into a pro-drug that works as a DADT moiety carrier, allowing the increasing of brain radiopharmaceutical uptake. Later on, synthetic routes and chemical purifications have been developed allowing the creation of the proposed chemical structure. Each new DADT derivative has been synthesized and analyzed in terms of elemental analysis, infrared and NMR spectra, in order to confirm its proposed chemical structure. Then, the new derivative has been labeled with 99m Tc, radiochemically purified, intravenously injected in Swiss mice, allowing its biodistribution to evidence its brain transport and uptake. The rational planning studies have been re-evaluated after each biodistribution had been performed, to see what kind of molecular descriptor was responsible for causing a stronger optimization in the brain perfusion characteristics and then, new DADT derivatives have been prepared. Three new DADT derivatives have been obtained by using

  14. Influence of iron deficiency in the radiopharmaceutical behavior of red blood cells labeled with 99mTc(99mTC-RBC)

    International Nuclear Information System (INIS)

    Calmanovici, G.; Salgueiro, M.J.; Pernas, L.; Collia, N.; Leonardi, N.; Zubillaga, M.

    2005-01-01

    Full text: Red blood cells (RBCs) labeled with 99m Tc are commonly used in the evaluation of cardiac function, gastrointestinal tract bleeding, red blood cell volume or splenic sequestration. Generally stannous ion is used as reducing agent. A proposed mechanism is that once the stannous ion (Sn) and the pertechnetate ( 99m Tc) reach the interior of the RBC, the radionuclide is mainly house in the β-chain of hemoglobin. The aim of this study was to determine if hemoglobin content reduction, an indicator of iron deficiency anemia, could affect the efficiency of RBC labeling and the biological distribution of this radiopharmaceutical. We studied 30 rats fed for 3 weeks after weaning with diets with iron contents of 6.5 ppm (group A), 18 ppm (group B) and 100 ppm (control). For all groups, the labeling yields were always higher than 97%; the percentage of radioactivity was mostly founded in blood with almost negligible radioactivity the rest of the studied organs. We can conclude that the decrease in hemoglobin content, an indicator of iron deficiency anemia, does not interfere neither in the labeling nor in the biodistribution of red blood cells labeled with 99m Tc. (author)

  15. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits (1978-79)

    International Nuclear Information System (INIS)

    McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    1982-01-01

    This report summarizes the results of quality control studies of Tc 99m-labelled normal albumin, macroaggregated albumin, and bone imaging radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed from January 1978 to December 1979. The results presented were obtained through the application of various in vitro and animal (mouse) biodistribution studies

  16. Exposure of employees engaged on the production and quality control of radiopharmaceuticals labelled with Tc-99m and I-131

    International Nuclear Information System (INIS)

    Trtic, T.; Jovanovic, M.; Vranjes, S.; Vucina, J.; Vuksanovic, Lj.

    1995-01-01

    In this paper, the analysis is presented, of exposure control of employees in the Laboratory for radioisotopes, of the Vinca Institute of nuclear sciences, engaged in the production and quality control of the Tc-99m generator and radiopharmaceuticals labelled with Tc-99m and I-131. Effective doses equivalent (mSv) was measured by personal thermoluminescent dosimeter in the Laboratory for radiation and environmental protection each month. We calculated effective dose equivalents for each year in the period 1986-1990. Thirty one employees were analysed. They were separated into the groups both on the basis of radioisotope which they worked with and the kind of the professional work. The highest average effective doses equivalent were received in the group producing of Tc-99m generator (4-12.5 mSv) and in the group producing I-131 radiopharmaceuticals (3.55-13.73 mSv). (author)

  17. Streptozotocin (STZ) and schistosomiasis mansoni change the biodistribution of radiopharmaceutical sodium 99mTc-pertechnetate in mice

    International Nuclear Information System (INIS)

    Góes, Vanessa Coelho; Neves, Renata Heisler; Arnóbio, Adriano; Bernardo-Filho, Mario; Machado-Silva, José Roberto

    2016-01-01

    Introduction: Technetium-99m ( 99m Tc) is a radionuclide commonly used in nuclear medicine to obtain 99m Tc-radiopharmaceuticals, which can be used to evaluate either physiological processes or changes related to diseases. It is also used in some experimental studies. Streptozotocin (STZ) administration to rodents causes lesions in very early stages and induces severe and permanent diabetes. Most morbidity of schistosomiasis mansoni is attributed to a granulomatous inflammatory response and associated liver fibrosis. This study was designed to investigate whether STZ administration and schistosomiasis modify the biodistribution of the radiopharmaceutical sodium 99m Tc-pertechnetate. Methods: Adult female mice were infected by exposure to 100 Schistosoma mansoni cercariae (BH strain, Belo Horizonte, Brazil) and euthanized after nine weeks. STZ was administered by a single intraperitoneal injection of 100 mg/kg body weight, 3 or 15 days before euthanasia. Each animal received 100 μl of sodium (Na) 99m Tc-pertechnetate ( 99m TcO 4 − ) (740 kBq). The animals were divided into four groups: A, uninfected; B, infected; C, uninfected + STZ; and D, infected + STZ. Blood, brain, thyroid, heart, lungs, liver, spleen, pancreas and kidneys were removed. The radioactivity was counted and the percentage of the injected dose of Na 99m TcO 4 per gram of the organ (% ID/g) was determined. Results: Three days after the STZ injection, there was a decrease of Na 99m TcO 4 uptake by the liver, lungs, pancreas and kidneys (p < 0.05) in group D when compared with group A. After 15 days, the decrease of Na 99m TcO 4 uptake occurred also in the brain, thyroid, heart, spleen and blood (p < 0.05) in group D. Conclusion: We demonstrated modifications on the biodistribution of Na 99m TcO 4 due to STZ administration and schistosomiasis, possibly due to physiological alterations in some organs. Advances in Knowledge and Implications for Patient Care: The biodistribution of radiopharmaceutical

  18. Preparation and stability of the {sup 99m} Tc-HNE{sub 2} radiopharmaceutical; Preparacion y estabilidad del radiofarmaco {sup 99m} TC-HNE{sub 2}

    Energy Technology Data Exchange (ETDEWEB)

    Estrada T, J

    2002-07-01

    A radiopharmaceutical is all substance containing a radioactive atom inside of its structure and what because of its pharmaceutical form, quantity and quality of radiation can be administered in the human beings with diagnostic or therapeutic aims. With the purpose to developing effective radiopharmaceuticals it is necessary to pick carefully the appropriate radionuclide in combination with the In vivo localization and the pharmacon kinetic properties of the carrier molecule. The peptides are designed by the nature to stimulate, regulate or inhibit numerous life functions, they act mainly as information transmitters and activity coordinators of several tissues in the body; it has been found that such substances are present in cells and in the body fluids in quantities extremely small, therefore the peptides have been considered as ideal agents for therapeutic applications. Elastase of human neutrophylls is a 29 kDa protease which is produced in high levels inside the neutrophyll and it is released as response for an inflammatory stimulus in infection/inflammation places. Once it liberated is quickly inhibited by the anti elastase {alpha} tripsine (HNE-2) peptide. Therefore, the neutrophylls elastase is considered as a target to obtain In vivo images of inflammatory/infectious processes by the intravenous application of {sup 99m} Tc-HNE-2. The objective of this work was to develop a labelling method with {sup 99m} Tc for the inhibitor peptide of the human neutrophyll elastase (HNE-2). Likewise, for evaluating its In vivo and In vitro stabilities. The methodology which was followed as first step to conjugate the (HNE-2) peptide with the bi chelating agents HYNIC and DTPA capable to chelate the {sup 99m} Tc metal. Therefore the attachment reactions to the peptide were realized starting from the NHS and HYNIC and the DTPA anhydride in buffer of 0.1 M, pH= 9.0/DMF (10:1) bicarbonates with a molar relation peptide/bi chelating agent 1:5. For the purification of the

  19. Dry Kit Development And Clinical Test Of 99mTc-L,L-ECD Radiopharmaceutical For Vrain Perfusion Imaging

    International Nuclear Information System (INIS)

    Kartini, Nani; Sofyan, Rohestri; Rukmini; Iswahyudi

    2000-01-01

    Technetium- 99m ethyl cysteinate dimer ( 99m Tc-L,L-ECD) has been synthesized and formulated based on ligand exchanged reaction with 99mTc-glucoheptonate. Considering the low stability of the dry kit produced, it was fairly necessary to develop the manufacture of L,L-ECD dry kit in order to obtain a more stable one that meet the requirements as brain perfusion imaging radiopharmaceutical. Experiment was done by modifying the packing of dry kit components of the previous formulation. Characteristics of 99m Tc-L,L-ECD produced from this formulation were studied by carrying out the sterility and toxicity test, then followed with clinical test to some volunteers. Evaluation of brain perfusion was done by tomography technique using gamma camera at Nuclear Medicine Installation, Hasan Sadikin Hospital. The modified formulation obtained consist of three components i.e. main ligand L,L-ECD; exchange ligand Ca-glucoheptonate and HaOH. Its stability could reach 8 months at-10 derajat C of storage. Effects of toxicity on mice did not appear. The result of clinical study shows that the radiopharmaceutical was distributed very rapidly in the blood brain circulations and retained in the brain for about one hour. The body scanning indicates that the substance was excreted in the brain for about one hour. The body scanning indicates that the substance was excreted though kidney, liver and spleen. Based on the results obtained the radiopharmaceutical could be promoted to be used for brain perfusion imaging

  20. Determination of radiochemical yield of 99mTc radiopharmaceutical preparations using gamma counter and linear radiochromatography scanner

    International Nuclear Information System (INIS)

    Martins, Patricia de A.; Moura, Rebeca G.; Shiki, Andressa M.; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.

    2013-01-01

    The radiochemical purity (RCP) evaluation is a prerequisite for radiopharmaceuticals before the administration in patients. RCP is defined as the proportion of the total radioactivity in the product that is present in the specified chemical form. The most widely used techniques for RCP determination in radiopharmaceutical preparations are thin layer chromatography (TLC-Al), instant thin layer chromatography (ITLC-SG) and paper chromatography (PC). These techniques combined with radioactivity detection are one of the most important tools in the RCP of the radiopharmaceutical compounds. Several methods are used for the determination of the spatial distribution of radioactivity on the strips. The aim of this study was to compare two methods for radioactivity measurement in the determination of RCP in 99m Tc radiopharmaceuticals using gamma counter and linear radiochromatography scanner. Lyophilized radiopharmaceuticals were labeled with 99m Tc. The analysis was carried out using TLC-Al and high performance thin layer chromatography (HPTLC-Cellulose) sheets, ITLC-SG and 3MM Whatman PC. The radioactivity distribution was determined by counting each strip during 1 minute in a radiochromatography TLC scanner. For comparison, the strips were cut into small pieces and each one was separately measured in a gamma-counter during 0.20 minutes in 70-210 KeV 99m Tc window. USP 36 and FDA specify that not less than 90% of the total radioactivity must be in the spot corresponding to 99m Tc labeled compound. In conclusion, the procedure for RCP determination of ALBUMINA-TEC, DEX500-TEC, ECD-TEC, MACRO-TEC and MIBI-TEC can be faster using radiochromatography. (author)

  1. Determination of radiochemical yield of {sup 99m}Tc radiopharmaceutical preparations using gamma counter and linear radiochromatography scanner

    Energy Technology Data Exchange (ETDEWEB)

    Martins, Patricia de A.; Moura, Rebeca G.; Shiki, Andressa M.; Fukumori, Neuza T.O.; Matsuda, Margareth M.N., E-mail: patyosborne@yahoo.com [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2013-07-01

    The radiochemical purity (RCP) evaluation is a prerequisite for radiopharmaceuticals before the administration in patients. RCP is defined as the proportion of the total radioactivity in the product that is present in the specified chemical form. The most widely used techniques for RCP determination in radiopharmaceutical preparations are thin layer chromatography (TLC-Al), instant thin layer chromatography (ITLC-SG) and paper chromatography (PC). These techniques combined with radioactivity detection are one of the most important tools in the RCP of the radiopharmaceutical compounds. Several methods are used for the determination of the spatial distribution of radioactivity on the strips. The aim of this study was to compare two methods for radioactivity measurement in the determination of RCP in {sup 99m}Tc radiopharmaceuticals using gamma counter and linear radiochromatography scanner. Lyophilized radiopharmaceuticals were labeled with {sup 99m}Tc. The analysis was carried out using TLC-Al and high performance thin layer chromatography (HPTLC-Cellulose) sheets, ITLC-SG and 3MM Whatman PC. The radioactivity distribution was determined by counting each strip during 1 minute in a radiochromatography TLC scanner. For comparison, the strips were cut into small pieces and each one was separately measured in a gamma-counter during 0.20 minutes in 70-210 KeV {sup 99m}Tc window. USP 36 and FDA specify that not less than 90% of the total radioactivity must be in the spot corresponding to {sup 99m}Tc labeled compound. In conclusion, the procedure for RCP determination of ALBUMINA-TEC, DEX500-TEC, ECD-TEC, MACRO-TEC and MIBI-TEC can be faster using radiochromatography. (author)

  2. In vivo and in vitro study of the 99mTc-DMSA radiopharmaceutical connection to blood elements

    International Nuclear Information System (INIS)

    Freitas, Rosimeire de S.; Gomes, Maria L.; Mattos, Deise M.M.; Moreno, Silvana R.F.; Dire, Glaucio F.; Lima, Elaine A.; Lima-Filho, Guilherme L.; Aleixo, Luiz Claudio; Bernardo-Filho, Mario; Instituto Nacional do Cancer, Rio de Janeiro

    2002-01-01

    Radiopharmaceuticals are widely used in nuclear medicine. The comprehension of their uptake mechanism in target organs, as well as their clearance may depend on the elucidation of their biochemical characteristics, for instance, their binding to blood elements. The reported precipitating studies of blood with radiopharmaceuticals have shown that the results can not be easily compared. Then, we decide evaluate of the binding proteins on the blood elements using trichloroacetic acid (TCA) to determine the radioactivity of the dimercaptosuccinic acid with technetium-99m (99mTc-DMSA) present in precipitating plasma (P) and blood cells (BC). Depending on the TCA concentration we have determined different values in the insoluble fractions of the plasma when the in vivo and in vitro evaluations were carried out. (author)

  3. A new efficient method for the preparation of 99mTc-radiopharmaceuticals containing the Tc≡N multiple bond

    International Nuclear Information System (INIS)

    Pasqualini, R.; Comazzi, V.; Bellande, E.; Duatti, A.; Marchi, A.

    1992-01-01

    An improved method for the preparation of 99m Tc-radiopharmaceuticals containing the Tc≡N multiple bond, in sterile and apyrogen conditions, is described. This method is based on the reaction of [ 99m Tc] pertechnetate with ligands derived from S-methyl dithiocarbazate [H 2 N-N(R)-C(=S)SCH 3 (R = H, CH 3 )] in the presence of HC1 and tertiary phosphines. It was found that these derivatives can behave both as sources of nitride nitrogen ions (N 3- ) and as coordinating ligands. The reaction leads to the formation of intermediate technetium-nitrido complexes in high yield. These intermediate species can be used as suitable prereduced substrates for the preparation of technetium-nitrido radiopharmaceuticals through simple substitution reactions with appropriate exchanging ligands. (Author)

  4. Preparation of the radiopharmaceutical 99m Tc-HYNIC-cyclo-Lys-D-Phe-RGD for In vivo image of integrines

    International Nuclear Information System (INIS)

    Hernandez H, E.

    2007-01-01

    The diagnostic of some pathological processes by means of images constitutes one of the used methods in the determination of the origin, condition and/or evolution of one illness. The use of contrast agents in conjunction with other techniques help to the obtaining and visualization of complex systems, among these we can find to those radiopharmaceuticals used in nuclear medicine to visualize diverse organs and corporal systems. At the moment it is sought to develop a radiopharmaceutical of third generation that can be used for image In vivo of integrines with the purpose of detecting angio genesis processes, that which would allow to diagnose in way it specifies a wide range of primary tumors and their metastasis. Presently work it developed the radiopharmaceutical 99m Tc-HYNIC-cycle-Lys-D-Phe-RGD, likewise the good conditions were determined for the formation of this complex. The HYNIC was employee as chelating agent, using as co ligands EDDA and Tricine for to complete the sphere of coordination of the 99m Tc. The conjugated HYNIC-RGD was synthesized, purified, characterized and radiolabelled In situ with 99m Tc using High pressure liquid chromatography as analysis method in Reverse Phase (RP-HPLC). By this way it was developed the lyophilized formulation for its instantaneous labelled to which were carried out quality control tests. The one conjugated was obtained free of impurities, showing stability at same as their complex formed with 99m Tc. The analysis method was validated turning out to be necessary, exact, lineal and specific for the quantification of the analyte of interest. The lyophilized formulation showed a radiochemical purity bigger than 95%, besides being sterile and free of pyrogens. The biodistribution tests in athymic mice with induced tumors showed that the radiopharmaceutical was united mainly to the tumor and that this it was excreted mainly for renal via. (Author)

  5. Radiolabeling of Ceftriaxone with 99mTc as a Targeting Radiopharmaceutical for Staphylococcus Aureus Detection in Mouse Model

    International Nuclear Information System (INIS)

    Fazli, A.; Saluti, M.; Ahmadi, Gh.; Mirshojaei, F.; Mazidi, M.; Heydari, Z.

    2012-01-01

    Bacterial infection is one of the major causes of morbidity and mortality especially in developing countries. Nuclear medicine has an important role in helping the diagnosis of deep-seated infections by developing more specific radiopharmaceuticals. The aim of this study was to evaluate 99mTc-labeling ceftriaxone as a new radiopharmaceutical for Staphylococcus aureus infection imaging in nuclear medicine. Radiolabeling of ceftriaxone was carried out by adding 370 MBq of 99mTc to 10 mg of ceftriaxone in the presence of 50 μg of SnCl 2 .2H 2 O at pH=5. The radiochemical purity and stability tests at room temperature and human blood serum were evaluated with ITLC. Intramuscular infection was induced by injection of Staphylococcus aureus into the left thigh muscle of the mice. The biodistribution of 99mTc-ceftriaxone was studied in normal and infected mice at various times post-injection. Radiochemical purity of the product was 94.5±5.4% with a good stability at room temperature and human serum, 80.6% and 71.2% after 24 h, respectively. The biodistribution studies showed the localization of 99mTc-ceftriaxone at the site of infection with high sensitivity without any significant accumulation in vital organs. Due to the ease of 99mTc-ceftriaxone conjugation method, high labeling efficiency, and high uptake in the infected muscle, it may provide a promising candidate as a targeting radiopharmaceutical for imaging infectious foci due to Staphylococcus aureus in nuclear medicine.

  6. Preparation of the radiopharmaceutical {sup 99m} Tc-HYNIC-[Lys{sup 3}]-BN; Preparacion del radiofarmaco {sup 99m} Tc-HYNIC-[Lys{sup 3}]-BN

    Energy Technology Data Exchange (ETDEWEB)

    Conde S, E [Universidad Autonoma del Estado de Mexico, Facultad de Quimica, 50000 Toluca, Estado de Mexico (Mexico)

    2007-07-01

    In accordance with their design, the radiopharmaceuticals can be divided in three generations. The radiopharmaceuticals of third generation are used in nuclear medicine to obtain images of specific molecular targets, and they are only in their capacity to detect in vivo such specific biochemical places as receivers and enzymes. The receivers of regulator peptides are over expressed in numerous carcinogenic cells. Those receivers have been used as molecular targets of radiolabelled peptides to locate cancerous tumors. The small peptide bombesin (BN, 14 amino acids) it was isolated of the frog skin and it belongs to a wide neuropeptides group with many biological functions. The equivalent human is the liberator peptide of the gastrin (GRP, 27 amino acids) and his receivers (r-GRP) that are on expressed in the membranes of the tumor cells. The receiving subtype 2 of bombesin (receiving GRP) it is on expressed in several human tumors including breast, prostate, lung cells and pancreatic cancer. Some radiopharmaceuticals similar of BN has been developed that were prepared to be used in nuclear medicine for the detection of wicked tumors and to evidence prostate cancers, breast and of lymphatic nodules. A technique was developed to allow the conjugation of HYNIC-[Lys3]-BN that allowed to obtain this product with a high purity. The identity was determined by HPLC chromatography. It was necessary the validation of the method and the HPLC system, to assure that the results were reliable. Linearity, specificity, accuracy and precision parameters were analyzed, that are those required by the Mexican pharmacopoeia for chromatographic methods. With this conjugated a formulation for lyophilized kits were analyzed, with the purpose of obtaining a radiochemical purity, after the labelled one with {sup 99m}Tc, bigger to 95%; the components used in the nucleus-equipment should favor the conjugation of the {sup 99m}Tc by means of a ligands exchange between the tricine and the

  7. In Vitro Evaluation of Tc-99m Radiopharmaceuticals for Gastric Emptying Studies

    Directory of Open Access Journals (Sweden)

    Türkan Ertay

    2014-02-01

    Full Text Available Objective: Gastrointestinal motility and functional motility disorders causing either delayed or accelerated gastric emptying (GE may result in similar symptoms including nausea, vomiting, early satiety, fullness, bloating, and abdominal discomfort or pain. Hence, it is important to evaluate patients for both rapid and delayed GE in the same test. The gold standard technique to measure GE is scintigraphy by radiolabeled test meals. The aim of this study was to test alternative Tc-99m agents to label eggs as the solid meal and compare to Tc-99m sulfur colloid (SC for gastric emptying studies. Methods: In search of alternative agents for gastric emptying studies, we mixed and fried eggs with four different particulate compounds (Tc-99m labeled SC, tin colloid, nanocolloid and MAA, as well as with free pertechnetate and Tc-99m DTPA. We then measured the stability of these compounds in simulated gastric juice. Results: Our experiments demonstrated that in addition to Tc-99m sulfur colloid;Tc-99m MAA, Tc-99m nanocolloid and Tc-99m tin colloid also appear to make stable complexes with eggs in acidic environment. Conclusion: Therefore, these agents may be used for gastric emptying studies which could be more practical in routine conditions.

  8. 99m Tc-labeled dendrimers as a potential radiopharmaceutical for tumor diagnosis process

    International Nuclear Information System (INIS)

    Tassano Hartwich, M.

    2008-01-01

    The present thesis to access the Bachelor of Biological Sciences studies the following: biology, molecular biology, pathology, radiotherapy, radiopharmaceuticals, research techniques and malignant neoplasms

  9. Effect of iron deficiency anemia on the biodistribution of 99mTc radiopharmaceuticals

    International Nuclear Information System (INIS)

    Calmanovici, Gabriela P.; Salgueiro, Maria J.; Janjetic, Mariana A.; Leonardi, Natalia M.; Boccio, Jose R.; Zubillaga, Marcela B.

    2006-01-01

    The distribution of colloids and labeled cells in organs is influenced by their intrinsic properties and by the state of the investigated subject. Iron deficiency remains an unsolved nutritional problem all over the world; one of its severe consequences is anemia. Because iron metabolism principally takes place in the liver, spleen, bone marrow, skeletal muscle and blood, we studied the effect of iron deficiency anemia on the biodistribution of 99m Tc phytate, 99m Tc gelatin colloid and 99m Tc RBC (red blood cells labeled with 99m Tc). Our results show that iron deficiency anemia modifies the pattern of biodistribution of the two colloids assayed. However, this behavior is different for both of them. This work contributes to studies that kinetically and statistically establish that iron deficiency anemia induces a significant inversion in the spleen-liver activity relationship when centellographic studies are performed with colloids such as 99m Tc phytate

  10. Study of technetium behaviour in radiopharmaceuticals. Characterization of sup(99m)Tc-pyrophosphate, sup(99m)Tc-dimercaptosuccinate, sup(99m)Tc-diethylenetriaminepentaacetate complexes and sup(99m)Tc-colloidal rhenium sulphide

    International Nuclear Information System (INIS)

    Saccavini, J.-C.

    1980-12-01

    The chemistry of technetium in extremely dilute solution was approached through the study of three complexing agents and a colloid. By the application of high-performance chromatographic techniques to the analysis of (Tc-pyro), (Tc-DTPA), (Tc-DMSA) complexes it was possible to isolate one or more chelates from a single complexing agent. Addition of pertechnetates to a solution of sodium pyrophosphates and stannous chloride at neutral pH leads to the formation of two complexes, both highly osteotropic. By the use of sup(117m)Sn it was shown that tin employed as reducing agent enters into the composition of one of the two complexes, either of which may be obtained preferentially by varying the (Sn)/(pyro) ratio. With technetium at acid pH (2.5) DMSA gives one or more chelates according to the concentration of the reagents present. DTPA with technetium at neutral pH gives a single complex for which a structure is proposed. The addition of calcium, indispensable for DTPA injection, leads to the appearance of a second bimetallic complex in very much smaller proportions than the first. The size distribution of some colloids was studied by ultrafiltration and permeation on gel. The preparation of colloidal rhenium sulphide and the technetium labelling conditions needed to obtain a very fine colloid were developed. The behaviour of technetium in the presence of colloidal rhenium sulphide and tin pyrophosphate was followed by sup(99m)Tc - sup(186)Re and sup(99m)Tc - sup(117m)Sn double-labelling tests. One reduced technetium fraction associates with the hydrolysed tin, the other follows the rhenium sulphide [fr

  11. The impact of technetium-99m-radiopharmaceuticals' design on their biological behavior

    International Nuclear Information System (INIS)

    Jankovic, D.Lj.; Djokic, D.Dj. . E-mail address of corresponding author: drinaj@vin.bg.ac.yu; Jankovic, D.)

    2005-01-01

    The coordination has a great and not always predictable impact on the in-vivo behaviour of the small molecule into which the technetium-bearing chelate units is integrated. The different valence state of technetium in the complexes with some ligands changes the properties of these complexes, such as physico-chemical parameters and biological behaviour. The change of their biological behaviour has a great impact on quality of imaging study and on radiation dose to the patient. The results of the labelling of DPD and EHIDA with 99mTc(I) and their biological behaviour, in comparison with the same one for 99mTc(III)-DPD and 99mTc(III)-EHIDA complexes, confirmed that different oxidation state of 99mTc make possible forming variety of complexes with quite a different and unexpected biological behaviour. (author)

  12. Active and passive vectorization of technetium99m and 188rhenium radiopharmaceuticals for medical imaging and radiotherapy

    International Nuclear Information System (INIS)

    Lepareur, N.

    2003-11-01

    Research for new molecules for nuclear medicine is a field in constant development. Over the past few years, development of new radiopharmaceuticals for radiotherapy has renewed interest for rhenium chemistry. Indeed, its two isotopes 186 Re and 188 Re, owing to their ideal properties and their similitude with 99m Tc, which is widely used as a radiotracer for diagnostic imaging, seem very promising for the preparation of radiopharmaceuticals. In the first part of this manuscript, the synthesis of rhenium and technetium-99 complexes, [M(RPhCS3)2(RPhCS2)] (M = Re, Tc), is described. The preparation of technetium 99m based radiopharmaceuticals, analogues to the pondered complexes, is also described. The stability/reactivity of these complexes has been studied by exchange reactions with potential ligands, specially dithiocarbamates, and also by UV-visible absorption spectroscopy and thermogravimetry. The reactivity of the complexes towards dithiocarbamates leads to the possibility to bind biomolecules to the metallic core, via the dithiocarbamate moiety. This method represents a potential alternative to current ones using the so-called bifunctional approach. In the second part of this manuscript, a new kit formulation for the 188 Re labeling of lipiodol is described, using a complex analogous to those described in the previous part. The labeled oil is a potential cure for hepatocellular carcinoma. The in vitro and in vivo stability of this 188 Re-SSS lipiodol and of its analogue 99m Tc-SSS lipiodol has been studied, and also their in vivo behavior in healthy pigs. This study has shown the quasi-exclusive hepatic fixation of the radiopharmaceutical, and has proven its good stability. Its selectivity for tumors remains to be shown before trying it on humans. (author)

  13. Thymidine kinase enzyme selective imaging radiopharmaceutical. {sup 99m}Tc(CO){sub 3}-Ganciclovir

    Energy Technology Data Exchange (ETDEWEB)

    Gedik, B.; Teksoez, S.; Ichedef, C.; Kilcar, A.Y.; Medine, E.I.; Ucar, E. [Ege Univ., Bornova, Izmir (Turkey). Dept. of Nuclear Applications

    2013-03-01

    The aim of this study is to radiolabel Ganciclovir, known as having selective antiviral properties against thymidine kinase, with technetium tricarbonylcore ({sup 99m}Tc(CO){sub 3}{sup +}) and to investigate the biological behavior of this complex in vitro and in vivo. Commercially provided Ganciclovir (GCV) was radiolabeled with {sup 99m}Tc(CO){sub 3}{sup +}. Initially, optimum radiolabeling conditions were determined by analyzing factors such as temperature, pH and time. Quality control of the radiolabeled compound was performed. The radiolabeling yield was found to be 97%. The {sup 99m}Tc(CO){sub 3}-GCV complex also displayed good in vitro stability during the 24 h period. In vitro cell uptake studies showed that the {sup 99m}Tc(CO){sub 3}-GCV complex is highly uptaken in A-549, PC-3, HeLa cell lines according to the control group {sup 99m}Tc(I)-tricarbonyl core. The knowledge gained from in vivo and in vitro studies of {sup 99m}Tc(CO){sub 3}-GCV could contribute to the development of a new HSV1-tk gene imaging agent. (orig.)

  14. Evaluation of 99mTcN-moxifloxacin dithiocarbamate, as a potential radiopharmaceutical for scintigraphic localization of infectious foci

    International Nuclear Information System (INIS)

    Syed Qaiser Shah; Muhammad Rafiullah Khan

    2011-01-01

    In the current study radio complexation of the moxifloxacin dithiocarbamate (MXND) with technetium-99m ( 99m Tc) using the [ 99m Tc-N] 2+ core through legend exchange reaction was explored. The 99m TcN-MXND complex was biologically evaluated as a potential radiopharmaceutical for in vivo scintigraphy using artificially infected male sprague-dawley rats (MSDR) with Staphylococcus aureus (S. aureus). The radiochemistry of the complex was explored in terms of radiochemical purity (RCP), in vitro stability in serum at 37 deg C for 16 h, in vitro binding with S. aureus and biodistribution in artificially infected with S. aureus MSDR. It was observed that the complex showed stability of more than 90% up to 4 h after reconstitution with a maximum RCP value of 97.55 ± 0.42% at 30 min. The complex showed significantly in vitro stability in serum at 37 deg C with an insignificant free species up to 16.50% within 16 h. In vitro saturated binding with S. aureus was noted up to 120 min with maximum value of 73.25% at 90 min of incubation. Almost sixfold uptake was noted in the infected muscle of the MSDR as compared to inflamed and normal muscle. The 97.55 ± 0.42% RCP values, stability in serum with insignificant untagged 16.50% species, 73.25% in vitro binding with S. aureus and sixfold uptake in the target organ posed the 99m TcN-MXND complex as a promising radiopharmaceutical for S. aureus infectious foci. (author)

  15. Instant thin layer chromatography (ITLC) - the most true and convenient method for the determination of radiochemical purity of Tc-99m Labeled radiopharmaceuticals

    International Nuclear Information System (INIS)

    Anwar-Ul-Azim, M.; Ansari, M.I.H.

    2007-01-01

    Full text: Determination of radiochemical purity usually involves paper chromatography method or some column chromatography such as ion exchange or gel filtration technique. In this study, a modified chromatography method with thin-layer support called instant thin Layer chromatography (ITLC) was used for the measurement of radiochemical purity. The aim of the study was to present instant thin layer chromatography-Silica-Gel (ITLC-SG) technique as a fairly rapid , convenient and inexpensive system for the screening of radiochemical impurities of 99mTc-labeled radiopharmaceuticals resulting from physical , chemical and/or radiation decomposition. Materials and Methods: The experiment was carried out at the Institute of Nuclear Medicine and Ultrasound, Dhaka for a period of 10 months from August '05 to May '06. Radiochemical purity of seven types of 99mTc-labeled radiopharmaceuticals, namely 99mTc-DTPA,99mTc- MI I, 99m Tc - HDP, 99m Tc - DMSA, 99m Tc - Tetofosmin, 99mTc-Fyton and 99mTc-ECD were measured by the use of two solvent dual-instant thin layer chromatography systems. Commercially available instant thin layer chromatography plate ( 20cm x20cm) impregnated with silica gel (ITLC-SG: Merck, Germany) was used as a stationary phase for the measurement of radiochemical impurities.Acetone, Ethyl methyl ketone, chloroform and methanol were used to measure the amount of free pertechnetate in the labelled radiopharmaceuticals and 0.9% saline was used in all cases as solvent (Mobile phase) to measure the amount of the hydrolyzed-reduced technetium colloid. Results: The results showed that the measured radiochemical purity of 99mTc-DTPA, 99mTc-MIBI, 99mTc-HDP, 99mTc-DMSA, 99mTc-Tetofosmin, 99mTc-Fyton and 99mTc-ECD were acceptable for all the studied samples except two samples of 99mTc-MIBI, one sample of 99mTc-Fyton and two samples of 99mTc-ECD, where the measured radiochemical purity were not within the acceptable RCP limits of commonly used radiopharmaceuticals (RCP

  16. Effect of iron deficiency anemia on the biodistribution of {sup 99m}Tc radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Calmanovici, Gabriela P. [Radioisotopes Laboratory, Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina); Salgueiro, Maria J. [Radioisotopes Laboratory, Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina); Janjetic, Mariana A. [Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina); Leonardi, Natalia M. [Radioisotopes Laboratory, Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina); Boccio, Jose R. [Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina); Zubillaga, Marcela B. [Radioisotopes Laboratory, Physics Department, School of Pharmacy and Biochemistry, University of Buenos Aires, Junin 956 - 1113, Buenos Aires (Argentina)]. E-mail: mzubi@ffyb.uba.ar

    2006-05-15

    The distribution of colloids and labeled cells in organs is influenced by their intrinsic properties and by the state of the investigated subject. Iron deficiency remains an unsolved nutritional problem all over the world; one of its severe consequences is anemia. Because iron metabolism principally takes place in the liver, spleen, bone marrow, skeletal muscle and blood, we studied the effect of iron deficiency anemia on the biodistribution of {sup 99m}Tc phytate, {sup 99m}Tc gelatin colloid and {sup 99m}Tc RBC (red blood cells labeled with {sup 99m}Tc). Our results show that iron deficiency anemia modifies the pattern of biodistribution of the two colloids assayed. However, this behavior is different for both of them. This work contributes to studies that kinetically and statistically establish that iron deficiency anemia induces a significant inversion in the spleen-liver activity relationship when centellographic studies are performed with colloids such as {sup 99m}Tc phytate.

  17. Sup(99m)Tc-Sn-pyrophosphate complex. A stable, lyophilized radiopharmaceutical for skeletal scanning

    Energy Technology Data Exchange (ETDEWEB)

    Cvoric, J; Jovanovic, V; Bzenic, J [Institut za Nuklearne Nauke Boris Kidric, Belgrade (Yugoslavia); Stefanovic, Lj; Selir, Z [Institute for Tuberculosis and Pectoral Diseases, Radioisotope Applications, Sremska Kamenica (Yugoslavia)

    1978-01-01

    After a systematic investigation of the different phosphate polymers, viz. hexametaphosphate, tripolyphosphate, meta- and diphosphonate, pyrophosphate (Na/sub 4/P/sub 2/O/sub 7/) was selected for sceletal scintigraphy. A procedure has been developed for obtaining a sup(99m)Tc-labelled Sn(II): PyP complex by addition of a sterile, apyrogenic pertechnetate solution from a sup(99m)Tc-generator to a lyophilized solution of Sn(II)-tetrasodium phosphate. ''Kit'' composition was determined on the basis of biodynamic data obtained when the Sn/pyrophosphate ratio, pH and other parameters were varied. In vivo distribution of different sup(99m)Tc-Sn-pyrophosphate complexes permitted the selection of the most suitable complex for sceletal scanning. The investigated complex is being successfully applied in human scintigraphy of bones in the Laboratory for Radioisotope Applications of the Institute for Tubercolosis and Pectoral Diseases in Sremska Kamenica.

  18. Effect of acidity and chemical composition of sup(99m)Tc-radiopharmaceuticals on sup(99m)Tc accumulation in necrotic tissue of rat myocardium

    Energy Technology Data Exchange (ETDEWEB)

    Vilcek, S; Machan, V; Kalincak, M [Ustav Radioekologie a Vyuzitia Jadrovej Techniky, Kosice (Czechoslovakia); Nicak, A [Univerzita P.J. Safarika, Kosice (Czechoslovakia). Lekarska Fakulta

    1981-04-30

    Experiments showed that the cumulation of technetium-99m following the administration of /sup 99m/Tc-Sn-pyrophosphate and s/sup 99m/Tc-Sn-oxytetracycline in the necrotic tissue of rat myocardium damaged by cauterization depended on the end pH value. The maximum /sup 99m/Tc cumulation in the myocardial lesion was noted when the end pH value ranged in 5.5 to 6.0. It appeared that pyrophosphate concentration decrease below the critical limit not only affected the cumulation of /sup 99m/Tc in the particular organs but also in the necrotic tissue of the myocardium.

  19. Effect of acidity and chemical composition of sup(99m)Tc-radiopharmaceuticals on sup(99m)Tc accumulation in necrotic tissue of rat myocardium

    International Nuclear Information System (INIS)

    Vilcek, S.; Machan, V.; Kalincak, M.; Nicak, A.

    1981-01-01

    Experiments showed that the cumulation of technetium-99m following the administration of sup(99m)Tc-Sn-pyrophosphate and sup(99m)Tc-Sn-oxytetracycline in the necrotic tissue of rat myocardium damaged by cauterization depended on the end pH value. The maximum sup(99m)Tc cumulation in the myocardial lesion was noted when the end pH value ranged in 5.5 to 6.0. It appeared that pyrophosphate concentration decrease below the critical limit not only affected the cumulation of sup(99m)Tc in the particular organs but also in the necrotic tissue of the myocardium. (author)

  20. Experimental biodistribution studies of 99mTc-recombinant human serum albumin (rHSA): a new generation of radiopharmaceutical

    International Nuclear Information System (INIS)

    Perkins, A.C.; Frier, M.

    1994-01-01

    Recombinant human serum albumin (rHSA) produced by cultured fermentation has been prepared in the form of microcapsules nominally 3-5 μm in diameter and radiolabelled with technetium-99m following reduction with stannous chloride. Radiochemical purity was assessed by chromatography on instant thin-layer chromatography and found to be greater than 90%. No evidence of aggregation was seen by microscopic examination. Imaging biodistribution studies in New Zealand white rabbits demonstrated targeting to the liver or lung, respectively, depending upon the size and surfactant properties of the microcapsules. This communication is the first to show scintigraphic studies using 99m Tc-labelled rHSA with the potential for lung, liver and cardiovascular imaging and demonstrates that recombinant DNA technology offers an important new source of materials suitable for use as radiopharmaceuticals without the need for pooled human blood products. (orig.)

  1. Preparation, chromatographic evaluation and biodistribution of {sup 99m}Tc-procainamide as a radiopharmaceutical for heart imaging

    Energy Technology Data Exchange (ETDEWEB)

    Motaleb, M.A.; Ibrahim, I.T.; Abo Rizq, R.S. [Atomic Energy Authority, Cairo (Egypt). Labeled Compound Dept.; Elzanfaly, E.S. [Cairo Univ. (Egypt). Analytical Dept.

    2017-06-01

    Procainamide (4-amino-N-[2-(diethylamino) ethyl] benzamide) is a sodium channel blocker, which acts as an effective antiarrhythmic agent used in the treatment of a variety of atrial and ventricular arrhythmias. The aim of this study was to prepare {sup 99m}Tc-procainamide complex, apply different chromatographic techniques for the assay of radiolabeling yield and study its biodistribution as a novel radiopharmaceutical for heart imaging. {sup 99m}Tc-procainamide was obtained with a maximum labeling yield of 95.76±0.20% via direct labeling method under optimum conditions of 200 μg of procainamide, 300 μL of buffer (carbonate) at pH 11, 30 μg SnCl{sub 2} . 2H{sub 2}O at room temperature (25 C) for 15 min. In terms of in vitro stability, the complex was stable for 3 h. Chromatographic evaluation using paper chromatography, thin layer chromatography, gel chromatography, and high performance liquid chromatography showed reliable results for measuring the radiochemical yield. Biodistribution study of {sup 99m}Tc-procainamide showed ratios of heart/lung and heart/liver (6.38±1.50, 2.06±0.31, respectively at 30 min post injection) which was comparable to that of {sup 99m}Tc-sestamibi (7.4±2.00, 0.97±0.10, respectively at 60 min, P<0.05).

  2. Preparation, chromatographic evaluation and biodistribution of "9"9"mTc-procainamide as a radiopharmaceutical for heart imaging

    International Nuclear Information System (INIS)

    Motaleb, M.A.; Ibrahim, I.T.; Abo Rizq, R.S.; Elzanfaly, E.S.

    2017-01-01

    Procainamide (4-amino-N-[2-(diethylamino) ethyl] benzamide) is a sodium channel blocker, which acts as an effective antiarrhythmic agent used in the treatment of a variety of atrial and ventricular arrhythmias. The aim of this study was to prepare "9"9"mTc-procainamide complex, apply different chromatographic techniques for the assay of radiolabeling yield and study its biodistribution as a novel radiopharmaceutical for heart imaging. "9"9"mTc-procainamide was obtained with a maximum labeling yield of 95.76±0.20% via direct labeling method under optimum conditions of 200 μg of procainamide, 300 μL of buffer (carbonate) at pH 11, 30 μg SnCl_2 . 2H_2O at room temperature (25 C) for 15 min. In terms of in vitro stability, the complex was stable for 3 h. Chromatographic evaluation using paper chromatography, thin layer chromatography, gel chromatography, and high performance liquid chromatography showed reliable results for measuring the radiochemical yield. Biodistribution study of "9"9"mTc-procainamide showed ratios of heart/lung and heart/liver (6.38±1.50, 2.06±0.31, respectively at 30 min post injection) which was comparable to that of "9"9"mTc-sestamibi (7.4±2.00, 0.97±0.10, respectively at 60 min, P<0.05).

  3. sup(99m)Tc-pyridoxylidene glutamate - a radiopharmaceutical for the hepatobiliary system

    International Nuclear Information System (INIS)

    Noronha, O.P.D.; Sewatkar, A.B.; Ganatra, R.D.; Subramanian, G.

    1976-01-01

    sup(99m)Tc-pyridoxylidene glutamate is a good agent to visualize the hepatobiliary system. The method of preparation and quality control, and preliminary data on its behaviour in human controls is presented. In humans the gall bladder could be well seen in about 15-20 minutes after intravenous injection. (orig.) [de

  4. Radiosynthesis and Biodistribution of 99mTc-Metronidazole as an Escherichia coli Infection Imaging Radiopharmaceutical.

    Science.gov (United States)

    Iqbal, Anam; Naqvi, Syed Ali Raza; Rasheed, Rashid; Mansha, Asim; Ahmad, Matloob; Zahoor, Ameer Fawad

    2018-05-01

    Bacterial infection poses life-threatening challenge to humanity and stimulates to the researchers for developing better diagnostic and therapeutic agents complying with existing theranostic techniques. Nuclear medicine technique helps to visualize hard-to-diagnose deep-seated bacterial infections using radionuclide-labeled tracer agents. Metronidazole is an antiprotozoal antibiotic that serves as a preeminent anaerobic chemotherapeutic agent. The aim of this study was to develop technetium-99m-labeled metronidazole radiotracer for the detection of deep-seated bacterial infections. Radiosynthesis of 99m Tc-metronidazole was carried by reacting reduced technetium-99m and metronidazole at neutral pH for 30 min. The stannous chloride dihydrate was used as the reducing agent. At optimum radiolabeling conditions, ~ 94% radiochemical was obtained. Quality control analysis was carried out with a chromatographic paper and instant thin-layer chromatographic analysis. The biodistribution study of radiochemical was performed using Escherichia coli bacterial infection-induced rat model. The scintigraphic study was performed using E. coli bacterial infection-induced rabbit model. The results showed promising accumulation at the site of infection and its rapid clearance from the body. The tracer showed target-to-non-target ratio 5.57 ± 0.04 at 1 h post-injection. The results showed that 99m Tc-MNZ has promising potential to accumulate at E. coli bacterial infection that can be used for E. coli infection imaging.

  5. The influence of reducing agents on the composition of technetium-99 complexes: implications for technetium-99m radiopharmaceutical preparation

    International Nuclear Information System (INIS)

    Baldas, J.; Bonnyman, J.; Pojer, P.M.; Williams, G.A.

    1981-05-01

    The use of hydrazine or formamidine sulphinic acid as reducing agents in the presence of 99 Tc-pertechnetate anion and the diethyldithiocarbamate ligand has been found to yield complexes containing Tc triple bond N and Tc=CO bonds respectively. The nitrido nitrogen atom and the carbon monoxide incorporated in these complexes as ligands originate from the reducing agents themselves. It is apparent that when reducing agents such as hydrazine or formamidine sulphinic acid are used in the preparation of Tc-99m-radiopharmaceuticals, the possibility of the formation of complexes structurally different to those obtained by use of stannous chloride must be considered

  6. Production of radiopharmaceutical 99mTc using wasteless reactor Zr-Mo gel-technology

    International Nuclear Information System (INIS)

    Savushkin, I.; Gurko, O.; Ravkova, E.

    2002-01-01

    An original methodology and technological process of the wasteless reactor gel-technology of 99m Tc producing on the basis of centralised Zr-Mo gel-generator have been developed by the Institute of Power Engineering Problems, National Academy of Sciences of Belarus in co-operation with the Research Institute of Oncology and Medical Radiology, Ministry of Health of Belarus. This approach allows 99m Tc to be produced on the basis of MoO 3 with an 99 Mo activity of 3-20 Ci. The technological process of 99m Tc sodium pertechnetate production is remotely controlled and automated. Based on clinical tests performed by the Ministry of Health of Belarus, the clinical application of 99m Tc produced by this technology has been approved. The irradiation conditions of the target, consequence of technological process, technological yield of objective product on the example of operation of one generator, reprocessing and rendering of the wastes are analysed and described. The distinctive features of the technology developed are as follows: (a) Use of native molybdenum as the starting target. (b) Absence of deleterious and toxic impurities from the final product (nitrates, organics, etc.). (c) Application of a modified method of 99m Tc extraction from 99 Mo with the help of the Zr-Mo-gel (that is, application of a true gel, not the powder obtained by gel drying), reducing the number of process stages and simplifying the technology. (d) Easy automation and remote control. (e) Simplicity of design and compactness, opening up wide application fields for the unit. It is suggested that clinical centres should be equipped with centralised high-performance 99m Tc generators. Such centres can supply 99m Tc sodium pertechnetate daily to radioisotope laboratories within the radius of 100 km. Technical and economic calculations show that the centralised gel-generators possess industrial, technical and economic parameters making them superior to small/portable generators based on loading with

  7. Testing the radiochemical purity of a radiopharmaceutical: study of 99mTc-Tetrofosmin (Myoview)

    International Nuclear Information System (INIS)

    Moati, F.; Quartarone, C.; Jourdain, J.R.; Rizzo, N.; Dumont, A.; De Beco, V.; Ait Ben Ali, S.; Lours, S.; Piketty, M.L.; Izembart, M.; Goudou, C.; Lemercier, V.; Schlageter, M.H.; Moretti, J.L.; Progent, A.

    1997-01-01

    The goal of this study is to optimize the testing method of radiochemical purity (RCP) of 99m Tc-Tetrofosmin proposed by the Amersham Company: thin-layer chromatography (TLC); ITLC-SG support, migration on 15 Cm; acetone-dichloromethane mobile phase, (35/65, v/v), This technique allows separating the reduced-Tc (Rf = 0), the TcO 4 - (Rf = 1), and in intermediary position (0.2 99m Tc-Tetrofosmin. The results of RCP depend on working conditions, particularly, on the volume of deposit (10 to 20 μl, expected). If the deposited is too small, the 99m Tc-Tetrofosmin does not migrate. With a volume of 20 μl, the separation is weak and the peak width is un-resolvable. The results obtained correspond to the following operational conditions: migration on 8 cm; deposit of 8 to 10 μl; no drying. In these conditions the peak of 99m Tc-Tetrofosmin is well singled out: migration Rf of 0.375 to 0.625. These results have been obtained by the analysis of radio-chromatographic peak. Every strip has been cut cm by cm and the activity was measured by a gamma counter. Repeatability of the method on a series of 8 tests is good: average RCP 93.22%, mean value = 93.24%. The reproducibility was realized by measuring directly by the activity-meter the activity corresponding to 3 identifiable peaks: Reduced Tc (Rf 4 - (Rf 99m Tc-Tetrofosmin (0.25 < Rf < 0.75). On the 21 effectuated tests the inter-test RCP reproducibility was good: average value = 95.24%, CV = 2.07%, mean value 95.3%). In conclusion, the miniaturization improves the separation by Myoview (0.25 < Rf < 0.75), diminishes the migration time by a factor 4 and lowers the reactive cost of testing by 50%

  8. Method for preparing 99mTc-labelled radiopharmaceuticals for myocardial scintigraphy

    International Nuclear Information System (INIS)

    Seifert, S.; Syhre, R.; Muenze, R.

    1987-01-01

    Radiopharmaceuticals which preferably concentrate in myocardial tissue are prepared, in particular technetium compounds with the reducing ligand molecule DMPE. A method is introduced to convert pertechnetate in one step into the proposed compound by means of a saline, slow-oxidizing and lyophilized form of the reducing ligand DMPE, preferably DMPE x 2HCl

  9. Preparation of i.v. 99mTc radiopharmaceuticals from spent moly 99Mo

    International Nuclear Information System (INIS)

    Noronha, O.P.D.

    1998-01-01

    Full text: Expiry dating is an important quality assurance precept in (radio) pharmacy. There are occasions when for the sake of patient service one may be forced to continue using an over aged source of 99 Mo to generate 99m Tc beyond 7d, especially when there is short/no supply of 99 Mo, (In the early days the expiry date was 3 d or 3 extractions, whichever one was earlier). With the passage of time a few physico-chemical changes (apart from decay) do occur in the 99 Mo/ 99m Tc milieu. The cocktail also begins to contain traces of carried over MEK which is subjected to strong β-, γ irradiation. These impurity (in trace amounts) is soluble in MEK and even, to an extent, in aqueous media. Furthermore, the concentrated impurity tends to seemingly increase in the bulk 99m TcO 4 - since one is compelled to leach TcO 4 - in lower volume of saline. On many occasions we have been constrained to extend the use of 99 Mo beyond 7 - 14 d. Adequate activities were obtained by pooling the previous week's lot of 99 Mo with the current over aged lot. On a few occasions over the past 26 years we have used 99 Mo much beyond 14 d and 2 - 3 occasions for 26 - 28 d (i.e. >10 t 1 /2 of 99 Mo). On each of these occasions the purity of 99m TcO- 4 was ascertained by pharmacopoeial procedures. It was found that despite depleting activities, the purity was not compromised and the trace impurities, even if present, did not cause any interference. We have profitably utilised the bulk TcO- 4 to formulate a variety of i.v. dosage forms of 99m Tc radiodiagnostics. The following strategy was adopted for the patient services - the agents requiring larger activity levels/patients dose were made available in the earlier period, the other during the latter half. It is concluded that pure 99m TcO- 4 can be obtained over the entire useful life-period of 99 Mo, even > 10t l/2

  10. Technetium-99m spiperone dithiocarbamate: a potential radiopharmaceutical for dopamine receptor imaging with SPECT

    Energy Technology Data Exchange (ETDEWEB)

    Ballinger, J R; Gulenchyn, K Y; Hassan, M N [Ottawa Civic Hospital (Canada). Div. of Nuclear Medicine and Neurology; Ottawa Univ., ON (Canada))

    1989-01-01

    Spiperone dithiocarbamate (SPDC) was prepared by reacting spiperone with carbon disulfide followed by sodium hydroxide. SPDC was labelled with {sup 99m}Tc by reduction of pertechnetate with formamidine sulfinic acid or sodium pertechnetate with formamidine sulfinic acid or sodium dithionite at alkaline pH, resulting in {similar to} 40% incorporation of {sup 99m}Tc. The lipophilic complex was conveniently isolated at high specific activity and high radiochemical purity by extraction into dichloromethane, which was then evaporated and the residue was redissolved in a 1:3 mixture of ethanol and saline containing 0.1mg/ml gentisic acid. Biodistribution studies following i.p. injection in rats showed low uptake of radioactivity in the brain, but striatum/cortex and striatum/cerebellum ratios were reduced by pretreatment with haloperidol. This agent may allow imaging of dopamine D-2 receptors using single-photon emission computed tomography (SPECT). (author).

  11. Tumor imaging using Tc(V)-99m dimercaptosuccinic acid, a newly developed radiopharmaceutical

    International Nuclear Information System (INIS)

    Ohta, Hitoya; Endo, Keigo; Koizumi, Mitsuru

    1985-01-01

    Being aware of the ideal nuclear properties of Tc-99m, we have developed a new tumor seeking agent, Tc-99m (V) dimercaptosuccinic acid (Tc(V)-DMS). In order to evaluate its clinical usefulness of Tc(V)-DMS, 400 untreated patients with histologically proven diagnoses were studied, and, in some selected cases, the results were compared with those of Ga-67 citrate. The Tc(V)-DMS scintigraphy was found especially useful in patients with head and neck tumors, medullary thyroid carcinomas, soft tissue tumors and bone tumors. But in patients with lung tumors, liver tumors, malignant melanoma or malignant lymphomas, it revealed no obvious advantage over Ga-67 scintigraphy, the results seemed to the different uptake mechanism of Tc(V)-DMS from that of Ga-67 citrate. Nevertheless the superiority of physical properties of Tc-99m, pharmacological advantage that may enable satisfactory imaging, and lower supply cost, Tc(V)-DMS would certainly offer good clinical applicability in some regions. (author)

  12. Impurities in Tc-99m radiopharmaceutical solution obtained from Mo-100 in cyclotron.

    Science.gov (United States)

    Tymiński, Zbigniew; Saganowski, Paweł; Kołakowska, Ewa; Listkowska, Anna; Ziemek, Tomasz; Cacko, Daniel; Dziel, Tomasz

    2018-04-01

    The gamma emitting impurities in 99m Tc solution obtained from enriched molybdenum 100 Mo metallic target after its irradiation in a cyclotron were measured using a high-purity germanium (HPGe) detector. The radioactivity range of tested samples of 99m Tc was rather low, in the range from 0.34 to 2.39 MBq, thus creating a challenge to investigate the standard measurement HPGe system for impurity detection and quantification. In the process of 99m Tc separation from irradiated target the AnaLig® Tc-02 resin, Dionex H + and Alumina A columns were used. Fractions of eluates from various steps of separation process were taken and measured for radionuclidic purity. The overall measurement sensitivity of gamma emitters in terms of minimum detectable activity (MDA) was found at the level of 14-70Bq with emission lines in range of 36 - 1836keV resulting in impurity content range of 6.7 × 10 -4 to 3.4 × 10 -3 % for 93 Tc, 93m Tc, 94 Tc, 94m Tc, 95 Tc, 95m Tc, 96 Tc 96 Nb, 97 Nb, 99 Mo contaminants and 9.4 × 10 -3 % for 97m Tc. The usefulness of the chosen measurement conditions and the method applied to testing the potential contaminators was proved by reaching satisfactory results of MDAs less than the criteria of impurity concentration of all nuclides specified in the European Pharmacopoeia. Copyright © 2017 Elsevier Ltd. All rights reserved.

  13. sup(99m)Tc-unithiol complex, a new radiopharmaceutical for kidney scintigraphy. Pt. 3

    International Nuclear Information System (INIS)

    Darte, L.; Oginski, M.; Persson, R.B.R.

    1979-01-01

    Labeling of 2,3-dimercaptopropane sodiumsulphonate (Unithiol) with sup(99m)Tc resulted in essentially three components in the GCS profile: the top zone, a low-molecular Complex A and a high-molecular Complex B. In the presence of tin metal a fourth component, Complex C, could be distinguished. Complex A was relatively independent of pH, the proportion of Complex B increased with increasing pH. Methods were developed for preparing, with over 80% labelling efficiency, either Complex A or Complex B, each having high stability in the preparation vials and in human blood. (orig.) [de

  14. Obtaining a metastasis model in vivo for the evaluation of the radiopharmaceuticals sensitivity labeled with 99mTc

    International Nuclear Information System (INIS)

    Gonzalez A, V. M.

    2015-01-01

    Nuclear medicine currently has a wide range of techniques that support the diagnosis of various diseases, including cancer that prevails as the most important. In the present research work was proposed to develop a model that would study the process known as metastasis, because this process is vital because most of the deaths in patients with some form of cancer are caused by metastasis. The objective was to obtain an in vivo model of metastasis induced with AR42J cells for studying the radiopharmaceuticals sensitivity labeled with 99m Tc. To achieve the objective proposed a study model in which it could make a real time evaluation of some radiopharmaceuticals with reported efficiency was development, in order to determine their sensitivity in similar conditions to the metastasis process. This required a mouse model that was used to observe a similar process to metastasis, inducing cells of the AR42J cell line, since these cells have good proliferation and have molecular targets for a minimum of 3 standardized radiopharmaceuticals. Was elected radionuclide 99m Tc, because of its low emission of radiation into the tissues, besides having a half life of 6 hours and provides a good visualization of anatomical structures. On the other hand the stable expression of green fluorescent protein in tumor cells appears to be a suitable tool for the detection of cancer development in early stages and the formation of in vivo micro metastases, so two fluorescence tests were performed and other by electrophoresis. The results showed that both study models can be carried out without increasing complexity and meeting the expectations expected for which they were designed. (Author)

  15. Composition of lyophilized kit for radiopharmaceutical 99mTc-DTPA

    International Nuclear Information System (INIS)

    Kovacheva, S.P.; Bychvarova, K.A.; Donev, T.N.

    1988-01-01

    The composition finds application for functional radioisotope studies of kidneys and brain. The radiopharmaceuticals, obtained from lyophilized kit with this composition possess a high radiochemical purity, long shelf life and minimal content of reduced hydrolised technetium. They are stable in vivo and in vitro and ensure high quality of examinations at low body background. The composition of the lyophilized kit is based on diethylenetriaminepentaacetic acid, tin dichloride dihydrate and ascorbic acid accordingly in relation 61:1:1 and concentrations 10.4 mg, 0.17 mg and 0.17 mg. 1 cl

  16. Biodistribution of the radiopharmaceutical sodium pertechnetate (Na99mTcO4) after massive small bowel resection in rats

    International Nuclear Information System (INIS)

    Chacon, Damaso de Araujo; Araujo-Filho, Irami; Villarim-Neto, Arthur; Brandao-Neto, Jose; Medeiros, Aldo Cunha; Rego, Amalia Cinthia Meneses; Azevedo, Italo Medeiros; Bernardo-Filho, Mario

    2007-01-01

    Purpose: To evaluate the biodistribution of sodium pertechnetate (Na 99m TcO 4 ) in organs and tissues, the morphometry of remnant intestinal mucosa and ponderal evolution in rats subjected to massive resection of the small intestine. Methods:Twenty-one Wistar rats were randomly divided into three groups of 7 animals each. The short bowel (SB) group was subjected to massive resection of the small intestine; the control group (C) rats were not operated on, and soft intestinal handling was performed in sham rats. The animals were weighed weekly. On the 30th postoperative day, 0.1 mL of Na 99m TcO 4 , with mean activity of 0.66 MBq was injected intravenously into the orbital plexus. After 30 minutes, the rats were killed with an overdose of anesthetic, and fragments of the liver, spleen, pancreas, stomach, duodenum, small intestine, thyroid, lung, heart, kidney, bladder, muscle, femur and brain were harvested. The biopsies were washed with 0.9% NaCl.,The radioactivity was counted using Gamma Counter Wizard TM 1470, Perkin-Elmer. The percentage of radioactivity per gram of tissue (%ATI/g) was calculated. Biopsies of the remaining jejunum were analysed by HE staining to obtain mucosal thickness. Analysis of variance (ANOVA) and the Tukey test for multiple comparisons were used, considering p 99m TcO 4 in the organs of the groups studied (p>0.05). An increase in the weight of the SB rats was observed after the second postoperative week. The jejunal mucosal thickness of the SB rats was significantly greater than that of C and sham rats (p 99m TcO 4 was not affected by massive intestinal resection, suggesting that short bowel syndrome is not the cause of misleading interpretation, if an examination using this radiopharmaceutical is indicated. (author)

  17. Deficiencies in product labelling instructions and quality control directions for 99mTc radiopharmaceuticals.

    Science.gov (United States)

    Buroni, Federica E; Lodola, Lorenzo; Persico, Marco G; Aprile, Carlo

    2014-02-01

    The aim of the study was to identify deficiencies in product labelling instructions for reconstitution and in the quality control directions detailed in the technical leaflets (TLs) or summary product characteristic (SPC) sheets of commonly used technetium labelling cold kits. The reconstitution and quality control directions in 25 TLs/SPCs were evaluated to identify deficiencies, incompleteness, restrictions, errors, impracticability, and vagueness. In addition, their congruence with the statements given in the relative European Pharmacopoeia (Ph. Eur. VII ed.) monography and diagnostic reference levels of Directive 97/43/EURATOM was evaluated. Deficiencies in information were scored and classified into five categories: 1, absent or incomplete; 2, restrictive; 3, inconsistent or wrong; 4, impractical; and 5, vague. In the 25 documents analyzed a total of 141 deficiencies were found (corresponding to 40.2% of the total scores assigned), and more frequently they pertained to quality control procedures (70.9%), followed by those related to quantitative composition (14.9%), preparation (8.5%), and particle size (5.7%). Nearly 80% of these deficiencies were classified as type 1 - that is, absent or incomplete information. The indications in TLs and SPCs should provide useful information for maintaining the quality and purity of the radiopharmaceutical preparation and ensure the safety level and effectiveness required by law. However, the instructions are often suboptimal or even erroneous, and consequently there are countless failures or difficulties, which represent an impediment to good laboratory practice. We believe that a 'smart' review of radiopharmaceutical documentation would be beneficial in order to align these indications to the real needs of the operators involved in routine in-house nuclear medicine practice.

  18. Development of nano radiopharmaceutical based on Bevacizumab labelled with Technetium-99m for early diagnosis of gastrointestinal stromal tumor

    International Nuclear Information System (INIS)

    Braga, Thais Ligiero

    2015-01-01

    The development of new radiopharmaceuticals is an essential activity to improve nuclear medicine, and essential for the early and effective diagnosis of oncological diseases. Among the various possibilities current research in the world, the radiopharmaceuticals to chemotherapeutic base may be the most effective in detecting tumors, particularly Gastrointestinal Stromal Tumor (GIST), the Metastatic Renal Cell Carcinoma and neuroendocrine pancreatic tumors. However, difficulties in directing, as well as adhesion of the radiopharmaceutical in the desired location, are currently the main problems in the early detection and treatment of some of these tumors. Advances in the field of nanotechnology, particularly in recent years, indicate significant contribution to overcoming these obstacles, particularly in the implementation of molecular barriers as well as the functionalization of the nanoparticles, thereby improving targeting by the use of surface nucleotides, and the increased adhesion, which facilitates the release of the drug and therefore increases the chances of early diagnosis and more effective treatment. This study aimed to the production, characterization and evaluation of cytotoxicity, as well as in vivo biodistribution test Bevacizumab nanoparticles labeled with Technetium-99m radionuclide for detection of type GIST tumors. Bevacizumab was encapsulated in the form of nanoparticles by the emulsification method using double poly-acetic acid and polyvinyl alcohol polymers (PLA / PVA) at a concentration of 2% of the monoclonal antibody. The characterization of the nanoparticles was performed by the technique of scanning electron microscopy (SEM). The cytotoxicity assessment was performed by XTT assay with various cell lines of solid tumor cells. The labeling with technetium-99m was done by the direct method, and its yield determined by paper chromatography using paper Whatmam 1 as the stationary phase and acetone as mobile phase. In the biodistribution study

  19. Breast tumor targeting with {sup 99m}Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

    Energy Technology Data Exchange (ETDEWEB)

    Salouti, Mojtaba [Department of Medical Physics, Tarbiat Modares University, Tehran (Iran, Islamic Republic of); Rajabi, Hossein [Department of Medical Physics, Tarbiat Modares University, Tehran (Iran, Islamic Republic of)], E-mail: hrajabi@modares.ac.ir; Babaei, Mohammad Hossein [Department of Radioisotope, Atomic Energy Organization of Iran, Tehran (Iran, Islamic Republic of); Rasaee, Mohammad Javad [Department of Medical Biotechnology, School of Medical Sciences, Tarbiat Modares University, Tehran (Iran, Islamic Republic of)

    2008-10-15

    Human epithelial mucin, MUC1, is commonly overexpressed in adenocarcinoma that includes more than 80% of breast cancers. The PR81 is a murine anti-MUC1 monoclonal antibody (MAb) that was prepared against the human breast cancer. We developed an indirect method for labeling of this antibody with {sup 99m}Tc in order to use the new preparation in immunoscintigraphy studies of BALB/c mice bearing breast tumors. The {sup 99m}Tc-PR81 complex was prepared using the HYNIC as a chelator and tricine as a coligand. The labeling efficiency determined by instant thin-layer chromatography (ITLC) was 89.2%{+-}4.7%, and radiocolloides measured by cellulose nitrate electrophoresis were 3.4%{+-}0.9%. The in vitro stability of labeled product was determined at room temperature by ITLC and in human serum by gel filtration chromatography - 88.3%{+-}4.6% and 79.8%{+-}5.7% over 24 h, respectively. The integrity of labeled MAb was checked by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis, and no significant fragmentation was seen. The results of cell binding studies showed that both labeled and unlabeled PR81 were able to compete for binding to MCF 7 cells. Biodistribution studies performed in female BALB/c mice with breast tumor xenografts at 4, 16 and 24 h after the {sup 99m}Tc-HYNIC-PR81 injection demonstrated a specific localization of the compound at the site of tumors and minimum accumulation in non target organs. The tumor imaging was performed in BALB/c mice with breast xenograft tumors at 4, 8, 12, 16, 20, 24, 28, 32 and 36 h after the complex injection. The tumors were visualized with high sensitivity after 8 h. The findings showed that the new radiopharmaceutical is a promising candidate for radioimmunoscintigraphy of the human breast cancer.

  20. Breast tumor targeting with 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

    International Nuclear Information System (INIS)

    Salouti, Mojtaba; Rajabi, Hossein; Babaei, Mohammad Hossein; Rasaee, Mohammad Javad

    2008-01-01

    Human epithelial mucin, MUC1, is commonly overexpressed in adenocarcinoma that includes more than 80% of breast cancers. The PR81 is a murine anti-MUC1 monoclonal antibody (MAb) that was prepared against the human breast cancer. We developed an indirect method for labeling of this antibody with 99m Tc in order to use the new preparation in immunoscintigraphy studies of BALB/c mice bearing breast tumors. The 99m Tc-PR81 complex was prepared using the HYNIC as a chelator and tricine as a coligand. The labeling efficiency determined by instant thin-layer chromatography (ITLC) was 89.2%±4.7%, and radiocolloides measured by cellulose nitrate electrophoresis were 3.4%±0.9%. The in vitro stability of labeled product was determined at room temperature by ITLC and in human serum by gel filtration chromatography - 88.3%±4.6% and 79.8%±5.7% over 24 h, respectively. The integrity of labeled MAb was checked by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis, and no significant fragmentation was seen. The results of cell binding studies showed that both labeled and unlabeled PR81 were able to compete for binding to MCF 7 cells. Biodistribution studies performed in female BALB/c mice with breast tumor xenografts at 4, 16 and 24 h after the 99m Tc-HYNIC-PR81 injection demonstrated a specific localization of the compound at the site of tumors and minimum accumulation in non target organs. The tumor imaging was performed in BALB/c mice with breast xenograft tumors at 4, 8, 12, 16, 20, 24, 28, 32 and 36 h after the complex injection. The tumors were visualized with high sensitivity after 8 h. The findings showed that the new radiopharmaceutical is a promising candidate for radioimmunoscintigraphy of the human breast cancer

  1. Synthesis and biodistribution of nitrido technetium-99m radiopharmaceuticals with dithiophosphinate ligands: a class of brain imaging agents

    International Nuclear Information System (INIS)

    Bellande, Emmanuel; Comazzi, Veronique; Laine, Jacques; Lecayon, Michele; Pasqualini, Roberto; Duatti, Adriano; Hoffschir, Didier

    1995-01-01

    The symmetrical complexes [ 99m Tc][TcN(R 2 PS 2 ) 2 ] [R = CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH 2 (CH 3 ) 2 ], and the unsymmetrical complex [ 99m Tc][TcN(Me 2 PS 2 )(Et 2 PS 2 )] have been prepared, at tracer level, through a two-step procedure involving the preliminary formation of a prereduced technetium nitrido intermediate followed by substitution reaction onto this species by the appropriate dithiophosphinate ligand [R 2 PS 2 ]Na. The chemical identity of the resulting complexes have been established by comparison with the corresponding 99 Tc-analogs prepared, at macroscopic level, by reacting the complex [ 99 TcNCl 4 ] [n-Bu 4 N] (n-Bu = n-butyl) with an excess of ligand in methanol, and characterized by elemental analyses and spectroscopic techniques. The complexes are neutral and lipophilic, and possess a square pyramidal geometry, with an apical Tc N group and two dithiophosphinate ligands spanning the four positions on the basal plane through the four sulfur atoms of the >PS 2 group. In vitro studies showed that these radiopharmaceuticals are stable in solution and that their chemical identity was not altered after incubation with rat blood. Biodistribution studies have been carried out in rats and primates. The results demonstrate that these compounds are significantly retained into the brain of these animals for a prolonged time. Planar gamma camera images have been obtained in monkeys showing a good visualization of the cerebral region. However, the existence of persistent blood activity yields a brain/blood ratio lower than that observed with other 99m Tc-based brain perfusion imaging agents

  2. Synthesis and biodistribution of nitrido technetium-99m radiopharmaceuticals with dithiophosphinate ligands: a class of brain imaging agents

    Energy Technology Data Exchange (ETDEWEB)

    Bellande, Emmanuel; Comazzi, Veronique; Laine, Jacques; Lecayon, Michele; Pasqualini, Roberto; Duatti, Adriano; Hoffschir, Didier

    1995-04-01

    The symmetrical complexes [{sup 99m}Tc][TcN(R{sub 2}PS{sub 2}){sub 2}] [R = CH{sub 3}, CH{sub 2}CH{sub 3}, CH{sub 2}CH{sub 2}CH{sub 3}, CH{sub 2}(CH{sub 3}){sub 2}], and the unsymmetrical complex [{sup 99m}Tc][TcN(Me{sub 2}PS{sub 2})(Et{sub 2}PS{sub 2})] have been prepared, at tracer level, through a two-step procedure involving the preliminary formation of a prereduced technetium nitrido intermediate followed by substitution reaction onto this species by the appropriate dithiophosphinate ligand [R{sub 2}PS{sub 2}]Na. The chemical identity of the resulting complexes have been established by comparison with the corresponding {sup 99}Tc-analogs prepared, at macroscopic level, by reacting the complex [{sup 99}TcNCl{sub 4}] [n-Bu{sub 4}N] (n-Bu = n-butyl) with an excess of ligand in methanol, and characterized by elemental analyses and spectroscopic techniques. The complexes are neutral and lipophilic, and possess a square pyramidal geometry, with an apical Tc N group and two dithiophosphinate ligands spanning the four positions on the basal plane through the four sulfur atoms of the >PS{sub 2} group. In vitro studies showed that these radiopharmaceuticals are stable in solution and that their chemical identity was not altered after incubation with rat blood. Biodistribution studies have been carried out in rats and primates. The results demonstrate that these compounds are significantly retained into the brain of these animals for a prolonged time. Planar gamma camera images have been obtained in monkeys showing a good visualization of the cerebral region. However, the existence of persistent blood activity yields a brain/blood ratio lower than that observed with other {sup 99m}Tc-based brain perfusion imaging agents.

  3. Effect of mitomycin-c on biodistribution of 99 mTc-sodium pyrophosphate radiopharmaceuticals in mice; Efeito da mitomicina-c na biodistribuicao do radiofarmaco pirofosfato de sodio marcado com Tecnecio-99m em camundongos

    Energy Technology Data Exchange (ETDEWEB)

    Gomes, Maria L.; Braga, Ana C.S.; Gutfilen, Bianca; Bernardo-Filho, Mario [Instituto Nacional do Cancer, Rio de Janeiro, RJ (Brazil)

    1997-12-01

    The desirable characteristics of technetium-99 have stimulated the development of labeling techniques for different molecular and cellular. It is generally acceptable that a variety of factors other than disease can alter the biodistribution of radiopharmaceutical and one such factor is the drug therapy. The absence of knowledge of these factors may result in an unexpected behavior of the radiopharmaceutical. Since patients on chemotherapeutic treatment ca be submitted, for different reasons, to a nuclear medicine procedure, we have studied in mice, the effect of mitomycin-C on the biodistribution of the radiopharmaceutical {sup 99m} Tc-pyrophosphate ({sup 99m} Tc-PYP). Mitomycin-C is an antineoplastic agent obtained from Streptomyces caesptosus. It was administered 0,15 mg of mitomycin-C in Balb/c in Balb/c female mice with an interval of 72 hours. After one hour of the last dose, 0.3 ml of {sup 99m} Tc-PYP (7.4 MBq) were injected after 0.5 h the animals were sacrificed. The organs were isolated, weighted and counted in a well counter. The percentages of radioactivity per gran of organs (% rad/g) were calculated and statistics analyses were performed (wilcoxon). The results have shown that the % rad/g has increased in pancreas, stomach, bone and lungs. These increased of radioactivity can be justified by the metabolic process or the therapeutic effect of mitomycin-C. (author). 8 refs., 2 tabs.

  4. Synthesis and evaluation of hydroxamamide-based tetradentate ligands as a new class of thiol-free chelating molecules for 99mTc radiopharmaceuticals.

    Science.gov (United States)

    Xu, L C; Nakayama, M; Harada, K; Nakayama, H; Tomiguchi, S; Kojima, A; Takahashi, M; Arano, Y

    1998-04-01

    Both N,N'-ethylene bis(benzohydroxamamide) [(C2(BHam)2)] and N,N'-propylene bis(benzohydroxamamide) [(C3(BHam)2)] were designed as new thiol-free chelating molecules for 99mTc radiopharmaceuticals. Synthetic procedures using oxadiazoline intermediates were developed for C2(BHam)2 and C3(BHam)2. Both C2(BHam)2 and C3(BHam)2 formed 99mTc complexes with high yields over a wide pH range (pH 3-12) at room temperature. Complexation yields of over 95% were achieved at ligand concentrations as low as 2.5 x 10(-6) M. Reversed-phase HPLC analyses indicated that both C2(BHam)2 and C3(BHam)2 formed 99mTc complexes as single species with stabilities much higher than those of 99mTc-BHam. Selective complex formation of 99mTc with the two ligands was observed in the presence of human IgG. No decomposition with low protein binding were demonstrated when the two 99mTc complexes were incubated in murine plasma. Although further structural studies are required, these findings implied that the Ham-based tetradentate ligands would serve as new chelating molecules for 99mTc radiopharmaceuticals.

  5. Synthesis and evaluation of hydroxamamide-based tetradentate ligands as a new class of thiol-free chelating molecules for 99mTc radiopharmaceuticals

    International Nuclear Information System (INIS)

    Xu Lecun; Nakayama, Morio; Harada, Kumiko; Nakayama, Hitoshi; Tomiguchi, Seiji; Kojima, Akihiro; Takahashi, Mutsumasa; Arano, Yasushi

    1998-01-01

    Both N,N'-ethylene bis(benzohydroxamamide) [(C 2 (BHam) 2 )] and N,N'-propylene bis(benzohydroxamamide) [(C 3 (BHam) 2 )] were designed as new thiol-free chelating molecules for 99m Tc radiopharmaceuticals. Synthetic procedures using oxadiazoline intermediates were developed for C 2 (BHam) 2 and C 3 (BHam) 2 . Both C 2 (BHam) 2 and C 3 (BHam) 2 formed 99m Tc complexes with high yields over a wide pH range (pH 3-12) at room temperature. Complexation yields of over 95% were achieved at ligand concentrations as low as 2.5 x 10 -6 M. Reversed-phase HPLC analyses indicated that both C 2 (BHam) 2 and C 3 (BHam) 2 formed 99m Tc complexes as single species with stabilities much higher than those of 99m Tc-BHam. Selective complex formation of 99m Tc with the two ligands was observed in the presence of human IgG. No decomposition with low protein binding were demonstrated when the two 99m Tc complexes were incubated in murine plasma. Although further structural studies are required, these findings implied that the Ham-based tetradentate ligands would serve as new chelating molecules for 99m Tc radiopharmaceuticals

  6. Drug interaction with radiopharmaceuticals: effect on the labeling of red blood cells with technetium-99m and on the bioavailability of radiopharmaceuticals

    Directory of Open Access Journals (Sweden)

    Maria Luisa Gomes

    2002-09-01

    Full Text Available The evidence that natural and synthetic drugs can affect radiolabeling or bioavailability of radiopharmaceuticals in setting of nuclear medicine clinic is already known. However, this drug interaction with radiopharmaceuticals (DIR is not completely understood. Several authors have described the effect of drugs on the labeling of blood elements with technetium-99m (99mTc and on the biodistribution of radiopharmaceuticals. When the DIR is known, if desirable or undesirable, the natural consequence is a correct diagnosis. However, when it is unknown, it is undesirable and the consequences are the possibility of misdiagnosis and/or the repetition of the examination with an increase of radiation dose to the patient. The possible explanation to the appearance of DIR are (a radiopharmaceutical modification, (b alteration of the labeling efficiency of the radiopharmaceutical, (c modification of the target, (d modification of no target and/or the (e alteration of the binding of the radiopharmaceutical on the blood proteins. The effect of drugs on the labeling of blood elements with 99mTc might be explained by (i a direct inhibition (chelating action of the stannous and pertechnetate ions, (ii damage induced in the plasma membrane, (iii competition of the cited ions for the same binding sites, (iv possible generation of reactive oxygen species that could oxidize the stannous ion and/or (v direct oxidation of the stannous ion. In conclusion, the development of biological models to study the DIR is highly relevant.A evidência de que drogas naturais ou sintéticas podem afetar a radiomarcação ou a biodisponibilidade de radiofármacos nos procedimentos de medicina nuclear já é bem conhecida. Entretanto, essa interação de droga com radiofármacos (IDR não está completamente compreendida. Vários autores têm descrito o efeito de drogas na marcação de elementos sanguíneos com tecnécio-99m (99mTce na biodistribuição de radiofármacos. Quando a

  7. Evaluation of Deoxyribonucleic Acid Toxicity Induced by the Radiopharmaceutical 99mTechnetium-Methylenediphosphonic Acid and by Stannous Chloride in Wistar Rats

    Directory of Open Access Journals (Sweden)

    Adriano Caldeira-de-Araujo

    2012-11-01

    Full Text Available Radiopharmaceuticals are employed in patient diagnostics and disease treatments. Concerning the diagnosis aspect, technetium-99m (99mTc is utilized to label radiopharmaceuticals for single photon computed emission tomography (SPECT due to its physical and chemical characteristics. 99mTc fixation on pharmaceuticals depends on a reducing agent, stannous chloride (SnCl2 being the most widely-utilized. The genotoxic, clastogenic and anegenic properties of the 99mTc-MDP(methylene diphosphonate used for bone SPECT and SnCl2 were evaluated in Wistar rat blood cells using the Comet assay and micronucleus test. The experimental approach was to endovenously administer NaCl 0.9% (negative control, cyclophosphamide 50 mg/kg b.w. (positive control, SnCl2 500 μg/mL or 99mTc-MDP to animals and blood samples taken immediately before the injection, 3, and 24 h after (in the Comet assay and 36 h after, for micronucleus test. The data showed that both SnCl2 and 99mTc-MDP-induced deoxyribonucleic acid (DNA strand breaks in rat total blood cells, suggesting genotoxic potential. The 99mTc-MDP was not able to induce a significant DNA strand breaks increase in in vivo assays. Taken together, the data presented here points to the formation of a complex between SnCl2 in the radiopharmaceutical 99mTc-MDP, responsible for the decrease in cell damage, compared to both isolated chemical agents. These findings are important for the practice of nuclear medicine.

  8. Synthesis of a novel class of nitrido Tc-99m radiopharmaceuticals with phosphino-thiol ligands showing transient heart uptake

    Energy Technology Data Exchange (ETDEWEB)

    Bolzati, Cristina; Uccelli, Licia; Boschi, Alessandra; Malago, Erica; Duatti, Adriano E-mail: dta@unife.it; Tisato, Francesco; Refosco, Fiorenzo; Pasqualini, Roberto; Piffanelli, Adriano

    2000-05-01

    A novel class of technetium-99m radiopharmaceuticals showing high heart uptake is described. These complexes were prepared through a simple and efficient procedure, and their molecular structure fully characterized. They are formed by a terminal Tc{identical_to}N multiple bond and two bidentate phosphine-thiol ligands [R{sub 2}P-(CH{sub 2}){sub n}SH, n=2,3] coordinated to the metal ion through the neutral phosphorus atom and the deprotonated thiol sulfur atom. The resulting geometry was trigonal bipyramidal. Biodistribution studies were carried out in rats. The complexes exhibited high initial heart uptake and elimination through liver and kidneys. The washout kinetic from heart was dependent on the nature of the lateral R groups on the phosphine-thiol ligands. When R=phenyl, heart activity was rapidly eliminated within 10-20 min. Instead, when R=tolyl,cyclohexyl, persistent heart uptake was observed. Extraction of activity from myocardium tissue showed that no change of the chemical identity of the tracer occurred after heart uptake. On the contrary, metabolization to more hydrophilic species occurred in liver and kidneys.

  9. Synthesis and in vitro/in vivo evaluation of novel mono- and trivalent technetium-99m labeled ghrelin peptide complexes as potential diagnostic radiopharmaceuticals

    International Nuclear Information System (INIS)

    Koźmiński, Przemysław; Gniazdowska, Ewa

    2015-01-01

    Introduction: Ghrelin is an endogenous hormone present in blood. It is released from the oxyntic cells (X/A-like cells) of the stomach and fundus and can exist in two forms: as an acylated and des-acylated ghrelin. Ghrelin is an endogenous ligand of the growth hormone receptor (growth hormone secretagogue receptor, GHS-R). Overexpression of GHS-R1a receptor was identified in cells of different types of tumors (e.g. pituitary adenoma, neuroendocrine tumors of the thyroid, lung, breast, gonads, prostate, stomach, colorectal, endocrine and non-endocrine pancreatic tumors). This fact suggests that gamma radionuclide labeled ghrelin peptide may be considered as a potential diagnostic radiopharmaceutical. Methods: Ghrelin peptide labeled with mono- and trivalent technetium-99m complexes, 99m Tc-Lys-GHR, has been prepared on the n.c.a. scale. The physicochemical (stability, charge, shape, lipophilicity) and biological (receptor affinity, biodistribution) properties of the conjugates have been studied relevant to use the conjugates as receptor-based diagnostic radiopharmaceuticals. Results: The obtained conjugates [ 99m Tc(CO) 3 L N,O (CN-Lys-GHR)] + , 99m Tc(CO) 3 L S,O (CN-Lys-GHR) and 99m Tc(NS 3 )(CN-Lys-GHR) show different shape, charge, lipophilicity and two of them, 99m Tc(CO) 3 L S,O (CN-Lys-GHR) and 99m Tc(NS 3 )(CN-Lys-GHR), high stability in neutral aqueous solutions, even in the presence of excess concentration of histidine/cysteine competitive standard ligands or human serum. The in vitro binding affinity of 99m Tc-Lys-GHR conjugates with respect to growth hormone secretagogue receptor (GHS-R1a) present on DU-145 cells was in the range of IC 50 from 45 to 54 nM. The conjugate 99m Tc(CO) 3 L S,O (CN-Lys-GHR) exhibited excretion route by the liver and kidney in comparable degree, while the more lipophilic conjugate 99m Tc(NS 3 )(CN-Lys-GHR)—mainly by the liver. Conclusions: Basing on the results concerning physicochemical and biochemical properties, the

  10. Technetium-99m-labeled N-(2,6-dimethylphenylcarbamoylmethyl) iminodiacetic acid (/sup 99m/Tc HIDA): a new radiopharmaceutical for hepatobiliary imaging studies. [/sup 14/C, /sup 113/Sn

    Energy Technology Data Exchange (ETDEWEB)

    Ryan, J.; Cooper, M.; Loberg, M.; Harvey, E.; Sikorski, S.

    1977-10-01

    An easily formulated, stable kit preparation of technetium-99m HIDA, suitable for use in humans, was developed and tested in mice and dogs. The tracer was cleared rapidly from the blood and excreted predominantly by the liver in both species. In dogs, the hepatobiliary clearance of Tc-99m HIDA was significantly greater than that of C-14 HIDA and Sn-113 HIDA. The LD/sub 50/ for HIDA in mice, 168 mg/kg, exceeded the average human dose by a factor of 1000 on a per-weight basis. Blood clearance curves for Tc-99m HIDA in 12 normal subjects were biexponential with half-times of 4.6 +- 1.0 min and 31.5 +- 7.0 min, and cumulative 90-min urine samples contained 14.2 +- 1.8% of the injected dose. Images in normal subjects and nonjaundiced patients showed rapid concentration of tracer by the liver and activity was present within the biliary system in 10 to 20 min. In jaundiced patients, the tracer blood clearance was delayed and urinary excretion increased, but intestinal activity, indicating biliary patency, was imaged in those patients without complete focal obstruction of the common duct. Technetium-99m HIDA is a nontoxic radiopharmaceutical useful for clinical evaluation of hepatobiliary disorders in humans.

  11. 99mTc-ceftriaxone, as a targeting radiopharmaceutical for scintigraphic imaging of infectious foci due to Staphylococcus aureus in mouse model

    International Nuclear Information System (INIS)

    Akram Fazli; Mojtaba Salouti; Mohammad Mazidi

    2013-01-01

    99m Tc-labeled antibiotics have opened an exciting field of research in infectious diseases diagnosis. Direct labeling of ceftriaxone with 99mTc was carried out using the various amounts of ceftriaxone and SnCl 2 ·2H 2 O at different pH and incubation time intervals to find the highest radiochemistry efficiency with high stability at room temperature and human blood serum. ITLC-SG and HPLC were performed to measure the radiochemical purity of the conjugate. The binding study showed 45 % specific binding to Staphylococcus aureus. The biodistribution study and scintigraphic imaging showed the localization of 99m Tc-ceftriaxone at the site of infection in comparison with normal and inflamed muscles with high sensitivity and specificity in mouse model. The results showed that 99m Tc-ceftriaxone is a promising candidate as a targeting radiopharmaceutical for Staphylococcal infection imaging in humans which needs further investigations. (author)

  12. Optimization of the production process of a lyophilized formulation for radiopharmaceutical obtaining 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2

    International Nuclear Information System (INIS)

    Sanchez R, S.

    2013-01-01

    In this work was optimized the production process of a lyophilized pharmaceutical formulation for the preparation of radiopharmaceutical 99m Tc-EDDA/HYNIC-E-[c(RGDfK)] 2 , the union specifies to the integrin s α v β 3 was demonstrated to be used in the nuclear medicine cabinets in the obtaining of scan images for the opportune detection of breast cancer. The good lyophilized pharmaceutical formulation for the preparation of radiopharmaceutical 99m Tc-EDDA/HYNIC-E-[c(RGDfK)] 2 was established like: HYNIC-E-[c(RGDfK)] 2 - 25 μg; Stannous chloride (SnCl 2 ) 20 μg; Ethylenediamine diacetic acid (EDDA) 10 mg; N-tris(hydroxymethyl)methyl glycin (Tricine) 20 mg; Mannitol 50 mg. The results of radiochemical purity of the sterile formulation and free of bacterial endotoxins for the three validation lots prepared under protocols of good manufacturing practices were 97.62 ± 1.48%, 96.54 ± 1.89%, and 97.66 ± 0.57%, for what the production procedure complies the predefined specifications. The radiopharmaceutical 99m Tc-EDDA/HYNIC-E-[c(RGDfK)]2 prepared from the lyophilized pharmaceutical formulation showed to be stable during a period 24 hours, for what can be used in the centers of molecular nuclear medicine. Images in vivo were obtained of the integrin s over-expression α v β 3 from the radiopharmaceutical 99m Tc-EDDA/HYNIC-E-[c(RGDfK)]2 obtained of the lyophilized and optimized pharmaceutical formulation. The lyophilized pharmaceutical formulation (HYNIC-RGD-Sn) showed stability during 12 months, due to this factor, is requested before the COFEPRIS the radiopharmaceutical expiration for this same period (accession number 123300401A0155). (Author)

  13. A solid-phase technique for preparation of no-carrier-added technetium-99m radiopharmaceuticals: application to the streptavidin/biotin system

    International Nuclear Information System (INIS)

    Dunn-Dufault, Robert; Pollak, Alfred; Fitzgerald, Jane; Thornback, John R.; Ballinger, James R.

    2000-01-01

    A high effective specific activity (HESA) formulation of a biotin-containing 99m Tc ligand [RP488: dimethyl-Gly-Ser-Cys(Acm)-Lys(Biotin)-Gly] conveniently prepared from solid phase was compared to a typical low effective specific activity (LESA) solution formulation to demonstrate improved targeting to streptavidin in an in vitro assay and in an in vivo rat model. RP488 was coupled to a maleimide-functionalized polyethylene glycol resin via a thiol ether linkage and labeled with 99m Tc-gluconate at room temperature, followed by elution of the HESA 99m Tc-RP488 in saline (minimum specific activity ∼ 1000 TBq/mmol by amino acid analysis). Both HESA and LESA 99m Tc-RP488 labeled at > 90% purity. In vitro, HESA 99m Tc-RP488 incubated with streptavidin-agarose was bound quantitatively, but there was competition from addition of increasing amounts of cold RP488. In rats, radiotracer uptake was evident at the site of implantation of streptavidin-agarose beads for the HESA dose, less uptake of low effective specific activity (LESA) material, and no appreciable uptake in the control rats of the LESA or HESA dose. The target-to-background ratio for HESA 99m Tc-RP488 was 5.4 times that of the control. The solid-phase technology offers a convenient way to prepare high specific activity receptor-targeting 99m Tc radiopharmaceuticals

  14. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives

    International Nuclear Information System (INIS)

    Decristoforo, C.; Cholewinski, W.; Donnemiller, E.; Riccabona, G.; Moncayo, R.

    2000-01-01

    [ 111 In-diethylene triamine penta-acetic acid-d-Phe 1 ]-octreotide (DTPA-octreotide) scintigraphy has gained widespread acceptance as a diagnostic clinical procedure in oncology for imaging somatostatin receptor-positive tumours. However, indium-111 as a radiolabel has several drawbacks, including limited availability, suboptimal gamma energy and high radiation burden to the patient. We have recently reported on the preclinical development of 99m Tc-EDDA/HYNIC-TOC, a new octreotide derivative which showed promising results both in vitro and in vivo. We now report our initial clinical experiences with this new radiopharmaceutical in ten oncological patients. The clinical diagnoses were: carcinoid syndrome (n=5), thyroid cancer (n=3), pancreatic cancer (n=1) and pituitary tumour (n=1). The biodistribution and kinetics of 99m Tc-EDDA/HYNIC-TOC were compared with those of 111 In-DTPA-octreotide in six cases, and with those of 111 In-DOTA-TOC in five cases. With the new tracer tumours were imaged within 15 min after injection and showed the highest target/non-target ratios 4 h after injection. Tumour uptake persisted up to 20 h p.i. The rate of blood clearance was similar to that of 111 In-DTPA-octreotide but faster than that of 111 In-DOTA-TOC, while urinary excretion was lower compared with the 111 In derivatives. Semi-quantitative region of interest analysis showed that 99m Tc-EDDA/HYNIC-TOC produced higher tumour/organ (target/non-target) ratios than the 111 In derivatives, especially in relation to heart and muscle. Significantly more lesions could be detected in 99m Tc images. We conclude that 99m Tc-EDDA/HYNIC-TOC shows better imaging properties for the identification of somatostatin receptor-positive tumour sites than currently available 111 In-labelled octreotide derivatives. (orig.)

  15. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

    Science.gov (United States)

    Decristoforo, C; Mather, S J; Cholewinski, W; Donnemiller, E; Riccabona, G; Moncayo, R

    2000-09-01

    [111In-diethylene triamine penta-acetic acid-D-Phe1]-octreotide (DTPA-octreotide) scintigraphy has gained widespread acceptance as a diagnostic clinical procedure in oncology for imaging somatostatin receptor-positive tumours. However, indium-111 as a radiolabel has several drawbacks, including limited availability, suboptimal gamma energy and high radiation burden to the patient. We have recently reported on the preclinical development of 99mTc-EDDA/HYNIC-TOC, a new octreotide derivative which showed promising results both in vitro and in vivo. We now report our initial clinical experiences with this new radiopharmaceutical in ten oncological patients. The clinical diagnoses were: carcinoid syndrome (n=5), thyroid cancer (n=3), pancreatic cancer (n=1) and pituitary tumour (n=1). The biodistribution and kinetics of 99mTc-EDDA/HYNIC-TOC were compared with those of 111In-DTPA-octreotide in six cases, and with those of 111In-DOTA-TOC in five cases. With the new tracer tumours were imaged within 15 min after injection and showed the highest target/non-target ratios 4 h after injection. Tumour uptake persisted up to 20 h p.i. The rate of blood clearance was similar to that of 111In-DTPA-octreotide but faster than that of 111In-DOTA-TOC, while urinary excretion was lower compared with the 111In derivatives. Semi-quantitative region of interest analysis showed that 99mTc-EDDA/HYNIC-TOC produced higher tumour/organ (target/non-target) ratios than the 111In derivatives, especially in relation to heart and muscle. Significantly more lesions could be detected in 99mTc images. We conclude that 99mTcEDDA/HYNIC-TOC shows better imaging properties for the identification of somatostatin receptor-positive tumour sites than currently available 111In-labelled octreotide derivatives.

  16. Harvard--MIT research program in short-lived radiopharmaceuticals. Progress report, September 1, 1977--April 30, 1978. [/sup 99m/Tc, positron-emitting radionuclides

    Energy Technology Data Exchange (ETDEWEB)

    Adelstein, S.J.; Brownell, G.L.

    1978-05-01

    Progress is reported on the following studies: chemistry studies designed to achieve a more complete understanding of the fundamental chemistry of technetium in order to facilitate the design of future radiopharmaceuticals incorporating the radionuclide /sup 99m/Tc; the development of new radiopharmaceuticals intended to improve image quality and lower radiation doses by the use of short-lived radionuclides and disease-specific agents; the development of short-lived positron-emitting radionuclides which offer advantages in transverse section imaging of regional physiological processes; and studies of the toxic effects of particulate radiation.

  17. Analytical methods for determination of radiochemical and radionuclidic purity of radiopharmaceuticals containing sup(99m)Tc and sup(113m)In. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Galatzeanu, I.

    1974-01-01

    The obtained results on radiochemical and radionuclidic purities determination of sup(99m)Tc and sup(113m)In-radiopharmaceuticals proved to be a good tool for small hospital units and laboratories in satisfying their duty to improve the quality control. The complicated behaviour of technetium in aqueous solutions during the preparation of radiopharmaceuticals, needs further research work to elucidate the mechanisms of interaction of reduced species with media and their disproportionation

  18. Clinical study with a new radiopharmaceutical (RP-517) for the in vivo labeling of neutrophils with 99mTc

    International Nuclear Information System (INIS)

    Parysow, O.; Mele, A.; Sarmiento, A.; Zubillaga, M.; Caro, R.; Calmanovici, G.; Nicolini, J.; Lazewatsky, J.; Camin, L.

    2002-01-01

    RP-517 is a 99m Tc labeled antagonist to the LTB 4 receptor which, with a single i.v. injection, allows the in vivo labeling of neutrophils for the detection and localization of infectious and/or inflammatory foci. Aim: To determine: 1) the safety and tolerance of the radiopharmaceutical in humans; 2) its pharmacokinetics and dosimetry; 3) its preliminary efficacy for the detection and localization of infectious foci. Materials and Methods: 20 subjects (14M, 6F) received 592 ± 111 MBq (16 ± 3 mCi) of RP-517 intravenously. All subjects were evaluated (medical history, physical exam, vital signs, ECG, blood and urine analysis) before and at several times up to 24 hours post-injection of RP-517. Blood samples were taken to determine pharmacokinetics and blood clearance. Urine and feces were collected to measure excretion. For dosimetry determination, whole body images, one transmission pre-injection and sequential emission images post-injection, were obtained with a dual head gamma camera (ADAC) in 2 patients and 14 volunteers. Sequential focal images were obtained in 4 patients. The presence of infection was determined by culture and/or follow-up. Results: There were no adverse clinical events or clinically significant changes in any of the laboratory analysis parameters, ECG or vital signs. RP-517 clears the blood mainly through the hepatobiliary system. The critical organ is the gall bladder wall, followed by the intestinal wall. A suggested maximum injected dose of about 740MBq of RP-517 would deliver ≤ 50 mGy to the critical organ. There were 6 patients with suspicion of infection: in 2 of them the infection was proven; a third subject had 2 suspected infectious foci, one was proven, the other one was equivocal; at the time of imaging, there was no infections process in the other 3 subjects. RP-517 images showed a clear and persistent uptake in the 3 proven infectious foci, was negative in the equivocal one and in the three patients without infection

  19. Development of kits for 99mTc radiopharmaceuticals for infection imaging. Report of a co-ordinated research project 2000-2003

    International Nuclear Information System (INIS)

    2004-09-01

    Infectious diseases remain a major health problem and cause of death worldwide, particularly in developing countries. Nuclear medicine imaging, because of its sensitivity, offers an attractive option for diagnosis of focal infections. This needs a reliable radiopharmaceutical that can selectively concentrate in sites of infection. Over the years 67 Ga and other radiopharmaceuticals that localize in inflammation associated with infection sites, also known as 'non-specific agents' have been used for infection imaging. However, experience has shown that an 'infection specific agent' that concentrates selectively at sites of infection and not inflammation would have several advantages. The first such agent developed more than two decades ago was 111 In-leucocytes which is still considered a 'gold standard'. Considerations of cost, availability, and superior properties for imaging make 99 mTc a better label than 111 In. 99 mTc white blood cell (WBC) was developed subsequently and used for infection imaging. However, both 111 In and 99 mTc WBCs have a number of drawbacks, in particular: each patient's blood sample has to be collected and individually radiolabelled; well-trained staff and suitable facilities for separating and labelling the patient's blood are needed; the risk of infection and cross-contamination associated with potential blood-borne microorganisms; and cost of materials. Because of these, considerable efforts have been continuously made towards developing convenient replacements for 99 mTc WBCs with limited success, 99 mTc antigranulocyte antibody being a good example. However, these radiopharmaceuticals still have many disadvantages, related to either their cost and availability or their performance. In view of the large potential for applications in patients, the development of new and improved 99 mTc labelled infection specific imaging agents was considered as a very worthwhile aim for scientific research in general and, in particular, for the

  20. Production of the radiopharmaceuticals labelling albumin nano-colloid with 99mTc for scintiscanning studies of the lymphatic system and bone marrow

    International Nuclear Information System (INIS)

    Gonzalez Alvarado, Alba Evelia

    1997-01-01

    The objective of the present work was to carried out the production in Guatemala, of a new radiopharmaceutical in the General Direction of Nuclear Energy for the detection of the cancer, as well as its implementation, the quality control by means of the radiochemical purity, the microbiology control and organoleptic quality , to evaluate the biodistribution in rats and to check its stability. The work was carried out formulating the pharmaco albumin Nano-colloid, then it was labelled with 99m Tc, the radiochemical purity was evaluated, measuring the disintegrations in minutes of the 99m Tc in an scintillation counter type well, being determined the percentage of union from the 99m Tc to the nanocolloid, with a purity bigger than 90%

  1. A retrospective analysis of the cost/benefit ratio for two nuclear medicine procedures performed with /sup 99m/Tc-radiopharmaceuticals

    International Nuclear Information System (INIS)

    Mariani, G.; Rosa, C.; Raciti, M.; Giganti, M.; Fatigante, L.; Giraldi, C.; Consoli, E.; Parenti, G.

    1986-01-01

    Technetium-99m is at present the most widely utilized radionuclide for in-vivo diagnostic nuclear medicine, either in the form of pertechnetate ion (as it is directly eluted from the generator column) or, more frequently, as a label for a number of molecules to which technetium-99m is attached to form radiopharmaceuticals characterized by a more or less selective accumulation in some organs or structures of the body. The impact of technetium-99m on the development of clinical nuclear medicine has reutilized with increasing frequency in diagnostic nuclear medicine, that is, whole-body skeletal scan and first-pass cerebral angioscintigraphy. These two procedures are, in fact, of great value, especially in the follow-up of two large categories of patients, namely cancer patients and patients with atherosclerotic cerebro-vascular disease

  2. Preliminary studies of EDDA-tricine-HYNIC-[Tyr3]octreotide labelled with Technetium-99m: radiopharmaceutical development for the diagnostic of neuroendocrine tumours

    International Nuclear Information System (INIS)

    Melero, Laura T.U.H.; Muramoto, Emiko; Arauho, Elaine Bortoleti de

    2007-01-01

    The use of labelled molecules with high specificity for an organ or receptor in scintigraphy, generate good local images of these specific receptors that are expressed for the biomolecule in question, minimizing the exposition of other organs. Small labelled peptides have showed a big potential for tumors image and other diseases in nuclear medicine. The octreotide was the first somatostatin synthetic analog introduced in clinical use in the localization of tumours with superexpression of somatostatin receptors which is a hundred times over in tumors cells that in normal cells. It did many attempts to development of a somatostatin analog labelled with 99mTc utilizing a variety of chelant systems until development the HYNIC-D-Phe1-Tyr3-octreotide, using tricine and EDDA as coligands, showing maintenance of in vivo affinity and promising of biodistribution in animals with induced tumours. This work involved the development of a 99mTc (technetium-99m) radiopharmaceutical based in a somatostatin peptide derivative (Tyr3-octreotide, TOC), with HYNIC chelating group, to be applied in the diagnostic of neuroendocrine tumors in nuclear medicine. Quality control methodologies to be applied in determination of the radiochemical purity of the labelled compound was also studied as well the biodistribution in normal Swiss mouse. The 99mTc-HYNIC-TOC was obtained in high radiochemical yield. Biodistribution studies suggests the potential of this radiopharmaceutical in the diagnostic of neuroendocrine tumours. (author)

  3. Development of nano radiopharmaceutical based on Bevacizumab labelled with Technetium-99m for early diagnosis of gastrointestinal stromal tumor; Desenvolvimento de nanorradiofarmaco a base de Bevacizumabe marcado com tecnecio-99m para diagnostico precoce do tumor estromal gastrointestinal

    Energy Technology Data Exchange (ETDEWEB)

    Braga, Thais Ligiero

    2015-06-01

    The development of new radiopharmaceuticals is an essential activity to improve nuclear medicine, and essential for the early and effective diagnosis of oncological diseases. Among the various possibilities current research in the world, the radiopharmaceuticals to chemotherapeutic base may be the most effective in detecting tumors, particularly Gastrointestinal Stromal Tumor (GIST), the Metastatic Renal Cell Carcinoma and neuroendocrine pancreatic tumors. However, difficulties in directing, as well as adhesion of the radiopharmaceutical in the desired location, are currently the main problems in the early detection and treatment of some of these tumors. Advances in the field of nanotechnology, particularly in recent years, indicate significant contribution to overcoming these obstacles, particularly in the implementation of molecular barriers as well as the functionalization of the nanoparticles, thereby improving targeting by the use of surface nucleotides, and the increased adhesion, which facilitates the release of the drug and therefore increases the chances of early diagnosis and more effective treatment. This study aimed to the production, characterization and evaluation of cytotoxicity, as well as in vivo biodistribution test Bevacizumab nanoparticles labeled with Technetium-99m radionuclide for detection of type GIST tumors. Bevacizumab was encapsulated in the form of nanoparticles by the emulsification method using double poly-acetic acid and polyvinyl alcohol polymers (PLA / PVA) at a concentration of 2% of the monoclonal antibody. The characterization of the nanoparticles was performed by the technique of scanning electron microscopy (SEM). The cytotoxicity assessment was performed by XTT assay with various cell lines of solid tumor cells. The labeling with technetium-99m was done by the direct method, and its yield determined by paper chromatography using paper Whatmam 1 as the stationary phase and acetone as mobile phase. In the biodistribution study

  4. Evaluation of the quality of the radiopharmaceutical 99mTc-MIBI and its influence on image quality in myocardial perfusion scintigraphy

    International Nuclear Information System (INIS)

    Santos, Poliane Angelo de Lucena

    2013-01-01

    This study evaluated the quality of the 99m Tc-MIBI radiopharmaceutical from different manufacturers, used in three nuclear medicine services (NMS) in Recife-PE, through labeling procedure of each service. It was observed their biodistribution by quantifying the activity present in the organs of interest (heart / liver), the influence and interference in image quality and in myocardial scintigraphy diagnosis exam. In these NMS (A, B and C) were done quality controls in the eluates of 99 Mo/ 99m Tc generators (radionuclidic, chemical and radiochemical purity and pH) and of the 99m Tc-MIBI radiopharmaceutical (radiochemical purity and pH) used in myocardial scintigraphy exam. In the case of radiochemical purity (RCP), was used the thin layer chromatography technique; after the chromatographic ran on, the plates were analyzed both in the dose calibrator, and in scintillation camera of each NMS. The radiopharmaceutical biodistribution was evaluated through the activities present in the heart and liver images in 60 patients, using the technique of combined images counting. Five nuclear physicians analyzed 24 images through myocardial perfusion visual interpretation during stress, it was verified the agreement degree among them. The results of the quality control showed that all eluate samples were in agreement with the manufacturers in relation to radionuclidic purity and pH. In relation to chemical purity, 10% of the services samples B and C showed Al +3 values above 10 ppm. In the RCP, it was observed that using the scintillation camera, only 22% of the samples would be discarded, while with dose calibrator would be 78%, indicating that the scintillation camera is more sensitive in chromatographic pale analysis. For the labeled radiopharmaceutical, the services B and C presented respectively one and three samples with RCP percentage below 90%. However, C service presented the lowest medium to liver/heart proportions, showing that this factor does not depends on the

  5. Biokinetics of osteotropic radiopharmaceuticals in metabolic osteopathies - comparison of 47Ca and sup(99m)Tc-MDP

    International Nuclear Information System (INIS)

    Knop, J.; Montz, R.

    1983-01-01

    Plasma clearance and osseous accumulation rates of sup(99m)Tc methylene diphosphonate (MDP) in the lumbar spine were measured in 11 patients with osteoporosis (OP), 7 patients with hyperparathyroidism (HPT), 4 patients with osteomalacia (OM) and in 3 patients (N) who were studied to exclude metabolic bone disease. The findings in 19 patients were compared with the results of 47 Ca kinetics. The plasma elimination of sup(99m)Tc-MDP during the first hour after application was normal in almost all the patients. The sup(99m)Tc-MDP accumulation rates in the lumbar spine were raised in patients with HPT and OM (p 0,05). 47 Ca kinetics were disturbed in most of the patients with metabolic bone disease, with minimal deviations in OP. The comparison of sup(99m)Tc-MDP accumulation rates with the results of 47 Ca kinetics revealed significant correlations with exchangeable bone and soft tissue calcium. The correlations with total calcium turnover and calcium accretion were poor. Only half of the patients had equal results of sup(99m)Tc-MDP accumulation rates and bone calcium accretion rates. It is concluded that the sup(99m)Tc-MDP uptake by bone is an index of bone metabolism presumably of the organic matrix, whereas 47 Ca kinetics represent the mineral metabolism of bone. (orig.) [de

  6. Biokinetics of osteotropic radiopharmaceuticals in metabolic osteopathies - comparison of /sup 47/Ca and sup(99m)Tc-MDP

    Energy Technology Data Exchange (ETDEWEB)

    Knop, J.; Montz, R.

    1983-10-01

    Plasma clearance and osseous accumulation rates of sup(99m)Tc methylene diphosphonate (MDP) in the lumbar spine were measured in 11 patients with osteoporosis (OP), 7 patients with hyperparathyroidism (HPT), 4 patients with osteomalacia (OM) and in 3 patients (N) who were studied to exclude metabolic bone disease. The findings in 19 patients were compared with the results of /sup 47/Ca kinetics. The plasma elimination of sup(99m)Tc-MDP during the first hour after application was normal in almost all the patients. The sup(99m)Tc-MDP accumulation rates in the lumbar spine were raised in patients with HPT and OM (p<=0,01) and normal in patients with OP and N (p>0,05). /sup 47/Ca kinetics were disturbed in most of the patients with metabolic bone disease, with minimal deviations in OP. The comparison of sup(99m)Tc-MDP accumulation rates with the results of /sup 47/Ca kinetics revealed significant correlations with exchangeable bone and soft tissue calcium. The correlations with total calcium turnover and calcium accretion were poor. Only half of the patients had equal results of sup(99m)Tc-MDP accumulation rates and bone calcium accretion rates. It is concluded that the sup(99m)Tc-MDP uptake by bone is an index of bone metabolism presumably of the organic matrix, whereas /sup 47/Ca kinetics represent the mineral metabolism of bone.

  7. The Chemistry of Re-188 Radiopharmaceuticals: Could Re-188 Play the Same Role in Therapy as Tc-99m in Diagnostics?

    International Nuclear Information System (INIS)

    Duatti, A.

    2009-01-01

    Radiopharmaceuticals incorporating the β-emitting radionuclide Re-188 are still attracting much interest for their potential application in nuclear medicine as therapeutic agents. There are many advantages of employing this class of radioactive compounds as briefly summarized in the following. (1) Re-188 emits a high-energy β- particle (2.1 MeV) that can be efficiently used to deliver high-dose radiation to the target. (2) Re-188 concomitantly emits a 155-keV γ photon that can be conveniently employed to obtain good-quality SPECT images of the biodistribution of Re-188 radiopharmaceuticals and, ultimately, following in vivo the course of the therapy. (3) Re-188 has a relatively short half-life (17 hours) that may allow multiple treatments of the same patient's disease. (4) Re-188 is a radiometal belonging to the same group of Tc-99m in the transition metal series of the Periodic Table, and shares with its cogener similar (though not identical) chemical properties that could be useful for designing a broad class of Re-188 radiopharmaceuticals having the same biodistribution properties of the corresponding Tc-99m analogues. (5) Similarly to Tc-99m, the radionuclide Re-188 is produced in high-specific activity through the 188 W/ 188 Re transportable generator system. A first challenge encountered in the attempt to develop efficient labeling procedures for Re-188 was related to the low radiochemical yield usually observed in tracer-level preparations of Re-188 radiopharmaceuticals starting from generator-produced [ 188 ReO 4 ]-. This drawback is commonly associated with the low value of the standard reduction potential of the tetraoxo anion as compared to the corresponding Tc-99m pertechnetate anion. In recent years, we reported a simple and efficient procedure for overcoming this problem based on a general chemical principle called 'expansion of the coordination sphere' and involving the addition to the reaction vial of an ancillary ligand (usually, chelating hard

  8. 99mTc-hexoprenaline and 131I-dapoxetine. Preparation, in silico modeling and biological evaluation as promising lung scintigraphy radiopharmaceuticals

    International Nuclear Information System (INIS)

    Rashed, H.M.; Ibrahim, I.T.; Motaleb, M.A.

    2017-01-01

    Hexoprenaline and dapoxetine (two lung selective pharmaceutical compounds) were radiolabeled to produce lung imaging radiopharmaceuticals using 99m Tc and 131 I, respectively. Different factors affecting labeling process were examined and optimum radiochemical purities of 91.3 ± 0.294 and 96.5 ± 0.342% were obtained, respectively. In silico molecular modeling studies for 99m Tc-hexoprenaline and 131 I-dapoxetine were done. Molecular modeling studies of the radiolabeled compounds examined the effect of radiolabeling on structure activity relationship for hexoprenaline and dapoxetine. Biodistribution studies in Swiss albino mice showed poor lung uptake of 99m Tc-hexoprenaline and high uptake for 131 I-dapoxetine (15.26 ± 0.11 and 55.82 ± 0.201%ID/g, respectively) matching the molecular modeling expectations. Consequently, 131 I-dapoxetine could be a hopeful radiopharmaceutical for lung scintigraphic imaging and further studies to radiolabel hexoprenaline with 131 I are recommended. (author)

  9. [99mTc]MAG3-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection

    International Nuclear Information System (INIS)

    Vera, David R.; Wallace, Anne M.; Hoh, Carl K.

    2001-01-01

    Technetium-99m-labeled benzoyl-mercaptoacetylglycylglycyl-glycine-mannosyl-dextran ([ 99m Tc]MAG 3 -mannosyl-dextran) is a receptor-binding radiotracer that binds to mannose-binding protein, a receptor expressed by reticuloendothelial tissue. This agent is composed of a 10.5-kilodalton molecule of dextran and multiple units of mannose, and benzoyl-mercaptoacetylglycylglycyl-glycine (BzMAG 3 ). The tetraflorophenol-activated ester of BzMAG 3 and the imidate of thiomannose were used to covalently attach BzMAG 3 and mannose to an amino-terminated conjugate of dextran. This yielded a 19-kilodalton macromolecule consisting of 3 BzMAG 3 and 21 mannose units per dextran. Dynamic light scattering was used to measure a mean diameter of 5.5 nanometers for BzMAG 3 -mannosyl-dextran and 0.28 microns for filtered Tc-99m sulfur colloid. A preliminary sentinel node detection study employing right fore and hind footpad injections of [ 99m Tc]MAG 3 -mannosyl-dextran and left fore and hind footpad injections of filtered Tc-99m sulfur colloid demonstrated greater sentinel lymph node uptake by the receptor-binding agent

  10. 99mTc-Hynic-minigastrin 1: a promising radiopharmaceutical for imaging gastrin/CCK-positive tumors: preclinical evaluation

    International Nuclear Information System (INIS)

    Guggenberg, E. von; Decristoforo, C.; Behe, M.; Behr, T.

    2002-01-01

    Full text: Gastrin/CCK receptors are over expressed in a number of tumors such as MW and SCLC. Therefore gastrin analogues binding to the CCK-B receptor are. promising peptides for Nuclear Medicine imaging. Recently minigastrin 1 has been labeled with 131 I, 111 In and 90 Y (Behr et al 1999). HYNIC as bifunctional chelator has shown favorable properties for 99m Tc-labeling of small peptides. The aim of this study was the preparation, 99m Tc-labeling and evaluation in vitro and in vivo of HYNIC-minigastrin 1. HYNIC-minigastrin 1 was prepared by coupling protected HYNIC to minigastrin immobilized on a resin, followed by TFA cleavage and HPLC purification. The peptide was characterized by RP-HPLC and MS. 99m Tc-labeling was performed using different coligands, such as tricine, EDDA, tricine ternary ligand systems. In vitro stability was tested in plasma and towards cystein, plasma protein binding was determined. Receptor binding assays using a CCK-B receptor positive cellline (AR42J) were performed and biodistribution in normal Wistar rats was studied with a gamma camera followed by dissection. At specific activities >1 Ci/μmol HYNIC-minigastrin 1 could be labeled with yields >95 % only using tricine as coligand. Other coligands or addition of a ternary ligand failed to give reasonable labeling yields. Two isomers of 99m Tc-tricine-HYNIC-minigastrin 1 were observed. At higher temperature quantitative yields of a stable isomer with high hydrophilicity, low protein binding and low intestinal excretion in rat biodistribution studies was obtained. Overall biodistribution in rats was similar to 111 In-DTPA-minigastrin 1 with rapid renal excretion and high kidney retention. 99m Tc-Tricine-HYNIC-minigastrin could be displaced by unlabelled Minigastrin from AR4-2J cell-membranes. A gastrin derivative could be labeled at high specific activities with 99m Tc showing isomerism dependent on labeling conditions. 99m Tc-labelled HYNIC-minigastrin 1 shows promising in vitro and in

  11. Synthesis, labeling with {sup 99m}Tc and biokinetics of brains scintigraphy diaminodithiol perfusion radiopharmaceuticals; Sintese, marcacao com {sup 99m}Tc e biocinetica de radiofarmacos perfusorios diaminoditiolicos para cintilografias cerebrais

    Energy Technology Data Exchange (ETDEWEB)

    Goncalves, Marcos Moises

    1999-07-01

    The recent tomography status using radiopharmaceuticals have been contributing greatly with the 'age of certainty' in the diagnosis examination of syndromes, pathologies and clinical signs, because they can evidence some phenomena occurring in a molecular manner. The purpose of this work have had the development of new diaminodithiol (DADT) perfusion radiopharmaceuticals to be used in brain diagnosis using S.P.E.T. (Single Photon Emission Tomography). Initially, the rational planning had been performed with the new DADT molecular structures as radiopharmaceutical candidates. Using of Q.S.A.R. (Quantitative Structure Activity Relationship) techniques, the molecular descriptors such as partition coefficient and effective polarizability, have been studied in order to increase the blood brain barrier transport and the brain uptake respectively. Applying the Q.S.P.R. (Quantitative Structure Property Relationship) concepts to perform drug latentiation, based on bio-labile functional groups, the congener DADT derivative has been transformed into a pro-drug that works as a DADT moiety carrier, allowing the increasing of brain radiopharmaceutical uptake. Later on, synthetic routes and chemical purifications have been developed allowing the creation of the proposed chemical structure. Each new DADT derivative has been synthesized and analyzed in terms of elemental analysis, infrared and NMR spectra, in order to confirm its proposed chemical structure. Then, the new derivative has been labeled with {sup 99m}Tc, radiochemically purified, intravenously injected in Swiss mice, allowing its biodistribution to evidence its brain transport and uptake. The rational planning studies have been re-evaluated after each biodistribution had been performed, to see what kind of molecular descriptor was responsible for causing a stronger optimization in the brain perfusion characteristics and then, new DADT derivatives have been prepared. Three new DADT derivatives have been

  12. Synthesis, labeling with {sup 99m}Tc and biokinetics of brains scintigraphy diaminodithiol perfusion radiopharmaceuticals; Sintese, marcacao com {sup 99m}Tc e biocinetica de radiofarmacos perfusorios diaminoditiolicos para cintilografias cerebrais

    Energy Technology Data Exchange (ETDEWEB)

    Goncalves, Marcos Moises

    1999-07-01

    The recent tomography status using radiopharmaceuticals have been contributing greatly with the 'age of certainty' in the diagnosis examination of syndromes, pathologies and clinical signs, because they can evidence some phenomena occurring in a molecular manner. The purpose of this work have had the development of new diaminodithiol (DADT) perfusion radiopharmaceuticals to be used in brain diagnosis using S.P.E.T. (Single Photon Emission Tomography). Initially, the rational planning had been performed with the new DADT molecular structures as radiopharmaceutical candidates. Using of Q.S.A.R. (Quantitative Structure Activity Relationship) techniques, the molecular descriptors such as partition coefficient and effective polarizability, have been studied in order to increase the blood brain barrier transport and the brain uptake respectively. Applying the Q.S.P.R. (Quantitative Structure Property Relationship) concepts to perform drug latentiation, based on bio-labile functional groups, the congener DADT derivative has been transformed into a pro-drug that works as a DADT moiety carrier, allowing the increasing of brain radiopharmaceutical uptake. Later on, synthetic routes and chemical purifications have been developed allowing the creation of the proposed chemical structure. Each new DADT derivative has been synthesized and analyzed in terms of elemental analysis, infrared and NMR spectra, in order to confirm its proposed chemical structure. Then, the new derivative has been labeled with {sup 99m}Tc, radiochemically purified, intravenously injected in Swiss mice, allowing its biodistribution to evidence its brain transport and uptake. The rational planning studies have been re-evaluated after each biodistribution had been performed, to see what kind of molecular descriptor was responsible for causing a stronger optimization in the brain perfusion characteristics and then, new DADT derivatives have been prepared. Three new DADT derivatives have been obtained by

  13. Testing the radiochemical purity of radiopharmaceuticals: application to {sup 99m}Tc-HMPAO; Controle de la purete radiochimique des radiopharmaceutiques: application au {sup 99m}Tc-HMPAO

    Energy Technology Data Exchange (ETDEWEB)

    Ait Ben Ali, S.; Darsin, D.; Rizzo, N.; Lours, S.; De Beco, V.; Dumont, A.; Goudou-Sinha, C.; Izembart, M.; Jourdain, J.R.; Lemercier, V.; Linsker, S.; Moati, F.; Piketty, M.L.; Schlageter, M.H.; Moretti, J.L. [Groupe de travail `Radiopharmaceutique - Ile de France` (France)

    1997-12-31

    The low stability of {sup 99m}Tc-HMPAO imposes to carry out the quality testing within the 15 minutes following the preparation. This study has the aim of comparing different methods of radiochemical purity determination (RP) of this radiopharmaceutical in order to validate a fast, reproducible, feasible technique, capable of separating the primary lipophilic {sup 99m}Tc-HMPAO (I) of impurities: hydrophilic secondary complex (II), TcO{sub 4}{sup -}, reduced and halyards Tc. The reference technique associating two thin-layer chromatographies (TLC), `C1` and `C2`, has been compared with a TLC `W` technique and with liquid-liquid extraction `E` technique: C1 - stationary phase, ITLC Silica gel/mobile phase, Butanone-2; C2 - stationary phase, ITLC Silica gel/mobile phase, 0.9% NaCl; W - stationary phase, Papier Whatman n{sup o} 1/mobile phase, Ether; E - extraction with ethyls acetate /0.9% NaCl (1/1 v/v). The `C1` chromatography allows isolating the reduced Tc and the complex II, the `C2` chromatography does the same with TcO{sub 4}{sup -} but it requires too long techniques (20 min.). The `W` and `E` techniques are rapid, reproducible and allow to separate the complex I from the other impurities without discrimination. However, as their results depend upon the deposited quantity of sampling, an optimization and standardization of the techniques are necessary. A forth technique by chromatography on Sep-Pak column is to be evaluated

  14. Application of photoactivation in the preparation of radiopharmaceuticals. Pt. 3. Human serum albumin labelled with technetium (99mTc)

    International Nuclear Information System (INIS)

    Komarek, P.; Kleisner, I.; Konopkova, M.; Komarkova, I.

    1997-01-01

    Human serum albumin was photoactivated with UV light at 254 nm and labelled with technetium ( 99m Tc) by reducing pertechnetate ( 99m Tc) with stannous chloride. Radiochemical purity was determined by using paper chromatography, columns and electrophoresis. The biodistribution of labelled albumin in rats was assessed by activity counting in isolated organs 15 and 60 minutes after administration. Photoactivation increases the number of free SH groups, which affect favourably the labelling efficiency. Irradiated albumin exhibits a higher labelling efficiency (99%) than non-irradiated albumin (96%). The structural changes depend on the UV radiation dose, concentration of irradiated substances, and metal ion content (Sn 2+ ). The results obtained suggest that the elimination from blood of albumin whose structure has been altered by photoactivation can be accelerated, thereby creating favourable conditions for its application in the diagnosis of inflammatory diseases. (author)

  15. New bis(dithiocarboxylato)nitridotechnetium-99m radiopharmaceuticals for leucocyte labelling: In vitro and in vivo studies

    Energy Technology Data Exchange (ETDEWEB)

    Demaimay, F.; Noiret, N.; Roucoux, A. E-mail: Alain.Roucoux@univ-Rennes1.Fr; Patin, H.; Bellande, E.; Pasqualini, R.; Moisan, A

    1997-07-01

    Dithiocarboxylate ligands were synthesized and characterized. New nitrido 99m-technetium complexes were obtained with these ligands and identified by thin layer chromatography. The nitrido complexes were tested in vitro in whole blood for leucocyte labelling and the design of the ligand was optimized. Best results were obtained with aliphatic linear ligands, containing 9 to 11 atoms of carbon. The in vivo experiment failed because an inflammated area could not be visualized by {gamma} imaging, the cell labelling mechanism being probably different.

  16. New bis(dithiocarboxylato)nitridotechnetium-99m radiopharmaceuticals for leucocyte labelling: In vitro and in vivo studies

    International Nuclear Information System (INIS)

    Demaimay, F.; Noiret, N.; Roucoux, A.; Patin, H.; Bellande, E.; Pasqualini, R.; Moisan, A.

    1997-01-01

    Dithiocarboxylate ligands were synthesized and characterized. New nitrido 99m-technetium complexes were obtained with these ligands and identified by thin layer chromatography. The nitrido complexes were tested in vitro in whole blood for leucocyte labelling and the design of the ligand was optimized. Best results were obtained with aliphatic linear ligands, containing 9 to 11 atoms of carbon. The in vivo experiment failed because an inflammated area could not be visualized by γ imaging, the cell labelling mechanism being probably different

  17. Technetium-99m-Labeled Sulfadiazine: a Targeting Radiopharmaceutical for Scintigraphic Imaging of Infectious Foci Due To Escherichia coli in Mouse and Rabbit Models.

    Science.gov (United States)

    Ahmed, Muhammad Tauqeer; Naqvi, Syed Ali Raza; Rasheed, Rashid; Zahoor, Ameer Fawad; Usman, Muhammad; Hussain, Zaib

    2017-09-01

    Bacterial infection is one of the vital reasons of morbidity and mortality, especially in developing countries. It appears silently without bothering the geological borders and imposes a grave threat to humanity. Nuclear medicine technique has an important role in helping early diagnosis of deep-seated infections. The aim of this study was to develop a new radiopharmaceutical 99m Tc-labeling sulfadiazine as an infection imaging agent. Radiolabeling of sulfadiazine with technetium-99m ( 99m Tc) was carried out using stannous tartrate as a reducing agent in the presence of gentistic acid at pH = 5. The quality control tests revealed ~98% labeling efficiency. Paper chromatographic (PC) and instant thin-layer chromatographic (ITLC) techniques were used to analyze radiochemical yield. Biodistribution and infection specificity of the radiotracer were performed with Escherichia coli (E. coli) infection-induced rats. Scintigraphy and glomerular filtration rate (GFR) study was performed in E. coli-infected rabbits. Scintigraphy indicated E. coli infection targeting potential of 99m Tc-SDZ, while biodistribution study showed minimal uptake of 99m Tc-SDZ in non-targeted tissues. The uptake in the kidneys was found 2.56 ± 0.06, 2.09 ± 0.10, and 1.68 ± 0.09% at 30 min, 1 h, and 4 h, respectively. The infected muscle (target) to non-infected muscle (non-target) ratio (T/NT) was found 4.49 ± 0.04, 6.78 ± 0.07, and 5.59 ± 0.08 at 30 min, 1 h, and 4 h, respectively.

  18. An improved method for determination of technetium-99m half-life for the quality assurance procedures of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Abd Jalil Abd Hamid; Juhari Mohd Yusof; Zakaria Ibrahim; Wan Mohd Ferdaus Wan Ishak; Mohamad Hafiz Ahmad

    2009-01-01

    An improve method for identity tests of technetium-99m for the quality assurance procedures are presented. Computerized methods based on the least-squares of decay curve fitting for half-life estimation of technetium-99m was tested. Thus, least-squares method was employ as a decay curve fitting procedures in our software. Theoretical calculated half-life of technetium-99m for evaluation was performed for comparison. In Fig. 3 is shown, the decay curve fitting of a sample over one second counting time interval. The R2 value of the curve suggests that the time of the study was too short to obtain acceptable value. A similar measurement for another data set was done for a longer period of time and in Table 1 is shown a representative decay curve fitting. The value was found to be 6.006 hours with a discrepancy of -0.28% from the value taken from the literature. The value is in agreement with the literature for time interval greater than 2 seconds. The results obtained by this method show that the used of least-squares method for decay curve fitting are appropriate for routine identity tests. This confirmed that the least-squares method applied in our decay curve fitting software are remarkably improved and convenient for routine identity tests purposes. (Author)

  19. Biodistribution dosimetric study of radiopharmaceutical 99mTc Ixolaris in mice for melanoma diagnosis by molecular image and translational model for human beings

    International Nuclear Information System (INIS)

    Soriano, Sarah Canuto Silva

    2015-01-01

    The labeling of Ixolaris with 99m Tc was developed by Barboza et.al. (2013) aiming its use primarily in glioblastoma and after in melanoma diagnosis, a less common but very aggressive cancer and with high mortality rate. Preliminary tests on animals have proven its effectiveness of labeling but a dosimetric study to human clinical trials should be performed. This study aimed to: (1) determine the biokinetic model for the radiotracer 99m Tc-Ixolaris in mice by imaging dosimetry method; and (2) estimate the absorbed and effective dose resulting from the use of a new radiopharmaceutical for melanoma and metastases diagnosis in human beings, since a dosimetric study of new radiopharmaceuticals in animals is necessary to test them subsequently in humans and apply for registration in ANVISA. According to SPECT images, was found a latency period of 15 to 21 days for the development of lung metastasis in mice. Three C57BL6 mice, one control animal, and two animals with induced cell line B16-F10 murine melanoma were tested. The 99m Tc-Ixolaris radiopharmaceutical was administered intravenously in a caudal vein, and SPECT images were acquired 0.5 h, 1.5 h, 2.5 h, 3.5 h and 24 h post-administration for analysis and biodistribution quantification. The biokinetic model was determined and thus, obtained cumulative activity in order to estimate the absorbed dose in each organ. The mass and metabolic differences between mice and humans were considered and used to extrapolate the data acquired at different scales. Based on dose factors provided by the software MIRDOSE and Olinda (S factor), absorbed doses in irradiated target organs were calculated for the source organs, and finally the effective dose was estimated. The results indicate that for diagnostic exams conducted in human melanoma patients by administering approximately 25.7 MBq the estimated effective dose was 4.3 mSv. Comparing with effective doses obtained in other diagnostic techniques with 99m Tc, a range of effective

  20. Detection of active alveolar bone destruction in human periodontal disease by analysis of radiopharmaceutical uptake after a single injection of 99m-Tc-methylene diphosphonate

    International Nuclear Information System (INIS)

    Jeffcoat, M.K.; Williams, R.C.; Holman, B.L.; English, R.; Goldhaber, P.

    1986-01-01

    Previous studies have shown that, following a single injection of 99m-Tc-MDP, measurement of bone-seeking radiopharmaceutical uptake can detect ''active'' alveolar bone loss due to periodontal disease in beagle dogs, as determined by radiographs taken at the time of, and several months after, the nuclear medicine procedure. The efficacy of this diagnostic test, however, had not been assessed in human periodontal disease. The ability of a single boneseeking radiopharmaceutical uptake examination to detect ''active'' alveolar bone loss due to periodontal disease in human patients was assessed by comparing a single uptake measurement to the rate of bone loss determined from serial radiographs taken over a 6-month period. Uptake was expressed as a ratio of the cpm from the alveolar bone divided by the cpm from the non-tooth supporting bone of the nuchal crest. High uptake ratios were associated with ''active'' loss and low uptake ratios were associated with little if any change in alveolar bone height (p<0.001). The nuclear medicine examination was an accurate detector of periodontal disease activity in nearly 80% of the individual teeth studied. These data indicate that high bone-seeking radiopharmaceutical uptake ratios may be pathognomonic of active bone loss in human periodontal disease. (author)

  1. Detection of active alveolar bone destruction in human periodontal disease by analysis of radiopharmaceutical uptake after a single injection of 99m-Tc-methylene diphosphonate

    Energy Technology Data Exchange (ETDEWEB)

    Jeffcoat, M.K.; Williams, R.C.; Holman, B.L.; English, R.; Goldhaber, P.

    1986-01-01

    Previous studies have shown that, following a single injection of 99m-Tc-MDP, measurement of bone-seeking radiopharmaceutical uptake can detect ''active'' alveolar bone loss due to periodontal disease in beagle dogs, as determined by radiographs taken at the time of, and several months after, the nuclear medicine procedure. The efficacy of this diagnostic test, however, had not been assessed in human periodontal disease. The ability of a single boneseeking radiopharmaceutical uptake examination to detect ''active'' alveolar bone loss due to periodontal disease in human patients was assessed by comparing a single uptake measurement to the rate of bone loss determined from serial radiographs taken over a 6-month period. Uptake was expressed as a ratio of the cpm from the alveolar bone divided by the cpm from the non-tooth supporting bone of the nuchal crest. High uptake ratios were associated with ''active'' loss and low uptake ratios were associated with little if any change in alveolar bone height (p<0.001). The nuclear medicine examination was an accurate detector of periodontal disease activity in nearly 80% of the individual teeth studied. These data indicate that high bone-seeking radiopharmaceutical uptake ratios may be pathognomonic of active bone loss in human periodontal disease.

  2. PEGylated N-methyl-S-methyl dithiocarbazate as a new reagent for the high-yield preparation of nitrido Tc-99m and Re-188 radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Boschi, Alessandra, E-mail: alessandra.boschi@unife.i [Laboratory of Nuclear Medicine, Department of Radiological Sciences, University of Ferrara, 44100 Ferrara (Italy); Massi, Alessandro [Department of Chemistry, University of Ferrara, 44100 Ferrara (Italy); Uccelli, Licia; Pasquali, Micol; Duatti, Adriano [Laboratory of Nuclear Medicine, Department of Radiological Sciences, University of Ferrara, 44100 Ferrara (Italy)

    2010-11-15

    A novel nitrido nitrogen atom donor for the preparation of {sup 99m}Tc and {sup 188}Re radiopharmaceuticals containing a metal-nitrogen multiple bond is presented. HO{sub 2}C-PEG{sub 600}-DTCZ was obtained by conjugation of N-methyl-S-methyl dithiocarbazate [H{sub 2}N-N(CH{sub 3})-C({identical_to}S)SCH{sub 3}, HDTCZ] with polyethylene glycol 600 (PEG{sub 600}). Asymmetrical heterocomplexes of the type [M(N)(PNP)(B)]{sup 0/+} (M={sup 99m}Tc, {sup 188}Re; PNP=diphosphine ligands, B=DBODC, DEDC, NSH, H{sub 2}OS, CysNAc, HDTCZ) and symmetrical nitride compounds of the type [M(N)(L){sub 2}] (L=DEDC, DPDC) have been prepared in high yield by using the newly designed nitride nitrogen atom donor HO{sub 2}C-PEG{sub 600}-DTCZ. A two-step procedure was applied for preparing the above symmetrical and asymmetrical complexes. The first step involved the preliminary formation of a mixture of nitride Tc-99m or Re-188 precursors, which contained the [M{identical_to}N]{sup 2+} core, through reduction of generator-eluted {sup 99m}Tc-pertechnetate or {sup 188}Re-perrhenate with thin (II) chloride in the presence of HO{sub 2}C-PEG{sub 600}-DTCZ. In the second step, the intermediate mixture was converted either in the final mixed asymmetrical complex by the simultaneous addition of diphosphine ligand and the suitable bidentate ligand B, or in the final symmetrical complex by the only addition of the bidentate ligand L. It was also demonstrated that the novel water-soluble nitride nitrogen atom donor HO{sub 2}C-PEG{sub 600}-DTCZ did not show coordinating properties toward the M{identical_to}N ({sup 99m}Tc, {sup 188}Re) core. Biodistribution studies in rats of the hitherto unreported [{sup 99m}Tc(N)(PNP{sub 3})DTCZ]{sup +} and [{sup 99m}Tc(N)(PNP{sub 5})DTCZ]{sup +} complexes showed that they selectively localize in the myocardium of rats with a favourable heart-to-lung and heart-to-liver uptake ratios. In particular, the heart-to-lung and heart-to-liver uptake ratios dramatically

  3. Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Hunt, F C; Wilson, J G

    1980-03-13

    The claim describes a reducing metal complex of a compound in a suitable form for labelling with technetium-99m for radiopharmaceutical purposes, the compound being a complex derived from an indene heterocycle structure. The indene heterocycle structure is selected from the group consisting of iminodiacetic acid derivates of benzimidazole, benzthiazole and benzoxazole.

  4. Scintigraphic evaluation of soft tissue tumors with technetium(V)-99m dimercaptosuccinic acid, a new tumor seeking radiopharmaceutical

    International Nuclear Information System (INIS)

    Ohta, H.; Yoshizumi, M.; Endo, K.; Torizuka, K.; Yokoyama, A.; Yamamoto, K.

    1984-01-01

    Recently, a very promising tumor seeking agent, a Tc(V)-99m dimercaptosuccinic acid (Tc(V)-DMS), which was labelled under optimal pH 8 and very low SnCl/sub 2/ concentrations, has been developed. An equilibrium between a stable form and a dissociated form of anion TcO/sub 4//sup 3-/, structural similarity to PO/sub 4//sup 3-/, postulated for tumor uptake. And the authors have previously reported that Tc(V)-DMS scintigram would be useful in the diagnosis of medullary thyroid carcinoma. In an attempt to widen its applicability, the scintigraphic examinations of soft tissue tumors with Tc(V)-DMS and comparative study with Ga-67 citrate were performed in 58 patients. Scintigrams were made 60-120 min after i.v. administration of 10 mCi Tc(V)-DMS using a conventional gamma camera. Tc(V)-DMS was found to have superior sensitivity of 90% for malignant tumors (including aggressive fibromatosis) to that with Ga-67 citrate of 56%, but inferior specificity of 71% to that with Ga-67 citrate of 80%. And the accuracy of the scan in soft tissue tumors with Tc(V)-DMS and Ga-67 citrate was 78% and 71%, respectively. Although the accumulation of Tc(V)-DMS has been detected in some benign soft tissue tumors and the exact mechanism of Tc(V)-DMS accumulation remains to be elucidated, these data indicated that Tc(V)-DMS scintigraphy would be of great use in the detection of extension or location of malignant soft tissue tumors

  5. A rapid kinetic chromogenic method for quantification of bacterial endotoxins in lyophilized reagents for labeling with 99mTc radiopharmaceuticals

    International Nuclear Information System (INIS)

    Fukumori, Neuza T.O.; Campos, Domingos G.; Silva, Laercio; Fernandes, Adriana V.; Mengatti, Jair; Silva, Constancia P.G.; Matsuda, Margareth M.N.

    2009-01-01

    A rapid quantitative kinetic chromogenic test in an automated Portable Test System (PTS) has been developed for determination of bacterial endotoxins in water, in-process and end-products using the Limulus amebocyte lysate (LAL). The aim of this work was to validate the method for lyophilized reagents for labeling with 99m Tc radiopharmaceuticals with no interfering factors. Experiments were performed in three consecutive batches of the lyophilized reagents Methylenediphosphonic Acid (MDP) and Pyrophosphate (PYRO) produced at IPEN-CNEN/ SP using the PTS from Endosafe, Inc. TM , Charleston, SC. The Maximum Valid Dilution (MVD) was calculated to establish the extent of dilution to avoid interfering test conditions (MVD=500). Better results were obtained above 1:20 dilution factor for MDP and 1:100 for PYRO. The parameters of coefficient correlation (R) -0.980, RPPC between 50 - 200% and coefficient variation (CV) of the samples less than 25% were satisfied and the endotoxin concentration was lower than the lowest concentration of the standard curve (0.05 EU mL -1 ), therefore less than the established limit in pharmacopoeias. The PTS is a rapid, simple and accurate technique using the quantitative kinetic chromogenic method for bacterial endotoxin determination. For this reason, it is very practical in the radiopharmaceutical area and it trends to be the method of choice for the pyrogen test. For MDP and PYRO, the validation was successfully performed. (author)

  6. Synthesis and evaluation in vitro in cancer cells AR42J of the radiopharmaceutical 99mTc-Tyr3-Octreotide-dendrimer similar of somatostatin

    International Nuclear Information System (INIS)

    Orocio R, E.

    2013-01-01

    The objective of this project was preparing a multimeric system through the conjugation of several molecules of the peptide Tyr 3 -Octreotide to a dendrimer molecule based on Poly-amidoamine (PAMAM), as well as radiolabeled with 99m Tc and evaluating its behavior like new radiopharmaceutical similar of somatostatin. The dendrimer PAMAM generation 3.5 that possesses terminal groups of sodium carboxylate, was functionalized to peptide Tyr 3 -Octreotide through a reaction of peptide coupling with HATU (hexafluorophosphate (V) of 1-oxide-3-(bis(dimethylamino)methylene)-3H-[1,2,3]triazole[4,5-b]pyridine) as activating agent of carboxylate groups using the Size Exclusion Chromatography (Sec) as purification method. The product was characterized by Ultraviolet visible spectrophotometry, Mid-infrared and Far-infrared, Elemental analysis, Energy dispersive X-ray spectroscopy, Scanning electron microscopy, Thermogravimetry and Differential scanning calorimetry. The radiolabeled with 99m Tc was carried out using a direct method that involves the reduction of the anion TcO 4 - with stannous chloride, so that the dendrimer is capable of coordinating to the technetium forming a chelate compound. The radiochemical purity of the radiolabeled compound was determined by thin layer chromatography using a sodium chloride solution to 20% (m/v) as mobile phase and was verified by molecular exclusion chromatography. The radiolabeled compound was possible to obtain it with a radiochemical purity superior to 90%. Also, the specific and not specific union was evaluated of the synthesized compound in mouse pancreas cancer cells AR42J, positive to somatostatin receptors, showing specific recognition for this receptors type with high cellular internalization. The biodistribution studies were carried out in BALB/c mice at different post injection times and in nude mice with induced tumors AR42J. The results showed that the 99m Tc-PAMAM-Tyr 3 -Octreotide is excreted by via renal as hepatobiliary

  7. Studying the biological feasibility of [99mTc(CO)3]-dextran-cysteine-cysteine-mannose as a potential molecular radiopharmaceutical for sentinel node detection

    International Nuclear Information System (INIS)

    Khan, I.U.; Shahid, A.; Ahmad, F.; Dar, U.K.; Ahmad, M.; Javed, M.

    2014-01-01

    The aim of this work was to radiolabel and bioevaluate the technetium-99m labeled dextran dicysteine mannose (DCCM) [ 99 mTc(CO) 3 ]-DCCM for sentinel lymph node detection. Dextran dicysteine mannose was radiolabeled using the carbonyl method. Various parameters were studied such as in vitro stability at room temperature up to 5 h, protein binding and partition coefficient. Bioevaluation was performed in a rabbit model by developing images under a gamma camera at various time intervals. Biodistribution was performed in Wistar rat models (n=3) by dissection and measurement of percent injected dose in various body organs, at 60 and 180 min post-injection intervals. Biodistribution was performed in two different groups of animals: in the first group, the radiolabeled compound was injected at a concentration of 200 μg/ml, thus delivering 10 μg radiolabeled compound at the site of injection; in the second group, the radiolabeled compound was injected at a concentration of 50 μg/ml, delivering 2.5 μg radiolabeled compound at the site of injection. Radiolabeling efficacy was 97.5 ± 1% which remained quite stable till 5 h. Protein binding data show that 71.1 ± 5% drug exhibited binding with blood proteins. Partition coefficient results show that our radiopharmaceutical is quite hydrophilic in nature. It can be inferred from the imaging data that sentinel node can be visualized within 30 min post-injection. Rat dissection data showed that when the radiolabeled compound was injected at a concentration of 50 μg/ml, at 60 min post-injection, ∼2.85% of activity was retained in the sentinel node with a significantly less accumulation, e.g., ∼0.12%, in the secondary node, which resulted in very high popliteal extraction (PE) value, e.g., ∼98%. At 180 min post-injection, 2.46 ± 0.29% was found to be retained in the sentinel node and PE (99.64 ± 0.23%), thus resulting in almost complete washout from the secondary node (0.05 ± 0.01%). The study demonstrates that

  8. Clean room for the production of cold kits: two year experience with the production of kits for 99mTc radiopharmaceuticals

    International Nuclear Information System (INIS)

    Muralidharan, Sheela H.; Nair, Preeti; Ghodke, Archana S.; Pillai, Thara; Sheri, Kumar Uma; Vanaja, R.; Mehra, Kiran S.; Sachdev, S.S.; Sivaprasad, N.

    2010-01-01

    A new clean room has been designed and constructed at Radiopharmaceuticals Programme, BRIT keeping in view the functional aspects for the production of 'cold' kits for the preparation of 99m Tc radiopharmaceuticals for supply to nuclear medicine centers and is in operation, since October, 2008. This clean room is the first clean room in the country designed exclusively for cold kit production. The clean room was validated and trial batches were produced and quality controlled prior to put it in regular production operation. The clean environment is maintained by separate AHU (air handling unit) located out side the clean room. A technical crew maintain the AHU unit and maintain record of parameters such as humidity, air flow, blower speed, chiller temperature etc. During a typical batch production not more than two persons are present in the formulation room. The formulated solution (filtered through 0.22μ membrane filter) is passed though a pass box between the formulation and dispensing area. The no. of people allowed in the dispensing area which is a critical area of class 100 is restricted to not more than four that too no person is allowed to be in between direct flow of HEPA filtered air and the dispensing table. The number of vials to be dispensed is arranged in trays and 1 ml of the formulated sterile solution is dispensed into each vial and the vials are transferred in to the lyophilization chamber. Sterile vials are introduced into class 100 area and the vials are removed after lyophilization though a pass box. After lyophilization vials are sealed with aluminum caps and stored at 2-10 deg C. Since the commissioning of the new clean room, about 120 batches of 10 different kit products were prepared and 1,20,000 kit vials were supplied to various hospitals for nuclear medicine investigation

  9. Gastric emptying scintigraphy: choice by in vitro test, of a new 99mTc marker to label solid phase and further analysis with the better radiopharmaceuticals

    International Nuclear Information System (INIS)

    Blanc, F.

    2005-05-01

    The study of gastric emptying by isotopic method occurs regularly in Brest nuclear medicine department. It consists in eating radiolabelled omelette with rhenium sulphide macro-colloid and in drinking radiolabelled water with 111 In-DTPA. The two phases are followed in stomach with gamma-camera. Rhenium sulphide macro-colloid have been taken off the market in january 2004 and no radiopharmaceutical has replaced them. in vitro test permitted us to test solid phase radiolabeling stability with 5 99m Tc-vectors used in nuclear medicine. Two of them are suitable for gastric emptying solid phase labelling: the tin fluoride colloids and the sodium phytate but tin fluoride colloids give better labelling stability than sodium phytate. In order to define solid phase marker properties, studies of medium composition by X fluorescence, size by laser granulometry, structure by NMR (nuclear magnetic resonance), TLC (thin layer chromatography) and by centrifugation are done either with the two vectors or only with sodium phytate. Structural properties of tin fluoride colloids are known. Results of this study indicate that phytates can be colloids. Finally, the good gastric emptying solid phase marker must be a colloid with a size of about 200 nm. (author)

  10. A novel device for automatic withdrawal and accurate calibration of 99m-technetium radiopharmaceuticals to minimise radiation exposure to nuclear medicine staff and patient

    International Nuclear Information System (INIS)

    Nazififard, M.; Mahdizadeh, S.; Meigooni, A. S.; Alavi, M.; Suh, K. Y.

    2012-01-01

    A Joint Automatic Dispenser Equipment (JADE) has been designed and fabricated for automatic withdrawal and calibration of radiopharmaceutical materials. The thermoluminescent dosemeter procedures have shown a reduction in dose to the technician's hand with this novel dose dispenser system JADE when compared with the manual withdrawal of 99m Tc. This system helps to increase the precision of calibration and to minimise the radiation dose to the hands and body of the workers. This paper describes the structure of this device, its function and user-friendliness, and its efficacy. The efficacy of this device was determined by measuring the radiation dose delivered to the hands of the nuclear medicine laboratory technician. The user-friendliness of JADE has been examined. The automatic withdrawal and calibration offered by this system reduces the dose to the technician's hand to a level below the maximum permissible dose stipulated by the international protocols. This research will serve as a backbone for future study about the safe use of ionising radiation in medicine. (authors)

  11. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures

    International Nuclear Information System (INIS)

    Heineman, W.R.

    1992-01-01

    The long-range objective of this research program is the development of more efficacious technetium-99m radiopharmaceuticals for use as imaging agents in diagnostic nuclear medicine. We seek to isolate and develop distinct site imaging agents, each of which has properties optimized to provide diagnostic information concerning a given pathological condition. The specific objectives during the period (9/1/89 to 8/31/92) include: (1) Development of strategies for improving yields of specific Tc-diphosphonate complexes with optimum imaging properties; (2) Development of electrodes for rapid in situ electrochemical generation of skeletal imaging agents; (3) Development of electrochemical sensors for T c and Re imaging agents; (4) Characterization of stable T c - and Re-diphosphonate complexes obtainable in high yield by structural studies with techniques such as NMR, EXAFS, and Raman spectroscopy; (5) Development of improved separation techniques for the characterization of diphosphonate skeletal imaging agents; (6) Evaluation of the effect of the biological milieu on T c -diphosphonate complexes; and (7) Electrochemical studies of technetium and rhenium complexes synthesized by Professor Deutsch's research group for heart and brain imaging

  12. Optimization of the production process of a lyophilized formulation for radiopharmaceutical obtaining {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]{sub 2}; Optimizacion del proceso de fabricacion de una formulacion liofilizada para la obtencion del radiofarmaco {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]{sub 2}

    Energy Technology Data Exchange (ETDEWEB)

    Sanchez R, S.

    2013-07-01

    In this work was optimized the production process of a lyophilized pharmaceutical formulation for the preparation of radiopharmaceutical {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]{sub 2}, the union specifies to the integrin s α{sub v}β{sub 3} was demonstrated to be used in the nuclear medicine cabinets in the obtaining of scan images for the opportune detection of breast cancer. The good lyophilized pharmaceutical formulation for the preparation of radiopharmaceutical {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]{sub 2} was established like: HYNIC-E-[c(RGDfK)]{sub 2} - 25 μg; Stannous chloride (SnCl{sub 2}) 20 μg; Ethylenediamine diacetic acid (EDDA) 10 mg; N-tris(hydroxymethyl)methyl glycin (Tricine) 20 mg; Mannitol 50 mg. The results of radiochemical purity of the sterile formulation and free of bacterial endotoxins for the three validation lots prepared under protocols of good manufacturing practices were 97.62 ± 1.48%, 96.54 ± 1.89%, and 97.66 ± 0.57%, for what the production procedure complies the predefined specifications. The radiopharmaceutical {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]2 prepared from the lyophilized pharmaceutical formulation showed to be stable during a period 24 hours, for what can be used in the centers of molecular nuclear medicine. Images in vivo were obtained of the integrin s over-expression α{sub v}β{sub 3} from the radiopharmaceutical {sup 99m}Tc-EDDA/HYNIC-E-[c(RGDfK)]2 obtained of the lyophilized and optimized pharmaceutical formulation. The lyophilized pharmaceutical formulation (HYNIC-RGD-Sn) showed stability during 12 months, due to this factor, is requested before the COFEPRIS the radiopharmaceutical expiration for this same period (accession number 123300401A0155). (Author)

  13. Influence of a reducing agent used to prepare radiopharmaceuticals labeled with technetium-99m on the adhesive properties of Corynebacterium diphtheriae strains

    International Nuclear Information System (INIS)

    Souza, S.M.; Bernardo-Filho, M.; Hirata, R. Jr.; Moreira, L.O.; Mattos-Guaraldi, A.L.

    2002-01-01

    Aim: In this work we investigated the influence of stannous chloride (SnCl 2 ) used in nuclear medicine as a reducing agent to prepare radiopharmaceuticals labeled with technetium-99m, on the survival and adhesive properties of two toxigenic C. diphtheriae of the sucrose fermenting (241strain) and non fermenting (CDC-E8392 strain) biotypes. Materials and Methods: Bacterial strains were submitted to survival and filamentation induction assays using different concentrations of SnCl 2 . The influence of SnCl 2 on the adhesive properties of C.diphtheriae were evaluated by bacterial autoaggregation, haemagglutination, adherence to glass surface and lectin-binding assays. Results: Differences in survival fractions suggested differences in susceptibility of microorganisms to bactericidal effect of stannous chloride. A percentage of 0.4% bacterial cells of no.241 strain and 0.04% of CDC-E8392 strain survived after 220 μl ml -1 SnCl 2 treatment. Results of both polystyrene and spontaneous autoaggregation tests showed an increase in the hydrophobic surface properties of C. diphtheriae strains. SnCl 2 induced spontaneous bacterial autoaggregation of sucrose fermenting 241 strain. SnCl 2 enhanced adherence to glass and totally inhibited the haemagglutinating activity of the non-sucrose fermenting strain CDC-E8392 strain (original titer=32). Decrease in haemagglutinatination was dependent on the concentration of SnCl 2 used. Lectin-binding assays demonstrated increase in the expression of cell surface receptors to lectin with affinity for molecules containing mannose residues after treatment with SnCl 2 . The presence of SnCl 2 induced differences in the expression of bacterial surface carbohydrates possibly related with differences in degrees of haemagglutination and adherence to glass of diphtheria bacilli. Conclusion: The presence of SnCl 2 may influence on the adhesive properties of bacterial pathogens. The occurrence of cell filamentation suggests a potential genotoxicity

  14. Preparation of the radiopharmaceutical {sup 99m} Tc-HYNIC-cyclo-Lys-D-Phe-RGD for In vivo image of integrines; Preparacion del radiofarmaco {sup 99m} Tc-HYNIC-ciclo-Lys-D-Phe-RGD para imagen In vivo de integrinas

    Energy Technology Data Exchange (ETDEWEB)

    Hernandez H, E [ININ, 52750 La Marquesa, Estado de Mexico (Mexico)

    2007-07-01

    The diagnostic of some pathological processes by means of images constitutes one of the used methods in the determination of the origin, condition and/or evolution of one illness. The use of contrast agents in conjunction with other techniques help to the obtaining and visualization of complex systems, among these we can find to those radiopharmaceuticals used in nuclear medicine to visualize diverse organs and corporal systems. At the moment it is sought to develop a radiopharmaceutical of third generation that can be used for image In vivo of integrines with the purpose of detecting angio genesis processes, that which would allow to diagnose in way it specifies a wide range of primary tumors and their metastasis. Presently work it developed the radiopharmaceutical {sup 99m}Tc-HYNIC-cycle-Lys-D-Phe-RGD, likewise the good conditions were determined for the formation of this complex. The HYNIC was employee as chelating agent, using as co ligands EDDA and Tricine for to complete the sphere of coordination of the {sup 99m}Tc. The conjugated HYNIC-RGD was synthesized, purified, characterized and radiolabelled In situ with {sup 99m}Tc using High pressure liquid chromatography as analysis method in Reverse Phase (RP-HPLC). By this way it was developed the lyophilized formulation for its instantaneous labelled to which were carried out quality control tests. The one conjugated was obtained free of impurities, showing stability at same as their complex formed with {sup 99m}Tc. The analysis method was validated turning out to be necessary, exact, lineal and specific for the quantification of the analyte of interest. The lyophilized formulation showed a radiochemical purity bigger than 95%, besides being sterile and free of pyrogens. The biodistribution tests in athymic mice with induced tumors showed that the radiopharmaceutical was united mainly to the tumor and that this it was excreted mainly for renal via. (Author)

  15. Evaluation of the internalization kinetics of the radiopharmaceutical 99mTc-N2S2-Tat(49-57)Lys3-Bn with diagnostic purposes, using comet assay

    International Nuclear Information System (INIS)

    Luna G, M. A.

    2011-01-01

    Gastrin-rea leasing peptide receptors (GRP-r) are over expressed in breast and prostate cancer cells. Bombesin (Bn) binds specifically and strongly to GRP-r and this is the base for to label the Bn with radionuclides by gamma rays. Tat (49-57) is a peptide that across the cell membrane easily so that, when it is conjugated to different proteins, it can works as a Trojan horse, facilitating the drug internalization to the cells. The radiopharmaceutical 99m Tc-N 2 S 2 -Tat(49-57)-Lys 3 -Bn was prepared for diagnosis and therapy at early stage of breast cancer. The objective of this study was to determine the role of Tat in the internalization kinetics of radiopharmaceuticals measured by DNA damage induced by means of comet assay. Human lymphocytes were treated with the following protocols: a) Tat-Bn, b) 99m Tc-Bn, or c) 99m Tc-N 2 S 2 -Tat(49-57)-Lys 3 -Bn, also an untreated group was conformed. The internalization was evaluated at 0, 5, 10, 15, 30 and 60 min after exposure with three repetitions each one, and for radiopharmaceuticals with 2.9, 6.6, 9.0 and 14.8 MBq activities. DNA damage was scored in 100 cells per time and treatment, as tail length and tail moment. A Kruskal-Wallis variance analysis with p≤ 0.05 was applied for comparison between treatments. The results showed that the damage caused by 99m Tc-N 2 S 2 -Tat(49-57)-Lys 3 -Bn is significantly higher than that caused by 99m Tc-Bn and Tat-Bn, showing that Tat favors the internalization of the radiopharmaceutical. (Author)

  16. Testing the radiochemical purity of a radiopharmaceutical: study of {sup 99m}Tc-Tetrofosmin (Myoview); Controle de la purete radiochimique d`un radiopharmaceutique: etude du {sup 99m}Tc-Tetrofosmin (Myoview)

    Energy Technology Data Exchange (ETDEWEB)

    Moati, F.; Quartarone, C.; Jourdain, J.R.; Rizzo, N.; Dumont, A.; De Beco, V.; Ait Ben Ali, S.; Lours, S.; Piketty, M.L.; Izembart, M.; Goudou, C.; Lemercier, V.; Schlageter, M.H.; Moretti, J.L.; Progent, A. [Groupe de travail `Radiopharmaceutiques - Ile de France` (France)

    1997-12-31

    The goal of this study is to optimize the testing method of radiochemical purity (RCP) of {sup 99m}Tc-Tetrofosmin proposed by the Amersham Company: thin-layer chromatography (TLC); ITLC-SG support, migration on 15 Cm; acetone-dichloromethane mobile phase, (35/65, v/v), This technique allows separating the reduced-Tc (Rf = 0), the TcO{sub 4}{sup -} (Rf = 1), and in intermediary position (0.299m}Tc-Tetrofosmin. The results of RCP depend on working conditions, particularly, on the volume of deposit (10 to 20 {mu}l, expected). If the deposited is too small, the {sup 99m}Tc-Tetrofosmin does not migrate. With a volume of 20 {mu}l, the separation is weak and the peak width is un-resolvable. The results obtained correspond to the following operational conditions: migration on 8 cm; deposit of 8 to 10 {mu}l; no drying. In these conditions the peak of {sup 99m}Tc-Tetrofosmin is well singled out: migration Rf of 0.375 to 0.625. These results have been obtained by the analysis of radio-chromatographic peak. Every strip has been cut cm by cm and the activity was measured by a gamma counter. Repeatability of the method on a series of 8 tests is good: average RCP 93.22%, mean value = 93.24%. The reproducibility was realized by measuring directly by the activity-meter the activity corresponding to 3 identifiable peaks: Reduced Tc (Rf < 0.25), TcO{sub 4}{sup -} (Rf < 0.75), and {sup 99m}Tc-Tetrofosmin (0.25 < Rf < 0.75). On the 21 effectuated tests the inter-test RCP reproducibility was good: average value = 95.24%, CV = 2.07%, mean value 95.3%. In conclusion, the miniaturization improves the separation by Myoview (0.25 < Rf < 0.75), diminishes the migration time by a factor 4 and lowers the reactive cost of testing by 50%

  17. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by characterization of radiopharmaceuticals. Final report, September 1, 1992--June 30, 1998

    International Nuclear Information System (INIS)

    Heineman, W.R.; Seliskar, C.J.

    1998-01-01

    The primary goals of this project were twofold: (1) Development of a microsensor that would demonstrate the capability for in vivo monitoring of a radiopharmaceutical after its injection into a test animal; and (2) Exploration of capillary electrophoresis (CE) as a separation technique for the analysis of radiopharmaceuticals that are mixtures of different compounds. The combination of in vivo sensors for real-time monitoring of specific chemical states of a radiopharmaceutical in individual organs and CE for analysis of radiopharmaceuticals prior to injection would provide valuable information regarding the fate of an imaging agent after administration. Such information should give insight into strategies for the development of more efficacious radiopharmaceuticals

  18. Evaluation of the quality of the radiopharmaceutical 99mTc-MIBI and its influence on image quality in myocardial perfusion scintigraphy; Avaliacao da qualidade do radiofarmaco {sup 99m}Tc-MIBI e sua influencia na qualidade da imagem em cintilografia de perfusao do miocardio

    Energy Technology Data Exchange (ETDEWEB)

    Santos, Poliane Angelo de Lucena

    2013-07-01

    This study evaluated the quality of the {sup 99m}Tc-MIBI radiopharmaceutical from different manufacturers, used in three nuclear medicine services (NMS) in Recife-PE, through labeling procedure of each service. It was observed their biodistribution by quantifying the activity present in the organs of interest (heart / liver), the influence and interference in image quality and in myocardial scintigraphy diagnosis exam. In these NMS (A, B and C) were done quality controls in the eluates of {sup 99}Mo/{sup 99m}Tc generators (radionuclidic, chemical and radiochemical purity and pH) and of the {sup 99m}Tc-MIBI radiopharmaceutical (radiochemical purity and pH) used in myocardial scintigraphy exam. In the case of radiochemical purity (RCP), was used the thin layer chromatography technique; after the chromatographic ran on, the plates were analyzed both in the dose calibrator, and in scintillation camera of each NMS. The radiopharmaceutical biodistribution was evaluated through the activities present in the heart and liver images in 60 patients, using the technique of combined images counting. Five nuclear physicians analyzed 24 images through myocardial perfusion visual interpretation during stress, it was verified the agreement degree among them. The results of the quality control showed that all eluate samples were in agreement with the manufacturers in relation to radionuclidic purity and pH. In relation to chemical purity, 10% of the services samples B and C showed Al{sup +3} values above 10 ppm. In the RCP, it was observed that using the scintillation camera, only 22% of the samples would be discarded, while with dose calibrator would be 78%, indicating that the scintillation camera is more sensitive in chromatographic pale analysis. For the labeled radiopharmaceutical, the services B and C presented respectively one and three samples with RCP percentage below 90%. However, C service presented the lowest medium to liver/heart proportions, showing that this factor

  19. Active and passive vectorization of technetium{sup 99m} and {sup 188}rhenium radiopharmaceuticals for medical imaging and radiotherapy; Vectorisations active et passive de radiopharmaceutiques du technetium-99m et du rhenium-188 pour l'imagerie medicale et la therapie

    Energy Technology Data Exchange (ETDEWEB)

    Lepareur, N

    2003-11-15

    Research for new molecules for nuclear medicine is a field in constant development. Over the past few years, development of new radiopharmaceuticals for radiotherapy has renewed interest for rhenium chemistry. Indeed, its two isotopes {sup 186}Re and {sup 188}Re, owing to their ideal properties and their similitude with {sup 99m}Tc, which is widely used as a radiotracer for diagnostic imaging, seem very promising for the preparation of radiopharmaceuticals. In the first part of this manuscript, the synthesis of rhenium and technetium-99 complexes, [M(RPhCS3)2(RPhCS2)] (M = Re, Tc), is described. The preparation of technetium{sup 99m} based radiopharmaceuticals, analogues to the pondered complexes, is also described. The stability/reactivity of these complexes has been studied by exchange reactions with potential ligands, specially dithiocarbamates, and also by UV-visible absorption spectroscopy and thermogravimetry. The reactivity of the complexes towards dithiocarbamates leads to the possibility to bind biomolecules to the metallic core, via the dithiocarbamate moiety. This method represents a potential alternative to current ones using the so-called bifunctional approach. In the second part of this manuscript, a new kit formulation for the {sup 188}Re labeling of lipiodol is described, using a complex analogous to those described in the previous part. The labeled oil is a potential cure for hepatocellular carcinoma. The in vitro and in vivo stability of this {sup 188}Re-SSS lipiodol and of its analogue {sup 99m}Tc-SSS lipiodol has been studied, and also their in vivo behavior in healthy pigs. This study has shown the quasi-exclusive hepatic fixation of the radiopharmaceutical, and has proven its good stability. Its selectivity for tumors remains to be shown before trying it on humans. (author)

  20. Active and passive vectorization of technetium{sup 99m} and {sup 188}rhenium radiopharmaceuticals for medical imaging and radiotherapy; Vectorisations active et passive de radiopharmaceutiques du technetium-99m et du rhenium-188 pour l'imagerie medicale et la therapie

    Energy Technology Data Exchange (ETDEWEB)

    Lepareur, N

    2003-11-15

    Research for new molecules for nuclear medicine is a field in constant development. Over the past few years, development of new radiopharmaceuticals for radiotherapy has renewed interest for rhenium chemistry. Indeed, its two isotopes {sup 186}Re and {sup 188}Re, owing to their ideal properties and their similitude with {sup 99m}Tc, which is widely used as a radiotracer for diagnostic imaging, seem very promising for the preparation of radiopharmaceuticals. In the first part of this manuscript, the synthesis of rhenium and technetium-99 complexes, [M(RPhCS3)2(RPhCS2)] (M = Re, Tc), is described. The preparation of technetium{sup 99m} based radiopharmaceuticals, analogues to the pondered complexes, is also described. The stability/reactivity of these complexes has been studied by exchange reactions with potential ligands, specially dithiocarbamates, and also by UV-visible absorption spectroscopy and thermogravimetry. The reactivity of the complexes towards dithiocarbamates leads to the possibility to bind biomolecules to the metallic core, via the dithiocarbamate moiety. This method represents a potential alternative to current ones using the so-called bifunctional approach. In the second part of this manuscript, a new kit formulation for the {sup 188}Re labeling of lipiodol is described, using a complex analogous to those described in the previous part. The labeled oil is a potential cure for hepatocellular carcinoma. The in vitro and in vivo stability of this {sup 188}Re-SSS lipiodol and of its analogue {sup 99m}Tc-SSS lipiodol has been studied, and also their in vivo behavior in healthy pigs. This study has shown the quasi-exclusive hepatic fixation of the radiopharmaceutical, and has proven its good stability. Its selectivity for tumors remains to be shown before trying it on humans. (author)

  1. Tc-99m imaging agents

    International Nuclear Information System (INIS)

    Weininger, J.; Trumper, J.

    1984-01-01

    A wide range of pharmaceuticals for labeling with Tc-99m, developed by the Soreq Radiopharmaceuticals Department, is described. Details of the production and quality control of 13 kits are given, as well as the range of results required for consistently high quality imaging agents

  2. Methods for the quality control of macroaggregates and colloids labelled with technetium-99m. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Cifka, J.

    1975-09-01

    Comprehensive studies of the antimony sulphide and sulphur colloids labelled with sup(99m)Tc was performed by the authors. Similar studies dealing with human serum albumin macroaggregates labelled with sup(99m)Tc were also initiated. The labelling processes were studied to determine the possible chemical forms of technetium-99m not bound to the colloidal particles. It was found that pertechnetate-99m is not the only possible impurity in the case of the colloids. Technetium-99m may be present as an soluble tartrate complex in the case of antimony sulphide colloid or as a soluble chlorocomplex in the case of the sulphur colloid. Techniques for the control of these colloids were developed. A method for the determination of particle size of the sulphur colloid is also described

  3. {sup 99m}Tc Nanocoll: A radiopharmaceutical for sentinel node localisation in breast cancer-In vitro and in vivo results

    Energy Technology Data Exchange (ETDEWEB)

    Gommans, G.M.M. [Department of Nuclear Medicine, West-Fries Hospital Hoorn (Netherlands); Department of Nuclear Medicine (0030), Medical Centre Alkmaar, Wilhelminalaan 12, 1815 JD Alkmar (Netherlands)], E-mail: g.m.m.gommans@mca.nl; Gommans, E. [Department of Chemical Engineering, Twente University of Technology (Netherlands); Zant, F.M. van der [Department of Nuclear Medicine (0030), Medical Centre Alkmaar, Wilhelminalaan 12, 1815 JD Alkmar (Netherlands); Teule, G.J.J. [Department of Nuclear Medicine, University Medical Centre Maastricht (Netherlands); Schors, T.G. van der [Department of Clinical Pharmacy, West-Fries Hospital Hoorn (Netherlands); Waard, J.W.D. de [Department of Surgery, West-Fries Hospital Hoorn (Netherlands)

    2009-09-15

    This study evaluated labelling efficiency and radiochemical purity of {sup 99m}Tc colloid albumin to identify an optimal labelling protocol for sentinel node detection. Results indicate that a 72 h eluate is not recommended for high specific labelling of {sup 99m}Tc colloid albumin. Ex vivo, significantly higher count rates were reached using a 2 h eluate in vacuum or nitrogen. Labelling 26 MBq/{mu}g {sup 99m}Tc colloid albumin with a 2 h eluate under nitrogen is recommended because of the ease of labelling.

  4. 99mTc Nanocoll: A radiopharmaceutical for sentinel node localisation in breast cancer-In vitro and in vivo results

    International Nuclear Information System (INIS)

    Gommans, G.M.M.; Gommans, E.; Zant, F.M. van der; Teule, G.J.J.; Schors, T.G. van der; Waard, J.W.D. de

    2009-01-01

    This study evaluated labelling efficiency and radiochemical purity of 99m Tc colloid albumin to identify an optimal labelling protocol for sentinel node detection. Results indicate that a 72 h eluate is not recommended for high specific labelling of 99m Tc colloid albumin. Ex vivo, significantly higher count rates were reached using a 2 h eluate in vacuum or nitrogen. Labelling 26 MBq/μg 99m Tc colloid albumin with a 2 h eluate under nitrogen is recommended because of the ease of labelling.

  5. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.

    Science.gov (United States)

    Guggenberg, Elisabeth Von; Mikolajczak, Renata; Janota, Barbara; Riccabona, Georg; Decristoforo, Clemens

    2004-10-01

    [(99m)Tc-EDDA-HYNIC-D-Phe(1),Tyr(3)]-Octreotide ((99m)Tc-EDDA/HYNIC-TOC) is a promising new radiopharmaceutical with the potential to replace [(111)In-DTPA-D-Phe(1)]-Octreotide ((111)In-DTPA-OCT) as the radiopharmaceutical for somatostatin receptor scintigraphy due to the advantage of improved image quality, lower radiation dose for the patient, and daily availability. Here we describe the development of a freeze-dried kit formulation based on the Tricine/EDDA exchange labeling approach for the preparation of this radiopharmaceutical in a clinical setting. Three parameters were of major importance to achieve a suitable formulation with a radiochemical purity (RCP) >90%: addition of bulking agent, the pH of the freeze-drying solution, and the content of stannous chloride. The final formulation consisted of 20 mg Tricine, 10 mg EDDA, 50 mg Mannitol, 20 microg SnCl(2). 2H(2)O, and 20 microg [HYNIC-D-Phe(1), Tyr(3)]-Octreotide (HYNIC-TOC). Radiolabeling was performed by addition of 0.2 M Na(2)HPO(4) to adjust the pH to 6-7, followed by 0.5-2 GBq (99m)Tc sodium pertechnetate, in a total volume of 2 mL and incubation for 10 min in a boiling water bath. Mean RCP values of 10 batches showed values >90% over a storage period of up to 1 year, a high stability up to 24 h of the final preparation, and retained biological activity. The developed kit formulation forms the basis for further clinical evaluation of this promising new radiopharmaceutical. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association

  6. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures. Progress report, May 1, 1981-April 30, 1982

    International Nuclear Information System (INIS)

    Heineman, W.R.; Deutsch, E.A.

    1981-12-01

    The objectives of this year's research were to develop a method for rapidly determining TcO 4 - in 99 Mo//sup 99m/Tc generator eluates, to improve the ability to chromatographically determine individual Tc-HEDP complexes in radiopharmaceuticals, and to investigate the effects of TcO 4 - concentration and electrochemical reduction on the types and relative amounts of Tc-HEDP complexes present in a radiopharmaceutical formulation. A rapid and sensitive high performance liquid chromatographic (HPLC) method for the quantitative determination of pertechnetate (TcO 4 - ) was developed. This HPLC-based analysis may be of considerable utility in assessing the history and function of 99 MO/sup 99m/Tc generators as well as in the routine analysis of reduced technetium radiopharmaceuticals for the presence of undesired TcO 4 - . Encouraging results were obtained on a dimethyl amine column using aqueous (NH 4 ) 2 SO 4 as the mobile phase. The preparation of Tc(NaBH 4 ) HEDP radiopharmaceutical analogues using varying concentrations of total TcO 4 - shows a dramatic effect in the number and distribution of Tc-HEDP complexes over a TcO 4 - concentration range of 10 -2 to 10 -8 M. These results suggest that total TcO 4 - concentration is an important parameter to be considered in the preparation of a specific Tc-HEDP complex to improve skeletal imaging. The preparation of Tc(electrode) HEDP radiopharmaceutical analogues by using electrochemical reduction was explored. The resulting solutions contain Tc-HEDP complexes that are tentatively identified as being the same complexes formed by NaBH 4 reduction, although the relative concentrations of these complexes are quite different with the two modes of reduction. Thus, electrochemical reduction shows promise as a viable route to the preparation of specific Tc-HEDP complexes for improved skeletal imaging

  7. Synthesis of the compound tetrakis (2- methoxy isobutyl isonitrile) copper (I) tetrafluoroborate -(Cu[MIBI]4BF4): substance used in the production of the radiopharmaceutical sestamibi 99m Tc

    International Nuclear Information System (INIS)

    Silva, Katia Suzi da Silveira

    2005-01-01

    The radiopharmaceutical SESTAMIBI- 99m Tc presents interest and application in the clinical routine in Nuclear Medicine, especially for evaluation of the myocardium function and in the diagnosis of some tumors types, and the Center of Radiopharmacy of the IPEN has interest in the development of this radiopharmaceutical for attendance of the nuclear medicine class necessities. In this work it was demonstrated the synthesis and characterization of the active compound tetrakis (2- methoxy isobutyl isonitrile) copper (I) tetrafluoroborate - Cu[MIBI] 4 BF 4 - to be used in the preparation of lyophilized reagents for labeling with technetium- 99m as well as labeling studies and biological distribution. The synthesis of the reagent Cu[MIBI] 4 BF 4 was carried out in accordance with previously described procedures, in 5 steps and the compounds were characterized for infra-red, magnetic nuclear resonance, melting point and thin layer chromatography. The characterization of the chelate of MIBI -Cu[MIBI] 4 BF 4 - was carried out using high performance liquid chromatography, compared with a standard sample of the product and presented similar results, as described in literature. The lyophilized reagent was prepared and labeled with technetium- 99m , showing high radiochemical purity, higher than 97%, with high stability. Biological distribution in different animals showed good uptake in the heart, in time compatible with the acquisition of scintigraphy images, demonstrating the applicability of the reagent synthesized in the attainment of cardiac scintigraphy images. (author)

  8. Design and biological evaluation of 99mTc-N2S2-Tat(49–57)-c(RGDyK): A hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins

    International Nuclear Information System (INIS)

    Ocampo-García, Blanca E.; Santos-Cuevas, Clara L.; De León-Rodríguez, Luis M.; García-Becerra, Rocío; Ordaz-Rosado, David; Luna-Guitiérrez, Myrna A.; Jiménez-Mancilla, Nallely P.; Romero-Piña, Mario E.; Ferro-Flores, Guillermina

    2013-01-01

    The α(ν)β(3) integrin is over-expressed in the tumor neovasculature and the tumor cells of glioblastomas. The HIV Tat-derived peptide has been used to deliver various cargos into cells. The aim of this research was to synthesize and assess the in vitro and in vivo uptake of 99m Tc-N 2 S 2 -Tat(49–57)-c(RGDyK) ( 99m Tc-Tat-RGD) in α(ν)β(3) integrin positive cancer cells and compare it to that of a conventional 99m Tc-RGD peptide ( 99m Tc-EDDA/HYNIC-E-[c(RGDfK)] 2 ). Methods: The c(RGDyK) peptide was conjugated to a maleimidopropionyl (MP) moiety through Lys, and the MP group was used as the branch position to form a thioether with the Cys 12 side chain of the Tat(49–57)-spacer-N 2 S 2 peptide. 99m Tc-Tat-RGD was prepared, and stability studies were carried out by size exclusion HPLC analyses in human serum. The in vitro affinity for α(v)β(3) integrin was determined by a competitive binding assay. In vitro internalization was determined using glioblastoma C6 cells. Biodistribution studies were accomplished in athymic mice with C6 induced tumors that had blocked and unblocked receptors. Images were obtained using a micro-SPECT/CT. Results: 99m Tc-Tat-RGD was obtained with a radiochemical purity higher than 95%, as determined by radio-HPLC and ITLC-SG analyses. Protein binding was 15.7% for 99m Tc-Tat-RGD and 5.6% for 99m Tc-RGD. The IC 50 values were 6.7 nM ( 99m Tc-Tat-RGD) and 4.6 nM ( 99m Tc-RGD). Internalization in C6 cells was higher in 99m Tc-Tat-RGD (37.5%) than in 99m Tc-RGD (10%). Biodistribution studies and in vivo micro-SPECT/CT images in mice showed higher tumor uptake for 99m Tc-Tat-RGD (6.98% ± 1.34% ID/g at 3 h) than that of 99m Tc-RGD (3.72% ± 0.52% ID/g at 3 h) with specific recognition for α(v)β(3) integrins. Conclusions: Because of the significant cell internalization (Auger and internal conversion electrons) and specific recognition for α(v)β(3) integrins, the hybrid 99m Tc-N 2 S 2 -Tat(49–57)-c(RGDyK) radiopharmaceutical is

  9. Biodistribution dosimetric study of radiopharmaceutical {sup 99mT}c Ixolaris in mice for melanoma diagnosis by molecular image and translational model for human beings; Estudo dosimetrico da biodistribuicao do radiofarmaco Ixolaris-{sup 99m}Tc em camundongos para diagnostico de melanoma atraves de imagem molecular e modelo translacional para humanos

    Energy Technology Data Exchange (ETDEWEB)

    Soriano, Sarah Canuto Silva

    2015-07-01

    The labeling of Ixolaris with {sup 99m}Tc was developed by Barboza et.al. (2013) aiming its use primarily in glioblastoma and after in melanoma diagnosis, a less common but very aggressive cancer and with high mortality rate. Preliminary tests on animals have proven its effectiveness of labeling but a dosimetric study to human clinical trials should be performed. This study aimed to: (1) determine the biokinetic model for the radiotracer {sup 99m}Tc-Ixolaris in mice by imaging dosimetry method; and (2) estimate the absorbed and effective dose resulting from the use of a new radiopharmaceutical for melanoma and metastases diagnosis in human beings, since a dosimetric study of new radiopharmaceuticals in animals is necessary to test them subsequently in humans and apply for registration in ANVISA. According to SPECT images, was found a latency period of 15 to 21 days for the development of lung metastasis in mice. Three C57BL6 mice, one control animal, and two animals with induced cell line B16-F10 murine melanoma were tested. The {sup 99m}Tc-Ixolaris radiopharmaceutical was administered intravenously in a caudal vein, and SPECT images were acquired 0.5 h, 1.5 h, 2.5 h, 3.5 h and 24 h post-administration for analysis and biodistribution quantification. The biokinetic model was determined and thus, obtained cumulative activity in order to estimate the absorbed dose in each organ. The mass and metabolic differences between mice and humans were considered and used to extrapolate the data acquired at different scales. Based on dose factors provided by the software MIRDOSE and Olinda (S factor), absorbed doses in irradiated target organs were calculated for the source organs, and finally the effective dose was estimated. The results indicate that for diagnostic exams conducted in human melanoma patients by administering approximately 25.7 MBq the estimated effective dose was 4.3 mSv. Comparing with effective doses obtained in other diagnostic techniques with {sup 99m

  10. Evaluation of sup(99m)Tc labeled amino acids as radiopharmaceuticals, 4. S-substituted cysteines and N-substituted iminodiacetic acids

    Energy Technology Data Exchange (ETDEWEB)

    Karube, Yoshiharu; Maeda, Tatsuo; Ohya, Masato; Sugata, Setsuro; Kono, Akira (Kyushu Cancer Center Research Inst., Fukuoka (Japan)); Matsushima, Yoshikazu

    1982-06-01

    Sixteen sup(99m)Tc labeled ligands were evaluated as scintigraphic agents. The ligands studied were cysteine, glutathione, their S-substituted derivatives, lysine-N sup(epsilon), N sup(epsilon)-diacetic acid, glycylglycine-N,N-diacetic acid, glycylglycylglycine-N,N-diacetic acid, taurine-N,N-diacetic acid, hydrazine-N,N-diacetic acid, ethylenediamine-N,N-diacetic acid, and propylne-1,3-diamine-N/sup 1/-,N/sup 1/-diacetic acid. The ligands were labeled with sup(99m)Tc by the SnCl/sub 2/ method with more than 95% yield. The in vivo behavior of the sup(99m)Tc labeled ligands were studied in golden hamsters and dogs. The organ distribution in golden hamsters indicated clearance both by hepatobiliary and renal systems. The pancreas/blood ratios were much lower in the sup(99m)Tc ligands than in /sup 75/Se-selenomethionine. Scintigraphic studies in dogs showed that the liver and kidneys were well visualized but the accumulation by the pancreas was not sufficient for clear visualization.

  11. Melanoma targeting with [99mTc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties

    International Nuclear Information System (INIS)

    Carta, Davide; Salvarese, Nicola; Morellato, Nicolò; Gao, Feng; Sihver, Wiebke; Pietzsch, Hans Jurgen; Biondi, Barbara; Ruzza, Paolo; Refosco, Fiorenzo; Carpanese, Debora; Rosato, Antonio; Bolzati, Cristina

    2016-01-01

    The purpose of this study was to evaluate the effect of cyclization on the biological profile of a [ 99m Tc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analog. A lactam bridge-cyclized H-Cys-Ahx-βAla 3 -c[Lys 4 -Glu-His-D-Phe-Arg-Trp-Glu 10 ]-Arg 11 -Pro-Val-NH 2 (NAP―NS2) and the corresponding linear H-Cys-Ahx-βAla-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH 2 (NAP―NS1) peptide were synthetized, characterized by ESI-MS spectroscopy and their melanocortin-1 receptor (MC1R) binding affinity was determined in B16/F10 melanoma cells. The consistent [ 99m Tc(N)(PNP3)]-labeled compounds were readily obtained in high specific activity and their stability and biological properties were assessed. As an example, the chemical identity of [ 99m Tc(N)(NAP–NS1)(PNP3)] + was confirmed by carrier added experiments supported by radio/UV HPLC analysis combined with ESI(+)-MS. Compared with the linear peptide, cyclization negatively affected the biological properties of NAP–NS2 peptide by reducing its binding affinity for MC1R and by decreasing the overall excretion rate of the corresponding [ 99m Tc(N)(PNP3)]-labeled peptide from the body as well as its in vivo stability. [ 99m Tc(N)(NAP–NS1)(PNP3)] + was evaluated for its potential as melanoma imaging probe in murine melanoma model. Data from in vitro and in vivo studies on B16/F10 melanoma model of [ 99m Tc(N)(NAP–NS1)(PNP3)] + clearly evidenced that the radiolabeled linear peptide keeps its biological properties up on the conjugation to the [ 99m Tc(N)(PNP3)]-building block. The progressive increase of the tumor-to-nontarget ratios over the time indicates a quite stable interaction between the radio-complex and the MC1R.

  12. Obtaining a metastasis model in vivo for the evaluation of the radiopharmaceuticals sensitivity labeled with {sup 99m}Tc; Obtencion de un modelo de metastasis in vivo para la evaluacion de la sensibilidad de radiofarmacos marcados con {sup 99m}Tc

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez A, V. M.

    2015-07-01

    Nuclear medicine currently has a wide range of techniques that support the diagnosis of various diseases, including cancer that prevails as the most important. In the present research work was proposed to develop a model that would study the process known as metastasis, because this process is vital because most of the deaths in patients with some form of cancer are caused by metastasis. The objective was to obtain an in vivo model of metastasis induced with AR42J cells for studying the radiopharmaceuticals sensitivity labeled with {sup 99m}Tc. To achieve the objective proposed a study model in which it could make a real time evaluation of some radiopharmaceuticals with reported efficiency was development, in order to determine their sensitivity in similar conditions to the metastasis process. This required a mouse model that was used to observe a similar process to metastasis, inducing cells of the AR42J cell line, since these cells have good proliferation and have molecular targets for a minimum of 3 standardized radiopharmaceuticals. Was elected radionuclide {sup 99m}Tc, because of its low emission of radiation into the tissues, besides having a half life of 6 hours and provides a good visualization of anatomical structures. On the other hand the stable expression of green fluorescent protein in tumor cells appears to be a suitable tool for the detection of cancer development in early stages and the formation of in vivo micro metastases, so two fluorescence tests were performed and other by electrophoresis. The results showed that both study models can be carried out without increasing complexity and meeting the expectations expected for which they were designed. (Author)

  13. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures: Progress report for period September 1, 1986-August 31, 1987

    International Nuclear Information System (INIS)

    Heineman, W.R.

    1987-06-01

    The long-range objective of this research is the development of more efficacious technetium-99m radiopharmaceuticals for use as imaging agents in diagnostic nuclear medicine. The author developed analytical techniques that are capable of separating radiopharmaceutical mixtures into their component technetium complexes for subsequent evaluation. During this one-year period, a chromatographic procedure has been developed for the separation of technetium phosphonoacetic acid (PAA) complexes and five Tc-PAA complexes have been isolated from radiopharmaceutical preparations. The concentration of each complex in the preparation varies significantly depending on the pH of the preparation. Radiopharmaceutical preparations based on the ligand methylene diphosphonate (MDP) have been prepared by electrochemical reduction of TcO 4 - . The yields of different Tc-MDP complexes are affected by the potential applied to the electrochemical cell. The control of both potential and pH enables a specific Tc-MDP complex to be produced in purer form and higher yield than by chemical reduction. An EXAFS spectrum of a solution of chromatographically isolated Tc-HEDP (hydroxyethylidine diphosphonate) complex shows evidence for a Tc-Tc bond, which is supportive of the postulated oligomeric/polymeric nature of these complexes. 9 refs., 4 figs

  14. Preparation, formulation and quality control of one step kit 99m Tc - EDDA/HYNIC-Tyr3-Octreotide as a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors

    International Nuclear Information System (INIS)

    Gandomkar, M.; Najafi, R.; Sadat-Ebrahimi, E.; Babaei, M.H.

    2004-01-01

    The high expression of somatostatin receptors in many tumours, have made receptor scintigraphy with 11I n-DTPA-Octreotide a widely used procedure in nuclear medicine. Despite its clinical success, some limitation and drawbacks of radiolabelling with 11I n remain, especially those concerned with the cost, availability and physical decay properties of this radionuclide. 99m Tc - EDDA/HYNIC-Tyr 3 -Octreotide was studied as a new agent with the potential to replace octreoscan in somatostatin receptor scintigraphy. This hydrazino nicotinic acid derivatized somatostatin complex contains ethylenediamine N, N diacetic acid as a co-ligand resulting in a high in vitro and in vivo stability. High labeling yields (>90%) were achieved at high specific activities. Characterization via HPLC, biodistribution and receptor binding of the resulting complex are described. The formulation developed enables rapid and simple labeling of 99m Tc - EDDA/HYNIC-TOC in a manner suitable for clinical setting

  15. Synthesis, bioevaluation and gamma scintigraphy of 99mTc-N-2-(furylmethyl iminodiacetic acid) complex as a new renal radiopharmaceutical

    International Nuclear Information System (INIS)

    Sanad, M.H.; Talaat, H.M.; Ibrahim, A.A.

    2018-01-01

    A ligand of N-2-(furylmethyl iminodiacetic acid) (FMIDA) has been easily labeled by a tetradentate chelating agent of [ 99m Tc]. Factors like a stannous chloride solution as a reducing agent (100 μg), substrate amount (100 μg), pH (7), in vitro stability (8 h) and temperature (37 °C) have been systematically studied to optimize high radiochemical yield (98.0%). The radiochemical conversion was calculated on thin-layer chromatography, paper electrophoresis, and high performance liquid chromatography. Biodistribution study showed that this complex was removed from the kidneys and bladder path way during 1 h post injection. Therefore, [ 99m Tc]FMIDA may be used as renal function radiotracer. (author)

  16. Study of the viability of technetium-99m labeling of whole antimyosin antibody and its fragment: development of radiopharmaceutical for cardiac survey

    International Nuclear Information System (INIS)

    Carvalho, Guilherme Luiz de Castro

    2007-01-01

    In the acute myocardium infarction, the myocytes cell membrane loses its integrity, allowing the influx of extracellular macromolecules such as circulating antibody into the damaged cell. The use of the specific antibodies against cardiac myosin labeled with 99m Tc allows to determine the localization and extension of myocardial infarction. The purpose of this work was to study the viability of labeling of the antimyosin monoclonal antibody and its fragment F(ab')2 with 99m Tc. Because of the high cost of antimyosin antibody, others antibodies were used to optimize the methodology and the best condition was used for antimyosin antibody. The intact antibody was cleaved by pepsin to produce F(ab') 2 fragment. The F(ab') 2 and the intact antibody were reduced by treatment with Dithiothreitol (DTT) and 2-Mercaptoethanol (2-ME) and labeled with 99m Tc by direct method. Different concentrations of reductant, mixing conditions and incubation times were studied. In the standard condition, incubation at molar ratio 1:1000 (antibody:reducing agent) at room temperature for 30 minutes with continuous rotation (850 rpm), 13.28 - SH groups were formed per molecule. It was studied the influence of p H, of the concentration of stannous chloride (Sn 2+ ) and incubation time in the labeling condition. The better radiochemical yield (90.06 +- 1.53%) was obtained using 2.5 μg of Sn 2+ in p H 4.5 for 60 minutes. The labeling of the fragment F(ab') 2 did not present satisfactory results because of the low yield of the digestion. After purification by PD-10, the biodistribution study was performed and showed that the intact antimyosin antibody labeled with 99m Tc presented fast kinetic compatible with the biodistribution of an intact antibody labeled with 99m Tc. Scintigraphy image of the animal with myocardial infarction was obtained and compared with the image of a normal animal. The studies allow to conclude that the use of fragment F(ab') 2 are not viable, but the use of the labeled

  17. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures. Progress report, May 1, 1982-April 30, 1983

    International Nuclear Information System (INIS)

    Heineman, W.R.; Deutsch, E.A.

    1982-11-01

    A procedure based on high performance liquid chromatography (HPLC) has been developed for separating individual Tc-diphosphonate complexes in skeletal-imaging radiopharmaceuticals prepared by reduction of TcO 4 - with NaBH 4 in the presence of methylene diphosphonate (MDP). Seven different Tc-MDP complexes have been detected and isolated in pure form. Significant differences in skeletal uptake and blood clearance are exhibited by the three complexes tested thus far by biodistribution studies in test animals. The relative quantities of these complexes present in a radiopharmaceutical preparation are dramatically influenced by the pH of the reaction mixture. Thus, control of pH is a simple means of forming in high yield the single, most efficacious Tc-MDP complex for skeletal imaginG. An HPLC method with electrochemical detection has been developed for the analytical determination of total TcO 4 - (/sup 99m/Tc + 99 Tc). Concentrations of TcO 4 - as low as 9 x 10 -9 M can be detected. The method is being evaluated for monitoring total TcO 4 - in 99 Mo//sup 99m/Tc generators

  18. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures

    International Nuclear Information System (INIS)

    Heineman, W.R.

    1991-04-01

    Capillary electrophoresis is being evaluated as a separation technique for analyzing Tc and Re diphosphonate radiopharmaceuticals. Advantages compared with currently used HPLC techniques include greater resolving power, smaller sample size and more rapid separations. Feasibility has been demonstrated with electropherograms obtained on a Re-HEDP sample. The Tc-PAA complexes in a radiopharmaceutical mixture were found to be unaffected by injection into a Sprague Dawley rat. This was determined by HPLC analysis of the rat's urine, which contained the same complexes as were in the injected sample. Proton NMR spectra have been obtained for samples of Tc-MDP and Re-MDP in order to provide structural information about these complexes. An in vivo sensor is being developed for a brain perfusion agent. Polymer coatings are being explored to extract the brain perfusion agent in order to enhance sensitivity for a microelectrode-based sensor. 4 refs., 2 figs

  19. Evaluation of the internalization kinetics of the radiopharmaceutical {sup 99m}Tc-N{sub 2}S{sub 2}-Tat(49-57)Lys{sup 3}-Bn with diagnostic purposes, using comet assay; Evaluacion de la cinetica de internalizacion del radiofarmaco {sup 99m}Tc-N{sub 2}S{sub 2}-TAT(49-57)Lys{sup 3}-BN con fines diagnosticos, empleando ensayo cometa

    Energy Technology Data Exchange (ETDEWEB)

    Luna G, M. A.

    2011-07-01

    Gastrin-rea leasing peptide receptors (GRP-r) are over expressed in breast and prostate cancer cells. Bombesin (Bn) binds specifically and strongly to GRP-r and this is the base for to label the Bn with radionuclides by gamma rays. Tat (49-57) is a peptide that across the cell membrane easily so that, when it is conjugated to different proteins, it can works as a Trojan horse, facilitating the drug internalization to the cells. The radiopharmaceutical {sup 99m}Tc-N{sub 2}S{sub 2}-Tat(49-57)-Lys{sup 3}-Bn was prepared for diagnosis and therapy at early stage of breast cancer. The objective of this study was to determine the role of Tat in the internalization kinetics of radiopharmaceuticals measured by DNA damage induced by means of comet assay. Human lymphocytes were treated with the following protocols: a) Tat-Bn, b) {sup 99m}Tc-Bn, or c) {sup 99m}Tc-N{sub 2}S{sub 2}-Tat(49-57)-Lys{sup 3}-Bn, also an untreated group was conformed. The internalization was evaluated at 0, 5, 10, 15, 30 and 60 min after exposure with three repetitions each one, and for radiopharmaceuticals with 2.9, 6.6, 9.0 and 14.8 MBq activities. DNA damage was scored in 100 cells per time and treatment, as tail length and tail moment. A Kruskal-Wallis variance analysis with p{<=} 0.05 was applied for comparison between treatments. The results showed that the damage caused by {sup 99m}Tc-N{sub 2}S{sub 2}-Tat(49-57)-Lys{sup 3}-Bn is significantly higher than that caused by {sup 99m}Tc-Bn and Tat-Bn, showing that Tat favors the internalization of the radiopharmaceutical. (Author)

  20. Determination of the worst case for cleaning validation of equipment used in the radiopharmaceutical production of lyophilized reagents for {sup 99m}Tc labelling

    Energy Technology Data Exchange (ETDEWEB)

    Porto, Luciana Valeria Ferrari Machado; Fukumori, Neuza Taeko Okasaki; Matsuda, Margareth Mie Nakamura, E-mail: luciana.porto@anvisa.gov.br [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Centro de Radiofarmacia

    2016-01-15

    Cleaning validation, a requirement of the current Good Manufacturing Practices (cGMP) for Drugs, consists of documented evidence that cleaning procedures are capable of removing residues to predetermined acceptance levels. This report describes a strategy for the selection of the worst case product for the production of lyophilized reagents (LRs) for labeling with {sup 99m}Tc from the Instituto de Pesquisas Energeticas e Nucleares (IPEN-CNEN/Sao Paulo). The strategy is based on the calculation of a 'worst case index' that incorporates information about drug solubility, cleaning difficulty, and occupancy rate in the production line. It allowed a reduction in the required number of validations considering the possible manufacturing flow of a given product and the subsequent flow, thus facilitating the process by reducing operation time and cost. The products identified as 'worst case' were LRs PUL-TEC and MIBI-TEC. (author). (author)

  1. Determination of the worst case for cleaning validation of equipment used in the radiopharmaceutical production of lyophilized reagents for 99mTc labelling

    International Nuclear Information System (INIS)

    Porto, Luciana Valeria Ferrari Machado; Fukumori, Neuza Taeko Okasaki; Matsuda, Margareth Mie Nakamura

    2016-01-01

    Cleaning validation, a requirement of the current Good Manufacturing Practices (cGMP) for Drugs, consists of documented evidence that cleaning procedures are capable of removing residues to predetermined acceptance levels. This report describes a strategy for the selection of the worst case product for the production of lyophilized reagents (LRs) for labeling with 99m Tc from the Instituto de Pesquisas Energeticas e Nucleares (IPEN-CNEN/Sao Paulo). The strategy is based on the calculation of a 'worst case index' that incorporates information about drug solubility, cleaning difficulty, and occupancy rate in the production line. It allowed a reduction in the required number of validations considering the possible manufacturing flow of a given product and the subsequent flow, thus facilitating the process by reducing operation time and cost. The products identified as 'worst case' were LRs PUL-TEC and MIBI-TEC. (author). (author)

  2. Synthesis and evaluation in vitro in cancer cells AR42J of the radiopharmaceutical {sup 99m}Tc-Tyr{sup 3}-Octreotide-dendrimer similar of somatostatin; Sintesis y evaluacion in vitro en celulas de cancer AR42J del radiofarmaco {sup 99m}Tc-Tyr{sup 3}-Octreotido-dendrimero analogo de la somatostatina

    Energy Technology Data Exchange (ETDEWEB)

    Orocio R, E.

    2013-07-01

    The objective of this project was preparing a multimeric system through the conjugation of several molecules of the peptide Tyr{sup 3}-Octreotide to a dendrimer molecule based on Poly-amidoamine (PAMAM), as well as radiolabeled with {sup 99m}Tc and evaluating its behavior like new radiopharmaceutical similar of somatostatin. The dendrimer PAMAM generation 3.5 that possesses terminal groups of sodium carboxylate, was functionalized to peptide Tyr{sup 3}-Octreotide through a reaction of peptide coupling with HATU (hexafluorophosphate (V) of 1-oxide-3-(bis(dimethylamino)methylene)-3H-[1,2,3]triazole[4,5-b]pyridine) as activating agent of carboxylate groups using the Size Exclusion Chromatography (Sec) as purification method. The product was characterized by Ultraviolet visible spectrophotometry, Mid-infrared and Far-infrared, Elemental analysis, Energy dispersive X-ray spectroscopy, Scanning electron microscopy, Thermogravimetry and Differential scanning calorimetry. The radiolabeled with {sup 99m}Tc was carried out using a direct method that involves the reduction of the anion TcO{sub 4}{sup -} with stannous chloride, so that the dendrimer is capable of coordinating to the technetium forming a chelate compound. The radiochemical purity of the radiolabeled compound was determined by thin layer chromatography using a sodium chloride solution to 20% (m/v) as mobile phase and was verified by molecular exclusion chromatography. The radiolabeled compound was possible to obtain it with a radiochemical purity superior to 90%. Also, the specific and not specific union was evaluated of the synthesized compound in mouse pancreas cancer cells AR42J, positive to somatostatin receptors, showing specific recognition for this receptors type with high cellular internalization. The biodistribution studies were carried out in BALB/c mice at different post injection times and in nude mice with induced tumors AR42J. The results showed that the {sup 99m}Tc-PAMAM-Tyr{sup 3}-Octreotide is

  3. Biodistribution of the radiopharmaceutical sodium pertechnetate (Na{sup 99m}TcO{sub 4}) after massive small bowel resection in rats; Biodistribuicao do radiofarmaco pertecnetato de sodio (Na{sup 99m}TcO{sub 4}) em ratos submetidos a resseccao extensa de intestino delgado

    Energy Technology Data Exchange (ETDEWEB)

    Chacon, Damaso de Araujo; Araujo-Filho, Irami; Villarim-Neto, Arthur; Brandao-Neto, Jose; Medeiros, Aldo Cunha [Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN (Brazil). Programa de Pos-graduacao em Ciencias da Saude]. E-mail: damasochacon@uol.com.br; Rego, Amalia Cinthia Meneses [Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN (Brazil). Programa de Iniciacao Cientifica; Azevedo, Italo Medeiros [Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN (Brazil). Dept. de Cirurgia; Bernardo-Filho, Mario [Universidade do Estado, Rio de Janeiro, RJ (Brazil). Dept. de Biofisica e Biometria

    2007-11-15

    Purpose: To evaluate the biodistribution of sodium pertechnetate (Na{sup 99m}TcO{sub 4}) in organs and tissues, the morphometry of remnant intestinal mucosa and ponderal evolution in rats subjected to massive resection of the small intestine. Methods:Twenty-one Wistar rats were randomly divided into three groups of 7 animals each. The short bowel (SB) group was subjected to massive resection of the small intestine; the control group (C) rats were not operated on, and soft intestinal handling was performed in sham rats. The animals were weighed weekly. On the 30th postoperative day, 0.1 mL of Na{sup 99m}TcO{sub 4}, with mean activity of 0.66 MBq was injected intravenously into the orbital plexus. After 30 minutes, the rats were killed with an overdose of anesthetic, and fragments of the liver, spleen, pancreas, stomach, duodenum, small intestine, thyroid, lung, heart, kidney, bladder, muscle, femur and brain were harvested. The biopsies were washed with 0.9% NaCl.,The radioactivity was counted using Gamma Counter Wizard{sup TM} 1470, Perkin-Elmer. The percentage of radioactivity per gram of tissue (%ATI/g) was calculated. Biopsies of the remaining jejunum were analysed by HE staining to obtain mucosal thickness. Analysis of variance (ANOVA) and the Tukey test for multiple comparisons were used, considering p<0.05 as significant. Results: There were no significant differences in %ATI/g of the Na{sup 99m}TcO{sub 4} in the organs of the groups studied (p>0.05). An increase in the weight of the SB rats was observed after the second postoperative week. The jejunal mucosal thickness of the SB rats was significantly greater than that of C and sham rats (p<0.05). Conclusion: In rats with experimentally-produced short bowel syndrome, an adaptive response by the intestinal mucosa reduced weight loss. The biodistribution of Na{sup 99m}TcO{sub 4} was not affected by massive intestinal resection, suggesting that short bowel syndrome is not the cause of misleading interpretation

  4. The first experience of using {sup 99m}Tc-Al{sub 2}O{sub 3}-based radiopharmaceutical for the detection of sentinel lymph nodes in cervical cancer patients

    Energy Technology Data Exchange (ETDEWEB)

    Sinilkin, I. G.; Chernov, V. I.; Medvedeva, A. A.; Zelchan, R. V.; Chernyshova, A. L. [Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation); National Research Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 (Russian Federation); Lyapunov, A. Yu., E-mail: Lyapunov1720.90@mail.ru [Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation); Kolomiets, L. A. [Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation); Siberian State Medical University, Moskovsky Trakt 2, Tomsk, 634050 (Russian Federation)

    2016-08-02

    The purpose of the study was to evaluate the feasibility of using {sup 99m}Tc-Al{sub 2}O{sub 3}-based radiopharmaceutical, a novel molecular imaging agent for sentinel lymph node detection in patients with invasive cervical cancer. The study included 23 cervical cancer patients (T1aNxMx-T2bNxMx) treated at the Tomsk Cancer Research Institute. In the 18 hours before surgery, 80 MBq of the {sup 99m}Tc-Al{sub 2}O{sub 3} in peritumoral injected, followed by single-photon emission computed tomography (SPECT) of the pelvis and intraoperative SLN identification. Twenty-seven SLNs were detected by SPECT, and 34 SLNs were identified by intraoperative gamma probe. The total number of identified SLNs per patient ranged from 1 to 3 (the mean number of SLNs was 1.4 per patient). The most common site for SLN detection was the external iliac region (57.2%), followed by the internal iliac (14%), obturator (14%), presacral and retrosacral regions (14%), and the parametrial region (1%). Sensitivity in detecting SLNs was 100% for intraoperative SLN identification and 79% for SPECT image.

  5. Lung radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP

  6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Theobald, A.E.

    1989-01-01

    This book is a review of the latest developments in radiopharmaceuticals. It covers the development of radiopharmaceutical compounds, the theory and practice of their synthesis, and examples of their application. Also covers safe handling of radiopharmaceuticals, legislation affecting their use, radiation monitoring, radiochromatography, and computer techniques

  7. Development of more efficacious /sup 99m/Tc organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceutical mixtures. Progress report, May 1, 1983-January 1, 1986

    International Nuclear Information System (INIS)

    Heineman, W.R.

    1986-01-01

    The formation of many different technetium complexes in the Tc(NaBH 4 )-HEDP, Tc(NaBH 4 )-MDP, and Tc(NaBH 4 )-DMAD systems has been clearly demonstrated by HPLC-separation of reaction mixtures. The dramatically different biodistributions exhibited by the various complexes strongly suggests that an improved skeletal radiopharmaceutical would result if the single technetium complex which exhibits the optimum biodistribution properties is administered to the patient. The influence of pH, time, concentrations of TcO 4 - and ligand, and the nature of reductant on the relative amounts of the different complexes formed were investigated. Electrochemical reduction offers a means of possibly generating a desired complex in very high yield due to the precision with which redox potential can be controlled. Additionally, we have developed HPLC methods with uv and electrochemical detection for the determination of total TcO 4 - in eluents from the 99 Mo//sup 99m/Tc radionuclide generator. The inadequacy of current theory to accurately predict total TcO 4 - in generator eluents was demonstrated in that the concentration of total TcO 4 - is a major factor determining the yield of individual Tc-diphosphonate complexes. Spectroelectrochemistry proved an effective technique to study the redox properties of Tc-complexes. 18 refs., 10 figs., 1 tab

  8. Labeling of creatinine with technetium-99m

    Energy Technology Data Exchange (ETDEWEB)

    Yurt Lambrecht, F. [Ege Univ., Bornova, Izmir (Turkey). Dept. of Nuclear Applications, Inst. of Nuclear Sciences; Durkan, K. [Dokuz Eylul Univ., Buca, Izmir (Turkey). Chemistry Technicianship Program, Izmir Vocational School; Soylu, A. [Dokuz Eylul Univ., Narlidere, Izmir (Turkey). Dept. of Pediatrics, Medical Faculty

    2004-07-01

    Creatinine is a clinically important index of renal glomerular filtration rate. Urine creatinine levels can be used as a screening test to evaluate kidney function or can be part of the creatinine clearance test. In case of kidney dysfunction or muscle disorders the creatinine concentration in serum/plasma may rise to a higher value than in healthy body. Technetium- 99m has been used in nuclear medicine and in biomedical research to label molecular and cellular structures employed as radiotracers. {sup 99m}Tc is utilized to label molecules and cells, used as radiopharmaceuticals, and also to label biological species. It presents many desirable characteristics. SnCl{sub 2} method is frequently used as a reducing agent in the {sup 99m}Tc- labeling process. Creatinine metabolism might be investigated by using labeled {sup 99m}Tc- creatinine in healthy or uremic rats. (orig.)

  9. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    1981-01-01

    The catalogue offers a wide-spread product range which meets the requirements of the international trend of in vivo application of radiopharmaceuticals. It includes: (1) conditions of sale and delivery, (2) delivery schedule for radiopharmaceuticals, (3) technical information, (4) product specifications, and (5) the complete delivery programme

  10. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1988-01-01

    Different forms of radiopharmaceuticals such as radioactive gases, aerosols and colloids used for diagnostic techniques and radiotherapy and methods of labelling them are discussed. Some reference is made to their documentation, handling and quality control. (U.K.)

  11. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Ganatra, R.D.

    1992-01-01

    Today there are an estimated ten million nuclear imaging procedures, performed each year, in just the United States, and the number is still growing. More than 30,000 therapy procedures are performed in the USA each year using radiopharmaceuticals. Moreover, while the numbers continue to grow, so also do the variety of the procedures being employed. A weakness of nuclear medicine is related also to one of its strengths. Unlike other types of imaging where only an instrument and the patient are required (e.g., with ultrasonics); nuclear medicine requires a radiopharmaceutical. At the same time, the variety of radiopharmaceuticals offers the ability to trace one or more particular functions of the human body. This provides nuclear medicine with great variety in detecting specific pathologies. Various nuclear medicine studies are possible because of the localization of radiopharmaceuticals in different organs

  12. Effect of milking efficiency on Tc-99 content of Tc-99m derived from Tc-99m generators

    International Nuclear Information System (INIS)

    Bonnyman, J.

    1983-01-01

    Tc-99m obtained by separation from its parent Mo-99 always contains Tc-99 produced by decay of Tc-99m and Mo-99. Factors effecting the Tc-99/Tc-99m ratios are discussed. An HPLC method has been developed to measure the 99 TcO 4- content of sodium pertechnetate from generators with a detection limit of 0.9 ng Tc-99 for a 500 μl/ aliquot of TcO 4- -99m. First eluates of 10 chromatograph-ic generators gave Tc-99/Tc-99m ratios ranging from 3.5-46 ng Tc/mCi Tc-99m measured at the time of milking. The measurements indicate that Tc-99/Tc-99m ratios high enough to cause adverse labelling effects could be found in 'instant pertechnetate' and in the first eluate from Tc-99m generators for the activities normally used in radiopharmaceutical production

  13. Studies on quality control of technetium-99m labelling kits

    International Nuclear Information System (INIS)

    Kim, Jae Rok; Park, Kyung Bae; Awh, Ok Doo

    1987-12-01

    Various experiments for the quality control of Tc-99m labelled radiopharmaceuticals such as Tc-99m-phytate, Tc-99m-MDP, Tc-99m-Tin Colloid, Tc-99m-DISIDA, Tc-99m-DTPA,Tc-99m-DMSA, Tc-99m-Gulcoheptonate, TC-99m-Pyrophosphate, Tc-99m-HSA, and Tc-99m-HAM were carried out. Labelling yield and radiochemical purity of each of the instant labelling kit of KAERI made were determined by means of radiochromatography. Biodistribution in mice and whole body or specific organ imagings of rabbits were also carried out and discussed the relationship between the data of biodistributions and radiochemical purities. Labelling yeilds were above 98% for almost all of the labelling kits. The radio-pharmaceuticals were accumulated at each target organ with moderate specifities. In case of radiochemical purity of above 98%, the biodistribution and gamma imagings were also better. The kits of MDP and DISIDA were stable at least for four moths while the other kits at least eight months. (Author)

  14. Concentration of sup(99m)Tc from the eluate of 99Mo-sup(99m)Tc generators

    International Nuclear Information System (INIS)

    Saucedo, T.; Mora, M.; Fraga de Suarez, A.H.; Mitta, A.E.A.

    1976-04-01

    A method is described to concentrate sup(99m)Tc solutions, originated in 99 Mo-sup(99m)Tc generators, independent of its age. The techniques of preparation of the different radiopharmaceuticals used in nuclear medicine are also described. (author) [es

  15. Revision: quality control of 99mTc

    International Nuclear Information System (INIS)

    Alves, S.M.; Kabad, M.C.; Teixeira, G.J.; Sousa, C H.S.

    2015-01-01

    The radiopharmaceutical most commonly used in nuclear medicine is technetium-99m. Radiopharmaceuticals labeled with 99m Tc are the main agents for diagnosis, being used in the vast majority of procedures due to radionuclide characteristics. During its preparation impurities can be generated that make products with different qualities of the desired. In this paper were presented some of the factors that can interfere with radiopharmaceuticals and the tests used for quality assurance, certifying that the product is fit for purpose. It is up to nuclear medicine centers deploy a program to raise the quality of exams and increase patient safety. (author)

  16. 99mTc-diethyl-IDA chloescintigraphy

    International Nuclear Information System (INIS)

    Kim, J. W.; Oh, K. C.; Bae, B. H.; Kim, Y. S.; Park, B. H.

    1981-01-01

    For many years, 131 I-rose bengal has been used as the main hepatobiliary radiopharmaceutical. The undesirable physical characteristics of the radioiodine, however, finally prevented its widespread use in clinical medicine. In recent years, a number of hepatobiliary radiopharmaceuticals employing 99m Tc and 123 I as indicator have been introduced. 99m Tc-diethyl-IDA is a most promising one in these agents. Cholescintigraphy, using 99m Tc-diethyl-IDA was performed in 10 normal subjects and 32 patients suffering from various hepatobiliary disturbances, from Sep. -'79 to Aug-' 80, at the department of radiology, Maryknoll Hospital. The following results are obtained: 1. In normal fasting subjects, the liver, GB, CBD, and the proximal portion of small bowel are clearly delineated within 30 min after the injection. After a fatty meal, the radioactivity of the liver and CBD is notably disappeared with increase of the activity in GB and small bowel. 2. A dilatation of the main biliary ducts is a pathognomomic sign of partial mechanical obstructive disorders and a key point of D.Dx from hepatocellular disorders. 3. In cases of complete biliary obstruction, the radioactivity of the liver, CBD, and small bowel is not separated and the background activity is markedly increased. The kidneys are well visualized. 4. In severe hyperbilirubinaemia of above 10mg%, this method is not valuable

  17. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer.

    Science.gov (United States)

    O'Connor, Michael K; Morrow, Melissa M B; Hunt, Katie N; Boughey, Judy C; Wahner-Roedler, Dietlind L; Conners, Amy Lynn; Rhodes, Deborah J; Hruska, Carrie B

    2017-12-01

    Molecular breast imaging (MBI) performed with 99m Tc sestamibi has been shown to be a valuable technique for the detection of breast cancer. Alternative radiotracers such as 99m Tc maraciclatide may offer improved uptake in breast lesions. The purpose of this study was to compare relative performance of 99m Tc sestamibi and 99m Tc maraciclatide in patients with suspected breast cancer, using a high-resolution dedicated gamma camera for MBI. Women with breast lesions suspicious for malignancy were recruited to undergo two MBI examinations-one with 99m Tc sestamibi and one with 99m Tc maraciclatide. A radiologist interpreted MBI studies in a randomized, blinded fashion to assign an assessment score (1-5) and measured lesion size. Lesion-to-background (L/B) ratio was measured with region-of-interest analysis. Among 39 analyzable patients, 21 malignant tumors were identified in 21 patients. Eighteen of 21 tumors (86%) were seen on 99m Tc sestamibi MBI and 19 of 21 (90%) were seen on 99m Tc maraciclatide MBI (p = 1). Tumor extent measured with both radiopharmaceuticals correlated strongly with pathologic size ( 99m Tc sestamibi, r = 0.84; 99m Tc maraciclatide, r = 0.81). The L/B ratio in detected breast cancers was similar for the two radiopharmaceuticals: 1.55 ± 0.36 (mean ± S.D.) for 99m Tc sestamibi and 1.62 ± 0.37 (mean ± S.D.) for 99m Tc maraciclatide (p = 0.53). No correlation was found between the L/B ratio and molecular subtype for 99m Tc sestamibi (r s  = 0.12, p = 0.63) or 99m Tc maraciclatide (r s  = -0.12, p = 0.64). Of 20 benign lesions, 10 (50%) were seen on 99m Tc sestamibi and 9 of 20 (45%) were seen on 99m Tc maraciclatide images (p = 0.1). The average L/B ratio for benign lesions was 1.34 ±0.40 (mean ±S.D.) for 99m Tc sestamibi and 1.41 ±0.52 (mean ±S.D.) for 99m Tc maraciclatide (p = 0.75). Overall diagnostic performance was similar for both radiopharmaceuticals. AUC from ROC

  18. Sup(99m)Tc compounds for diagnostic purposes

    International Nuclear Information System (INIS)

    Cifka, J.; Budsky, F.

    1980-01-01

    The applications of sup(99m)Tc in nuclear medicine are discussed, such as sodium pertechnetate in thyroid and brain scintigraphy, complex compounds in lungs and liver diao.nosis. Technetium generators are classified according to the method of separating sup(99m)Tc from 99 Mo. Adsorption generators are used, molybdate-99 is adsorbed on an Al 2 O 3 -packed column while pertechnetate-99m is eluted with 0.9% NaCl solution. Also used is continuous pertechnetate-99m extraction with methyl ethyl ketone from 0.5 M potassium molybdate and 2.5 M of potassium carbonate. The manufacture is described of kits for sup(99m)Tc radiopharmaceuticals preparation, eg., Diagos I, a gluconate complex, a lyophilisate for sup(99m)Tc-sodium pyrophosphate injections, a diagnostic kit for lung scintiscanning. (H.S.)

  19. 99mTc renal tubular function agents: Current status

    International Nuclear Information System (INIS)

    Eshima, D.; Fritzberg, A.R.; Taylor, A. Jr.

    1990-01-01

    Orthoiodohippuric (OIH) acid labeled with 131I is a widely used renal radiopharmaceutical agent and has been the standard radiopharmaceutical agent for the measurement of effective renal plasma flow (EPRF). Limitations to the routine clinical use of 131I OIH are related to the suboptimal imaging properties of the 131I radionuclide and its relatively high radiation dose. 123I has been substituted for 131I; however, its high cost and short shelf-life have limited its widespread use. Recent work has centered on the development of a new 99mTc renal tubular function agent, which would use the optimal radionuclidic properties and availability of 99mTc and combine the clinical information provided by OIH. The search for a suitable 99mTc renal tubular function agent has focused on the diamide dithiolate (N2S2), the paraaminohippuric iminodiacetic acid (PAHIDA), and the triamide mercaptide (N3S) donor ligand systems. To date, the most promising 99mTc tubular function agent is the N3S complex: 99mTc mercaptoacetyltriglycine (99mTc MAG3). Studies in animal models in diuresis, dehydration, acid or base imbalance, ischemia, and renal artery stenosis demonstrate that 99mTc MAG3 behaves similarly to 131I OIH. A simple kit formulation is available that yields the 99mTc MAG3 complex in high radiochemical purity. Studies in normal subjects and patients indicate that 99mTc MAG3 is an excellent 99mTc renal tubular agent, but its plasma clearance is only 50% to 60% that of OIH. In an effort to develop an improved 99mTc renal tubular function agent, changes have been made in the core N3S donor ligand system, but to date no agent has been synthesized that is clinically superior to 99mTc MAG3. 61 references

  20. Evaluation of the absorbed dose to the kidneys due to Tc99m (DTPA) / Tc99m (Mag3) and Tc99m (Dmsa)

    International Nuclear Information System (INIS)

    Vasquez A, M.; Murillo C, F.; Castillo D, C.; Rocha J, J.; Sifuentes D, Y.; Sanchez S, P.; Idrogo C, J.; Marquez P, F.

    2015-10-01

    The absorbed dose in the kidneys of adult patients has been assessed using the biokinetics of radiopharmaceuticals containing Tc 99m (DTPA) / Tc 99m (Mag3) or Tc 99m (Dmsa).The absorbed dose was calculated using the formalism MIRD and the Cristy-Eckerman representation for the kidneys. The absorbed dose to the kidneys due to Tc 99m (DTPA) / Tc 99m (Mag3), are given by 0.00466 mGy.MBq -1 / 0.00339 mGy.MBq -1 . Approximately 21.2% of the absorbed dose is due to the bladder (content) and the remaining tissue, included in biokinetics of Tc 99m (DTPA) / Tc 99m (Mag3). The absorbed dose to the kidneys due to Tc 99m (Dmsa) is 0.17881 mGy.MBq -1 . Here, 1.7% of the absorbed dose is due to the bladder, spleen, liver and the remaining tissue, included in biokinetics of Tc 99m (Dmsa). (Author)

  1. Production and clinical evaluation of 99mTc-octreotide

    International Nuclear Information System (INIS)

    Fettich, J.; Kolenc-Peitl, P.

    2004-01-01

    Full text: Due to advantages of 99m-Tc labelled radiopharmaceuticals we examined the feasibility of producing 99m-Tcoctreotide in our laboratory and compare the results with 111-In-octreotide in the same patients. Keeping constant amount of components without exceeding amount of the peptide used, preparation of 99m-Tc-ethylendiaminediacetic- acidhydrazinonicotinamide-D-Phe1,Tyr3-octreotide (99m-Tc EDDA/HYNIC-TOC) was achieved. Radiochemical purity was tested using high-pressure liquid chromatography for 24 hours. In vitro stability testing of the product showed that radiochemical purity remained above 95% for 24 hours and the radiopharmaceutical was found suitable for human use. 5 - 10 μg of the peptide labelled with 550-650 MBq of 99m-Tc was prepared for each patient. 32 patients with clinically suspicious or confirmed carcinoid were investigated with 550 - 650 MBq 99m-Tcoctreotide prepared in our laboratory followed by 110 MBq 111-In-octreotide (Octreoscan, Mallinkrodt). Whole body scintigraphy and abdominal SPECT were performed 4 and 20 hrs after injection of respective radiopharmaceutical. In all patients both studies were acquired within 5 days. All patients gave informed consent for the study as required by Ethics committee. No abnormal tracer uptake was seen anywhere in the body in 12 patient with either of the radiopharmaceuticals. These were used to assess normal distribution of both radiopharmaceuticals. Normal accumulation was seen in case of both radiopharmaceuticals in the spleen, kidneys, liver and gallbladder. Biliary activity was seen in the gut in patients that were not well prepared for the study. There was significantly less activity seen in the kidneys in case of 99m-Tc-octreotide. This could be explained by higher hydrophilicity of the 99m-Tc-EDDA/HYNEC-TOC molecules as compared with 111-In-DTPA-octreotide. 20 patients with confirmed carcinoids showed abnormal uptake but without any difference in distribution of the two radiopharmaceuticals

  2. Discordant results in Tc-99m tetrofosmin and Tc-99m sestamibi parathyroid scintigraphies; Resultados discordantes em cintilografias das paratireoides realizadas com tetrofosmin-99mTc e com sestamibi-99mTc

    Energy Technology Data Exchange (ETDEWEB)

    Duarte, Paulo Schiavom; Domingues, Fernanda C.; Santi Costa, Michele; Brandao, Cynthia; Oliveira, Marco A.C. de; Vieira, Jose G.H. [Fleury - Centro de Medicina Diagnostica, Sao Paulo, SP (Brazil)]. E-mail: paulo.duarte@fleury.com.br

    2007-10-15

    Parathyroid scintigraphies have been used to detect pathological parathyroid glands either before as well as after the parathyroid resection surgery in patients with hyperparathyroidism. One of the most utilized techniques to perform the studies is the double-phase images with Tc-99m sestamibi, which has been shown to be very accurate in the localization of enlarged parathyroid glands. Similar to Tc-99m sestamibi, Tc-99m tetrofosmin is a radiopharmaceutical initially developed to perform myocardial perfusion study that has been used to perform parathyroid scintigraphies. Although most of the papers suggest that the overall sensitivities of both radiopharmaceuticals are similar, there are some papers questioning the accuracy of Tc-99m tetrofosmin to detect abnormal parathyroid glands. In the present article, we report a case with discordant results by both methods. (author)

  3. Quality control of techetium 99m radiopharmacentical in nuclear medicine

    International Nuclear Information System (INIS)

    Darte, L.

    1981-03-01

    Gel chromatography column scanning (GCS) is a new method for radiochemical quality control. GCS techniques for Technetium-99m radiopharmaceuticals in nuclear medicine have been developed for use in both research and routine clinical work. The dependence on several of the parameters of the GCS method have been investigated, e.g. type of gel, column dimensions, eluent, equilibration, elution volume, flow rate and resolution of the recording system (radiochromatographic scanner or scintillation camera). The GCS method has been compared with conventional gel filtration, thinlayer cromatography (TLC) and paper cromatography (PC). The GCS method is to be preferred due to few artifacts, much information, good reproducibility, rapidity, simplicity and the convenience of the test. The GCS method has been applied to the development of labelling techniques for the new radiopharmaceuticals Tc-99m plasmin and Tc-99m unithiol (2.3 dimercaptopropane sodiumsulphonate), use for investigating deep vein thrombosis and renal cortical morphology respectively. The GCS method has also been applied for studying some labelling parameters, the radiochemical purity and the labelling of Tc-99m macroaggregated albumin, Tc-99m pyrophosphate, Tc-99m methylenedisphosphate, in addition to Tc-99m plasmin and Tc-99m unithiol. (Author)

  4. Lung radiopharmaceuticals; Radioformacos pulmonares

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez, B M [Instituto Nacional de Pediatroa (Mexico)

    1994-12-31

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP.

  5. 99mTc tetrosfosmin mamoscintigraphy in the diagnose of the breast cancer

    International Nuclear Information System (INIS)

    Batista, Juan F.

    1997-01-01

    Background: Several radiopharmaceuticals such as Tc-99m Metoxi-isobutiol-isonitrile, Tc-99m MDP, Gallium Citrate and Thallium Chloride have been tested for the detection of breast cancer and lymph node involvement. To date, only report has been published related with the uptake of Tc-99m tetrosfosmin in one patient with breast cancer

  6. 99mTc-Tetrofosmin scintimammography in suspected breast cancer patients: comparison with 99mTc-MIBI

    International Nuclear Information System (INIS)

    Kim, Seong Jang; Kim, In Ju; Kim, Yong Ki; Bae, Young Tae

    2000-01-01

    The aim of this study was to investigate the diagnostic role of 99m Tc-Tetrofosmin in detection of breast cancer and compared with that of 99m Tc-MIBI. Forty-eight patients with a clinically palpable mass or abnormal mammographic or ultrasonographic findings had 99m Tc-MIBI and 99m Tc-Tetrofosmin scintimammographies after intravenous injection of 925 MBq of radiopharmaceuticals. The scintimammographs were correlated with histopathologic findings. Thirty-three patients were diagnosed with breast cancer and 15 patients with benign breast diseases. The numbers of true positive, true negative, false positive, and false negative cases of 99m Tc-MIBI scintimammography were 29, 10, 5, and 4 respectively. The sensitivity, specificity, positive predictive value, and negative predictive value of 99m Tc-MIBI scintimammographies were 87.8%, 66.7%, 85.3%, and 71.4% respectively. The numbers of true positive, true negative, false positive, and false negative cases of 99m Tc-Tetrofosmin were 31, 10, 5, and 2 respectively. The sensitivity, specificity, positive predictive value, negative predictive value of 99m Tc-Tetrofosmin were 93.9%, 66.7%, 86.1%, and 73.3% respectively. One patient was false negative in both 99m Tc-Tetrofosmin scintimammographies and its size was 0.5cm. 99m Tc-Tetrofosmin and 99m Tc-MIBI were non-invasive and useful in detection of breast cancer and 99m Tc-Tetrofosmin was comparable to the 99m Tc-MIBI in detection of primary breast cancer.=20

  7. Process for preparing radiopharmaceuticals

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.S.

    1977-01-01

    A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical

  8. Design and synthesis of a redox-active tc-99m radiopharmaceutical with ferrocenedithiocarboxylate [FcCS=Fe(C{sub 5}H{sub 4}CS{sub 2})(C{sub 5}H{sub 5}){sup -}

    Energy Technology Data Exchange (ETDEWEB)

    Uccelli, Licia; Bolzati, Cristina; Boschi, Alessandra; Duatti, Adriano E-mail: dta@ifeuniv.unife.it; Morin, Christophe; Pasqualini, Roberto; Giganti, Melchiore; Piffanelli, Adriano

    1999-01-01

    The synthesis, at tracer level, of two Tc-99m complexes having the same chemical composition and structure, but differing by one electron in the total electron counting, is reported. These compounds have been prepared by reacting [{sup 99m}TcO{sub 4}]{sup -} with the piperidinium salt of the ligand ferrocenedithiocarboxylate {l_brace}[Fe(II)(C{sub 5}H{sub 4}CS{sub 2})(C{sub 5}H{sub 5})]{sup -}=FcCS{r_brace}, in the presence of N-methyl S-methyldithiocarbazate as donor of N{sup 3-} groups, and triphenylphosphine or SnCl{sub 2} as reducing agents. The formation of the neutral complex [{sup 99m}Tc(N)(FcCS){sub 2}] (compound A) and of the monocationic, mixed-valence complex [{sup 99m}Tc(N)(FcCS) (FcCS*)]{sup +} (compound B) {l_brace}FcCS* [Fe(III)(C{sub 5}H{sub 4}CS{sub 2})(C{sub 5}H{sub 5})]{r_brace} was obtained in high yield. Both complexes comprise a terminal Tc{identical_to}N multiple bond and two FcCS ligands coordinated to the metal center through the two sulfur atoms of the -CS{sub 2} group, but they differ in the oxidation state of one of the two iron atoms of the coordinated FcCS ligands. In complex A, the two Fe atoms are both in the +2 oxidation state, while in B, one Fe atom is in the +2 and the other is in the +3 oxidation state. Thus, B is a mixed-valence Fe(II)-Fe(III) complex. B is easily converted into A by one-electron exchange with various reductants such as triphenylphosphine and excess SnCl{sub 2}. Biodistribution studies in rats showed that complexes A and B are mostly retained in lungs and liver without any significant uptake in organs such as heart and brain.

  9. Chapter 19. Design and evaluation of potential 99mTc radiopharmaceuticals based on the Tc-Carbonyl, 4 + 1 mixed ligand chelate system and Tc-nitrido approaches

    International Nuclear Information System (INIS)

    Giglio, J.; Muslera, A.; Leon, E.; Paolino, A.; Leon, A.; Rey, A.; Incerti, M.; Fernandez, R.; Manta, E.; Brugnini, A.; Chabalgoity, A.

    2007-01-01

    The aim of the work was to explore the possibilities of the novel labelling strategies in the development of 99m Tc labelled small biomolecules. Different steps required to fulfil this objective were undertaken: organic synthesis of glucose derivatives, optimization of labelling and in vitro and in vivo evaluation of Rd peptides and anne xin 13 derivatives using either the Hyonic bifunctional ligand, the Tc-tricarbonyl, the 4 + 1 mixed ligand or the Tc(V)-nitri do approaches. Glucose-O-hexyl bromide, glucose- O-butylbromide and glucose-O-butylamine were successfully synthesized, opening the possibility of introducing different chelators according to the desired labelling procedure. c(RGDyK) derivatives bearing different chelators were labelled with 99m Tc using novel approaches and evaluated both in vitro and in vivo in order to compare the effect of the chelator and labelling method on the physicochemical and biological behaviour. Annexin 13 peptides were also labelled using the HYNIC and Tc(I)-tricarbonyl approaches. A primary evaluation in normal animals and in a model of cardiac apoptosis is also presented. Cooperation with other participants was crucial to develop this work. (author)

  10. Evaluation of the absorbed dose to the kidneys due to Tc{sup 99m} (DTPA) / Tc{sup 99m} (Mag3) and Tc{sup 99m} (Dmsa); Evaluacion de la dosis absorbida en los rinones debido al Tc{sup 99m} (DTPA) / Tc{sup 99m} (MAG3) y Tc{sup 99m} (DMSA)

    Energy Technology Data Exchange (ETDEWEB)

    Vasquez A, M.; Murillo C, F.; Castillo D, C.; Rocha J, J.; Sifuentes D, Y.; Sanchez S, P. [Universidad Nacional de Trujillo, Av. Juan Pablo II s/n, Trujillo (Peru); Idrogo C, J.; Marquez P, F., E-mail: marvva@hotmail.com [Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos 2520, Lima (Peru)

    2015-10-15

    The absorbed dose in the kidneys of adult patients has been assessed using the biokinetics of radiopharmaceuticals containing Tc{sup 99m} (DTPA) / Tc{sup 99m} (Mag3) or Tc{sup 99m} (Dmsa).The absorbed dose was calculated using the formalism MIRD and the Cristy-Eckerman representation for the kidneys. The absorbed dose to the kidneys due to Tc{sup 99m} (DTPA) / Tc{sup 99m} (Mag3), are given by 0.00466 mGy.MBq{sup -1} / 0.00339 mGy.MBq{sup -1}. Approximately 21.2% of the absorbed dose is due to the bladder (content) and the remaining tissue, included in biokinetics of Tc{sup 99m} (DTPA) / Tc{sup 99m} (Mag3). The absorbed dose to the kidneys due to Tc{sup 99m} (Dmsa) is 0.17881 mGy.MBq{sup -1}. Here, 1.7% of the absorbed dose is due to the bladder, spleen, liver and the remaining tissue, included in biokinetics of Tc{sup 99m} (Dmsa). (Author)

  11. Technetium-99m-dimethylglyoxime ([sup 99m]Tc-DMG) as renal imaging agent

    Energy Technology Data Exchange (ETDEWEB)

    Adonaylo, V.N. (Buenos Aires Univ. (Argentina). Facultad de Ciencias Exactas y Naturales Buenos Aires Univ. (Argentina). Dept. de Ciencias Biologicas); Stahl, Adriana; Pomilio, A.B.; Vitale, A.A. (Buenos Aires Univ. (Argentina). Facultad de Ciencias Exactas y Naturales); Canellas, C.O. (Buenos Aires Univ. (Argentina). Facultad de Ciencias Exactas y Naturales Comision Nacional de Energia Atomica, Buenos Aires (Argentina))

    1993-06-01

    Dimethylglyoxime (DMG) labelled with [sup 99m]Tc is presented as a renal imaging agent. The behaviour of this complex was analysed at different pH by means of UV spectral data and using DMG-calcium chloride as a reference complex. Biokinetic data were evaluated in two biological models, Sprague-Dawley rats and Didelphis albiventris argentine opossum. Biodistribution in rats demonstrated fast and specific renal excretion. Time-activity values over both kidneys could be quantified for this complex. Renographic studies led to mean time-to maximum values on twelve assays of 2.0 [+-] 0.1 min and a mean relative function of 53.0 [+-] 2.3 and 47.0 [+-] 3.2 for right and left kidneys, respectively. [sup 99m]Tc-DMG showed specificity for the renal excretion pathway and therefore seems to be a very useful radiopharmaceutical for renal function studies. (Author).

  12. Adsorption of technetium-99m tetrofosmin and technetium-99m furifosmin on plastic syringes

    International Nuclear Information System (INIS)

    Bartosch, R.; Granegger, S.; Sinzinger, H.

    1998-01-01

    Some groups have reported that adsorption of radiopharmaceuticals on disposable plastic syringes can reach levels of almost 50%. This high loss of radioactivity stimulated us to carry out similar studies. Our measurements were done in combination with patient studies. Therefore, we used 2-ml syringes, all of the same brand. The radioactivity in the syringe was measured immediately before and after injection. a total of 500-600 MBq technetium-99m labelled tetrofosmin or technetium-99m furifosmin was administered to 48 patients using four different injection techniques (n = 6 for each technique with each tracer): with needles, 1 min blood incubation at 22 C, 10 or 30 min after preparation of the tracer; with butterflies, 1 min blood incubation at 22 C, 10 or 30 min after preparation of the tracer. Neither in syringes nor in needles or butterflies did more than 7% of the initial radioactivity remain. The entire residual activity in syringe plus needle or syringe plus butterfly together never exceeded the 9% limit. Furthermore, in a pilot study we measured the remaining radioactivity in the vial; here, too, we found no more than 14% of total radioactivity. These findings indicate that total retention of radioactivity during elution and application of 99m Tc-tetrofosmin and 99m Tc-furifosmin with material used in our setting does not approach relevant amounts. (orig.)

  13. Adsorption of technetium-99m tetrofosmin and technetium-99m furifosmin on plastic syringes

    Energy Technology Data Exchange (ETDEWEB)

    Bartosch, R.; Granegger, S.; Sinzinger, H. [Department of Nuclear Medicine, University of Vienna (Austria)

    1998-09-01

    Some groups have reported that adsorption of radiopharmaceuticals on disposable plastic syringes can reach levels of almost 50%. This high loss of radioactivity stimulated us to carry out similar studies. Our measurements were done in combination with patient studies. Therefore, we used 2-ml syringes, all of the same brand. The radioactivity in the syringe was measured immediately before and after injection. a total of 500-600 MBq technetium-99m labelled tetrofosmin or technetium-99m furifosmin was administered to 48 patients using four different injection techniques (n = 6 for each technique with each tracer): with needles, 1 min blood incubation at 22 C, 10 or 30 min after preparation of the tracer; with butterflies, 1 min blood incubation at 22 C, 10 or 30 min after preparation of the tracer. Neither in syringes nor in needles or butterflies did more than 7% of the initial radioactivity remain. The entire residual activity in syringe plus needle or syringe plus butterfly together never exceeded the 9% limit. Furthermore, in a pilot study we measured the remaining radioactivity in the vial; here, too, we found no more than 14% of total radioactivity. These findings indicate that total retention of radioactivity during elution and application of {sup 99m}Tc-tetrofosmin and {sup 99m}Tc-furifosmin with material used in our setting does not approach relevant amounts. (orig.) With 4 figs., 1 tab., 7 refs.

  14. Chemical form of tumor-tropic 99mTc-DL-homocysteine

    International Nuclear Information System (INIS)

    Takeda, A.; Okada, S.

    1989-01-01

    Analyses of the chemical forms of 99m Tc-complexes provide important information for the development of a new tumor-tropic 99m Tc-labeled radiopharmaceutical. We attempted to determine the chemical form of 99m Tc-DL-homocysteine ( 99m Tc-Hcy) which was previously reported to be tumor-tropic. By analyzing the functional residues of Hcy in the 99m Tc-Hcy molecule, it was estimated that the sulfhydryl and amino residues participated in the chelate formation. Gel filtration analysis of 99m Tc-Hcy indicated that its molecular size was bigger than that of 99m Tc-penicillamine monomer. The analysis also indicated that 99m Tc-Hcy complex seemed to be a relatively small oligomer. Although an uncertainty remains on the valency of Tc in 99m Tc-Hcy molecule and the accurate molecular size of this complex, its putative chemical form is described. (author)

  15. Serum protein-binding ability of sup(99m)Tc-diethyl IDA and sup(99m)Tc-para-butyl IDA studied by electrophoresis and precipitation experiments

    International Nuclear Information System (INIS)

    Sawas-Dimopoulou, C.; Simitzis, G.; Papanicolaou, N.

    1982-01-01

    The aim of the study was to separate and to identify by electrophoresis the proteins which are able to bind 99mTc-diethyl IDA and 99mTc-p-butyl IDA when these radiopharmaceuticals are incubated in vitro with human serum. The determinations were completed by precipitation experiments. Electrophoresis showed that both radiopharmaceuticals have negative charge and move to the anode like organic anions. And it is known that organic anions can interact with cationic groups on the albumin. Moreover, it is generally accepted that the extent to which a drug is bound to a particular protein depends on the concentration of the drug. Consequently, the logical hypothesis that binding of each radiopharmaceutical to the various serum proteins could be easier demonstrated on autoradiographies and electrophoregrams by high concentrations of 99mTc-diethyl IDA and 99mTc-parabutyl IDA in the incubation medium was put to trial

  16. Usefulness of L,L-ethylenedicysteine - 99mTc complex (EC-99mTc) for the kidney investigations

    International Nuclear Information System (INIS)

    Surma, M.J.; Wiewiora, J.; Kapuscinksi, J.; Liniecki, J.

    1992-01-01

    To assess the usefulness of own EC- 99m Tc complex for the kidney function examination, the renoscintigraphy with EC- 99m Tc and clearance determinations were performed. During renoscintigraphy the kidney images were of superb quality, with overlaying organs (liver, spleen) not visualized. Renograms showed typical shapes, their TMAX and T1/2 values being insignificantly different from the obtained with other radiopharmaceuticals, used in renoscintigraphy (MAG 3 , hippuran). Very strict correlations were found between values of EC- 99m Tc and OIH- 131 I clearances (r=0.91) and excretion rate constants (r=0.92) of both radiopharmaceuticals. The correlation enabled formulation of an equation by which ERPF could be established from EC- 99m Tc clearance: ERPF OIH =1.245 x Cl EC +51.52. On the basis of this equation a lower boundary of the normal EC- 99m Tc clearance was established; it amounts to 300 ml/min/1.73 m 2 . (author). 17 refs, 5 figs, 1 tab

  17. Method for in vitro labelling of erythrocytes with 99mTc-pertechnetate

    International Nuclear Information System (INIS)

    Kostadinova, I.D.; Hadzhikostova, H.K.; Shejretova, E.T.; Garcheva-Tsacheva, M.B.

    1987-01-01

    The method is easy to apply and gives a possibility to lead the radiopharmaceutical directly to erythrocytes. It includes: blocking of the structures accumulating 99m Tc-pertechnetate by potassium perchlorite; attenuation of the erythrocytes by an intervenous injection of tin pyrophosphate; preparation of the necessary blood quantity with acidum citricum dextrose mixing with 99m Tc-pertechnetate and reinjection. 1 cl

  18. Placental transfer of selected radiopharmaceuticals

    International Nuclear Information System (INIS)

    Wegst, A.V.

    1992-01-01

    This paper reviews animal experiments carried out to determine the transfer of radiopharmaceuticals from mother to fetus. Animal data are compared to any human data available. The radiopharmaceuticals included in the discussion are Tc-99m pertechnetate, Tc-99m DTPA, Ga-67 citrate and Tl-201 chloride. (6 tab., 5 refs.)

  19. Preparation of sup(99m) Tc - L - asparagine

    International Nuclear Information System (INIS)

    Okada, H.; Silva, C.P.G. da; Pereira, N.P.S. de.

    1986-05-01

    The interrelationship between technetium-99m, different reducing agents and the L-asparagine is studied. The maximum labelling yield, aboult 95%, is obtained by using the following molar ratios for ligand to reducing agents: L-asparagine: stannous ascorbate, 150:1; the L-asparagine: ascorbic acid, 50:1, and L-asparagine:stannous chloride, 800:1. This radiopharmaceutical is used for visualization of dependent asparagine tumours. (Author) [pt

  20. Renal 99M-technetium dimercaptosuccinic acid scintigraphy

    International Nuclear Information System (INIS)

    Ajdinovic, B.; Jaukovic, L.; Jankovic, Z.; Krstic, Z.

    2004-01-01

    99m-Technetium dimercaptosuccinic acid (99mTc-DMSA) whose ligand was used as a radioprotective agent and as a chelating compound for metal poisoning was reported to be an excellent renal imaging agent. As 99mTc-DMSA concentrates actively in the proximal convoluted tubule, it gives an image functional renal mass. Its integrity is dependent upon several factors, predominently intrarenal blood flow and intact enzyme function.Considering low radiation dose delivered by 99mTc DMSA and wide pediatric use of this radiopharmaceutical we calculate abnormal findings incidence (%).Results of 592 99m Tc-DMSA renal scintigraphy (348 children), which were classified as: 1. normal, 2. probably normal, 3. equivocal, 4. probably abnormal, 5. abnormal, are presented.Normal results were found in 269 patients (45,4%), 25% of whom was normal and 75% probably normal. Equivocal findings were found in 47 patients (7,9%). Abnormal results were presented in 276 patients (82% abnormal, 18% probably abnormal).The highest abnormal findings incidence was found in patients with congenital anomaly (88%), calculosis (87%) and policystic renal disease (79,3%). The lowest abnormal findings percentage was present in patients with urinary tract infection (12,9%) and arterial hypertension (17,3%)The role 99mTc-DMSA renal scintigraphy in pathology is clear in pyelonephrifis, hydronephrotic kidneys, and pediatric disease (urinary tract infections, congenital anomalies) and is confirmed by our results. (authors)

  1. Triamide mercaptide (N/sub 3/S) ligands for Tc-99m as potential Tc-99m renal function agents

    International Nuclear Information System (INIS)

    Fritzberg, A.R.; Kasina, S.; Johnson, D.L.; Eshima, D.

    1985-01-01

    A number of diamide dimercaptide (N/sub 2/S/sub 2/) complexes of Tc-99m have shown potential as renal tubular function radiopharmaceuticals that could replace radioiodinated hippurate (OIH). Evaluation of such ligands suggested that maximum efficiency for tubular secretion and specificity resulted from addition of a carboxylate group. However, such derivatives resulted in chelate ring stereoisomers that were differently transported by the renal tubular system. The problem of stereoisomers was obviated by replacing one sulfur with an effectively planar amido nitrogen. Groups on the nitrogen then result in diastereomers only when an additional asymetric center is present. A series of triamide mercaptide compounds have been synthesized to evaluate this class as ligands for Tc-99m. One of the simplest of the series, mercaptoacetylglycylglycylglycine (MAG/sub 3/), formed a single Tc-99m product in high yield as determined by HPLC. Preliminary results with pmr and ms of the Tc-99 complex indicate a structure consistent with a 1:1 metal to ligand ratio and monooxo technetium group. Biological evaluation of Tc-99m MAG/sub 3/ showed high renal specificity and rate of excretion exceeding OIH in several species including humans. Members of the N/sub 3/S series studied include mercaptoacetylglycylglycyl-amino acids. In some cases with second asymmetric centers, two components were seen on HPLC. In mice several dianionic Tc-99m complexes were excreted faster than OIH, Tc-99m MAG/sub 2/-ala, -asn, and -gln. Trianionic Tc-99m MAG/sub 2/-asp and -glu were excreted more slowly, and Tc-99m MAG/sub 2/-phe showed hepatobiliary excretion. Triamide mercaptides represent a new ligand class for Tc-99m

  2. Comparative biological evaluation between 99mTc tricarbonyl and 99mTc-Sn(II) levosalbutamol as a β2-adrenoceptor agonist

    International Nuclear Information System (INIS)

    Sanad, Mahmoud H.; Borai, Emad H.

    2015-01-01

    This study describes the comparison between 99m Tc-tricarbonyl and 99m Tc-Sn (II) levosalbutamol as a β 2 -adrenoceptors radiopharmaceutical and evaluation of their different biological characteristics using experimental animals. Levosalbutamol was labeled firstly with 99m Tc in the presence of SnCl 2 . 2H 2 O as a reducing agent under the optimum conditions: pH 8, 50 μg SnCl 2 . 2H 2 O, room temperature, 40 μg levosalbutamol and 30 min reaction time to give a maximum radiochemical yield of 98 ± 0.1%. The obtained 99m Tc-levosalbutamol was stable for a time up to 8 h. Secondly, 99m Tc-tricarbonyl ([ 99m Tc(CO) 3 (H 2 O) 3 ] + ) levosalbutamol was prepare under 30 min heating at 100 C. Labeling yield and stability were analyzed by high performance liquid chromatography (labeling yield >99% and stability for 8 h). Biodistribution investigation showed that, the maximum uptake ratio of the 99m Tc-levosalbutamol ( 99m Tc-Lev) between lung and heart was 2.34 ± 0.62 % of the injected activity/g tissue organ, at 30 min post-injection. But in case of 99m Tc-tricarbonyl levosalbutamol ( 99m Tc-tricarbonyl Lev) the maximum uptake ratio was 3.6 ± 0.11 of the injected activity/g tissue organ, at 30 min post-injection. This indicates that 99m Tc-tricarbonyl levosalbutamol was more selective for lung β 2 -adrenoceptors than 99m Tc-levosalbutamol. These results introduce 99m Tc-tricarbonyl levosalbutamol as a novel potential radiopharmaceutical for lung imaging.

  3. Development of 99mTc-DMSA for kidney imaging

    International Nuclear Information System (INIS)

    Shafii Khamis; Nurshuhadah Mohd Yusof

    2006-01-01

    In nuclear medicine studies, 99m Tc-Dimercaptosuccinic acid ( 99m Tc-DMSA) has been shown to be an excellent radiopharmaceutical agent for detecting focal abnormalities of the renal cortex in patients. The agent, however, oxidizes readily and must be used within 30 minutes of preparation. The instability of the radiopharmaceutical renders the kit less economical to use. Several factors affecting the labeling yield such as the kit formulation, stannous and stabilizer content were investigated. The radiochemical determination of the radiolabelled product was analyzed using I TLC-SG system developed in methyl ethyl ketone and the radiolabelled 99m Tc-DMSA biological distributions were carried out in female rats. Stability study of the radiolabelled 99m Tc-DMSA was carried out using ascorbic acid as stabilizer. Comparative study was also carried out on both the prepared kit and those obtained commercially. The DMSA kit was successfully developed and the result obtained was found to be comparable to that of the commercially available kit. (Author)

  4. Radioisotope and radiopharmaceutical generators

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.W.

    1975-01-01

    A chromatographic column for generating technetium-99m isotopes and technetium-99m labeled pharmaceuticals in a simple two-step process is described. Technetium-99m pertechnetate in a first step is isolated by adsorption upon an adsorbent packing. Then the technetium-99m in a second step is eluted from the packing, either with an immediately labeled biological compound to form a radiopharmaceutical, or by a controlled volume of eluant to produce a 99m-technetium-bearing eluate of a desired specific concentration. (Official Gazette)

  5. 6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Schiller, P.; Havranek, E.; Majer, J.

    1981-01-01

    Radionuclides commonly used in medicine are surveyed and their nuclear characteristics are presented. The methods are given of their preparation, most frequent use and detection. The list is given of radiopharmaceuticals included in the Czechoslovak Pharmacopoeia CsL 3 , ie., sodium chromate( 51 Cr), sodium iodide( 131 I), hippuran( 131 I), sodium phosphate( 32 P), colloidal gold( 198 Au), rose bengal sodium salt( 131 I), and sodium pertechnetate(sup(99m)Tc) injections. Characteristics, chemical preparation, identification tests, packaging, storage, application and dosage are shown for each preparation. Also listed are important unofficial radiopharmaceuticals, their main characteristics and data on their preparation and application. (B.S.)

  6. Development of Tc99m-Saccharic Acid for Heart Imaging

    International Nuclear Information System (INIS)

    Shafii Khamis; Mohd Azfar Adenan; Bohari Yaacob; Amir Fitri Shafii

    2014-01-01

    Cardiovascular disease especially the coronary heart disease (CHD) is the leading cause of death worldwide. Coronary heart disease is a common term for the buildup of plaque in the heart coronary arteries that could block the blood supply to the myocardial and this could lead to heart attack. An estimated 17 million people died from cardiovascular disease in 2008 representing 30% of all global death. In United Kingdom, coronary heart disease killed as much as 82,000 people each year. Hence, early detection of the coronary heart disease is very important in reducing the mortality among the world population. One of the most sensitive detection methods is by radioimaging using Technetium-99m radiopharmaceuticals. Several different radio imaging agents such as Tc99m radiopharmaceutical were developed as radiagnostic agent in determining the CHD especially in identifying the blockage of the coronary artery of the heart muscle. Despite the success of Tc99m-sestamibi and Tc99m-tetrofosmin as effective agents for myocardial perfusion study, the search for other Tc99m heart imaging agents has never been interrupted. This report described the formulation of the Tc99m-saccharic acid radiopharmaceutical kit, radiolabelling of the kit, radiochemical purity evaluation of the Tc99m labeled saccharaic acid, and animal study involving radio imaging using gamma camera. The animal are then sacrificed and the biological distribution of the Tc99m-saccharic acid in-vivo was determined. Comparative study was also conducted using commercially available Tc99m-tetrafosmin, a CHD radiopharmaceutical kit. The Tc99m-saccharic acid developed gave a very high labeling efficiency of >92% with Tc99m and good uptake in the heart muscle. The saccharic acid kit developed was also found to be comparable in quality to the commercially available Tc99-tetrafosmin kit. (author)

  7. Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease

    International Nuclear Information System (INIS)

    Mariani, G.; Molea, N.; La Civita, L.; Porciello, G.; Lazzeri, E.; Ferri, C.

    1996-01-01

    We report here on the use of the lipophilic cationic complex technetium-99m sestamibi ( 99m Tc-MIBI), employed as an indicator of increased cellular density and metabolic activity, to evaluate Gaucher cell infiltrates in the bone marrow; 99m Tc-hexametazime ( 99m Tc-HMPAO) was also employed, as a pure indicator of lipidic infiltration in the bone marrow. A 67-year-old patient with known type 1 Gaucher's disease presented with a painful left hip and knee and difficulty in gait subsequent to traumatic fracture of the left femoral neck that had required implant of a fixation screw-plaque. Bone scan with 99m Tc-methylene diphosphonate revealed reduced uptake at the distal metaphyseal-epiphyseal femoral region. In addition, whole-body maps and spot-view acquisitions of the thighs and legs were recorded at both 30 min and 2.5 h after the injection of 99m Tc-MIBI: the scintigraphic pattern clearly showed increased uptake at several sites involved by Gaucher deposits in the bone marrow (both knees, with variable intensity in different areas), matching the bone changes detected by conventional x-ray. The target to non-target ratios slowly decreased with time, from an average value of 2.25 in the early scan to an average value of 2 in the delayed scan. The lipid-soluble agent 99m Tc-HMPAO exhibited a superimposable scintigraphic pattern of accumulation at the involved sites, though with lower target to non-target ratios (1.27-1.48). The results obtained in this patient suggest a potential role of 99m Tc-MIBI in the scintigraphic evaluation of Gaucher's lipid deposits in the bone marrow. If the results are confirmed in other patients, this radiopharmaceutical would offer clear advantages over 133 Xe because of its wider availability and greater practicality (i.v. administration of 99m Tc-MIBI versus inhalation of 133 Xe, and use of a single gamma camera instead of two as with 133 Xe). (orig.). With 3 figs

  8. Rapid radiochemical methods for preparation of sup(99m)Tc labelled compounds

    International Nuclear Information System (INIS)

    Narasimhan, D.V.S.; Banodkar, S.M.; Kothari, K.; Mani, R.S.

    1981-01-01

    Several inorganic and organic compounds incorporating sup( 99 m)Tc are being extensively used for imaging various body organs. The preparation of these sup( 99 m)Tc compounds with the necessary purity requirements is carried out by controlled reduction of sup( 99 m)Tc-pertechnetate using Sn(II) ions as the reducing agent followed by complexation with various active ingredients. The authors here present procedures developed at Radiopharmaceuticals Section of BARC for preparing sup( 99 m)Tc-diphosphonate, sup( 99 m)Tc-glucoheptonate, sup( 99 m)Tc-albumin microspheres and sup( 99 m)Tc-phytate with high radiochemical purity. The paper also describes procedures for the preparation of freeze-dried kits for single step preparation of these compounds. The paper also describes the authors' experience with various analytical procedures for the determination of radiochemical purity of these preparations. (author)

  9. Radiopharmaceuticals for nuclear cardiology

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases

  10. Clinical comparison of diisopropyl-IDA Tc 99m and diethyl-IDA Tc 99m for evaluation of the hepatobiliary system

    International Nuclear Information System (INIS)

    Klingensmith, W.C.; Fritzberg, A.R.; Spitzer, V.M.; Kuni, C.C.; Shanahan, W.S.

    1981-01-01

    Thirty-one patients with a wide range of hepatobiliary function and clinical diagnoses were studied with both diisopropyl-IDA Tc 99m and diethyl-IDA Tc 99m. Images were similar except for an increased liver-to-kidney ratio with diisopropyl-IDA Tc 99m (p less than 0.01) and a tendency toward an increased liver-to-background ratio at five minutes with diisopropyl-IDA Tc 99m (p greater than 0.05). Quantification of the relative hepatocyte extraction efficiency indicated a 16% higher extraction efficiency for diisopropyl-IDA Tc 99m (p greater than 0.05). Cumulative three-hour urine collections following injection demonstrated no significant difference in renal excretion in patients with normal total serum bilirubin levels. Both radiopharmaceuticals demonstrated increasing renal excretion with increasing total serum bilirubin levels; however, renal excretion of diisopropyl-IDA Tc 99m increased more slowly than excretion of diethyl-IDA Tc 99m (p less than 0.01). We conclude that, while the overall differences between these two radiopharmaceuticals are small, diisopropyl-IDA Tc 99m is superior because of a lower renal excretion rate in patients with decreased hepatocyte function

  11. Development and biodistrubition modeling of 99mTc-DTPA

    Directory of Open Access Journals (Sweden)

    Mohammed Bricha

    2015-09-01

    Full Text Available Purpose: In this study, the team modeled the biodistribution and the efficiency of two 99m-technetium diethylene triamine penta acetate (99mTc-DTPA based radiopharmaceuticals.Methods: The first radiopharmaceutical (DTPA-CNESTEN is developed at the laboratories of the radiopharmaceutical production unit of the National Center for Nuclear Energy, Sciences and Technologies (CNESTEN-Morocco, and the second one is the commercial DTPA (DTPA-ref. Freeze-dried kits were successfully radiolabeled (radiochemical purity >95% with the 99m Tc. Then drugs were injected to male BALB/c mice. In each 2 min, 5 min, 15 min, 1 h and 2 h time points after injections we evaluate tissue’s distributions characteristics. At the end, an automatic modeling of the data were recorded from thyroid, blood and urinary excretion kinetics and biodistribution in mice using both DTPA kits. The study aimed to extract the parameters of the function used to fit the recorded data. Results and Conclusion: the team concluded that the biodistribution of 99mTc-DTPA can be modeled using a combination of two exponential parts. Moreover, the resultant plots showed that there is strong correlation between the formula found in literature and the one derived on the basis of the fit of data sets in this study. In addition, it was found that the biodistribution behaviors of the developed kit and the commercial one were very close. The obtained results suggest that the developed DTPA has practically the same kinetics as the commercial one.

  12. Preparation and bioevaluation of 99mTc-carbonyl complex of guanine

    International Nuclear Information System (INIS)

    Cigdem Ichedef; Serap Teksoez; Kamile Senocak; Eser Ucar; Ayfer Yurt Kilcar

    2011-01-01

    The aim of this study is to prepare radiolabeled guanine with 99m Tc(CO) 3 + core. For this purpose, guanine has been radiolabeled with 99m Tc(CO) 3 + core. Quality control study of radiolabeled guanine molecule with 99m Tc(CO) 3 + core was performed by thin layer radio chromatography (TLRC) and high performance liquid radio chromatography (HPLRC). The results showed that the radiolabeling yield was quite high (94 ± 3%). Beside that 99m Tc(CO) 3 -Gua complex has showed good in vitro stability during the 24 h period. Radiopharmaceutical potential of this complex was evaluated in Wistar Albino Rats. It was concluded that 99m Tc(CO) 3 -Gua could be used as a nucleotide radiopharmaceutical for in vivo applications. (author)

  13. Preparation and biological characteristics of 99mTc-diol a renal agent

    International Nuclear Information System (INIS)

    Castanheira, I.; Paulo, A.; Neves, M.; Patricio, L.; Sawas-Dimopoulou, C.

    1993-01-01

    The present work concerns the production of 1,2-dihydroxypropyl-1-phosphonic acid (diol) by acid hydrolysis of (-cis) 1,2-epoxypropylphosphonic acid (phosphomycin), and its formation as a kit easily labeled with [ 99m Tc]pertechnetate. Biodistribution studies and whole-body autoradiographies in mice show that 99m Tc-diol has a specific affinity for the kidneys: it is rapidly cleared from the blood and excreted in urine. Part of the injected activity remains in the kidney cortex sufficiently long to permit kidney imaging. In comparison with other agents which also localize in the kidney cortex, such as 99m Tc-DMSA and 99m Tc-glucoheptonate ( 99m Tc-GHA), the main differences are the following: the peak of renal activity is reached early in the 5 min post-injection period for 99m Tc-diol, only at about 10 min post-injection for 99m Tc-GHA and after 3 h post-injection for 99m Tc-DMSA. The uptake of 99m Tc-diol by other organs, especially by bones, is much smaller than in the case of 99m Tc-DMSA. Unlike 99m Tc-DMSA, the biodistribution of 99m Tc-diol is not significantly influenced by acid-base imbalance. Moreover, the retention effect of hyperuricemia on 99m Tc-diol blood clearance and kidney excretion could be the result of a competition mechanism between this radiopharmaceutical and uric acid for a common transport system. The above biological characteristics suggest that 99m Tc-diol is a kidney radiopharmaceutical with an ability for functional and imaging studies. (author)

  14. ''In vitro'' and ''in vivo'' studies 2,6 - diisopropyl-fenil-carboilmethyl iminodiacetic acid labeled with99mTc (Disida -99mTc)

    International Nuclear Information System (INIS)

    Martinez, D.Y.F.; Barbosa, M.R.F.F. de; Muramoto, E.; Achando, S.S.; Silva, C.P.G. da.

    1988-07-01

    The ''in vivo'' and ''in vitro'' studies on DISIDA - 99m Tc at the hepatobiliary level were made. The binding of DISIDA - 99m Tc to plasmatic proteins and the fraction at which this binding occurs were determined. The distribution coefficient in n-octanol/saline solution was 0.41 showing the lipophilicity of the compound. The images in rats show the biological distribution as well as the hepatobiliary clearance of the radiopharmaceutical under its unmetabolized form. (author) [pt

  15. Comparison of carrier-added [99mTc] EDTMP and carrier-free preparations of [99mTc] EDTMP and [99mTc] DPD

    International Nuclear Information System (INIS)

    Krcal, A.; Kletter, K.; Dudczak, R.; Pirich, C.; Mitterhauser, M.

    2002-01-01

    Full text: High uptake of bone-seeking radiopharmaceuticals in malignant bone lesions is a prerequisite for adequate bone scanning. Visual image analysis is impaired due to high soft-tissue activity with currently available [ 99m Tc]-EDTMP-kits. This study aimed to compare carrier-added [ 99m Tc]-EDTMP with carrier-free [ 99m Tc]-EDTMP and [ 99m Tc]-DPD preparations in clinical routine. 15 μg and 150 μg perrhenic acid respectively were added to [ 99m Tc]-pertechnetate (>6 GBq in 3 ml phys. saline). The solution was then transferred into a vial, containing 1 mg of EDTMP, 3.6 mg stannous(II)chloride and 10 mg ascorbic acid under inert conditions. Under vigorous stirring the reaction mixture was heated to 45 o C for 10 min. After cooling down to room temperature the labelling mixture was sterile filtrated (millipore 0.22 μm). Quality control was performed using radio-ITLC (Whatman SG; acetone or ethanol: R f perrhenate/pertechnetate 0.87, colloid/product 0.05; phys. saline: R f colloid 0.00, perrhenate/pertechnetate and product 0.9) allowing rapid and efficient assessment of the product. Carrier free [ 99m Tc]-EDTMP and [ 99m Tc]-DPD were prepared according to instructions of the manufacturer. Clinical studies were performed in 29 patients according to a routine bone scanning protocol by injecting 700-800 MBq of the respective tracer and whole body imaging 3 h thereafter. Radiochemical purity and radiochemical yield relied on various parameters such as concentration of carrier and reducing agent and reaction conditions (pH, reaction time, temperature). Means of the labelling yield were 22 % for the preparation using 150 μg of carrier (5 preparations), 80 % for the preparation using 15 μpg of carrier (10 preparations) and 91 % for the carrier free products (5 preparations). Radiochemical purity was >96 % in all experiments. Colloid was formed in very low amounts, and was completely removed by sterile filtration. In clinical studies quantitative analysis

  16. Pharmaceutical design and pharmacological characterization of Tc99m [99mTc] labelled somatostatin and gastrin analogues

    International Nuclear Information System (INIS)

    Guggenberg, E. von

    2004-10-01

    The development of regulatory peptide analogues radiolabelled with 99m Tc is of great interest for nuclear medicine applications, as 99m Tc shows very favourable imaging characteristics, such as low radiation burden to the patient, optimal image quality in SPECT, one-day-acquisition-protocol, availability on demand and cost effectiveness. In this work the principles of pharmaceutical design and preclinical pharmacological characterization of regulatory peptide analogues labelled with 99m Tc with possible application in tumour diagnosis are described. [ 99m Tc-EDDA-HYNIC0,Tyr3]octreotide ( 99m Tc-EDDA-HYNIC-TOC) is a promising new radiopharmaceutical with the potential to replace [ 111 In-DTPA0]octreotide in receptor scintigraphy of somatostatin receptor-positive tumours. Radiolabelling at high labelling yields and high specific activities could be obtained applying a coligand exchange labelling approach from tricine for EDDA under optimized conditions of pH, EDDA and stannous ion concentration. The resulting complex was characterized via HPLC, receptor binding and LC-MS. For the development of a freeze-dried kit formulation with long shelf-life, high stability of the final preparation and retained biological activity, the addition of bulking agent, the pH of the freeze-drying solution and the content of stannous chloride were of major importance. Different methods of radiochemical purity testing were evaluated to guarantee high quality of the preparation in a clinical setting, forming the basis for a further clinical evaluation of this promising new radiopharmaceutical. Radiolabelling of [D-Glu1]minigastrin (MG) with 99m Tc was studied applying two different labelling approaches. HYNIC-MG could be labelled using tricine and EDDA as coligands; and (Nalpha-His)Ac-MG was used as tridentate ligand for the 99m Tc carbonyl core. Stability experiments by HPLC analysis in PBS, serum, histidine- and cysteine-solutions as well as rat liver and kidney homogenates, receptor

  17. /sup 99m/Tc-aminohexylidendiphosphonate and /sup 99/mTc-Pyrophosphate in the scintigraphic diagnosis of experimental cardiomyopathy in dogs

    Energy Technology Data Exchange (ETDEWEB)

    Duska, F; Kafka, P; Mazurova, Y; Hadas, L; Vizda, J; Palicka, V; Grossman, V

    1987-10-01

    Experimental cardiomyopathy was provoked in 24 dogs with high intravenous doses of adrenaline and theophylline. These lesions were studied by means of the new agent /sup 99m/Tc-AHDP and /sup 99m/Tc-PYP in comparison. Cardiomyopathy could be imaged as early as 4 h after the onset of involvement but not later than 7 days. A maximum accumulation occurred in lesions 24 h old, /sup 99m/Tc uptake in the myocardium was graded scintigraphically, /sup 99m/Tc-AHDP was accumulated in the altered myocardium to a greater extent than /sup 99m/Tc-PYP. Scintigraphic findings were in good agreement with plasma levels of creatine-kinase. A comparison with histology demonstrated that the maximum accumulation of radiopharmaceuticals occurred at the time when the development of myocardium involvement reached the stage of myocytolysis.

  18. Method of producing radioactive technetium-99M

    International Nuclear Information System (INIS)

    Karageozian, H.L.

    1979-01-01

    A chromatographic process of producing high purity and high yield radioactive Technetium-99m. A solution containing Molybdenum-99m and Technetium-99m is placed on a chromatographic column and eluted with a neutral solvent system comprising an organic solvent and from about 0.1 to less than about 10% of water or from about 1 to less than about 70% of a solvent selected from the group consisting of aliphatic alcohols having 1 to 6 carbon atoms. The eluted solvent system containing the Technetium-99m is then removed leaving the Technetium-99m as a dry, particulate residue

  19. Technetium-99m DMSA preparation: Trivial issues causing severe problems

    International Nuclear Information System (INIS)

    Kumar, V.

    1997-01-01

    Urinary tract infection (UTI) in children involving renal parenchyma, upper collecting system or bladder is one of the major causes for consideration in the diagnosis and management of paediatric nuclear medicine. Acute pyelonephritis is one of the prime causes of morbidity associated with urinary tract infection in children which can lead to progressive renal damage. Technetium-99m dimercaptosuccinic acid (DMSA) is used extensively for the assessment of UTI in paediatrics. The radiopharmaceutical preparation could be influenced by several factors, most of them are trivial, but invariably have severe impact on the quality of the scintiphotographs. This communication is mainly to highlight some of the issues related to 99 mTc-DMSA preparation and the possible precautionary measures that need to be taken to obviate unwarranted problems. (author)

  20. Osteomyelitis diagnosis by {sup 99m}Tc radiolabeled aptamers

    Energy Technology Data Exchange (ETDEWEB)

    Santos, S.R.; Ferreira, I.M.; Andrade, A.S.R., E-mail: sararoberta7@hotmail.com, E-mail: imendesf@yahoo.com.br, E-mail: antero@cdtn.br [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil); Barros, A.L.B.; Cardoso, V.N.; Diniz, O.F., E-mail: brancodebarros@yahoo.com.br, E-mail: valbertcardoso@yahoo.com.br, E-mail: simoneodilia@yahoo.com.br [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil). Faculdade de Farmacia. Departamento de Analises Clinicas e Toxicologicas

    2015-07-01

    Osteomyelitis, which is characterized by progressive inflammatory destruction and new opposition of bone, is still a difficult infection to treat. The clinical diagnosis in late stages is achieved easily, but an early diagnosis is more challenging. Staphylococcus aureus is a common agent found in osteomyelitis and bone prostheses infection. Diagnosis by scintigraphy has advantages because it is a non-invasive procedure and is able to perform an early diagnosis even before anatomic changes. Thus, nuclear medicine could contribute to an accurate diagnosis since specific radiopharmaceuticals were developed. In this study, aptamers selected to Staphylococcus aureus were labeled with {sup 99m}Tc and used for bacteria identification in an osteomyelitis experimental model. The aptamers selected to S. aureus were directly labelled with {sup 99m}Tc and were evaluated by biodistribution studies. Wistar rats with intraosseous infection in the right paw were used. A random aptamer labelled with {sup 99m}Tc was as control. Six animals were used in each group. The aptamers labeled with {sup 99m}Tc were able to identify the infection foci caused by S. aureus displaying a target/non-target ratio of 2,23 ± 0,20, after 3 h. The control group presented a target/non-target ratio 1,08 ± 0.23. The results indicated that the radiolabeled aptamers were able to identify specifically the infection foci and they should be further explored for infection diagnosis by scintigraphy. (author)

  1. Osteomyelitis diagnosis by 99mTc radiolabeled aptamers

    International Nuclear Information System (INIS)

    Santos, S.R.; Ferreira, I.M.; Andrade, A.S.R.; Barros, A.L.B.; Cardoso, V.N.; Diniz, O.F.

    2015-01-01

    Osteomyelitis, which is characterized by progressive inflammatory destruction and new opposition of bone, is still a difficult infection to treat. The clinical diagnosis in late stages is achieved easily, but an early diagnosis is more challenging. Staphylococcus aureus is a common agent found in osteomyelitis and bone prostheses infection. Diagnosis by scintigraphy has advantages because it is a non-invasive procedure and is able to perform an early diagnosis even before anatomic changes. Thus, nuclear medicine could contribute to an accurate diagnosis since specific radiopharmaceuticals were developed. In this study, aptamers selected to Staphylococcus aureus were labeled with 99m Tc and used for bacteria identification in an osteomyelitis experimental model. The aptamers selected to S. aureus were directly labelled with 99m Tc and were evaluated by biodistribution studies. Wistar rats with intraosseous infection in the right paw were used. A random aptamer labelled with 99m Tc was as control. Six animals were used in each group. The aptamers labeled with 99m Tc were able to identify the infection foci caused by S. aureus displaying a target/non-target ratio of 2,23 ± 0,20, after 3 h. The control group presented a target/non-target ratio 1,08 ± 0.23. The results indicated that the radiolabeled aptamers were able to identify specifically the infection foci and they should be further explored for infection diagnosis by scintigraphy. (author)

  2. Chemistry of /sup 99m/Tc labeling kits

    International Nuclear Information System (INIS)

    Srivastava, S.C.; Meinken, G.; Richards, P.

    1976-01-01

    Problems have been reported with the use of kit-produced /sup 99m/Tc radiopharmaceuticals. This study was undertaken to understand the chemistry involved in various stannous kit systems. The relation between Tc, tin, and the ligands used to complex the reduced Tc was investigated. It is concluded that for reliable performance, stannous kits should be prepared so that most of the tin is kept in the usable (reducing) form; a solution would be to use minimum tin and a large excess of complexing agent. Oxidation of the Tc complex to free pertechnetate is not a major problem in most kit systems. 5 figures

  3. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.

    Science.gov (United States)

    Gabriel, Michael; Decristoforo, Clemens; Maina, Theodosia; Nock, Berthold; vonGuggenberg, Elisabeth; Cordopatis, Paul; Moncayo, Roy

    2004-02-01

    Tetraamine-[Tyr3]octreotate (Demotate) is a somatostatin (SST) analogue that can be easily labeled with 99mTc at high specific activities and showed promising preclinical properties for SST receptor scintigraphy. This study reports on the first intra-patient comparison of 99mTc-Demotate and another 99mTc-labeled SST analogue, 99mTc-EDDA/HYNIC-TOC (HYNIC-TOC). Five patients with carcinoid tumors (n = 2) and endocrine pancreatic tumors (n = 3) were investigated with both radiopharmaceuticals. 99mTc-Demotate rapidly visualized somatostatin receptor positive tumors as early as 15 minutes post-injection (p.i.) with maximum tumor uptake and tumor/organ ratios already 1 hour p.i. Organs of predominant physiological uptake were the spleen and the kidneys with no intestinal excretion detectable up to 24 hours. 99mTc-Demotate exhibited faster pharmacokinetic properties compared to HYNIC-TOC. Tumor/organ ratios at equivalent time points were higher or comparable for 99mTc-Demotate in three patients with a matching scan result. Equivocal findings were observed in two patients, i.e. comparable uptake behavior in larger lesions with differences in smaller ones. 99mTc-Demotate is a promising agent for somatostatin receptor scintigraphy providing images of excellent quality as early as 1 hour after injection.

  4. sup(99m)Tc-labeled N-phosphoryl-aminoethyl-phosphate (sup(99m)Tc-PAEP), as bone and myocardial infarct agent. Studies in experimental animals

    International Nuclear Information System (INIS)

    Chiotellis, E.; Varvarigou, A.; Vavouraki, H.

    1982-01-01

    99m-Tc-PAEP appears as a promising new bone-seeking radiopharmaceutical. The biological experiments indicate high bone affinity and satisfactory localization in experimentally produced myocardial infarctions in rats and dogs. The data obtained suggest a further evaluation of this derivative in comparison to other technetium-phosphorus complexes

  5. A fundamental study on brain scanning with sup(99m)Tc-citrate

    International Nuclear Information System (INIS)

    Ishii, Katsumi; Kobayashi, Takeshi; Yamada, Nobuaki; Horiike, Shigeharu; Nakazawa, Keiji

    1978-01-01

    We examined the sup(99m)Tc-citrate obtained by labelling citrate with sup(99m)Tc-pertechnetate using Solcocitran Kit. For our fundamental study--we measured the ratio of labelling by means of paper chromatography. By picking out each organs of each rats we also measured the velocity at which radiopharmaceuticals disappeared in each of their organs, and the distribution of radio-pharmaceuticals in their organs. For our clinical study--we performed brain scanning on 47 patients. The following are the results; Citrate was labelled as much as 99 - 95% into sup(99m)Tc-pertechnetate. The velocity of disappearance in each organ of the rats was quicker than in the case of sup(99m)TcO 4 - . Accumulation in the choroid plexus and salivary gland was not obserbed despite the fact that we did not use KClo 4 , and images of brain tumor were obtainable to a high degree. (author)

  6. Hot spot(s) of the lung in technetium-99m albumin colloid liver-spleen scintigraphy: case report

    International Nuclear Information System (INIS)

    Shih, W.J.; Brandenburg, S.; Coupal, J.J.; Sullivan, J.D.; Beeler, J.A.; Magoun, S.; Ryo, U.Y.

    1988-01-01

    The authors replaced /sup 99m/Tc albumin colloid for /sup 99m/Tc sulfur colloid as a radiopharmaceutical for liver-spleen imaging and found two instances of hot spot(s) in the lung. The preparation procedure of albumin colloid is easier and more convenient as compared to that of sulfur colloid. Whereas replacement of /sup 99m/Tc sulfur colloid by /sup 99m/Tc albumin colloid is inevitable, it should be emphasized that one should avoid blood withdrawal in the syringe containing albumin colloid to prevent formation of clot(s) during the venous puncture for /sup 99m/Tc albumin colloid

  7. Compact device for the extraction of sup(99m)TcO4Na

    International Nuclear Information System (INIS)

    Pliego, O.H.; Mitta, A.E.A.

    1982-01-01

    A non automatic device for the extraction of sup(99m)TcO 4 Na by liquid-liquid extraction method is described. It has been developed at the Laboratory of Labelled Molecules of the CNEA and was installed at the Nuclear Medicine Centre of the Hospital de Clinicas Jose de San Martin. The solutions of sup(99m)TcO 4 Na are used for the labelling of radiopharmaceuticals and also for making radiodiagnosis. (author) [es

  8. Abnormal gastrointestinal accumulation of radiotracer by gastric bleeding during 99mTc-MDP bone scintigraphy

    International Nuclear Information System (INIS)

    Chun, Kyung A.; Lee, Sang Woo; Lee, Jae Tae; Lee, Kyu Bo

    1998-01-01

    We present a case in which a patient with acute hemorrhagic gastritis demonstrated abnormal gastrointestinal accumulation of radiotracer during 99m Tc-methylene diphosphonate (MDP) skeletal scintigraphy. A hemorrhagic gastritis was subsequently demonstrated by endoscopy. The mechanism for the intestinal localization of 99m Tc-MDP in this patients is not clear, but we guess that the extravasated blood containing the radiopharmaceutical cannot recirculate and stays at the bleeding site, so we can see the intestinal activity

  9. Technetium-99m-Labeled Autologous Serum Albumin: A Personal-Exclusive Source of Serum Component

    OpenAIRE

    Wang, Yuh-Feng; Chen, Yi-Chun; Li, Dian-Kun; Chuang, Mei-Hua

    2011-01-01

    Technetium-99m human serum albumin (99mTc-HSA) is an important radiopharmaceutical required in nuclear medicine studies. However, the risk of transfusion-transmitted infection remains a major safety concern. Autopreparation of serum component acquired from patient provides a “personal-exclusive” source for radiolabeling. This paper is to evaluate the practicality of on-site elusion and subsequent radiolabeling efficacy for serum albumin. Results showed that the autologous elute contained more...

  10. Bone scintigraphy with 99m Tc MIBI. Its importance for the detection of malignant bone tumors

    International Nuclear Information System (INIS)

    Marrero, Luis O.; Tamayo, Alicia; Rodriguez, Oscar; Solano, Maria E.; Perera, Alejandro; Perez, Marylin

    1997-01-01

    99mT c-MIBI is a radiopharmaceutical widely employed for the detection and follow-up of different oncological diseases. The aim of the present work was to determine the value of the scintigraphy with 99mT c-MIBI for the diagnosis of malignant bone tumors, its metastases and recurrences. Twenty patients aged 24+- years old, suspected of having bone neoplasms, were studied. I

  11. Determination of Cyclam as Impurity in 99mTc-CTMP Using Radio electrophoresis Method

    International Nuclear Information System (INIS)

    Isti Daruwati; Misyetti; Maula Eka Sriyani; Teguh Hafiz AW

    2009-01-01

    Labelled compound of CTMP that are used for bone seeking radiopharmaceuticals must have to fulfill the standard requirements, such as have high radiochemical purity. CTMP compounds was in house synthesized from cyclam and formaldehyde in an acidic condition (conc. HCl) using Mannich methods. Impurities in CTMP product are the residue of cyclam, phosphoric acid, formaldehyde and hydrochloric acid. Formaldehyde and hydrochloride acid in the aqueous form is easily removed through the rinse process in the synthesis, while cyclam in the solid phase could be mix with CTMP. Therefore the impurities of cyclam in 99m Tc-CTMP must be determined. With nuclear technique, the determination of cyclam could be assessed simultaneously with labelled of CTMP with technetium-99m. Separation of 99m Tc-CTMP and 99m Tc-cyclam in solution was conducted with radio-electrophoresis method simultaneously. The radiochemical purity for both radiolabelled compound was determined by paper chromatography. The purity of radiolabelled 99m Tc-CTMP from cyclam was determined using electrophoresis method. The result show that the amount of cyclam in CTMP can be determined simultaneously using nuclear techniques with the labeling of 99m Tc-CTMP. Electrophoresis method can separated 99m Tc-cyclam, 99m Tc-CTMP, 99m TcO4 and 99m Tc-reduced with limit quantitation of cyclam until 0,4% w/w. (author)

  12. Experimental study of {sup 99m}Tc-aluminum oxide use for sentinel lymph nodes detection

    Energy Technology Data Exchange (ETDEWEB)

    Chernov, V. I., E-mail: Chernov@oncology.tomsk.ru; Sinilkin, I. G.; Zelchan, R. V.; Medvedeva, A. A. [Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation); Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 (Russian Federation); Lyapunov, A. Yu., E-mail: Lyapunov1720.90@mail.ru [Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 (Russian Federation); Bragina, O. D.; Varlamova, N. V.; Skuridin, V. S. [Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 (Russian Federation)

    2016-08-02

    The purpose of the study was a comparative research in the possibility of using the radiopharmaceuticals {sup 99m}Tc-Al{sub 2}O{sub 3} and {sup 99m}Tc-Nanocis for visualizing sentinel lymph nodes. The measurement of the sizes of {sup 99m}Tc-Al{sub 2}O{sub 3} and {sup 99m}Tc-Nanocis colloidal particles was performed in seven series of radiopharmaceuticals. The pharmacokinetics of {sup 99m}Tc-Al{sub 2}O{sub 3} and {sup 99m}Tc-Nanocis was researched on 50 white male rats. The possibility of the use of {sup 99m}Tc-Al{sub 2}O{sub 3} and {sup 99m}Tc-Nanocis for lymphoscintigraphy was studied in the experiments on 12 white male rats. The average dynamic diameter of the sol particle was 52–77 nm for {sup 99m}Tc-Al{sub 2}O{sub 3} and 16.7–24.5 nm for {sup 99m}Tc-Nanocis. Radiopharmaceuticals accumulated in the inguinal lymph node in 1 hour after administration; the average uptake of {sup 99}mTc-Al{sub 2}O{sub 3} was 8.6% in it, and the accumulation of {sup 99m}Tc-Nanocis was significantly lower—1.8% (p < 0.05). In all study points the average uptake of {sup 99m}Tc-Al{sub 2}O{sub 3} in the lymph node was significantly higher than {sup 99m}Tc-Nanocis accumulation. The results of dynamic scintigraphic studies in rats showed that {sup 99m}Tc-Al{sub 2}O{sub 3} and {sup 99m}Tc-Nanocis actively accumulated into the lymphatic system. By using {sup 99m}Tc-Al{sub 2}O{sub 3} inguinal lymph node was determined in 5 minutes after injection and clearly visualized in all the animals in the 15th minute, when the accumulation became more than 1% of the administered dose. Further observation indicated that the {sup 99m}Tc-Al{sub 2}O{sub 3} accumulation reached a plateau in a lymph node (average 10.5%) during 2-hour study and then its accumulation remained practically at the same level, slightly increasing to 12% in 24 hours. In case of {sup 99m}Tc-Nanocis inguinal lymph node was visualized in all animals for 15 min when it was accumulated on the average 1.03% of the administered dose

  13. [99m Tc (CNCH2COO-)6]-5: preliminary evaluation as tracer for studies of renal function

    International Nuclear Information System (INIS)

    Verdera, E.S.; Lopes L, J.J.; Balter, H.; Leon, E.; Oliver, P.; Tagle, R.

    1992-01-01

    The preliminary results for obtaining [ 99m Tc (CNCH 2 COO - )6] -5 are described. This complex is prepared by chemical hydrolysis of resultant molecule from carboethoxi methyl isonitrile labelling with Na 99m Tc O 4 and the yield of these reactions is determined by RP-HPLC. The radiopharmaceutical behaviour in dogs are made, confirming the attributes of [ 99m Tc (CNCH 2 COO - )6] 5 as radiodiagnosis for renal function studies. (C.G.C.)

  14. DMSA 99mTc an old molecule for a new future

    International Nuclear Information System (INIS)

    Moretti, J.L.

    1992-01-01

    This lecture is concerned with the use of DMSA 99m Tc in nephrology. It described human pharmaceutic and clinical applications of this radiopharmaceutical. As DMSA 99m Tc concentrates actively in the proximal convoluted tubule, it gives an image of functional renal mass. Its integrity is dependent upon several factors, predominantly intrarenal blood flow and intact enzyme function. Its role in pathology is clear in pyelonephritis, hydronephrotic kidney and pediatric diseases. The irradiation dosimetry of DMSA 99m Tc is well established, the critical organ is the renal cortex which receives between 15 and 250 mGy per MBq. Dosimetry remains favourable for the patients if compared with intravenous urography

  15. Usefulness of 99mTc-ECD SPECT in diseases of central nerve system

    International Nuclear Information System (INIS)

    Ono, Shimato; Yanagimoto, Shinichi; Mimura, Hiroaki

    1992-01-01

    The usefulness of a new cerebral perfusion imaging radiopharmaceutical, 99m Tc-ethyl cysteinate dimer (ECD), was clinically evaluated. The subjects of this study were 14 patients with neurological disorders including 10 patients with cerebral infarction and 4 patients with other diseases. A total of 15 examinations was performed. 99m Tc-hexamethylpropyleneamine oxime ( 99m Tc-HM-PAO) or 123 I-N-isopropyl-p-iodoamphetamine ( 123 I-IMP) SPECTs were performed simultaneously, and the findings from those examinations were compared with 99m Tc-ECD. As to the count ratio of lesions to normal area (L/N), the L/N ratio in severe ischemic patients was lower in 99m Tc-ECD than in 99m Tc-HM-PAO or 123 I-IMP. In mild ischemic patients, on the other hand, the L/N ratio was the lowest in 123 I-IMP. When the relationship between regional cerebral blood flows (rCBFs) obtained from 123 I-IMP and the values of L/N in 99m Tc-ECD or 99m Tc-HM-PAO was compared, the values of L/N in 99m Tc-ECD or 99m Tc-HM-PAO were found to have decreased linearity with increasing rCBF. In a patient showing luxury perfusion, the accumulation pattern of 99m Tc-ECD was different from that of the other two radiopharmaceuticals, and focal defect was revealed in 99m Tc-ECD SPECT. On the dynamic SPECT of 99m Tc-ECD in a patient with meningioma, the tumor showed a change from high to low perfusion with the passage of time. This finding indicated that care should be taken in the evaluation of accumulation of 99m Tc-ECD. Therefore, 99m Tc-ECD was found to be useful as a cerebral perfusion agent. In addition, as accumulation of 99m Tc-ECD might somehow reflect metabolism in some cases, further careful investigation of many cases should be carried out. (author)

  16. Process for producing radioactive technetium 99 m

    International Nuclear Information System (INIS)

    Karageozian, H.L.

    1979-01-01

    Active aluminium oxide containing Molybdenum 99 and technetium 99 m is treated with a neutral solvent consisting of water, methylethylketone and ethanol. Technetium 99 m remains on the chromatographic material after drying, in the form of a dry powder. Other aliphatic alcohols can also be utilised. (DG) [de

  17. Radiopharmaceuticals in Czechoslovakia

    International Nuclear Information System (INIS)

    Hron, M.; Kronrad, L.; Svoboda, K.; Melichar, F.

    1986-01-01

    The history is briefly described of the production of radiopharmaceuticals in Czechoslovakia for nuclear medicine purposes. 131 I-labelled orthoiodohippurate and rose Bengal were first produced. Currently, 99m Tc is the most frequently requested radionuclide for radiopharmaceutical labelling. The preparation of 99m Tc is described in detail, a flow chart is shown and the network of 99m Tc distribution to hospitals outlined. In addition of 99m Tc and 131 I, UJV Rez produces other radionuclides for nuclear medicine, such as 113m In, 67 Ga, 35 S, 32 P, 203 Hg, 85 Sr. The methods are being developed of the production of 201 Tl, 125 I and 131 I-labelled bromosulfophthalein. (E.S.)

  18. Technetium-99 m generator safety simulation

    International Nuclear Information System (INIS)

    Kang, Sang Koo; Kim, Chong Yeal

    2008-01-01

    Technetium ( 99m Tc) is one of the most widely used radioactive isotopes for diagnosis in the world. In general, 99m Tc is produced inside the so called technetium generator where 99Mo decays to 99m Tc. And the generator is usually made out of lead to shield relatively high energy radiation from 99m Tc and 99 Mo. In this paper, a GEANT4 simulation is carried out to test the safety of the 99m Tc generators, taking domestic and Japanese products with radioactivity of 18.50 GBq (500 mCi) for example. According to the domestic regulation on radiation safety, the dose at 10 cm and 100 cm away from the surface of radiation shielder should not exceed 2 mSv∙h -1 and 0.02 mSv∙h -1 , respectively. The simulated dose turned out about only 10% of the limit, satisfying the domestic regulation

  19. Cyclotron Production of Technetium-99m

    Science.gov (United States)

    Gagnon, Katherine M.

    Technetium-99m (99mTc) has emerged as the most widely used radionuclide in medicine and is currently obtained from a 99Mo/ 99mTc generator system. At present, there are only a handful of ageing reactors worldwide capable of producing large quantities of the parent isotope, 99Mo, and owing to the ever growing shutdown periods for maintenance and repair of these ageing reactors, the reliable supply 99mTc has been compromised in recent years. With an interest in alternative strategies for producing this key medical isotope, this thesis focuses on several technical challenges related to the direct cyclotron production of 99mTc via the 100Mo(p,2n)99mTc reaction. In addition to evaluating the 100Mo(p,2n)99mTc and 100Mo(p,x)99Mo reactions, this work presented the first experimental evaluation of the 100Mo(p,2n) 99gTc excitation function in the range of 8-18 MeV. Thick target calculations suggested that large quantities of cyclotron-produced 99mTc may be possible. For example, a 6 hr irradiation at 500 μA with an energy window of 18→10 MeV is expected to yield 1.15 TBq of 99mTc. The level of coproduced 99gTc contaminant was found to be on par with the current 99Mo/99mTc generator standard eluted with a 24 hr frequency. Highly enriched 100Mo was required as the target material for 99mTc production and a process for recycling of this expensive material is presented. An 87% recovery yield is reported, including metallic target preparation, irradiation, 99mTc extraction, molybdate isolation, and finally hydrogen reduction to the metal. Further improvements are expected with additional optimization experiments. A method for forming structurally stable metallic molybdenum targets has also been developed. These targets are capable of withstanding more than a kilowatt of beam power and the reliable production and extraction of Curie quantities of 99mTc has been demonstrated. With the end-goal of using the cyclotron-produced 99mTc clinically, the quality of the cyclotron

  20. A clinical compariosn of sup(99m)Tc-DPD and two sup(99m)Tc-MDP agents

    International Nuclear Information System (INIS)

    Vorne, M.; Vaehaetalo, S.; Lantto, T.

    1983-01-01

    Two hundred and fifty-seven patients were studied with bone-seeking radiopharmaceuticals. They were randomly divided into three groups. Two groups were injected with two different sup(99m)Tc-methylene diphosphonates from two manufactures (MDP 1 and MDP 2) and the third group with sup(99m)Tc-dicarboxypropane diphosphonate (DPD). DPD was found to be superior with respect to blood clearance, femur to soft tissue ratio and subjectivly assessed image quality. There seemed to be no marked differences between the bone-seeking agents in the visualisation of pathological foci. The image quality seemed to be better in the MDP 2 group than in the MDP 1 group but they were similar in other respects. The femur to soft tissue ratio decreased with increasing age in the DPD group but not in the MDP groups. With all agents worsening of scan quality with increasing age was noted and the image quality was better with men than with women. When short incubation times of radiopharmaceuticals were used before injection, the bone to soft tissue ratio was lower and the scan quality was poorer than with incubation times longer than 20 min. (orig.)

  1. Tc99m-sestamibi dosimetry in myocardial perfusion imaging

    International Nuclear Information System (INIS)

    Toledo, Janine M.; Trindade, Bruno M.; Campos, Tarcisio P.R.

    2015-01-01

    This paper addressed myocardial perfusion imaging providing a spatial dosimetric investigation of the 99m Tc-radiopharmaceutical dose distribution at the myocardium. Radiological data manipulation was performed in order to create a computational voxel model of the heart. A set of images obtained by thoracic angiotomography and abdominal aorta was set up providing anatomic and functional information for heart modeling in SISCODES code. A homogeneous distribution of 99m Tc was assumed into the cardiac muscle. Simulations of the transport of particles through the voxel and the interaction with the heart tissues were performed on the MCNP - Monte Carlo Code. The spatial dose distribution in the heart model is displayed as well as the dose versus volume histogram of the heart muscle. The present computational tools can generate spatial doses distribution in myocardial perfusion imaging. Specially, the dosimetry performed elucidates imparted dose distribution in the myocardial muscle per unit of injected 99m Tc activity, which can contribute to future deterministic effect investigations. (author)

  2. 99mTc DMSA scintigraphic findings in renal tuberculosis

    International Nuclear Information System (INIS)

    Moon, Tae Yong; Kim, Kun Il; Yoon, Chi Soon; Lee, Suck Hong; Kim, Byung Soo

    1993-01-01

    Evaluations of residual renal function and the therapeutic effectiveness in renal tuberculosis have largely been dependent on intravenous pyelogram or Contrast-CT scan, even though, exact renal functions are not evaluate with there methods. 99m Tc- DMSA is a radiopharmaceutical that is trapped in the functioning tubular cells of the kidney and therefore, quantitative renal function could be evaluated by insuring the counts of renal radioactivity and concomitant evaluation of renal morphology could be passable with the analog images of the radioactivity. The authors retrospectively analyzed 99mTc-DMSA scans of 75 kidneys of 67 patients with confirmed renal tuberculosis. We classified the morphologies of tuberculous kidneys as 6 types. We classified the morphologies of tuberculous kidneys as 6 types such as the type with small cortical defect, with parenchymal ulcerocavernous lesions, ulcerocavernous fistula to pelvis, mass-like defects, contracted kidney with ureter visualization, and the type with non visualization of kidney, corresponding to the characters of renal tuberculous pathogenesis with abscess formation, ulcerocavernous fistula, and fibrosis, and corresponding to the renal anatomy with parenchyma, and pelvocalyceal collecting system. Their mean residual renal functions measured with 99mTc-DMSA uptake rates were 19.0%,18.4%, 7.9%, 12%, 4.1%, 3.4% respectively

  3. Technetium-99m in nuclear medicine and radiation protection experience

    International Nuclear Information System (INIS)

    Ninkovic, M. M.; Raicevic, J. J.; Pavlovic, S.; Glisic, R.

    2002-01-01

    The one of the major contributors to personnel exposure whithin nuclear medicine laboratories is primarily now ubiquitous 99 Mo- 99m Tc generators. These generators, first available about more than forthy years ago, are now providing large quantities of 99m Tc radioactive source daily in the most laboratories, both for direct injection, as a per-technetate ion, and through the utilization of the kits for the preparation of dipherent radiopharmaceuticals. The safe and efficient utilization of technetium-99m in nuclear medicine, as other radionuclides, begin with the design, construction and operation of the 'Hot'Laboratory area, where radionuclide are stored and patient doses are prepared. Regardless of the specific physical configuration, suitable facilities need to be provided and good working practices established in order to get these principal objectives: (a) keep radiation exposure to personnel at ALARA levels; (b) prevent contamination of personnel; (c) prevent contamination of measuring instruments (including imaging devices such as gamma cameras and rectilinear scanners), and (d) prevent spread of contamination to places or persons outside the laboratory

  4. Survey of /sup 99m/Tc contamination of laboratory personnel: hand decontamination

    International Nuclear Information System (INIS)

    Nishiyama, H.; Van Tuinen, R.J.; Lukes, S.J.; Feller, P.A.

    1980-01-01

    Decontamination after exposure to various /sup 99m/Tc radiopharmaceuticals was tested with serial hand washings both with and without soap. All radiopharmaceuticals were removed more effectively with soap and the degree of decontamination related closely to the number of washings. The affinity of the radiopharmaceuticals for the skin varied, depending upon the labeled material, and only macroaggregated albumin was effectively removed to less than 1% of its original activity with soap. Activity transfer to the opposite hand could be substantial with macroaggregated albumin and sulfur colloid if soap is not used

  5. Technetium-99m Sestamibi in Multiple Myeloma

    International Nuclear Information System (INIS)

    Saber, R.A.

    2002-01-01

    Technetium-99m 2-methoxy - isobutyl - isonitrile (99mTc-MIBI) has been reported to be useful in evaluating patients with multiple myeloma. The aim of this study is to evaluate the role of technetium-99m sestamibi (99mTc-MIBI) scintigraphy in the diagnosis. staging and follow-up of patients with multiple myeloma. Methods and Materials: twenty-five consecutive patients with multiple myeloma were studied using 99mTc- MIBI. Of the 25 patients included in this study, 6 were in stage I, II in stage II and 8 in stage III. Anterior and posterior whole-body imaging were obtained 20 min after I.V. injection of 740 MBq of 99mTc-MIBI. Four different MIBI patterns could be described in our patients: physiological (P), diffuse (D), focal (F) and combined diffuse and focal (D+F). All patients in stages II and III as well as 3 patients in stage I were treated with chemotherapy (cyclophosphamide and prednisone) then 99mTc-MlBI scans were repeated after 6 courses. Results: in comparison to conventional X-ray skeletal survey, 99mTc-MIBI scans showed a higher number of myeloma bone disease at diagnosis. All patients with stage II and III multiple myeloma were positive with 99mTc-MlBl scans at diagnosis. The pattern of positive MIBI accumulation was diffuse in 13 (52%) patients, focal in 4 (16%) and combined focal and diffuse in 6 (24%) patients. The intensity of 99mTc-MIBI correlated with disease activity as determined by lactate dehydrogenase (LDH), number of plasma cells in bone marrow and serum electrophoresis. There was a direct correlation between 99mTc-MIBI scan result and clinical outcome of patients following 6 courses of chemotherapy. Sensitivity and specificity of 99mTc-MIBI scintigraphy in detecting myeloma bone lesions were 92% and 90% respectively. Conclusion: 99mTc-MIBI scintigraphy is a reliable method to evaluate bone marrow activity in patients with multiple myeloma and follow-up of myeloma bone lesions

  6. Study of {sup 99m}Tc-DMSA biodistribution in experimental animals

    Energy Technology Data Exchange (ETDEWEB)

    Castro, Thais O.M. de; Silva, Natanael G. da; Colturato, Maria T.; Felgueiras, Carlos F.; Mengatti, Jair; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.; Araújo, Elaine B. de, E-mail: thais.castrom@gmail.com [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Centro de Radiofarmacia

    2017-11-01

    {sup 99m}Tc-DMSA, succimer ({sup 99m}Tc), is a radiopharmaceutical commonly used in nuclear medicine for renal function evaluation by imaging. In order to achieve adequate labeling of the product with good radiochemical yield and standardized biological distribution, the interval of 185 - 3700 MBq should be kept in a maximum volume of 3 mL for product labeling. Moreover, one should avoid exposing the reconstituted solution to oxygen and using the product after four hours post labeling. The aim of the study was to quantify and evaluate the influence of different DMSA complexes on biological distribution of the radiopharmaceutical in experimental animals, taking in account variations in the labeling parameters. Radiochemical purity was determined by paper and thin layer chromatography using both acetone/Whatman 3MM, 0.9% NaCl/TLC-SG and n-propanol/ H{sub 2}O/acetic acid (4:3:1 V/V/V)/TLC-SG systems respectively for quantification of {sup 99m}TcO{sub 4} - and {sup 99m}TcO{sub 2} plus some {sup 99m}Tc-DMSA complexes. The labeling activity did not significantly affect the extent of the main complex generation. The presence of oxygen and the concentration of {sup 99}Tc did not markedly change the percentage of the radiochemical impurities in the preparation. Radiochemical purity tests of the DMSA-{sup 99m}Tc based on IPEN-CNEN DMSA-TEC reagent and on another producer's reagent showed similar results. Although the routine method used by IPEN-CNEN to determine the radiochemical yield of {sup 99m}Tc-DMSA was not able to discriminate among {sup 99m}Tc-DMSA complexes, the renal uptake and the kidney to liver plus spleen uptake ratio in rats met the official compendia criteria for the radiopharmaceutical. (author)

  7. Study of "9"9"mTc-DMSA biodistribution in experimental animals

    International Nuclear Information System (INIS)

    Castro, Thais O.M. de; Silva, Natanael G. da; Colturato, Maria T.; Felgueiras, Carlos F.; Mengatti, Jair; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.; Araújo, Elaine B. de

    2017-01-01

    "9"9"mTc-DMSA, succimer ("9"9"mTc), is a radiopharmaceutical commonly used in nuclear medicine for renal function evaluation by imaging. In order to achieve adequate labeling of the product with good radiochemical yield and standardized biological distribution, the interval of 185 - 3700 MBq should be kept in a maximum volume of 3 mL for product labeling. Moreover, one should avoid exposing the reconstituted solution to oxygen and using the product after four hours post labeling. The aim of the study was to quantify and evaluate the influence of different DMSA complexes on biological distribution of the radiopharmaceutical in experimental animals, taking in account variations in the labeling parameters. Radiochemical purity was determined by paper and thin layer chromatography using both acetone/Whatman 3MM, 0.9% NaCl/TLC-SG and n-propanol/ H_2O/acetic acid (4:3:1 V/V/V)/TLC-SG systems respectively for quantification of "9"9"mTcO_4 - and "9"9"mTcO_2 plus some "9"9"mTc-DMSA complexes. The labeling activity did not significantly affect the extent of the main complex generation. The presence of oxygen and the concentration of "9"9Tc did not markedly change the percentage of the radiochemical impurities in the preparation. Radiochemical purity tests of the DMSA-"9"9"mTc based on IPEN-CNEN DMSA-TEC reagent and on another producer's reagent showed similar results. Although the routine method used by IPEN-CNEN to determine the radiochemical yield of "9"9"mTc-DMSA was not able to discriminate among "9"9"mTc-DMSA complexes, the renal uptake and the kidney to liver plus spleen uptake ratio in rats met the official compendia criteria for the radiopharmaceutical. (author)

  8. Successful labeling of 99mTc-MDP using 99mTc separated from 99Mo produced by 100Mo(n,2n)99Mo

    International Nuclear Information System (INIS)

    Nagai, Yasuki; Hatsukawa, Yuichi; Kin, Tadahiro; Hashimoto, Kazuyuki; Motoishi, Shoji; Konno, Chikara; Ochiai, Kentaro; Takakura, Kosuke; Sato, Yuichi; Sato, Norihito; Ohta, Akio; Yamabayashi, Hisamichi; Tanase, Masakazu; Fujisaki, Saburo; Kawauchi, Yukimasa; Teranaka, Tomoyuki; Takeuchi, Nobuhiro; Igarashi, Takashi

    2011-01-01

    We have for the first time succeeded in separating 99m Tc from a MoO 3 sample irradiated with accelerator neutrons free from any radioactive impurities and in formulating 99m Tc-methylene diphosphonate ( 99 mTc-MDP). 99 Mo, the mother nuclide of 99m Tc, was produced by the 100 Mo(n,2n) 99 Mo reaction using about 14 MeV neutrons provided by the 3 H(d,n) 4 He reaction at the Fusion Neutronics Source of Japan Atomic Energy Agency. The 99m Tc was separated from 99 Mo by sublimation and its radionuclide purity was confirmed to be higher than 99.99% by γ-spectroscopy. The labeling efficiency of 99m Tc-MDP was shown to be higher than 99% by thin-layer chromatography. These values exceed the United States Pharmacopeia requirements for a fission product, 99 Mo. Consequently, a 99m Tc radiopharmaceutical preparation formed by using the mentioned 99 Mo can be a promising substitute for the fission product 99 Mo, which is currently produced using a highly enriched uranium target in aging research reactors. A longstanding problem to ensure a reliable and constant supply of 99 Mo in Japan can be partially mitigated. (author)

  9. Radiopharmaceuticals for cerebral studies

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way

  10. sup(99m)Tc-2-mercaptopropionylglycine

    International Nuclear Information System (INIS)

    Saji, Hideo; Odori, Teruo; Morita, Rikushi; Yokoyama, Akira; Tanaka, Hisashi.

    1979-01-01

    Labeling of 2-mercaptopropionylglycine (2-MPG) with sup(99m)Tc, was studied and its chemical characteristics were examined. Further, biliary excretion behavior of this complex was comparatively estimated in mice, rats and rabbits. sup(99m)Tc-2-MPG was rapidly excreted in large quantities into the bile in mice and rats: within 1 hr after injection, 51% of the injected dose was recovered from the bile in rats. On the other hand, the ligand exchange reaction between this complex and penicillamine indicates that a low hydrolyzed sup(99m)Tc species is coordinated with 2-MPG. These results suggest that a low hydrolyzed sup(99m)Tc state is an effective feature in biliary excretion behavior of sup(99m)Tc compounds. Another interesting in vivo behavior of sup(99m)Tc-2-MPG is the difference observed in mice and rabbits: in mice, very high sup(99m)Tc activity is concentrated in the gallbladder and the clearance from tissues other than the gallbladder is rapid, whereas in rabbits, although a rapid and high excretion into the gallbladder is observed, a considerable high sup(99m)Tc activity is retained in the liver and the kidney. One reason for this different in vivo behavior is the low stability of this complex at high dilution: a big animal has the large dilution volume which lead to higher decomposition estimated by the higher liver and kidney retention or the lower bile excretion. In conclusion, studies carried on sup(99m)Tc-2-MPG showed a good biliary excretion behavior but an in vivo unstableness in big animals. (author)

  11. Role of scintigammagraphy with 99mTc-Gluthatione and 99mTc-MIBI in the evaluation and staging of lymphoma

    International Nuclear Information System (INIS)

    Pena Quian, Yamile; Perera Pintado, Alejandro; Coca Perez, Marco A.; Batista Cuellar, Juan F.; Prats Capote, Anais; Sanchez Mendoza, Elvia; Sosa, Adriana; Mesa Cuervo, Jose R.; Hernandez Ramirez, Porfirio

    2004-01-01

    Full text: The aim of this study was to assess the utility of scintigammagraphy using 99mTc-MIBI and 99mTc-Gluthatione for the evaluation and staging of patients with lymphomas. We studied thirty patients (age range 16-66 years) of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). A control group (CG) of 8 patients with negative histological results was also studied. The patients were divided in three groups; HD group: thirteen patients (7 males and 6 females); NHL: seventeen patients (10 males and 7 females); CG: eight patients (2 males and 6 females). Scintigammagraphy studies were performed 20 min and 2 h after intravenous administration of 925-1110 MBq of 99mTc-MIBI or 99mTc-Gluthatione (GSH) using a gamma camera (Sophy DS-7, Sopha Medical System, France) equipped with low energy all purpose parallel hole collimator. Anterior and posterior images of thorax, abdomen and pelvis in 128x128 pixels matrix each for 1 million counts per view were acquired. A 20% window centered on the 140 keV was used for all acquisitions. All images were processed and analysed on a workstation (Power Vision, SMV, Canada) and interpreted by three qualified and experienced nuclear medicine specialist. The final diagnosis was reached by consensus. The images with a focal abnormal intense uptake were considered positive. Images showing diffuse bilateral and symmetrical uptake, bilateral lung uptake and intestinal uptake were considered negative. The overall sensitivity, specificity and accuracy of results for both radiopharmaceuticals were calculated using the histological findings, x-ray, ultrasound and CT scanning as confirmation criterion as gold standard. The nodular sclerosis was the most frequent type in HD group. In this group twelve patients were positive with 99mTc-MIBI scintigammagraphy while one was negative (nodular sclerosis, grade II). Scintigammagraphy with 99mTc-GSH was positive in all patients in HD group. However, scintigammagraphy with both radiopharmaceuticals

  12. 99mTechnetium labelled Escherichia coli

    International Nuclear Information System (INIS)

    Diniz, S.O.F.; Cardoso, V.N.; Resende, B.M.; Nunan, E.A.; Simal, C.J.R.

    1999-01-01

    Samples of a culture of unlabeled Escherichia coli were incubated with different concentrations of stannous chloride for various time periods. 99m Tc (26.0 MBq) was added to each preparation and the results showed a labelling yield of 98% for E. coli. Since the bacterial viability of 99m Tc-E. coli and E. coli did not show any statistical differences, these results demonstrate that labelling of E. coli with 99m Tc does not modify the bacterial viability, and the radiolabelled bacteria may be a good model to study bacterial translocation

  13. Quality control and assurance of Tc-99m generators and kits applied in SAEC laboratories

    International Nuclear Information System (INIS)

    Yassine, T.

    1998-01-01

    A brief description of quality assurance and quality control system applied in SAEC laboratories for production of 99m Tc-radiopharmaceuticals, is provided. The system includes documentation, procedures, releasing of the products and responsibilities. The system described here undergoes a continues development. (author)

  14. Testing of 99mTc labelled sucralfate in induced gastric and duodenal ulcers

    International Nuclear Information System (INIS)

    Pallagi, Katalin; Janoki, Gyoezoe

    1988-01-01

    The conditions of in vitro labelling of sucralfate available in medical practice were established according to literature data including some modifications. Labelling efficiency proved to be 98.1%. The radiopharmaceutical is stable over 6 hours in vitro. 99m Tc-sucralfate accumulates in experimentally induced gastric and duodenal ulcers thus tracing the site of the ulcerous lesion. (author) 14 refs.; 3 tabs

  15. Liver metastases of breast carcinoma detected on /sup 99m/Tc-methylene diphosphonate bone scan

    International Nuclear Information System (INIS)

    Baumert, J.E.; Lantieri, R.L.; Horning, S.; McDougall, I.R.

    1980-01-01

    The accumulation of bone-seeking radiopharmaceuticals has been reported in liver metastases from colon carcinoma and oat cell carcinoma of the lung. Two patients with breast carcinoma in whom hepatic metastases were visualized on /sup 99m/Tc-methylene diphosphonate bone images are described. This has not been previously reported

  16. Radiopharmaceuticals - current state and trends

    International Nuclear Information System (INIS)

    Muenze, R.

    1981-07-01

    The current state as well as the tendencies of modern radiopharmaceutical development and application is reviewed. After an evaluation of the fundamental preconditions of decay characteristics and pharmaceutical properties the problems concerning sup(99m)Tc-radiopharmaceuticals, metabolizable compounds and the use of specific biological interactions are discussed. (author)

  17. The hospital preparation of radiopharmaceuticals

    International Nuclear Information System (INIS)

    The subject is covered in sections: introduction; preparation ((general - sterilization), production areas (laboratories), working methods for injections, working methods for oral preparations and iodination procedures); analytical testing (general, standards common to injections and oral preparations, standards for injections, standards for oral preparations); reliable methods of preparing sup(99m)Tc-radiopharmaceuticals and 51 Cr-red cells; commercial radiopharmaceutical kits. (U.K.)

  18. [99mTc]teboroxime and [99mTc]Cl(DMG)3B2MP: binding characteristics and metabolism of two [99mTc]BATOs in blood and tissues

    International Nuclear Information System (INIS)

    Rosenspire, K.C.; Rumsey, W.L.; Jurisson, S.; Hirth, W.; Narra, R.K.

    1993-01-01

    Studies were performed in vitro and in vivo to evaluate the binding properties and metabolism of [ 99m Tc]Cl(CDO) 3 BMe (Teboroxime) and [ 99m Tc]Cl(DMG) 3 B2MP in blood and target issues of rats. Both radiopharmaceuticals displayed rapid binding (within 1-3 min) with high affinity to plasma proteins and blood cells. The amounts of radioactivity associated with blood components became progressively greater with time of exposure to either compound. There was a higher proportion of the radiopharmaceuticals associated with blood components during in vivo conditions, likely due, at least in part, to clearance of the free fraction from the plasma pool. Exposure of both compounds to blood results in axial ligand exchange of the chloro atom to a hydroxyl. The results suggest that it is the free species that is extracted primarily by tissues. (Author)

  19. [99mTc]teboroxime and [99mTc]Cl(DMG)3B2MP: binding characteristics and metabolism of two [99mTc]BATOs in blood and tissues

    International Nuclear Information System (INIS)

    Rosenspire, K.C.; Rumsey, W.L.; Jurisson, S.; Hirth, W.; Narra, R.K.

    1993-01-01

    Studies were performed in vitro and in vivo to evaluate the binding properties and metabolism of [ 99m Tc]Cl(CDO) 3 BMe (Teboroxime) and [ 99m Tc]Cl(DMG) 3 B2MP in blood and target tissues of rats. Both radiopharmaceuticals displayed rapid binding (within 1-3 min) with high affinity to plasma proteins and blood cells. The amounts of radioactivity associated with blood components became progressively greater with time of exposure to either compound. There was a higher proportion of the radiopharmaceuticals associated with blood components during in vivo conditions, likely due, at least in part, to clearance of the free fraction from the plasma pool. Exposure of both compounds to blood results in axial ligand exchange of the chloro atom to a hydroxyl. The results suggest that it is the free species that is extracted primarily by tissues. (author)

  20. Evaluation of the in vivo binding of 99mTc-MDP on serum proteins

    International Nuclear Information System (INIS)

    Freitas, R.S.F.; Mattos, D.M.M.; Gomes, M.L.; Moreno, S.R.F.; Lima, E.A.C.; Dire, G.F.; Aleixo, L.C.M.; Lima Filho, G.L.; Bernardo-Filho, M.

    2002-01-01

    Aim: In the clinical application of technetium-99m-radiopharmaceuticals (99mTc) these agents are injected into the blood stream and they may bind reversibly and irreversibly to the blood proteins. To evaluate the protein binding of the radiopharmaceutical, the protein-bound 99mTc-radiopharmaceuticals must be separated from the free 99mTc-radiopharmaceuticals complexes. This has been accomplished by precipitation of the proteins. In this study, we have compared the results obtained with the evaluation of the binding of the radiopharmaceutical Tc-99m methylenediphosphonic acid (99mTc-MDP) on serum proteins using precipitation methods with TCA and AS. Material and Methods: 99mTc-MDP was administrated in Wistar rats and after 10 minutes blood was withdrawn and serum (S) isolated. Aliquots of S were precipitated with 1 ml of TCA or AS at various concentrations (0.1, 0.5, 1.0, 5.0, 10.0 and 20.0%) and soluble (SF) and insoluble fractions (IF) were separated. The samples (IF-S and SF-S) were counted in a well counter with NaI(TI)crystal. The percent of the radioactivity (%ATI) was determined in each fraction. Results: The results obtained with the comparison of the in vivo binding of 99mTc-MDP when the precipitation was performed with TCA showed that the %ATI was only statistically different (ANOVA, p<0.05) to the 20% TCA concentration. When various concentrations of AS were used no differences in the %ATI were found and the results were similar to the obtained with TCA, except to the concentration of 20%(TCA - 51.70 ± 10.19 and SA - 10.17 ± 0.98 %). Conclusion: It is possible to suggest that the different concentrations of the precipitating agents (TCA and AS) act, in general, on the same binding sites of the evaluate radiopharmaceutical to the proteins of the serum, except to concentration of 20%

  1. Uses of Tc99m complexes

    International Nuclear Information System (INIS)

    Kubiatowicz, D.O.; Bolles, T.F.

    1978-01-01

    The invention deals with the use of a complex of the radioactive metastable isotope Tcsup(99m) together with water-soluble mercaptane for the preparation of a parenterally administered renal diagnostic agent. (VJ/orig.) [de

  2. Technetium-99m-human fibrinogen

    International Nuclear Information System (INIS)

    Wong, D.W.; Mishkin, F.S.

    1975-01-01

    Exogenous fibrinogen has been successfully labeled with /sup 99m/Tc using a modified electrolytic method. The exact labeling mechanism has not been determined. Experimental data suggest that the labeling process of /99m/Tc-fibrinogen is quite similar to that of /sup 99m/Tc-human serum albumin as reported earlier by Benjamin. Technetium-99m-fibrinogen is stable in human plasma or in 1 percent buffered human serum albumin. A binding efficiency of 76 percent has been achieved with approximately 25 percent clottable protein. The entire labeling procedure requires less than 1 hr of preparation time. This short labeling time in a closed system may allow development of a practical method for labeling autologous fibrinogen, thus eliminating the risk of hepatitis transmission. (U.S.)

  3. 99m-technetium tetrofosmin and 99mTc-methylene diphosphonate in pre-surgical breast cancer

    International Nuclear Information System (INIS)

    Piperkova, E.; Gavrilov, I.; Timcheva, K.; Garanina, Z.; Aleksandrova, E.; Katerinski, K.; Dimitrova, M.

    2004-01-01

    Full text: The aim of this study was to assess the role of the Tc-99m Tetrofosmin (TF) in conjunction with Tc-99m methylenediphosphonate (MDP) in pre-surgical breast cancer (BC) staging. Thirty-six female patients, age range was 32-70 years (average 51.45 years), where the clinical examination, mammography (MG) and fine-needle aspiration cytology were inconclusive were subjected to Tc-99m TF Scintimammography (SMM). All the patients were examined in a specialized breast clinic by experienced surgeons and radiologists. Of the 36 patients, 24 had hyperdense breasts, 8 had undergone lumpectomy or mastectomy due to cancer in one of the breasts and were included in the present study because of suspicion of lesion in the contra lateral breast, 2 had palpable axillary lymph nodes (LN) but no palpable breast lump and 2 patients were of mastitis carcinomatosis. All biopsies were histopathologically verified 740 MBq of Tc-99m TF (Myoview-Amersham) was injected in the arm opposite to the side of the breast lesion. In patients with bilateral breast lesions (BL) radiopharmaceutical was injected in a pedal vein. Planar imaging in prone position was done 10-15 min later. Two lateral views of the left and right breasts including axilla were acquired followed by an anterior view in supine position with arm in an upright position so as to include both breasts and axillary region in the field of imaging view. Imaging was done using a large field of view single-head gamma camera (Diacam-Siemens) coupled with low-energy high-resolution collimator. In patients with locally advanced BC who were to receive pre-operative neo-adjuvant chemotherapy, cardiac GATED SPECT was also acquired using standard protocol. After few days, Tc-99m MDM scintimammography and whole-body bone scintigraphy was also performed. SMM, using the same acquisition protocol as with 99mTc-TF, was done 5-10 min after intravenous injection of 555-740 MBq 99mTc MDP. Standard WBBS was acquired two to three hours later. SMM

  4. Techneticum-99m pharmaceuticals. Preparation and quality control in nuclear medicine

    International Nuclear Information System (INIS)

    Zolle, I.

    2007-01-01

    Radioactive drug development is a multi-disciplinary task, therefore, in a concerted effort, dedicated scientists and experts from different fields of specialisation have contributed to this book. It is presented in two sections. Section 1 contains basic principles and methods used for analysis, information on the chemistry of technetium and on radiopharmaceuticals labelled with technetium-99m, the characteristics of the 99 Mo/99mTc-generator, of 'kits' and formulations for in-vitro labelling, and special safety aspects for in-vivo labelling of blood cells. Section 2 contains monographs of 99mTc-radiopharmaceuticals used in nuclear medicine. Each monograph includes information on the chemistry, formulation, commercial products and trade names, factors affecting in-vivo performance, clinical information on pharmacokinetics, as well as details concerning the clinical application and the radiation dose to patients. (orig.)

  5. Quality controls of radiopharmaceuticals used in nuclear medicine

    International Nuclear Information System (INIS)

    Gomez de Castiglia, S.I.; Fraga de Suarez, A.H.; Mitta, A.E.A.

    1981-01-01

    Chromatographic quality controls for Tc-99m; In-113m; I-131; Tl-201 and Ga-67 radiopharmaceuticals are described. Moreover, a chromatographic system which allows to separate different radiopharmaceuticals from In-113m is pointed out. (author) [es

  6. The development of 99mTc-d, 1-HM-PAO

    International Nuclear Information System (INIS)

    Bai Lanqin; Huang Jinjie; Fan Li; Bai Suzhen; Li Guoli; Jing Hui; Xiao Lun

    1991-12-01

    The 99m Tc-d,1-HM-PAO is an ideal radiopharmaceutical for regional cerebral blood perfusion imaging. The improvement of synthesis and separation of diastereoisomers leads to obtain high purity (>99%) of d, 1-HM-PAO and meso-HM-PAO. During separation H NMR spectroscopy was used to monitor the relative composition of these two diastereoisomers that can ensure the purity of pligand of d,1-HM-PAO. The intravenous injection of 99m Tc-d,1-HM-PAO was formed by adding fresh 99m Tc washing liquor into a sterile. Pyrogen-free and freeze-dried vial. The radiochemical purity (RCP) of 99m Tc-d,1-HM-PAO was greater than 80%. From the experiments of 99m Tc-d,1-HM-PAO in mice, after two minutes of intravenously (I>V>) administration about 2.24% of injected dose (I.D.)appeared in the brain, and after 24 hours about 72% of radioactivity of injected dose still left in the brain. But for the 99m Tc-meso-HM-PAO after two minutes of i.v. administration, about 1.93% of I.D. appeared in the brain, and 24 hours later, 25% of radioactivity of I.D. was in the brain. This result shows that in the brain the radioactivity of 99m Tc-meso-HM-PAO declines faster than that of 99m Td-d,1-HM-PAO

  7. Technetium-99m ceftizoxime kit preparation

    International Nuclear Information System (INIS)

    Diniz, Simone Odilia Fernandes; Siqueira, Cristiano Ferrari; Nelson, David Lee; Cardoso, Valbert Nascimento

    2005-01-01

    The aim of this work was to prepare a kit of 99 m Tc-ceftizoxime ( 99m Tc-CFT), with stability and biological activity preserved, able to identify a septic focus (E. coli) in the experimental infection model in rats. The preparation of the CFT kit involved the use of lyophilized solutions containing the antibiotic ceftizoxime and the sodium dithionite reducing agent (6.0 mg/m L). After lyophilization, the kit was reconstituted with 1.0 mL of sodium 99m Tc pertechnetate solution (Na 99m Tc O 4- ) with an activity of 370 MBq. The solution was boiled for 10 min and filtered through a cellulose ester filter. The labeling efficiency was on the order of 92%, remaining stable for six hours and the kit remained stable for two months. The biological activity of the 99m Tc-CFT was evaluated by diffusion in agar impregnated with E.coli and S. aureus. Seven Wistar rats, weighing from 200 to 250 g, were used for the development of the septic focus. After 24 hours from the induction of the infectious site (E.coli), the animals were anesthetized and 0.1 mL of 99m Tc-CFT (37 MBq) was injected into the tail veins of the animals. The images were obtained with a gamma camera one, two and six hours after injection and the regions of interest (ROIs) were calculated. The diameters of the inhibition halos for 99 m Tc-CFT were 27.16 ± 0.23 and 27.17 ± 0.20 for S.aureus and E.coli, respectively, while those for the unlabeled CFT were 30.4 ± 0.33 and 29.43 ± 0.26, respectively. The results for the biodistribution of 99m Tc-CFT in infected animals furnished a ratio of 1.97 ± 0.31, 2.10 ± 0.42 and 2.01 ± 0.42 for cpm-target/cpm-no target for the one, two and six-hour periods, respectively. The images showed a clear uptake of labeled antibiotic ( 99m Tc-CFT) by the infectious site during the experiment. The results attest to the viability of producing a kit with 99m technetium-labeled ceftizoxime for the investigation of infectious processes. (author)

  8. Technetium-99m ceftizoxime kit preparation

    Energy Technology Data Exchange (ETDEWEB)

    Diniz, Simone Odilia Fernandes; Siqueira, Cristiano Ferrari; Nelson, David Lee; Cardoso, Valbert Nascimento [Minas Gerais Univ. Federal, Belo Horizonte, MG (Brazil). Faculdade de Farmacia]. E-mail: simone@farmacia.ufmg.br; Martin-Comin, Josep [Bellvitge Univ., Barcelona (Spain)

    2005-10-15

    The aim of this work was to prepare a kit of {sup 99}m Tc-ceftizoxime ({sup 99m} Tc-CFT), with stability and biological activity preserved, able to identify a septic focus (E. coli) in the experimental infection model in rats. The preparation of the CFT kit involved the use of lyophilized solutions containing the antibiotic ceftizoxime and the sodium dithionite reducing agent (6.0 mg/m L). After lyophilization, the kit was reconstituted with 1.0 mL of sodium {sup 99m} Tc pertechnetate solution (Na {sup 99m} Tc O{sub 4-}) with an activity of 370 MBq. The solution was boiled for 10 min and filtered through a cellulose ester filter. The labeling efficiency was on the order of 92%, remaining stable for six hours and the kit remained stable for two months. The biological activity of the {sup 99m} Tc-CFT was evaluated by diffusion in agar impregnated with E.coli and S. aureus. Seven Wistar rats, weighing from 200 to 250 g, were used for the development of the septic focus. After 24 hours from the induction of the infectious site (E.coli), the animals were anesthetized and 0.1 mL of {sup 99m} Tc-CFT (37 MBq) was injected into the tail veins of the animals. The images were obtained with a gamma camera one, two and six hours after injection and the regions of interest (ROIs) were calculated. The diameters of the inhibition halos for {sup 99}m Tc-CFT were 27.16 {+-} 0.23 and 27.17 {+-} 0.20 for S.aureus and E.coli, respectively, while those for the unlabeled CFT were 30.4 {+-} 0.33 and 29.43 {+-} 0.26, respectively. The results for the biodistribution of {sup 99m} Tc-CFT in infected animals furnished a ratio of 1.97 {+-} 0.31, 2.10 {+-} 0.42 and 2.01 {+-} 0.42 for cpm-target/cpm-no target for the one, two and six-hour periods, respectively. The images showed a clear uptake of labeled antibiotic ({sup 99m} Tc-CFT) by the infectious site during the experiment. The results attest to the viability of producing a kit with {sup 99m} technetium-labeled ceftizoxime for the

  9. Hepato-biliary scan using sup(99m)Tc-pyridoxylidene isoleucine (sup(99m)Tc-PI) and its clinical significance

    Energy Technology Data Exchange (ETDEWEB)

    Nakano, S; Watahiki, H; Takeda, I; Kitamura, K; Ichikawa, H [Ogaki Municipal Hospital, Gifu (Japan)

    1978-05-01

    The hepato-biliary scan with sup(99m)Tc-pyridoxylidene Isoleucine (sup(99m)Tc-PI) was able to demonstrate the biliary system much more clearly than that using usual radiopharmaceuticals such as /sup 131/I-BSP of /sup 131/I-Rose Bengal. The hepato-biliary scan with sup(99m)Tc-PI demonstrated the hepatobiliary system more clearly than DIC in 47.6% of all cases studied. Especially the demonstration of changes of intra-hepatic biliary tree in cases with intra-hepatic gall stone and cholangiocarcinoma was quite superior to DIC, although there was somewhat difficulty in getting information about the right hepatic duct. For the diagnosis of gall stone in the gall bladder, DIC was more suitable than sup(99m)Tc-PI hepatobiliary scan. The sup(99m)Tc-PI hepato-biliary scan was able to demonstrate the biliary system even in cases having moderate jaundice, in which cases DIC could not demonstrate the biliary system. This sup(99m)Tc-PI hepato-biliary scan was proved to be useful in determing a certain cause of defects shown on the conventional liver scan. No side effect was noticed in this series of the study.

  10. Synthesis of 99mTc-aroylhydrazinocarbo-nylmethyliminodiacetic acids and their animal study, hepatobiliary pharmaceuticals

    International Nuclear Information System (INIS)

    He Yong; Zhou Xirui; Chen Shaoliang; Chen Guohui

    1994-01-01

    Based on the structure specificity of a new compound isonicotinoylhydrazino-carbonylmethyliminodiacetic acid, nine similar derivatives were synthesized by esterification of aromatic acids, followed by hydrazinolysis, and acylation with nitrilotriacetic acid. The 99m Tc-complexes of these compounds were prepared by stannous chloride reduction of sodium pertechnetate in aqueous solution at pH 6 ∼ 7. The experimental results in mice and rabbits showed that the 99m Tc-complexes all exhibited varying degrees in the uptake by the liver cells, cleared off from the blood and excreted into the biliary tract. The hepatobiliary specificity of 99m Tc-2-methoxy-5-bromobenzoylhydrazinocarbonylmethyliminodiacetic acid was the best among them. It is concluded preliminarily that the aroylhydrazinocarbonylmethyliminodiacetic acids provide to be a fruitful source for 99m Tc-labeledhepatobiliary radiopharmaceuticals

  11. Labelling, biodistribution and compartmental analysis of N-acetylcysteine labelled with Tc-99m. Comparative investigation with with {sup 99m} Tc-MIBI in an in vivo tumoral model; Estudo de marcacao, biodistribuicao e analise compartimental da N-acetil cisteina marcada com Tc-99m. Investigacao comparativa com MIBI-{sup 99m}Tc em modelo tumoral in vivo

    Energy Technology Data Exchange (ETDEWEB)

    Faintuch, Bluma Linkowski

    1997-07-01

    Labelling and biodistribution studies were done with two different ligands, respectively Methoxy isobutyl isonitrile (MIBI) and N-acetylcysteine (NAC), employing Tc-99m as a tracer. The main objective was to assess the pharmacokinetic properties of the second substance, aiming at its possible application in cancer diagnosis. To this purpose an in vivo investigation was done using healthy and tumor-bearing rats with experimental cancer. Images of tumor-bearing rats registered in a scintillation camera indicated that with {sup 99m} Tc-MIBI none of the two selected times was adequate for visualization of the cancer mass. In contrast, {sup 99m} Tc-NAC permitted clear identification of the humor, four hours after injection. The results have demonstrated that {sup 99m} Tc-NAC is a radiopharmaceutical with affinity for cancer tissue and promising for further investigation concerning imaging diagnosis of tumors. (author)

  12. Installation of Tc-99m generator manufacturing facilities

    International Nuclear Information System (INIS)

    Shin, B. C.; Choung, W. M.; Park, J. H.; Park, S. H.; Kim, S. J.; Park, K. B.

    2004-01-01

    For the characteristics of radiopharmaceuticals, the manufacturing facility should be complied with the radiation safety standards for operators as well as GMP (Good Manufacturing Practice) cleanness standards for production. We intensively modified the existing Radioisotope production facilities, which were installed only in radiation safety points of view, to meet cleanness criteria. And the concept of multi-barrier buffer zones was introduced to apply negative air pressure for hot cell with first priority and to continue relative positive air pressure for clean room. The manufacturing area for Tc-99m Generator can be entered only through a second change. The doors of each change area are interlocked to maintain air pressure differentials. The pass box for material transfer are also interlocked so that only one side may be opened at any one time to keep cleanness. Two door-type autoclave was installed crossing the wall between preparing room and aseptic room to keep cleanness after sterilization. Three lead hot cells were installed and final inspection including gamma survey test were performed. The clean room was installed and TAB for this facility was performed in order to acquire the necessary air flow. The filter bank for filtration of exhausted radiation air was installed and its efficiency test was performed. In this facility, radiation shielding utilities and manufacturing instruments were set up and their operating manuals were documented. Efficiency tests for every utilities and instruments were satisfied and the approval for use of the facilities was achieved from MOST (Ministry of Science and Technology). The Sam Young Unitech, the lessee of the facilities set up the equipment in the hot cell, which is needed to produce Tc-99m Generator, supported by IPPE in Russia. They are composing the systems complied with the guidelines and the regulations, and keep in contact to KFDA for acquiring its approval. It is expected to produce Tc-99m Generator within

  13. Tc-99m labeled Sparfloxacin: A specific infection imaging agent

    International Nuclear Information System (INIS)

    Singh, A.K.; Verma, J.; Bhatnagar, A.; Ali, A.

    2003-01-01

    Radiolabeled antibiotics are being used for the specific diagnosis of infection by exploiting their specific binding properties to the bacterial component, thereby making it possible to differentiate infection from sterile lesions. A new radiopharmaceutical, Tc-99m Sparfloxacin has been developed for infection imaging. Sparfloxacin is a quinolone based broad-spectrum antibiotic, which is more potent than Ciprofloxacin. Radiolabeling of Sparfloxacin with Tc-99m was standardized using direct labeling protocol. Labeling efficiency, in-vitro and in-vivo stability, blood kinetics and organ distribution studies (in balb/c mice and New Zealand White Rabbits at different time interval up to 24hrs) were carried out. Biological activity of Sparfloxacin after its labeling with Tc-99m was evaluated with S.aureus using Peptone water (DIFCO) as media. Turpentine oil (100 μl) in left thigh and S.aureus (100μl of 3x10 7 cells) in right thigh were injected intramuscularly to create sterile and infective inflammation respectively in six New Zealand white rabbits. The localization kinetics of the radiolabeled complex were studied in the animal model by injecting 70-75MBq of Tc-99m Sparfloxacin intravenously in the ear of rabbit and the images were taken with a Gamma-camera (ECIL) at different post-injection time intervals. Standardized protocol produced >95% labeled complex. About 8% of tracer leached out at 24 hrs when incubated in serum at 37 0 C, confirming high stability of the complex. Blood clearance in rabbit revealed biphasic pattern and 50% of the complex clears from the blood within 5 min. Biodistribution studies in balb/c mice showed hepatobiliary route of excretion. Presence of insignificant amount of tracer at 24 hrs in the stomach confirmed high in vivo stability of the complex. Imaging in rabbits showed significant concentration of tracer in lesions with infection. Typical imaging patterns revealed initial accumulation of radiotracer in both sterile inflammatory

  14. Technetium-99m ceftizoxime kit preparation

    Directory of Open Access Journals (Sweden)

    Simone Odília Fernandes Diniz

    2005-10-01

    Full Text Available The aim of this work was to prepare a kit of 99mTc-ceftizoxime (99mTc-CFT, with stability and biological activity preserved, able to identify a septic focus (E. coli in the experimental infection model in rats. The preparation of the CFT kit involved the use of lyophilized solutions containing the antibiotic ceftizoxime and the sodium dithionite reducing agent (6.0 mg/mL. After lyophilization, the kit was reconstituted with 1.0 mL of sodium 99mTc-pertechnetate solution (Na99mTcO4- with an activity of 370 MBq. The solution was boiled for 10 min and filtered through a cellulose ester filter. The labeling efficiency was on the order of 92%, remaining stable for six hours and the kit remained stable for two months. The biological activity of the 99mTc-CFT was evaluated by diffusion in agar impregnated with E.coli and S. aureus. Seven Wistar rats, weighing from 200 to 250 g, were used for the development of the septic focus. After 24 hours from the induction of the infectious site (E.coli, the animals were anesthetized and 0.1 mL of 99mTc-CFT (37 MBq was injected into the tail veins of the animals. The images were obtained with a gamma camera one, two and six hours after injection and the regions of interest (ROIs were calculated. The diameters of the inhibition halos for 99mTc-CFT were 27.16 ± 0.23 and 27.17 ± 0.20 for S.aureus and E.coli, respectively, while those for the unlabeled CFT were 30.4 ± 0.33 and 29.43 ± 0.26, respectively. The results for the biodistribution of 99mTc-CFT in infected animals furnished a ratio of 1.97 ± 0.31, 2.10 ± 0.42 and 2.01 ± 0.42 for cpm-target/cpm-no target for the one, two and six-hour periods, respectively. The images showed a clear uptake of labeled antibiotic (99mTc-CFT by the infectious site during the experiment. The results attest to the viability of producing a kit with 99m technetium-labeled ceftizoxime for the investigation of infectious processes.O objetivo deste trabalho foi preparar um kit de Tc

  15. 99mTc-EDTA and 99mTc-DTPA complexes as hydrological tracers

    International Nuclear Information System (INIS)

    Dominguez, J.; Borroto, J.; Nazco, J.; Perez, E.; Gamboa, R.; Cruz, J.

    2002-01-01

    The [ 99m Tc-DTPA] 2- and [ 99m Tc-EDTA] 1- were evaluated as radiotracers for short time hydrological studies. Their complex stability after labelling with 9.25 GBq of 99m Tc, the behaviour against pH variations, from 5 to 9, in simulated solutions and in natural river waters and the sorption of these compounds on the river sediments, were tested in laboratory experiments. Finally field double tracing experiments were carried out for each of labelling complexes and Rhodamine WT. From recovery calculations not losses of the 99m Tc activity were observed. The shape of the RTD curves of the [ 99m Tc-DTPA] 2- and [ 99m Tc-EDTA] 1 were quite similar to the Rhodamine Wt ones. May be concluded that both complexes behaved conservatively on the studied environmental conditions. (author)

  16. Under used technetium-99m generators

    International Nuclear Information System (INIS)

    Mushtaq, A.

    2001-01-01

    Health care reform truly has become a global issue and it will undoubtedly have a dramatic impact on the future of nuclear medicine business in particular. A bigger concern within the nuclear medicine community is its competitiveness with other modalities and cost effectiveness.Technetium-99m and its generators are playing key role for the majority of diagnostic scans performed in the world today. Availability of ''9''9''mTc can be increased if it is separated from ''9''9Mo after much shorter growth times. After proper planning with the extra ''9''9''mTc, a significant number of scans can be performed or we would be able to order approximately 30% low activity ''9''9Tc generators to fulfill our requirements

  17. Problems in clinical practice of domestic supply of 99Mo/99mTc. Considerations on the domestic production of 99Mo/99mTc

    International Nuclear Information System (INIS)

    Yamabayashi, Hisamichi

    2012-01-01

    At present, a bulky import product, 99 Mo supplied in Japan is produced by a nuclear fission method which enables to produce a generator system with no need of commercially preparing 99m Tc-labeled radiopharmaceuticals due to its high specific activity. However its usage of enriched uranium target leads to avoiding the fission method from the option of domestic production. In order to secure the domestic supply of 99 Mo/ 99m Tc, the neutron activation method, aiming to meet about 20% of domestic demand, is under development along with the re-start program of JMTR. Development of various production methods using accelerators are also in progress. In those non-fission methods with reactors or accelerators, rapid and effective procedures for concentration and refinement of 99m Tc solution eluted from 99 Mo of low specific activity are the subjects to be considered for attaining the stable labeling performances. (author)

  18. Can tumor uptake Tc-99m MDP

    International Nuclear Information System (INIS)

    Yang, Y.S.F.; Zeng, Z.J.; Yao, Y.M.; Shi, S.M.P.; Shi, S.Z.Y.

    2002-01-01

    Aim: To study a distribution of Tc-99m MDP in mice bearing tumor cell lines. Methods: The uptake of Tc-99m MDP was analyzed in seven human tumor cell lines (SPC-A1 adenocarcinoma of lung cancer, P37 Breast cancer, T24 Bladder cancer, SKOV2 Ovary carcinoma, Hela-229 Cervical carcinoma, Osteosarcoma, A375 Melanoma) and one mouse lung cancer cell line (Lewis). They were transplanted into 13, 4, 5, 5, 4, 5 athymic mice, 6 SCID nude mice and 4 C57 black mice, respectively. Approximately 10(7) cells of each cell line were injected subcutaneously into a right chest of mouse. After 5∼6 weeks, the Tc-99m MDP scintigraphy were determined 5-6 hours after i.v. injection of 74MBq in 0.05ml every mouse. Result: Biodistribution and tumor uptake MDP was different in the various cell types investigated. Region of interests (RIOs) placed on a small part of the tumor and horizontal copied to left chest or spine of mice in Tc-99m MDP imaging and the average count ratio (tumor to background ratio: T/B, tumor to spine ratio: T/NT) in each ROI was calculated. 13 nude mice bearing the adenocarcinoma (SPC-A1) were sacrificed and biodistribution was determined after Tc-99m MDP scintigraphy. Results were expressed as % injected dose/gram (%ID/g), mean±SD. T-ulcer=ulcer of tumor, T-round=surrounding of tumor, T-center=the center of tumor, Thor-sp=thoracic spine, Lum-ver=lumbar vertebra, LN=lymph node. Conclusions: Tumor can uptake Tc-99m MDP including adenocarcinoma. Higher uptake rate in the center tissue of tumor is than other part of tumor. It maybe connected with necrosis or fibrosis of tumor

  19. Radioisotopes and radiopharmaceuticals catalogue

    International Nuclear Information System (INIS)

    2002-01-01

    The Chilean Nuclear Energy Commission (CCHEN) presents its radioisotopes and radiopharmaceuticals 2002 catalogue. In it we found physical characteristics of 9 different reactor produced radioisotopes ( Tc-99m, I-131, Sm-153, Ir-192, P-32, Na-24, K-42, Cu-64, Rb-86 ), 7 radiopharmaceuticals ( MDP, DTPA, DMSA, Disida, Phitate, S-Coloid, Red Blood Cells In-Vivo, Red Blood Cells In-Vitro) and 4 labelled compounds ( DMSA-Tc99m, DTPA-Tc99m, MIBG-I131, EDTMP-Sm153 ). In the near future the number of items will be increased with new reactor and cyclotron products. Our production system will be certified by ISO 9000 on March 2003. CCHEN is interested in being a national and an international supplier of these products (RS)

  20. Technetium 99mTc Pertechnetate Brain Scanning

    International Nuclear Information System (INIS)

    Rhee, Sang Min; Park, Jin Yung; Lee, Ahn Ki; Chung, Choo Il; Hong, Chang Gi; Rhee, Chong Heon; Koh, Chang Soon

    1968-01-01

    Technetium 99 mTc pertechnetate brain scanning were performed in 3 cases of head injury (2 chronic subdural hematomas and 1 acute epidural hematoma), 2 cases of brain abscess and 1 case of intracerebral hematoma associated with arteriovenous anomaly. In all the cases brain scintigrams showed 'hot areas.' Literatures on radioisotope scanning of intracranial lesions were briefly reviewed. With the improvement of radioisotope scanner and development of new radiopharmaceuticals brain scanning became a safe and useful screening test for diagnosis of intracranial lesions. Brain scanning can be easily performed even to a moribund patient without any discomfort and risk to the patient which are associated with cerebral angiography or pneumoencephalography. Brain scanning has been useful in diagnosis of brain tumor, brain abscess, subdural hematoma, and cerebral vascular diseases. In 80 to 90% of brain tumors positive scintigrams can be expected. Early studies were done with 203 Hg-Neohydrin or 131 I-serum albumin. With these agents, however, patients receive rather much radiation to the whole body and kidneys. In 1965 Harper introduced 99 mTc to reduce radiation dose to the patient and improve statistical variation in isotope scanning.

  1. Technetium {sup 99m}Tc Pertechnetate Brain Scanning

    Energy Technology Data Exchange (ETDEWEB)

    Rhee, Sang Min; Park, Jin Yung; Lee, Ahn Ki; Chung, Choo Il; Hong, Chang Gi [Capital Army Hospital, ROKA, Seoul (Korea, Republic of); Rhee, Chong Heon; Koh, Chang Soon [Radiological Research Institute, Seoul (Korea, Republic of)

    1968-03-15

    Technetium {sup 99}mTc pertechnetate brain scanning were performed in 3 cases of head injury (2 chronic subdural hematomas and 1 acute epidural hematoma), 2 cases of brain abscess and 1 case of intracerebral hematoma associated with arteriovenous anomaly. In all the cases brain scintigrams showed 'hot areas.' Literatures on radioisotope scanning of intracranial lesions were briefly reviewed. With the improvement of radioisotope scanner and development of new radiopharmaceuticals brain scanning became a safe and useful screening test for diagnosis of intracranial lesions. Brain scanning can be easily performed even to a moribund patient without any discomfort and risk to the patient which are associated with cerebral angiography or pneumoencephalography. Brain scanning has been useful in diagnosis of brain tumor, brain abscess, subdural hematoma, and cerebral vascular diseases. In 80 to 90% of brain tumors positive scintigrams can be expected. Early studies were done with 203 Hg-Neohydrin or {sup 131}I-serum albumin. With these agents, however, patients receive rather much radiation to the whole body and kidneys. In 1965 Harper introduced {sup 99}mTc to reduce radiation dose to the patient and improve statistical variation in isotope scanning.

  2. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma.

    Science.gov (United States)

    Parisella, Maria; D'Alessandria, Calogero; van de Bossche, Bieke; Chianelli, Marco; Ronga, Giuseppe; Papini, Enrico; Mikolajczak, Renata; Letizia, Claudio; De Toma, Giorgio; Veneziani, Augusto; Scopinaro, Francesco; Signore, Alberto

    2004-04-01

    An early diagnosis of distant metastases or local recurrences of medullary thyroid carcinoma (MTC) can be achieved by several conventional radiological modalities (e.g., ultrasonography, computed tomography [CT], and magnetic resonance imaging [MRI] as well as by radioisotopic procedures, such as positron emission tomography (PET), scintigraphy with different types of radiopharmaceuticals, and radiolabeled receptor-ligands in particular. The aim of this study was to evaluate the clinical utility of 99mTc-EDDA/HYNIC-TOC, a new octreotide derivative, to detect recurrences of disease or distant metastases in MTC. Images obtained of 5 patients with high levels of serum calcitonin were compared to findings obtained with other diagnostic procedures: 111In-octreotide, 99mTc-DMSA-V, 18F-flouro-D-deoxyglucose-PET, and CT/MRI. 99mTc-EDDA/HYNIC-TOC was positive in all patients and showed 15 areas of pathological uptake in the cervical and mediastinal regions. 111In-octreotide was positive in 3 of 3 patients and showed 4 areas, compared to 8 of 99mTc-EDDA/HYNIC-TOC. 99mTc-V-DMSA was positive in 3 of 4 patients but showed 6 pathological areas, compared to 13 of 99mTc-EDDA/HYNIC-TOC. 18F-FDG-PET was positive in 5 of 5 patients but showed only 11 areas, compared to 15 of 99mTc-EDDA/HYNIC-TOC. The CT scan was positive in only 2 patients. In conclusion, 99mTc-EDDA/HYNIC-TOC detected more sites of pathological uptake than other modalities, showed better imaging properties than 111In-octreotide, and might be the radiopharmaceutical of choice for providing a rationale for radioisotopic therapy.

  3. An expedient method for the preparation of 99mTc-MIBI and 99mTc-MAG3 using microwave and teflon 'bomb'

    International Nuclear Information System (INIS)

    Varelis, P.; Poot, M.T.

    1998-01-01

    Full text: The recommended method for the preparation of 99mTc-MIBI and 99mTc-MAG3 requires that they be heated in a boiling water bath for 10 minutes, after reconstitution with sodium pertechnetate. This method is both inconvenient and time consuming. A more rapid and convenient method for the preparation of these radiopharmaceuticals employs a conventional microwave oven. However, a serious limitation of this method is the hazard associated with an explosion of a vessel containing a radioactive substance. Traditionally, mixtures that can potentially explode are contained in a device called a 'bomb'. We have developed a method, utilising such a device, that allows us to rapidly and safely prepare 99mTc-MIBI and 99mTc-MAG3 using a microwave oven. This device is used in our department on a daily basis. Since using the teflon bomb, there has been one incidence of an explosion, which was successfully contained within the bomb. There was no statistically significant difference between the radiochemical purity (RCP) of the microwave prepared samples and those obtained using the recommended method. In conclusion, 99mTc-MIBI and 99mTc-MAG3 can be safely prepared and quality controlled in under ten minutes using a microwave oven and our teflon bomb. The average RCP for 99mTc-MIBI and 99mTc-MAG3 prepared using a microwave oven were 97.0+2.0% (n=19) and 99.8+0.2 (n=7) respectively

  4. An expedient method for the preparation of 99mTc-MIBI and 99mTc-MAG3 using microwave and teflon `bomb`

    Energy Technology Data Exchange (ETDEWEB)

    Varelis, P.; Poot, M.T. [St George Hospital, Sydney, NSW (Australia). Department of Nuclear Medicine

    1998-06-01

    Full text: The recommended method for the preparation of 99mTc-MIBI and 99mTc-MAG3 requires that they be heated in a boiling water bath for 10 minutes, after reconstitution with sodium pertechnetate. This method is both inconvenient and time consuming. A more rapid and convenient method for the preparation of these radiopharmaceuticals employs a conventional microwave oven. However, a serious limitation of this method is the hazard associated with an explosion of a vessel containing a radioactive substance. Traditionally, mixtures that can potentially explode are contained in a device called a `bomb`. We have developed a method, utilising such a device, that allows us to rapidly and safely prepare 99mTc-MIBI and 99mTc-MAG3 using a microwave oven. This device is used in our department on a daily basis. Since using the teflon bomb, there has been one incidence of an explosion, which was successfully contained within the bomb. There was no statistically significant difference between the radiochemical purity (RCP) of the microwave prepared samples and those obtained using the recommended method. In conclusion, 99mTc-MIBI and 99mTc-MAG3 can be safely prepared and quality controlled in under ten minutes using a microwave oven and our teflon bomb. The average RCP for 99mTc-MIBI and 99mTc-MAG3 prepared using a microwave oven were 97.0+2.0% (n=19) and 99.8+0.2 (n=7) respectively

  5. A Tc-99m-labeled long chain fatty acid derivative for myocardial imaging.

    Science.gov (United States)

    Magata, Yasuhiro; Kawaguchi, Takayoshi; Ukon, Misa; Yamamura, Norio; Uehara, Tomoya; Ogawa, Kazuma; Arano, Yasushi; Temma, Takashi; Mukai, Takahiro; Tadamura, Eiji; Saji, Hideo

    2004-01-01

    C-11- and I-123-labeled long chain fatty acid derivatives have been reported as useful radiopharmaceuticals for the estimation of myocardial fatty acid metabolism. We have reported that Tc-99m-labeled N-[[[(2-mercaptoethyl)amino]carbonyl]methyl]-N-(2-mercaptoethyl)-6-aminohexanoic acid ([(99m)Tc]MAMA-HA), a medium chain fatty acid derivative, is metabolized by beta-oxidation in the liver and that the MAMA ligand is useful for attaching to the omega-position of fatty acid derivatives as a chelating group for Tc-99m. On the basis of these findings, we focused on developing a Tc-99m-labeled long chain fatty acid derivative that reflected fatty acid metabolism in the myocardium. In this study, we synthesized a dodecanoic acid derivative, MAMA-DA, and a hexadecanoic acid derivative, MAMA-HDA, and performed radiolabeling and biodistribution studies. [(99m)Tc]MAMA-DA and [(99m)Tc]MAMA-HDA were prepared using a ligand-exchange reaction. Biodistribution studies were carried out in normal mice and rats. Then, a high initial uptake of Tc-99m was observed, followed by a rapid clearance from the heart. The maximum heart/blood ratio was 3.6 at 2 min postinjection of [(99m)Tc]MAMA-HDA. These kinetics were similar to those with postinjection of p-[(125)I]iodophenylpentadecanoic acid. Metabolite analysis showed [(99m)Tc]MAMA-HDA was metabolized by beta-oxidation in the body. In conclusion, [(99m)Tc]MAMA-HDA is a promising compound as a long chain fatty acid analogue for estimating beta-oxidation of fatty acid in the heart.

  6. The development and characterization of Tc-99m mecaptoacetyltriglycine (MAG3)

    International Nuclear Information System (INIS)

    Taylor, A. Jr.; Eshima, D.

    1990-01-01

    I-131 orth-iodohippuric (OIH) acid is a widely used renal radiopharmaceutical but it is limited due to the suboptimal imaging properties of the I-131 radionuclide and the relatively high radiation dose. Recent work has focused on the development of Tc-99m renal tubular function agents which would utilize the optimal radionuclidic properties and availability of Tc-99m, provide comparable clinical information to that obtained with OIH and allow the evaluation of renal perfusion. The triamide mercaptide (N 3 S) donor ligand system has yielded the most promising Tc-99m tubular function agent to date. Tc-99m mercaptoacetyltriglycine MAG 3 does not enter the red blood cell. A simple kit formulation has been developed which yields a stable Tc-99m MAG 3 complex in high radiochemical purity. Studies in normal volunteers and patients indicate that Tc-99m MAG 3 is an excellent Tc-99m renal tubular agent but its clearance is only 50-60% that of OIH. 42 refs., 2 tabs., 2 figs

  7. Molybdenum-99/technetium-99M generators

    International Nuclear Information System (INIS)

    Morcos, N.A.; Bruno, G.A.; Haney, T.A.

    1981-01-01

    A 99 Mo/sup(99m)Tc generator is described which has an alumina support medium consisting of multiple beds of controlled pH and in which no bed has a pH value higher than the bed preceding it. It is claimed that by using this method low yield problems of such generators can be mitigated. (U.K.)

  8. MIBI-99mTc mammary scintigraphy

    International Nuclear Information System (INIS)

    Mayosky, Maria C.; Parma, Elvira P.; Armesto, Amparo M.; Zarlenga, Ana C.; Cresta, Carlos; Azar, Maria E.; Noblia, Cristina

    1999-01-01

    121 patients suspected of breast cancer were studied with MIBI- 99m Tc to evaluate the suitability of the mammary scintigraphy in patients with doubtful cancer diagnosis.The results show 93 % sensitivity and 95 % specificity and indicate the usefulness of this procedure to increase the accuracy of the diagnosis

  9. An introduction to technetium-99m generators

    International Nuclear Information System (INIS)

    Abrashkin, S.

    1984-02-01

    The role played by technetium-99m generators in diagnostic medicine, their physical and chemical fundamentals and their main technical characteristics are discussed. This report is intended as a general introduction to a group of reports which summarize the work done on the development and production of the generators, and research on the chemical and physical aspects of the generator systems

  10. Solvation effects on brain uptakes of isomers of 99mTc brain imaging agents

    Institute of Scientific and Technical Information of China (English)

    2002-01-01

    Analysis of electrostatic hydration free energies of the isomers of the 99mTc-BAT and 99mTc-DADT complexes is carried out using the computer simulation technique. The results show that not only a correlation exists between the logarithm of the brain uptake and the electrostatic hydration free energy for the isomers of 99mTc-brain radiopharmaceuticals, but also a linear relationship exists between the logarithm of the ratio of the brain uptake of the syn isomer to that of the anti one and the difference between the electrostatic hydration free energy of the syn-isomer and that of the anti one. Furthermore, the investigation on the important factors influencing the brain uptakes of 99mTc-radiopharmaceuticals and the reasons of the different biodistribution of the isomers of the 99mTc-complexes is explored at the molecular level. The results may provide a reference for the rational drug design of brain imaging agents.

  11. Interaction between green tea extract and 99mTc-pertechnetate on in vivo distribution

    International Nuclear Information System (INIS)

    Burak Sabuncu; Fazilet Zumrut Biber Muftuler; Ayfer Yurt Kilcar; Betul Cekic; Eser Ucar; Perihan Unak

    2014-01-01

    People drink various types of tea without knowing the side effects of biological and chemical contents and radiopharmaceutical interactions. In current study, it is aimed to evaluate the effects of green tea extract in different extraction solvents on the radiolabeling of the blood constituents with 99m Tc and on the biodistribution of radiopharmaceutical sodium pertechnetate (Na 99m TcO 4 ) in male Wistar Albino rats. The extraction of green tea was performed in different solvents. Biodistribution studies were performed on male rats which were treated via gavage with green tea extract in different extraction solvents or saline (0.9 % NaCl) as a control group for 7 days. The radiolabeling of blood constituents performed incubating with SnCl 2 and 99m Tc. According to experimental results, radiolabeling blood components with 99m Tc were not modified in the usage of the different extraction solvents for green tea extraction, but a significant alteration (P 99m TcO 4 was observed after treatment with green tea extract in distilled water. Although there is no considerable effect on radiolabeling of blood components, there is an outstanding change on the biodistribution studies especially with green tea extract in distilled water. The identified change monitored in this study may cause to reduce the risk of misdiagnosis and/or avoid the repetition of the examinations in nuclear medicine. (author)

  12. Development of 99mTc agents for imaging central neural system receptors

    International Nuclear Information System (INIS)

    2004-01-01

    Radiopharmaceuticals that bind to central neural system (CNS) receptors in vivo are potentially useful for understanding the pathophysiology of anumber of neurological and psychiatric disorders, their diagnosis and treatment. Carbon-11 labelled compounds and positron emission tomography(PET) imaging have played a vital role in establishing the usefulness of imaging the dopaminergic, cholinergic, serotonergic and benzodiazapine receptors, and relating the receptor density to disease status. Since the use of 11C agents is constrained due to their 20 min half-life, various radiohalogenated analogues based on the structure of 11C compounds have been successfully developed, providing comparable information. Iodine- 123 is the most widely employed of these radioisotopes; it has a longer, 13 h, half-life. Through the use of 123I, there has been a steady growth in CNS receptor imaging studies employing single photon emission computerized tomography (SPECT). SPECT, as compared with PET, has slightly inferior image resolution but has the advantage of being readily available worldwide. However, the 123I radiopharmaceutical is expensive and the distribution system outside of the major markets is not well developed for its supply on a routine basis. The ideal radioisotope for SPECT imaging is 99mTc, due to its low cost per dose, availability through commercially available generator systems and physical decay characteristics. Over 80% of all diagnostic nuclear medicine imaging studies worldwide are conducted using this radioisotope. Development of 99mTc radiopharmaceuticals for imaging CNS receptors is therefore of considerable importance. On the basis of the recommendations of a consultants meeting, the International Atomic Energy Agency (IAEA) initiated in 1996 a Co-ordinated Research Project (CRP) on Development of Agents for Imaging CNS Receptors based on 99mTc. At that time there were no 99mTc CNS receptor imaging radiopharmaceuticals available even though work on

  13. Neutral and stereospecific Tc-99m complexes: [99mTc]N-benzyl-3,4-di-(N-2-mercaptoethyl)-amino-pyrrolidines (P-BAT)

    International Nuclear Information System (INIS)

    Zhuang Zhiping; Ploessl, Karl; Kung Meiping; Mu Mu; Kung, Hank F.

    1999-01-01

    Technetium-99m-labeled radiopharmaceuticals are currently the most commonly used agents in nuclear medicine. To prepare binding site-specific small molecules containing a Tc-99m complexing core, it is important to consider a ligand system, which selectively forms only one stereoisomer. A novel series of bisaminoethanethiol (BAT) derivatives as a model system were prepared. Stereoisomers of N-benzyl-3,4-di-(N-2-mercaptoethyl)-amino pyrrolidines (P-BAT): (3R,4R)-P-BAT (R,R-4) and (3,4)meso-P-BAT (8), the trans and meso isomer, respectively, as a chelating group were prepared successfully. The desired Tc-99m P-BAT complexes were obtained by using Sn(II)/glucoheptonate as the reducing agent for [ 99m Tc]pertechnetate. As predicted, after complexation with [ 99m Tc]Tc v O, the trans isomer, (3R,4R)-P-BAT (R,R-4), showed only one isomer; whereas the corresponding meso isomer, (3,4)meso-P-BAT (8), produced two distinctive complexes isolated readily by high performance liquid chromatography (HPLC). The [ 99m Tc](R,S)meso-P-BAT (8) isomers showed a different lipophilicity (partition coefficient [P.C.]=54.3 and 55.4 for peak A and peak B, respectively), as compared with that of the corresponding [ 99m Tc](3R,4R)-P-BAT (R,R-4), trans isomer ( P.C.=163). Results of the biodistribution study in rats of these isomers show different heart and brain uptake, suggesting that the intrinsic differences in biodistribution are due to structural and stereospecific factors. Examples in this report confirm that it is possible to design stereospecific Tc-99m complexes based on the bisaminoethanethiol (N 2 S 2 , BAT) ligand system. Consideration on stereoselectivity of site-specific agents labeled with Tc-99m is likely an essential requirement on developing binding-site specific radiopharmaceuticals

  14. Development and evaluation of electro chemical methods for the separation of Tc-99m labelled compounds of medical importance

    International Nuclear Information System (INIS)

    Mani, R.S.

    1978-03-01

    The preparation of sup(99m)Tc radiopharmaceuticals using the electrolytic reduction of sup(99m)Tc pertechnetate was investigated. The effect of current intensity, amount of current, pH and applied voltage on the reduction of the Tc-VII and its incorporation into the radiopharmaceuticals was evaluated. The results indicate that the electrolytic method gives high and reproducible labelling yields and compounds with good radiochemical purity. Procedures for the preparation and control of the following sup(99m)Tc radiopharmaceuticals were standardized by the authors: Tc-tin colloid, Tc-red blood cells, Tc-HSA, Tc-albumin microspheres, Tc-EHDP, Tc-gluconate and Tc-glucoheptonate. A portable electrolytic labelling instrument was designed for use in hospitals

  15. Gentc99m, computational system for the technetium-99m generator

    International Nuclear Information System (INIS)

    Suparman, I.

    1997-01-01

    The technetium-99m generator is one of the main products of the PPR, as the continuity of the technetium-99m generator production is important for supporting the development of nuclear medicine. GENTC99M has been made for computational for the technetium-99m generator and includes data processing, documentation and information GENTC99M is also very useful in quality control application especially for the determinations of yield and radionuclidic impurities which consume much time. microsoft visual basic for MS-DOS and visual basic for windows have been used for making GENTC99M. Microsoft visual basic has several features that make it an ideal development language for both MS-DOS and Microsoft Windows. These features not only increase productivity, they also provide all the tools and hooks needed to develop some very sophisticated applications. for a production centre like PPR, GENTC99M is very useful to support the data processing, documentation and information system of the technetium-99m generator and it can also be modified for other products

  16. Evaluation of 99mTc-labeled antibiotics for infection detection

    International Nuclear Information System (INIS)

    Lambrecht, F.Y.

    2011-01-01

    One of the fields of research in nuclear medicine is the development of new radiopharmaceuticals for imaging infection and inflammation in humans. For this development, several antimicrobial peptides, antibiotics, antibiotic peptide and chemotactic peptides, etc., have been radiolabeled with different radionuclides ( 67 Ga, 99m Tc, 111 In, 18 F, 131 I, etc.) and their imaging potentials studied. Actually, it is very important to distinguish between infection and inflammation. In this respect, radiolabeled antibiotics have advantages because many of the properties of the ideal infection-specific agent through antibiotics localizes in infection site. In this review, only 99m Tc-labeled antibiotics are evaluated and discussed. (author)

  17. Automation drying unit molybdenum-zirconium gel radioisotope production technetium-99M for nuclear medicine

    International Nuclear Information System (INIS)

    Chakrova, Y.; Khromushin, I.; Medvedeva, Z.; Fettsov, I.

    2014-01-01

    Full text : Since 2001 the Institute of Nuclear Physics of the Republic of Kazakhstan has began production of radiopharmaceutical based on technetium-99m from irradiated reactor WWR-K of natural molybdenum, which allows to obtain a solution of technetium-99m of the required quality and high volume activity. In 2013 an automated system is started, which is unique and urgent task is to develop algorithms and software in Python, as well as the manufacture of certain elements of technological systems for automated production

  18. Rapid and accurate determination of radiochemical purity of sup(99m)Tc compounds

    International Nuclear Information System (INIS)

    Tamat, S.R.

    1977-01-01

    The wide spread use of sup(99m)Tc-labelled radiopharmaceuticals and limitation of the short half-life of the isotope, is associated with an urgent need for a rapid, simple but accurate method for determining the radiochemical purity of the compound. A short paper chromatographic (KK) or thin layer chromatographic (KLT) method using 95% methanol or 0.9% saline solution as solvents, has solved the problem. With these methods, the amount of free sup(99m)Tc pertechnetate in a compound, can be determined in only a few minutes. These methods compare satisfactorily with lengtheir procedures. (author)

  19. Evaluation in dogs and humans of three potential technetium-99m myocardial perfusion agents

    International Nuclear Information System (INIS)

    Gerundini, P.; Savi, A.; Gilardi, M.C.

    1986-01-01

    The biodistribution of the three cationic /sup 99m/Tc complexes [/sup 99m/Tc(TMP)6]+, [/sup 99m/Tc(POM-POM)3]+, and [/sup 99m/Tc(TBIN)6]+--where TMP represents trimethylphosphite, POM-POM represents 1,2-bis(dimethyoxyphosphino)ethane, and TBIN represents t-butylisonitrile--have been evaluated in humans and dogs. Each agent was studied in three normal volunteers at rest, while [/sup 99m/Tc(POM-POM)3]+ and [/sup 99m/Tc(TBIN)6]+ were each studied in one normal volunteer at exercise. Even though all three agents yield good myocardial images in dogs, none appear suitable for clinical use as myocardial perfusion imaging radiopharmaceuticals. In humans, [/sup 99m/Tc(TMP)6]+ and [/sup 99m/Tc(POM-POM)3]+ clear very slowly from the blood and provide myocardial images only several hours after injection. [/sup 99m/Tc(TBIN)6]+ clears rapidly from the blood, but accumulation in the lung obscures the myocardial image for the first hour after injection; at later times, activity in the liver and spleen masks the apical wall. These results correlate with the blood-binding properties of the three complexes. [/sup 99m/Tc(TMP)6]+ and [/sup 99m/Tc(POM-POM)3]+ bind tightly to the plasma of human blood, but not to the plasma of dog blood; [/sup 99m/Tc(TBIN)6]+ does not bind tightly to the plasma of either dog or human blood. Among the Tc(I) complexes studied to date in humans, [/sup 99m/Tc(TBIN)6]+ appears to be unique in biodistribution pattern, blood-binding properties, and the fact that exercise improves the ultimate myocardial image. All the Tc(I) complexes appear to undergo myocardial accumulation by a mechanism different from that utilized by Tc(III) complexes. Animal studies alone are not adequate to evaluate the potential utility of /sup 99m/Tc cationic complexes for myocardial perfusion studies

  20. Imaging human atherosclerosis with /sup 99m/Tc-labeled low density lipoproteins

    International Nuclear Information System (INIS)

    Lees, A.M.; Lees, R.S.; Schoen, F.J.; Isaacsohn, J.L.; Fischman, A.J.; McKusick, K.A.; Strauss, H.W.

    1988-01-01

    The feasibility of localizing human atherosclerotic plaques by gamma scintillation camera external imaging with technetium-99m-labeled low density lipoproteins (99mTc-LDL) was tested in 17 patients who had atherosclerosis. Imaging demonstrated focal accumulation of radiolabel consistent with 99mTc-LDL sequestration by plaques in the carotid, iliac, or femoral vessels of four patients 8 to 21 hours after intravenous injection of the radiopharmaceutical. Focal accumulation of 99mTc-LDL also appeared in the location of coronary lesions in four patients, but this accumulation could not be distinguished with certainty from residual blood pool radioactivity. When carotid endarterectomy specimens from six patients who received 99mTc-LDL 1 day before endarterectomy were examined, the specimens had focal accumulations of radiolabel, with two to four times greater radioactivity in some regions of each specimen than in others; this occurred whether or not the lesions were detected on the gamma camera images. Lesion composition may have determined whether accumulation was quantitatively sufficient to produce an external image. Histologically, the imaged carotid specimen had abundant foam cells and macrophages and poorly organized intramural blood consistent with a plaque hemorrhage; in contrast, nonimaged endarterectomy specimens were mature, fibrocalcific plaques. We conclude that: 1) 99mTc-LDL did accumulate in human atherosclerotic plaques; 2) in some patients, the accumulation of 99mTc-LDL was sufficient for detection by gamma camera imaging; 3) the amount of LDL that accumulated appeared to depend on lesion composition; and 4) the design of new radiopharmaceuticals with reduced residual blood pool activity relative to plaque accumulation should lead to improved external imaging of atherosclerosis

  1. 3. Congress of the SA Society of nuclear medicine: Technetium-99m technology

    International Nuclear Information System (INIS)

    Beyers, M.

    1988-08-01

    The Atomic Energy Corporation of SA Limited have been engaged in the manufacture of radioisotopes since 1967, shortly after the SAFARI-1 reactor at Pelindaba was commissioned. Since then the use of radioisotopes in South Africa has grown rapidly and at present 95% of the in vivo diagnostic radioisotopes (radiopharmaceuticals) utilized in nuclear medicine are manufactured locally. Because radioisotopes are applied mainly in sophisticated chemically or mechanically processed forms, production requires not only a skilled production team, but also the appropriate facilities for the manufacture of high-quality products which comply with the necessary safety standards. Compliance with such standards is especially important for the routine production of radiopharmaceuticals for use in nuclear medicine. Over the past 20 years technetium-99m has achieved a dominant position among the diagnostic tools in modern nuclear medicine.The scope of nuclear medicine is expanding continuously and its future lies primarily in the development of new organspecific technetium-99m radiodiagnostic agents. Many improvements and changes have been made to Tc-99m generators, the major source of Tc-99m, since they were introduced to nuclear medicine in the late 1950's. The new Peltek-F sterile Tc-99m generator developed by the Isotope Production Centre is a symbol of progress made. In order to commemorate the launching of the new Peltek-F technetium-99m generator during August 1988 it was decided to publish six papers that were presented at the Third Congress of the Society of Nuclear Medicine held at Bloemfontein during the period 15 - 17 August 1988 by members of the Isotope Production Centre. This will serve as a useful reference on various aspects of technetium-99m technology and will stimulate the use of this product as well as new research in this field

  2. Abnormal gastrointestinal accumulation of radiotracer by gastric bleeding during {sup 99m}Tc-MDP bone scintigraphy

    Energy Technology Data Exchange (ETDEWEB)

    Chun, Kyung A.; Lee, Sang Woo; Lee, Jae Tae; Lee, Kyu Bo [College of Medicine, Kyungpook National Univ., Taegu (Korea, Republic of)

    1998-06-01

    We present a case in which a patient with acute hemorrhagic gastritis demonstrated abnormal gastrointestinal accumulation of radiotracer during {sup 99m}Tc-methylene diphosphonate (MDP) skeletal scintigraphy. A hemorrhagic gastritis was subsequently demonstrated by endoscopy. The mechanism for the intestinal localization of {sup 99m}Tc-MDP in this patients is not clear, but we guess that the extravasated blood containing the radiopharmaceutical cannot recirculate and stays at the bleeding site, so we can see the intestinal activity.

  3. Ligand-free, protein-bound technetium-99m iron-dextran enhancement of technetium pyrophosphate uptake in tumours

    International Nuclear Information System (INIS)

    Pojer, P.M.; Jakovljevic, A.C.; Wise, K.N.

    1985-01-01

    The biodistribution of technetium-99m was studied in T-cell lymphoma and selected organs of iron-dextran treated and control mice given technetium-99m pyrophosphate. The results showed that high serum iron levels increased tumour uptake of technetium pyrophosphate. This supports the hypothesis that technetium, in common with other metal-based tumour seeking radiopharmaceuticals, is transported to tumours as a ligand-free protein-bound cation. (U.K.)

  4. Reagent' sets for the concentration of sup(99m)Tc and sup(113m)In

    International Nuclear Information System (INIS)

    Bianco de Salas, G.N.; Arciprete, J.; Mitta, A.E.A.

    1976-10-01

    A simple technique for the concentration of the eluates from 99 Mo/sup(99m)Tc and 113 Sn/sup(113m)In generators is described. The reagents' sets provided by the C.N.E.A. for the labelling of different radiopharmaceuticals can be used by only reducing their volumes proportionally. Both concentration techniques for Tc-99m and In-113m will be supplied to users as reagents' sets. (author) [es

  5. The study of interaction of modified fatty acid with {sup 99m}Tc in alcoholic media

    Energy Technology Data Exchange (ETDEWEB)

    Skuridin, V. S.; Stasyuk, E. S.; Varlamova, N. V.; Nesterov, E. A.; Sadkin, V. L.; Rogov, A. S., E-mail: rogov@tpu.ru; Ilina, E. A.; Larionova, L. A.; Villa, N. E. [Institute of Physics and Technology, Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Sinilkin, I. G.; Zelchan, R. V. [Institute of Physics and Technology, Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Tomsk Cancer Research Institute, Tomsk, 634050 (Russian Federation); Sazonova, S. I. [Institute of Physics and Technology, Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Research Institute of Cardiology, Tomsk, 634012 (Russian Federation)

    2016-08-02

    The paper presents the results of laboratory research aimed at the development of methods of synthesis of new radiodiagnostic agents based on modified fatty acid labelled with technetium-99m intended for scintigraphic evaluation of myocardial metabolism. In particular, the interaction of substance with {sup 99m}Tc in alcoholic media and the use of ethanol as solvent in the synthesis of the radiopharmaceutical were studied.

  6. Hypoxia-induced redox alterations and their correlation with {sup 99m}Tc-MIBI and {sup 99m}Tc-HL-91 uptake in colon cancer cells

    Energy Technology Data Exchange (ETDEWEB)

    Abrantes, Ana Margarida [Biophysics/Biomathematics Institute, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Centre of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal)], E-mail: mabrantes@ibili.uc.pt; Silva Serra, Maria Elisa [Chemistry Department, Faculty of Sciences and Technology, University of Coimbra, 3000-535 Coimbra (Portugal); Goncalves, Ana Cristina [Biochemistry Institute, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Centre of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Rio, Joana; Oliveiros, Barbara; Laranjo, Mafalda [Biophysics/Biomathematics Institute, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Rocha-Gonsalves, Antonio Manuel [Chemistry Department, Faculty of Sciences and Technology, University of Coimbra, 3000-535 Coimbra (Portugal); Centre of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Sarmento-Ribeiro, Ana Bela [Biochemistry Institute, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Centre of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Filomena Botelho, Maria [Biophysics/Biomathematics Institute, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal); Centre of Investigation on Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra (Portugal)

    2010-02-15

    Colorectal cancer is one of the most common malignancies in the Western world and is an example of a solid tumour in which hypoxia is a common feature and develops because of the inability of the vascular system to supply adequate amounts of oxygen to growing tumours. Hypoxia effects on tumour cell biology can be detected and characterized using different methods. The use of imaging with {gamma}-emitting radionuclides to detect hypoxic tissue was first suggested by Chapman in 1979 [N Engl J Med 301 (1979) 1429-1432]. {sup 99m}Tc-4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime, also known as {sup 99m}Tc-HL-91, has been among the most studied hypoxia markers. The objective of this study was to correlate the uptake of {sup 99m}Tc-HL-91 and {sup 99m}Tc-MIBI in colon cancer cells under normoxic and hypoxic conditions and to compare this information with some parameters such as oxidative stress and mitochondrial dysfunction of the cells analyzed by flow cytometry. Our results show that the in vitro {sup 99m}Tc-HL-91 uptake is higher in hypoxic conditions, which is confirmed by the decreased uptake of {sup 99m}Tc-MIBI. Flow cytometry results demonstrate that hypoxic conditions used are not enough to induce cellular death, but are responsible for the alterations in the intracellular redox environment, namely, increase of ROS production, proteic pimonidazol-derived adduct formation and alteration in the mitochondrial membrane permeability. Therefore, these results confirm that {sup 99m}Tc-HL-91 is a radiopharmaceutical with favourable characteristics for detecting hypoxia.

  7. Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells

    International Nuclear Information System (INIS)

    Abrantes, Ana Margarida; Silva Serra, Maria Elisa; Goncalves, Ana Cristina; Rio, Joana; Oliveiros, Barbara; Laranjo, Mafalda; Rocha-Gonsalves, Antonio Manuel; Sarmento-Ribeiro, Ana Bela; Filomena Botelho, Maria

    2010-01-01

    Colorectal cancer is one of the most common malignancies in the Western world and is an example of a solid tumour in which hypoxia is a common feature and develops because of the inability of the vascular system to supply adequate amounts of oxygen to growing tumours. Hypoxia effects on tumour cell biology can be detected and characterized using different methods. The use of imaging with γ-emitting radionuclides to detect hypoxic tissue was first suggested by Chapman in 1979 [N Engl J Med 301 (1979) 1429-1432]. 99m Tc-4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime, also known as 99m Tc-HL-91, has been among the most studied hypoxia markers. The objective of this study was to correlate the uptake of 99m Tc-HL-91 and 99m Tc-MIBI in colon cancer cells under normoxic and hypoxic conditions and to compare this information with some parameters such as oxidative stress and mitochondrial dysfunction of the cells analyzed by flow cytometry. Our results show that the in vitro 99m Tc-HL-91 uptake is higher in hypoxic conditions, which is confirmed by the decreased uptake of 99m Tc-MIBI. Flow cytometry results demonstrate that hypoxic conditions used are not enough to induce cellular death, but are responsible for the alterations in the intracellular redox environment, namely, increase of ROS production, proteic pimonidazol-derived adduct formation and alteration in the mitochondrial membrane permeability. Therefore, these results confirm that 99m Tc-HL-91 is a radiopharmaceutical with favourable characteristics for detecting hypoxia.

  8. Asialoglycoprotein-receptor-targeted hepatocyte imaging using {sup 99m}Tc galactosylated chitosan

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Eun-Mi [Department of Nuclear Medicine, Research Institute of Clinical Medicine, Chonbuk National University School of Medicine, Jeonju, Jeonbuk (Korea, Republic of); Jeong, Hwan-Jeong [Department of Nuclear Medicine, Research Institute of Clinical Medicine, Chonbuk National University School of Medicine, Jeonju, Jeonbuk (Korea, Republic of)]. E-mail: jayjeong@chonbuk.ac.kr; Kim, Se-Lim [Department of Nuclear Medicine, Research Institute of Clinical Medicine, Chonbuk National University School of Medicine, Jeonju, Jeonbuk (Korea, Republic of); Sohn, Myung-Hee [Department of Nuclear Medicine, Research Institute of Clinical Medicine, Chonbuk National University School of Medicine, Jeonju, Jeonbuk (Korea, Republic of); Nah, Jae-Woon [Division of Applied Materials Engineering, Department of Polymer Science and Engineering, Sunchon National University, Sunchon, Jeonnam (Korea, Republic of); Bom, Hee-Seung [Department of Nuclear Medicine, Chonnam National University School of Medicine, Gwangju (Korea, Republic of); Park, In-Kyu [School of Agricultural Biotechnology, Seoul National University, Seoul (Korea, Republic of); Cho, Chong-Su [School of Agricultural Biotechnology, Seoul National University, Seoul (Korea, Republic of)

    2006-05-15

    This study investigated the usefulness of {sup 99m}Tc hydrazinonicotinamide-galactosylated chitosan (HGC) in hepatocyte imaging. HGC was obtained by coupling the galactose moiety of both lactobionic acid and succinimidyl 6-hydrazinonicotinate hydrochloride (succinimidyl HYNIC). The coupled product was then radiolabeled with {sup 99m}Tc using stannous chloride and tricine as reducing agent and coligand, respectively. Labeling efficiency was >90% both in room temperature and in serum up to 24 h after injection. The hepatic uptake properties of {sup 99m}Tc HGC were studied in Balb/C mice. {sup 99m}Tc HGC and {sup 99m}Tc hydrazinonicotinamide chitosan (HC) were intravenously injected into mice, with receptor binding identified by coinjection with 9 and 14 mg of free galactose. Images were acquired with a {gamma}-camera. After injection via the tail vein of the mice, {sup 99m}Tc HGC showed high selectivity for the liver, while {sup 99m}Tc HC without a galactose group showed low liver uptake. In addition, the hepatic uptake of {sup 99m}Tc HGC was blocked by coinjection of free galactose. Tissue distribution was determined at three different times (10, 60 and 120 min). The liver accumulated 13.16{+-}2.72%, 16.11{+-}5.70% and 16.55{+-}2.28% of the injected dose per gram at 10, 60 and 120 min after injection, respectively. {sup 99m}Tc HGC showed specific and rapid targeting of hepatocytes. It is a promising receptor-specific radiopharmaceutical with potential applications in liver imaging for the evaluation of hepatocytic function.

  9. In vitro incorporation studies of 99mTc-alendronate sodium at different bone cell lines

    International Nuclear Information System (INIS)

    Evren Gundogdu; Derya Ilem-Ozdemir; Makbule Asikoglu

    2014-01-01

    Bisphosphonates can be labeled with Technetium-99m ( 99m Tc) and are used for bone imaging because of their good localization in the skeleton and rapid clearance from soft tissues. Over the last decades bone scintigraphy has been used extensively in the evaluation of oncological patients to provide information about the sites of bone lesions, their prognosis and the effectiveness of therapy by showing the sequential changes in tracer uptake. Since the lesion visualization and lesion/bone ratio are important utilities for a bone scanning radiopharmaceutic; in this study incorporation of 99m Tc labeled alendronate sodium ( 99m Tc-ALD) was evaluated in U 2 OS (human bone osteosarcoma) and NCI-H209 (human bone carcinoma) cell lines. ALD was directly labeled by 99m Tc, radiochemical purity and stability of the complex were analyzed by radioactive thin layer chromatography and radioactive high performance liquid chromatography studies. For cell incorporation study, NCI-H209 and U 2 OS cell lines were used with standard cell culture methods. The six well plates were used for all experiments and the integrity of each cell monolayer was checked by measuring its transepithelial electrical resistance (TEER) with an epithelial voltammeter. Results confirmed that ALD was successfully radiolabeled with 99m Tc. 99m Tc-ALD incorporated with NCI-H209 and U 2 OS cells. The uptake percentages of 99m Tc-ALD in NCI-H209 and U 2 OS cell lines were found significantly different. Since 99m Tc-ALD highly uptake in cancer cell line, the results demonstrated that radiolabeled ALD may be a promising agent for bone cancer diagnosis. (author)

  10. Comparison of Tc-99m-tetrofosmin and Tc-99m-MIBI scintimammography in differential diagnosis of breast mass

    International Nuclear Information System (INIS)

    Park, Jung Mi; Choi, Joon Young; Lee, Kyung Han; Choi, Yong; Choe, Yearn Seong; Kim, Sang Eun; Kim, Byung Tae; Nam, Seok Jin; Yang, Jeong Hyun

    2000-01-01

    Tc-99m-MIBI (MIBI) and Tc-99m-Tetrofosmin (TF) are commonly used for scintimammog (SMM). We compared the diagnostic ability of SMM using Tc-99m-MIBI and Tc-99m-TF for the differ diagnosis of breast mass. The study subjects were comprised of 123 breast lesior 86 normal breasts of 114 patients who underwent SMM. Bilateral prone images and anterior supine images obtained at 5 minutes and 1 or 3 hours after intravenous injection of 740 MBq of either MIBI or TF. of tumors were not significantly different between the MIBI and TF groups. First, two observers independ read the SMM without clinical information (1st interpretation), then read again with information about location (2nd interpretation). Sensitivity and specificity of each radiopharmaceutical for the diagnosis of cancer were evaluated in terms of image acquisition time, tumor size, and location. The SMM sb a good agreement between two observers for 1st and 2nd interpretation, except for TF SMM at hr. For first interpretation, the sensitivities at 5 min, 1 hr, and 3 hr were not significantly different between MIE TF SMM (81.6%, 80.0%, 60.9% in MIBI vs. 88.9%, 80.6%, 42.9% in TF), although the sensitivities of images were significantly lower than 5 min images in both MIBI and TF SMM. The specificity of TF at was superior to that of MIBI (81.5%, 90.0%, 82.9% in MIBI vs. 96.7%, 100%, 90.0% in TF, p<0.01 MB TF at 5 min). For the second interpretation with information of mass location, the sensitivities at 3 hr in were significantly lower than 5 min images (86.8%, 86.7%, 78.3% in MIBI vs. 88.9%, 93.5%, 57.1% in between MIBI and TF SMM. However, there was no significant difference in the specificity (60.0%, 5 75.0% for MIBI vs. 86.7%, 100%, 100% for TF). MIBI and TF SMM showed lower sensitivities for the t with less than 1 cm than tumors with more than 1 cm. However, the location of tumors did not influence sensitivity and specificity between MIBI and TF SMM. The ability for the differential diag of breast tumor is

  11. New series of Tc-99m-labeled hepatobiliary tracers: N'-acyl- and N'-sulfonyl ethylenediamine-N,N-diacetic acids

    International Nuclear Information System (INIS)

    Karube, Y.; Kono, A.; Maeda, T.; Ohya, M.; Matsushima, Y.

    1981-01-01

    Various Tc-99m-labeled N'-substituted derivatives of ethylenediamine-N,N-diacetic acid (EDDA) are evaluated as hepatobiliary imaging agents. N'-substituted aromatic acyl and aromatic sulfonyl derivatives of EDDA, labeled with Tc-99m, were administered to rabbits and golden hamsters, and the distribution indicated clearance by the hepatobiliary system. N'-aromatic sulfonyl EDDAs were labeled with Tc-99m by the SnCl 2 method with more than 99% yield. Clearance of Tc-99m-p-toluenesulfonyl EDDA from the blood and the liver was as rapid as that of Tc-99m N-(2,6-diethylphenylcarbamoylmethyl)iminodiacetic acid (Tc-99m diethyl IDA). Substitution of a bulky group at the aromatic ring in Tc-99m benzene-sulfonyl EDDA lowered urinary excretion. It is concluded that the sulfonyl EDDAs provide a fruitful source for Tc-99m-labeled hepatobiliary radiopharmaceuticals

  12. Can tumor uptake Tc-99m MDP ?

    International Nuclear Information System (INIS)

    Yand Shun, Fang; Yao, Ming; Zeng, Jun; Shi Zhen, Yu; Zhao Lan, Xiang; Dong Qiang, Gang

    2003-01-01

    To explore the mechanism of technetium-99m-methylene diphosphonate (MDP) uptake within tumor through analyze a distribution of Tc-99m MDP in mice bearing tumor cell lines. Methods: The uptake of Tc-99m MDP was analyzed in seven human tumor cell lines ( SPC-A1 adenocarcinoma of lung cancer, Bcap-37 Breast cancer, T-24 Bladder cancer, SKOV3 Ovary carcinoma, Hela-229 Cervical carcinoma, SCI-OS Osteosarcoma, SCI-375 Melanoma) and mouse Lewis lung cancer cell line. They were transplanted into athymic mice, SCID nude mice and C57BL/6 mice, respectively. Approximately 10(6) cells of each cell line were injected subcutaneously into a right chest of mouse. After 4 and 5 weeks, the Tc-99m MDP scintigraphy were determined 6 hours after tail vein injection of 74MBq in 0.05ml every mouse. Result: Biodistribution and tumor uptake MDP was different in the various cell types investigated. According to the Region Ratio program of Siemens Power Macintosh 9500 Computer System, region of interests (RIOs) placed on a small part of the tumor and horizontal copied to left background (T/B) and thoracic spine (T/N) of mice in Tc-99m MDP imaging. The average cpm/pixel ratios were calculated by standardized uptake measure (SUM) and determined the tumor-positive value (T/B) greater than or equal to 1.2. T/B of cell lines were sorted from higher to lower as follows: SCI-OS, Lewis, SKOV3, SCI-375, T-24, SPC-A1, Bcap-37, Hela-229. T/N: SCI-OS, SKOV3, T-24, SCI-375, Lewis, SPC-A1, Bcap-37, Hela-229. The biodistribution data of 99Tcm-MDP in SPC-A1 tumor-bearing BALB/c nude mice were given as ID/g and represent the means D (n=13) in 30 hours after injection of Tc-99m MDP. ID/g of major tissue were sorted from higher to lower as follows: thoracic spine, lumbar, ribs, kidneys, the center of tumor, the ulcer of tumor, the surrounding of tumor, lymph node, blood, lungs, heart, liver. Conclusions: Most of tumor can uptake Tc-99m MDP including human adenocarcinoma. The uptake rate in the center tissue of

  13. PNRI Pioneering the Establishment and Operation of the Tc-99m Generator Production Facility for Nuclear Medicine Applications

    International Nuclear Information System (INIS)

    Bulos, Adelina DM.; Borras, Ma. Teresa L.; Ciocson, Gregory R.; Mascariñas, Rommel D.C.; Nuñez, Ivy Angelica A.; Dela Rosa, Alumanda M.

    2015-01-01

    In response to the increasing demand in the nuclear medicine sector in the Philippines, the Philippine Nuclear Research Institute (PNRI) initiated the establishment of a radioisotope production facility. To date, the most commonly used radioisotope in nuclear medicine, Technetium-99m or Tc-99m has been successfully produced in the new laboratory, the PNRI facility has already obtained a license to operate from the Philippine FDA. The new facility is envisioned to meet the country’s requirements for all the major medical radioisotope starting with the local production of Tc-99m and the most commonly used Tc-99m radiopharmaceuticals. At present, all radioisotope supplies in the country are sourced overseas at price that varies accordingly. With the establishment of the PNRI’s laboratories, we now have a GMP-grade Tc-99m generator facility capable of producing 50 Tc-99m generators per batch. Instead of Tc-99m being imported, it will be the parent Mo-99m that will be transferred to PNRI facility from Mo-99 processing facilities overseas, contained in specialized transport containers and via airfreight arrangements so it can be processed locally to make Tc-99m generators. But, to make radiopharmaceuticals, the other non-radioactive components are needed to be sourced from abroad. Thus, it has become imperative to also locally produce these non-radioactive components. All of these components, radioactive and non-radioactive, from the radiopharmaceutical finished products which are utilized in nuclear medicine caters for the diagnosis and detection of critical and non-critical human illnesses. The completion of this program is foreseen as another concrete validation on the capacity of the Philippine as a country that is at par with advanced nations on competency and expertise in the research and development of nuclear medicine application for better healthcare delivery and management. (author)

  14. A method for the preparation of lipophilic macrocyclic technetium-99m complexes

    International Nuclear Information System (INIS)

    Troutner, D.E.; Volkert, W.A.

    1991-01-01

    A procedure for the preparation of technetium complexes applicable as diagnostic radiopharmaceuticals is suggested and documented with 27 examples. Technetium-99m is reacted with a suitable complexant selected from the class of alkylenamine oximes containing 2 or 3 carbon atoms in the alkylene group. The lipophilic macrocyclic complexes possess an amine, amide, carboxy, carboxy ester, hydroxy or alkoxy group or a suitable electron acceptor group. (M.D.). 7 tabs

  15. Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin

    International Nuclear Information System (INIS)

    Ferro-Flores, G.; Rivero, I.A.; Santos-Cuevas, C.L.; Sarmiento, J.I.; Arteaga de Murphy, C.; Ocampo-Garcia, B.E.; Garcia-Becerra, R.; Ordaz-Rosado, D.

    2010-01-01

    99m Tc-HYNIC labeled Lys 3 -bombesin has shown specific binding to gastrin-releasing peptide receptors (GRP-r) over-expressed in cancer cells. Click chemistry offers an innovative functionalization strategy for biomolecules such as bombesin. The aim of this research was to apply a click chemistry approach for [ 99m Tc(CO) 3 ] labeling of Lys 3 -bombesin and to compare the in vitro MCF7 breast cancer cell uptake and biodistribution profile in mice with that of 99m Tc-EDDA/HYNIC-Lys 3 -bombesin. The results suggest a higher lipophilicity for 99m Tc(CO) 3 -triazole-Lys 3 -bombesin which explains its higher in vivo hepatobiliary elimination. Pancreas-to-blood ratio for 99m Tc(CO) 3 -triazole-Lys 3 -bombesin was 4.46 at 3 h and both bombesin radiopharmaceuticals showed specific recognition for GRP receptors in MCF7 cancer cells. Click chemistry is a reliable approach for [ 99m Tc(CO) 3 ] labeling of Lys 3 -bombesin.

  16. Preparation of the 99mTc-dextran lymphoscin tigraphic agent and its preliminary clinical application

    International Nuclear Information System (INIS)

    Lu Weiyue; You Dejian; Ma Yuanming; He Guangren; Zhang Wei; Tu Zhipei; Jin Bixia

    1991-01-01

    Dextran-70 was treated by gradient sedimentation, and that with a mean molecular weight of 105000 which was optimal for lymphatic system imaging rabbits was selected. Sn-Dextran kit was produced containing the above-mentioned dextran. Sn-Dextran kits can be stored at 4 deg C for 8 months. Its efficiency of labelling is more than 95%. The biodistribution, pharmacokinetics studies and lymphoscintigraphy in rabbits for 99m Tc-dextran showed: (1) high radioactivity in the popliteal nodes and very low redioactivity in other nontarget organs except kidneys through which it was excreted; (2) 99m Tc-dextran accumulated markedly and rapidly in lymphatic system. The lymph channels and nodes were well visualized in scintigrams; (3) 99m Tc-dextran cleared rapidly from the injection site. Radioactivity of 95% of the injected dose disappearing after 6.5h. Toxicity tests indicated that: 99m Tc-dextran is a drug of low toxicity and safe. Preliminary clinical applications of 99m Tc-dextran in 100 cases provided satisfactory results. The process of imaging usually took less than 1h after injection, and no side-effects occurred in any patient. In most cases, the results corresponded basically with the clinical diagnosis. Hence, 99m Tc-dextran is an ideal radiopharmaceutical that can be used for the visualization of the lymphatic system. It is recomminded for routine use in clincal practice

  17. Evaluation of the liver scintigraphy with sup(99m)Tc-Sn-colloid, 2

    International Nuclear Information System (INIS)

    Kimura, Kazufumi; Nishimura, Tsunehiko; Takeda, Hiroshi; Furukawa, Toshiyuki; Kajiya, Fumihiko.

    1975-01-01

    Clinical significance of the liver scintigraphy with sup(99m)Tc-Sn-colloid was evaluated in comparison with those with 198 Au-colloid. The liver scintigrams with sup(99m)Tc-Sn-colloid and 198 Au-colloid were done in 36 cases of various hepatic diseases and RI accumulation curves in the liver and the spleen, and the blood disapearance curves were also obtained. The conclusions were as follows. The liver scintigrams with sup(99m)Tc-Sn-colloid proved to be more sensitive in the detection of tumors, especially, in the lower margin, left lobe and superficial layers of the liver than those with 198 Au-colloid. In all cases, including normal and cirrhotic subjects, visualizations of the spleen were seen on the scintigrams with sup(99m)Tc-Sn-colloid. In diffuse hepatic diseases, comparing both radiopharmaceuticals, the splenic accumulations were studied qualitatively and quantitatively. As a result, the ratio (spleen/liver) was thought to be useful for the differentiation of diffuse hepatic diseases concerned with splenic function and/or size. It was also shown that sup(99m)Tc-Sn-colloid was useful as a spleen scanning agent. The Tl/2 in the liver accumulation curves with sup(99m)Tc-Sn-colloid were not as clearly differentiated in the various hepatic diseases as those with 198 Au-colloid where those indexes were useful in the evaluation of liver functions. (auth.)

  18. The transport, hepatobiliary distribution and clearance of sup(99m)Tc-Sn-lidocaine iminodiacetic acid, sup(99m)Tc-Sn-Lida

    International Nuclear Information System (INIS)

    Noronha, O.P.D.; Sewatkar, A.B.; Ganatra, R.D.; Subramanian, G.

    1977-01-01

    Details are given of the preparation of stable sterile solutions of the radiopharmaceutical sup(99m)Tc-Sn-LIDA for use as a hepatobiliary scanning agent. Toxicity and survival studies in mice showed no untoward response even at a concentration of up to 210 mg/kg mouse, and the usual human dose is very much less than this. Tissue distribution studies in rats and mice showed a rapid decrease in liver activity with concomitant increase in gut activity. Scintiscans of a rabbit injected (i.v.) with 2.0 mCi of sup(99m)Tc-Sn-LIDA also showed extremely rapid excretion of the radiopharmaceutical. Sequential gamma camera images obtained 2 to 60 min after administration to overnight fasting normal human subjects revealed rapid liver uptake and gall bladder localization in about 20 min, followed by a gradual decrease in liver activity and increase in the activity in the intestinal tract. After about 40 min the liver has been washed-out of activity, leaving the gall bladder visible. sup(99m)Tc-Sn-LIDA is therefore an excellent hepatobiliary scanning agent. (U.K.)

  19. Technetium99m shortage: Practical solutions to manage lack of the radio-isotope in nuclear medicine departments

    International Nuclear Information System (INIS)

    Biechlin-Chassel, M.L.; Francois-Joubert, A.; Bolot, C.; Desruet, M.D.; Bourrel, F.; Pelegrin, M.; Couret, I.; Lao, S.; Quelven, I.

    2010-01-01

    Technetium 99m ( 99m Tc) shortage crisis regularly affect nuclear medicine activity and oblige the community to find solutions in order to perform most of the prescribed exams and avoid systematic substitutions by other non-nuclear medicine techniques. Firstly, some practical solutions can be set up in radiopharmacy departments such as using more than two generators together, realizing fractionated elutions, preparing radiopharmaceuticals with elutions providing from different generators.. Then, it could be interesting to have a reflexion in nuclear medicine departments to convene patients the days when 99m Tc supply is sufficient, to pool some exams or to make substitutions with more available isotopes. (authors)

  20. Comparative evaluation of different nanostructured metal oxides for preparation of clinically useful 99Mo/99mTc generators

    International Nuclear Information System (INIS)

    Ram, Ramu; Chakravarty, Rubel; Dash, Ashutosh

    2015-01-01

    The potential of nanostructured metal oxides such as nanotitania, nanozirconia, nanoalumina and mesoporous alumina, as new generation sorbent materials for preparation of 99 Mo/ 99m Tc generator has recently been demonstrated. A comparative assessment of such materials is essential for determination of their suitability for preparation of clinically useful generators using (n,γ) 99 Mo. Characteristics which were compared included the sorption capacity, shelf-life of the generator, radioactive concentration and purity of 99m Tc for radiopharmaceutical applications. Mesoporous alumina was identified as the most suitable sorbent for ensuring sustainable production of clinical grade 99 Mo/ 99m Tc generators using low specific activity 99 Mo. (author)

  1. Chemistry and biology of Tc-99m renal function agents. Final report

    International Nuclear Information System (INIS)

    Fritzberg, A.M.

    1986-01-01

    A major aim of the project was to develop a Tc-99m renal tubular function radiopharmaceutical. Progress was made in synthesizing and evaluating Tc-99m 2,3-dimercaptoaceta-midoprepanoate (CO 2 DADS). In animals and clinical studies the A epimer (early component on reversed phase HPLC) demonstrated high efficiency and specificity for renal tubular secretion. We were unable to obtain only the desired stereoisomer. Synthesis of about twenty diamide dimercaptide N 2 S 2 ligand analogs suggested two others that were of comparable efficiency in humans, but with less difference between stereoisomers; Tc-99m 1,3-dimercaptoacetamide-2-hydroxypropane (HoDADS) and 1,8-dithiol- 2,7-dioxo-3,6-diazanonanoate (α -S-CO 2 DADS). 15 refs

  2. 99mTc-methoxy-isobutyl-isonitrile (sestamibi) imaging of malignant canine lymphoma

    International Nuclear Information System (INIS)

    Steyn, P.F.; Ogilvie, G.

    1995-01-01

    Technetium-99m methoxy-isobutyl-isonitrile (sestamibi) imaging of malignant canine lymphoma was performed in thirteen dogs 1 hour after intravenous injection of 99mTc-sestamibi at 13 MBq (0.35 mCi) per kilogram body weight. Abnormal tracer uptake was visualized in the liver, spleen, bone marrow, and mesenteric, inguinal, popliteal, sternal, cranial cervical and mandibular lymph nodes. Radiopharmaceutical uptake was also noted in a nasal mass. One large neoplastic renal mass did not have demonstrable sestamibi uptake. Other regions had no significant difference in the target:background ratios when compared with values from normal dogs (P > 0.05). 99mTc-sestamibi can be used to image malignant lymphoma, and has potential applications in the management of patients to document response to treatment and to stage of extent of disease

  3. Gamma-ray impurities of {sup 111}In, {sup 201}Tl, {sup 177}Lu and {sup 99m}Tc determined by means of a HPGE spectrometer

    Energy Technology Data Exchange (ETDEWEB)

    Koskinas, Marina F.; Almeida, Jamille da Silveira; Moreira, Denise Simões; Semmler, Renato; Dias, Mauro da Silva, E-mail: koskinas@ipen.br, E-mail: jamillealmeida@gmail.com, E-mail: denise.moreira@ipen.br, E-mail: rsemmler@ipen.br, E-mail: msdias@ipen.br [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2017-11-01

    This work aims to present the radioactive impurities gamma rays emitters detected in some radiopharmaceuticals widely applied to diagnosis and therapy purposes, supplied to nuclear medicine services in Brazil by the Radiopharmaceutical Center(CR) of Nuclear and Energy Research Institute, IPEN, in São Paulo. The analysis was undertaken by means of an HPGe gamma spectrometer. The radiopharmaceuticals analyzed were: {sup 111}In, {sup 201}Tl, {sup 177}Lu and {sup 99m}Tc. (author)

  4. Advances in technetium chemistry towards 99mTc receptor imaging agents

    International Nuclear Information System (INIS)

    Johannsen, B.; Spies, H.

    1997-01-01

    The development of the chemistry of technetium and its non-radioactive surrogate rhenium has been prompted by the trends and needs of nuclear medicine, which predominantly uses 99m Tc radiopharmaceuticals for a broad range of diagnostics. Technetium-99m is the ideal radioisotope for tomographic single-photon emission tomography (SPECT) imaging due to its nuclear properties (6.2 h, E γ 140 keV) and ready availability through generator systems. Transition metals offer many opportunities for designing molecules by modifying the environment around the core, allowing certain biological properties to be imposed upon the molecule. Whereas research in the past was mainly concerned with biological properties that allow relatively unspecific functional imaging, as in brain or myocardium perfusion studies, nuclear medicine is now requiring more and more biochemical information on low capacity, high specificity targets. Many research groups have become involved in the search for new technetium-based compounds, called the third generation of 99m Tc radiopharmaceuticals, that employ the principles of modern pharmacology to achieve biochemical specificity. There has been considerable interest in imaging CNS and other receptors with 99m Tc receptor-binding ligands. Such a 99m Tc CNS receptor-imaging agent is currently not yet in use because of the significant hurdles to be overcome in attaining this ambitious goal. However, some Tc and Re complexes of remarkable affinity in vitro, and the first high-affinity 99m Tc probes able to label the dopamine transporter in the brain by SPECT imaging prove the feasibility of this approach. (Author)

  5. Evaluation of usefulness of Tc-99m-GSA liver scintigraphy in chronic liver diseases

    International Nuclear Information System (INIS)

    Fukui, Hiroyuki; Kashiwagi, Toru; Kasahara, Akinori

    1991-01-01

    Liver scintigraphy was performed using a newly developed radiopharmaceutical, Tc-99m-DTPA-galactosyl-human-serum-albumin (Tc-99m-GSA), which binds specifically to the receptors on the hepatic cell surface, in 15 patients with chronic liver disease. The scintigraphy was evaluated qualitatively and quantitatively, and the results were compared with those obtained from the Tc-99m-PMT or Tc-99m-sn-phytate scintigraphy, and the liver function tests. The Tc-99m-GSA scintigraphy showed clear liver images in chronic hepatitis. However, in liver cirrhosis, the liver images were not clear and the cardiac images still existed 40 minutes after administration of Tc-99m-GSA, suggesting that the image quality of the Tc-99m-GSA scintigrams may be inferior to that of Tc-99m-sn-phytate or Tc-99m-PMT in some cases of severe liver dysfunction. The time-activity curves of the heart and liver were analyzed by non-linear regression analysis. The clearance rate from plasma (Kd) were obtained from the time-activity curve of the heart, and the hepatic uptake rate (Ku), hepatic excretion rate (Ke) and peak time of hepatic uptake-excretion curve (PT) were obtained from the time-activity curve of the liver. Kd, Ku, and PT values were more significantly decreased or prolonged in the patients with chronic hepatitis. Kd, Ku, and PT values had positive correlations with the result of the serum liver function tests, ICG-R15 and ICG-K. Ku and PT values had also correlations with the histological degree of hepatic fibrosis. On the other hand, the indices obtained using Tc-99m-PMT or Tc-99m-sn-phytate did not have correlations with the histological degrees of hepatic fibrosis. It is concluded that the liver scintigraphy using Tc-99m-GSA may be useful and give different information from those with conventional liver scintigraphies in evaluating chronic liver diseases. (author)

  6. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).

    Science.gov (United States)

    Sun, Hua; Jiang, Xu-Feng; Wang, Shu; Chen, Hao-Yan; Sun, Jiao; Li, Pei-Yong; Ning, Guang; Zhao, Yong-Ju

    2007-06-01

    A promising radiopharmaceutical (99m)Tc-HYNIC-TOC ((99m)Tc-HYNIC-Octreotide) can be applied for somatostatin receptor scintigraphy with the potential to replace Indium-111 labeled somatostatin analogus. Here we evaluate whether orbital (99m)Tc-HYNIC-TOC scintigraphy can be used as a Graves' ophthalmopathy (GO) activity parameter to predict the retrobulbar irradiation response. Orbital (99m)Tc-HYNIC-TOC scintigraphy was performed on 14 consecutive patients demonstrating moderated to severe Graves' ophthalmopathy. The patients were treated with retrobulbar irradiation following the octreoscan and the response to this therapy was assessed at 3 months after the start of treatment. The orbital (99m)Tc-HYNIC-TOC uptake was calculated to assess the effects of treatment. Among the 14 GO patients, eight (57.1%) responded to retrobulbar radiotherapy; six (42.9%) showed no change. We compared the eight responders and six non-responders in terms of orbital (99m)Tc-HYNIC-TOC uptake, using the orbital/occipital ratio. On the 4-h (99m)Tc-HYNIC-TOC scintigraphy, responders had a higher orbital/occipital uptake ratio than the no-responders (P = 0.001). A significant correlation was found between the orbital/occipital ratio and the clinical activity score (CAS) (P = 0.034). The Receiving-Operator-Characteristic curve showed the best threshold for discriminating active and inactive disease was 1.40 (sensitivity, 100%; specificity, 83.3%). In the responders group, all these eight patients had positive scintigraphy. While there were five patients who had negative scintigraphy in the non-responders group. Orbital (99m)Tc-HYNIC-TOC scintigraphy can be a useful method for the estimation of disease activity and prediction the response to subsequent radiotherapy in GO patient. And the patients with positive octreoscan were more likely to respond to irradiation.

  7. Sup(99m)Tc-thioglucose

    International Nuclear Information System (INIS)

    Deckart, H.; Weiland, J.; Blottner, A.; Weiss, M.L.

    1978-01-01

    A procedure for labelling thioglucose with sup(99m)Tc with an efficiency of more than 95% yielding a compound with good in vitro and in vivo stability is presented. Pharmakokinetic studies in rats show slow blood-clearance and significant binding to plasma proteins and erythrocytes. Uptake in the kidneys was high and persistent. The whole body retention curve showed components with effective half-lives of 5 h (44,7%), 1,24 h (19,3%) and 7 min (36%). Autoradiography of kidney tissue reveal concentration of the compound in the epithelial cells of the tubulus of the cortex. No excretion via the liver was observed. The new compound was compared with other kidney scanning agents. Normal controls show in agreement with the animal experiments slow blood clearance and high as well as strong binding to plasma proteins. Whole-body retention combined with organ uptake studies show fast and persistent uptake in the kidneys so that the compound can be used for kidney imaging up to 24 h after application. Cumulative renal excretion is 18% of the dose during the first six hours. Finally, comparative studies of the differences in kidney imaging in normal patients and in patients with diseased kidneys using the new compound as well as conventional scanning agents ( 197 Hg neohydrine) and other sup(99m)Tc labelled compounds are presented. (author)

  8. Comparison of technetium-99m sulfur colloid and technetium-99m albumin colloid labeled solid meals for gastric emptying studies.

    Science.gov (United States)

    Taillefer, R; Douesnard, J M; Beauchamp, G; Guimond, J

    1987-08-01

    A Tc-99m albumin colloid (Tc-AC) kit has been introduced as an alternative to Tc-99m sulfur colloid (Tc-SC) for liver-spleen imaging. Since there is no need for boiling, the use of Tc-AC reduces preparation time and manipulation. Tc-SC is one of the most commonly used radiopharmaceuticals for the labeling of solid-phase markers in gastric emptying studies. In vitro studies were performed to evaluate the labeling efficiency and stability in hydrochloric acid and in human gastric juice of intracellularly labeled chicken liver and scrambled eggs labeled with Tc-SC and Tc-AC. Gastric emptying studies also were performed on 20 healthy volunteers with both Tc-SC and Tc-AC labeled scrambled egg sandwiches. There was no significant difference between Tc-SC and Tc-AC in the labeling efficiency of chicken liver (98% +/- 1% for Tc-SC, 96% +/- 2% for Tc-AC) and scrambled eggs (92% +/- 2% for Tc-SC, 91% +/- 3% for Tc-AC). However, both Tc-SC and Tc-AC labeled scrambled eggs showed a lower stability than chicken liver, particularly in human gastric juice. Gastric emptying curves from both meals in 20 normal subjects were also similar, with a mean half-emptying time of 85 +/- 13 minutes and 87 +/- 16 minutes for the meals containing Tc-SC and Tc-AC respectively. Tc-AC is a reliable alternative to Tc-SC as a radiotracer for solid-phase gastric emptying studies.

  9. Csintigraphic imaging of experimental cardiomyopathy in dogs using /sup 99m/Tc-hexylidene aminodiphosphonate (/sup 99m/Tc-AHDP)

    Energy Technology Data Exchange (ETDEWEB)

    Duska, F; Vizda, J; Kafka, P; Kubicek, J; Mazurova, Y; Palicka, V; Grossmann, V

    1987-11-01

    Scintiscanning of the myocardium using /sup 99m/Tc-AHDP (hexylidene aminodiphosphonate) was performed in 12 dogs with experimental cardiomyopathy, induced by a large intravenous dose of theophylline and adrenaline. A marked positivity of the scan was determined in animals with 4 and 24 hours-old lesions. The scans proved to be negative after 7 days. The scintigraphic examinations yielded results which were in agreement with the plasma level of creatine kinase, a comparison with histological examination revealed that the maximum accumulation of the radiopharmaceutical occurred at the time the myocardium damage reached the stage of myocytolysis. /sup 99m/Tc-AHDP is therefore suitable for the detection of mild myocardium damage at its early stages. (author). 1 fig., 1 tab., 20 refs.

  10. Radiation dose to bladder wall following the administration of sup(99m)Tc-microspheres and sup(99m)Tc-DTPA

    International Nuclear Information System (INIS)

    Smith, T.

    1981-01-01

    Castronovo et al. (Health Phys. Vol. 39, p 112, 1980) reported a method of calculating the dose to the bladder wall following administration of sup(99m)Tc human albumin microspheres (sup(99m)Tc-HAM) for lung perfusion scanning. The present note comments that (1) the dosimetry is estimated for an unusual bladder voiding schedule and no indication is given of the variation of dose to be expected with different schedules, and (2) that the method assumes linear biological excretion of the radiopharmaceutical into the bladder in any particular filling period. It is shown that whilst this is a valid approximation in the case considered, it is not a generally applicable principle. Values of bladder wall dose commitments following intravenous administration of sup(99m)Tc-HAM or sup(99m)Tc DTPA are tabulated. Values for constant voiding cycles are presented for four different bladder voiding periods between 2 and 8 hr, and for three different methods of calculation:-a method described in this paper, the linear excretion method of Castronovo et al., and the method of Snyder et al. (ORNL-4584, pp. 206-208, 1970) which allows for urine flow rate. (U.K.)

  11. Union of 99m Tc-HYNIC-TOC at the somatostatin receptors in cells of pancreas cancer

    International Nuclear Information System (INIS)

    Rodriguez C, J.; Ramirez I, M.T.; Ferro F, G.; Pedraza L, M.

    2005-01-01

    The radiation toxic effects have been used in therapy however much 50 years. The absorbed radiation dose can be determined at cellular level using cancerous cell cultures. If the deposited In vitro radiation dose coming from similar activities of several therapeutic radiopharmaceuticals it can compare it will be possible to choose the therapeutic radiopharmaceutical that it offers better dosimetric characteristics for the patient. The objective of this original investigation was to determine the union percentage of the octreotide 99m Tc-HYNlC-TOC to the somatostatin receivers in cells of cancer pancreas as well as the internalization, externalization and cellular viability. It was used the octapeptide, (octreotide, TOC) labelled with 99m Tc by means of the HYNIC chelating agent (6-hydrazine pyridine-3-carboxylic acid) and 3 cellular lines of murine pancreas cancer (AR42J), of cancer of human pancreas (CAPAN) and of one negative cellular line for somatostatin receivers (WRL-68). The 99m Tc-HYNIC-TOC was compared against two negative proofs for somatostatin receivers: the peptide 99m Tc-UBI and the 99m TcO 4 . The cellular lines were conserved in the synthetic media Dulbecco-Eagle. After 2, 4 and 24 h of exhibition to the radiation, the cells are picked up and its are determined the viability by count in a Neubauer camera using tripan blue. In the same times it was calculated the union percentage of the radiopharmaceutical to the cells and the internalization (union to the cytoplasm) and the externalization (union to membrane receivers). With those figures it was calculated the absorbed radiation dose at cellular level. Results: At 4 hours the union percentage of the 99m Tc-HYNlC-TOC to the AR42-J cells was 6.83 times greater than for the WRL-68 control cells of human papilloma, (without receivers of the somatostatin) and for the CAPAN them 4 times greater than for the same cells used as negative control, for the case of the 99m Tc-UBI and the 99m TcO 4 one doesn

  12. New bisaminoethanethiol (BAT) ligands which form two interconvertible Tc-99m complexes

    Energy Technology Data Exchange (ETDEWEB)

    Oya, Shunichi; Kung, Mei-Ping; Frederick, Dana; Kung, Hank F

    1995-08-01

    Most commonly used radiopharmaceuticals in diagnostic nuclear medicine are labeled with Tc-99m. This is due to its superior physical characteristics (T{sub (1(2))} = 6 h and gamma energy 140 KeV) and convenient availability from the {sup 99}Mo/{sup 99mm}Tc generator. In an attempt to fine tune the properties of Tc-99m complexes, the synthesis and radiolabeling of two novel N{sub 2}S{sub 2} ligands, N,-2-mercaptobenzyl-N'-(1-oxo-2-mercapto-2-methyl)propyl ethylenediamine,8, and N,-2-methylthiobenzyl-N'-(1-oxo-2-mercapto-2-methyl)propyl ethylenediamine, 11, with an ionizable SH or unionizable SMe group, respectively, for the formation of complexes with Tc{sup v}O center cores, have been examined. Both ligands initially formed one apparently stable, lipophilic and neutral complex (HPLC, Rt = 7 min, reverse-phase column, acetonitrile: buffer, pH 7.0; (55(45)); V/V; partition coefficient between 1-octanol and buffer of 410 and 335, respectively) with [{sup 99m}Tc]pertechnetate in the presence of stannous chloride. After treatment with a reducing agent, NaCNBH{sub 3}, the initial [{sup 99m}Tc]8 and 11 complexes were reduced; the reduced complexes were less lipophilic (shorter retention time, Rt = 5 min, on the same reversed phase HPLC). However, only the oxidized form showed sufficient stability. The reduced forms of both [{sup 99m}Tc]8 and 11 were readily and completely converted back to the oxidized forms by a stream of air. Biodistribution studies in rats demonstrated that the [{sup 99m}Tc]8 (oxidized form) penetrated the blood-brain barrier (0.67% dose/organ at 2 min postinjection), but washed out from the brain quickly (0.29% dose/organ at 30 min postinjection). On the contrary, [{sup 99m}Tc]11 (oxidized form) did not show any brain uptake (0.03% dose/organ at 2 min postinjection), despite its higher lipophilicity. The disparity between these two Tc-99m complexes may be related to the relative instability of [{sup 99m}Tc]11 (oxidized form) by the introduction of the

  13. New bisaminoethanethiol (BAT) ligands which form two interconvertible Tc-99m complexes

    International Nuclear Information System (INIS)

    Oya, Shunichi; Kung, Mei-Ping; Frederick, Dana; Kung, Hank F.

    1995-01-01

    Most commonly used radiopharmaceuticals in diagnostic nuclear medicine are labeled with Tc-99m. This is due to its superior physical characteristics (T (1(2)) = 6 h and gamma energy 140 KeV) and convenient availability from the 99 Mo/ 99mm Tc generator. In an attempt to fine tune the properties of Tc-99m complexes, the synthesis and radiolabeling of two novel N 2 S 2 ligands, N,-2-mercaptobenzyl-N'-(1-oxo-2-mercapto-2-methyl)propyl ethylenediamine,8, and N,-2-methylthiobenzyl-N'-(1-oxo-2-mercapto-2-methyl)propyl ethylenediamine, 11, with an ionizable SH or unionizable SMe group, respectively, for the formation of complexes with Tc v O center cores, have been examined. Both ligands initially formed one apparently stable, lipophilic and neutral complex (HPLC, Rt = 7 min, reverse-phase column, acetonitrile: buffer, pH 7.0; (55(45)); V/V; partition coefficient between 1-octanol and buffer of 410 and 335, respectively) with [ 99m Tc]pertechnetate in the presence of stannous chloride. After treatment with a reducing agent, NaCNBH 3 , the initial [ 99m Tc]8 and 11 complexes were reduced; the reduced complexes were less lipophilic (shorter retention time, Rt = 5 min, on the same reversed phase HPLC). However, only the oxidized form showed sufficient stability. The reduced forms of both [ 99m Tc]8 and 11 were readily and completely converted back to the oxidized forms by a stream of air. Biodistribution studies in rats demonstrated that the [ 99m Tc]8 (oxidized form) penetrated the blood-brain barrier (0.67% dose/organ at 2 min postinjection), but washed out from the brain quickly (0.29% dose/organ at 30 min postinjection). On the contrary, [ 99m Tc]11 (oxidized form) did not show any brain uptake (0.03% dose/organ at 2 min postinjection), despite its higher lipophilicity. The disparity between these two Tc-99m complexes may be related to the relative instability of [ 99m Tc]11 (oxidized form) by the introduction of the unionizable methylated thiol group as one of the donor

  14. Pharmacological study of 99mTc-CO-MIBI, a new mycoardial perfusion imaging agent comparison to 99mTc-MIBI

    International Nuclear Information System (INIS)

    Zhao Jiandong; Wang Jincheng; Mi Hongzhi

    2004-01-01

    offer a great opportunity for successful heart imaging than 99m Tc-MIBI as a myocardial perfusion imaging agent. This new class of radiopharmaceuticals meet the demand of clinical use and warrant further investigations to develop the potential in clinical study. (authors)

  15. Clinical application of 99mTc-DTPA-HSA

    International Nuclear Information System (INIS)

    Kawamura, Yasuaki; Yamazaki, Junichi; Okuzumi, Ichio

    1989-01-01

    A newly developed blood pool imaging agent, Tc-99m DTPA-HSA (Tc-99m HSA-D), was clinically assessed in blood pool studies of patients with heart disease. Twenty mCi of Tc-99m HSA-D was iv injected to the patients. Similarly, conventional Tc-99m HSA was injected one week later for comparison. Blood counts of Tc-99m HSA-D were significantly higher than those of Tc-99m HSA at 30 minutes after iv injection (p<0.01) and at one, 3, and 6 hours (p<0.001). For the heart, liver, and lungs, sequential counts of Tc-99m HSA-D were also significantly higher than those of Tc-99m HSA. Free Tc-99m uptake in the stomach, thyroid gland, and kidneys was higher on Tc-99m HSA images than Tc-99m HSA-D images. Hepatic and pulmonary uptake of free Tc-99m that were visualized on Tc-99m HSA-D did not influence the diagnostic ability. None of the patients had clinical toxicity of Tc-99m HSA-D. The results indicate that Tc-99m HSA-D is a stable blood pool imaging agent. (Namekawa, K)

  16. Status of Tc-99m and 99Mo/99mTc generator production in Bangladesh

    International Nuclear Information System (INIS)

    Abedin, Md. Zainul; Haque, Md. Azizul; Ali, Md. Ramjan; Hossain, Md. Anwar; Razzaque, Md. Abdur; Yasmin, Lyzu; Waheed, M. Fatima; Akhter, Rabeya; Mondal, Rafiuddin

    2007-01-01

    Radioisotope Production Division (RIPD) produced instant technetium-99m by solvent extraction method for several years. On R and D basis, the division produced portable sterile Tc-99m sublimation generator by irradiating titanium molybdate in the reactor. The division produced (4/batch) from imported fission Mo-99 till June 2005. Since August 2005, as per demand of the government hospitals, the division have been producing 12-14 pieces of 15 GBq chromatographic 99m Tc-generators weekly by using the new generator production plant installed last year having online Mo-99 loading system with the of producing 50 generator per batch. Development of PZC and (n,γ) 99 Mo based generator holds potential in Bangladesh. (author)

  17. Bioavailability of {sup 99m}Tc-paclitaxel-glucuronide ({sup 99m}Tc-PAC-G)

    Energy Technology Data Exchange (ETDEWEB)

    Biber Muftuler, F.Z.; Demir, I.; Uenack, P.; Ichedef, C.; Yurt Kilcar, A. [Ege Univ., Izmir (Turkey). Dept. of Nuclear Applications

    2011-07-01

    An antitumor agent paclitaxel (PAC) has been proved to be efficient in the treatment of breast and ovarian cancer. Glucuronic acid-derived paclitaxel compound (paclitaxel-glucuronide (PAC-G)) was enzymatically synthesized using microsome preparate separated from rat livers. The biodistribution mechanism of PAC-G in healthy female Albino Wistar rats has been investigated. The expected structure is confirmed according to LC/MS results, and the possible attachment is to C2-hydroxyl group. PAC-G was labeled with {sup 99m}Tc and the radiochemical yield of radiolabeled compound ({sup 99m}Tc-PAC-G) was 98.0 {+-} 02.74% (n=9). The range of the breast/blood and breast/muscle ratios is approximately between 3 and 35 in 240 min. All these experimental studies indicate that {sup 99m}Tc-PAC-G may potentially be used in breast tissue as an imaging agent. (orig.)

  18. A novel electrochemical technique for the production of clinical grade 99mTc using (n, γ)99Mo

    International Nuclear Information System (INIS)

    Chakravarty, Rubel; Dash, Ashutosh; Venkatesh, Meera

    2010-01-01

    Introduction: In order to meet the growing demand for 99m Tc and to reduce the reliance on fission-produced 99 Mo, an electrochemical pathway for accessing 99m Tc through the (n, γ) 99 Mo was explored as a back-up measure and to supplement 99m Tc supply for radiopharmaceuticals application. Methods: 99m Tc from an equilibrium mixture of 99 Mo/ 99m Tc was selectively deposited on a platinum cathode in an electrochemical cell by applying optimal voltage and stripped back again into the 0.9% saline solution. The radiochemical and radionuclidic purity of the product were determined using standard techniques. 99m Tc thus obtained was used for labeling standard ligands such as dimercaptosuccinic acid (DMSA) and ethylene dicysteine (EC), to ascertain the usability. Results: Selective deposition of 99m Tc on the platinum electrode was achieved at a potential of 5 V over a period of 1 h in NaOH electrobath. The overall yield of 99m Tc was >90%, with >99.99% radionuclidic purity and >99% radiochemical purity. The performance of the generator remained consistent over a period of 10 days. The compatibility of the product in the preparation of 99m Tc-labeled formulations such as 99m Tc-DMSA and 99m Tc-EC was found to be satisfactory in terms of high labeling yields (>98%). Conclusion: A novel and attractive method has been developed to obtain highly concentrated 99m Tc, without using fission-produced 99 Mo.

  19. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.

    Science.gov (United States)

    Ferro-Flores, Guillermina; Luna-Gutiérrez, Myrna; Ocampo-García, Blanca; Santos-Cuevas, Clara; Azorín-Vega, Erika; Jiménez-Mancilla, Nallely; Orocio-Rodríguez, Emmanuel; Davanzo, Jenny; García-Pérez, Francisco O

    2017-05-01

    Prostate-specific membrane antigen (PSMA) is highly over-expressed in advanced prostate cancers. 68 Ga-labeled PSMA inhibitors (iPSMA) are currently used for prostate cancer detection by PET imaging. The availability of simple, efficient and reproducible radiolabeling procedures is essential for developing new SPECT radiopharmaceuticals for clinical translation. The aim of this research was to prepare 99m Tc-EDDA/HYNIC-Lys(Nal)-Urea-Glu ( 99m Tc-EDDA/HYNIC-iPSMA) obtained from lyophilized kit formulations and evaluate the in vitro and in vivo radiopharmaceutical binding to prostate cancer cells over-expressing PSMA, as well as the 99m Tc-EDDA/HYNIC-iPSMA normal biodistribution in humans and the preliminary uptake in patients with prostate cancer. 99m Tc labeling was performed by adding sodium pertechnetate solution and a 0.2M phosphate buffer (pH 7.0) to a lyophilized formulation containing HYNIC-iPSMA, EDDA, tricine, mannitol and stannous chloride. The radiochemical purity was evaluated by reversed-phase HPLC and ITLC-SG analyses. Stability studies in human serum were performed by size-exclusion HPLC. In vitro cell uptake was tested using prostate cancer cells (LNCaP) with blocked and non-blocked receptors. Biodistribution and tumor uptake were determined in LNCaP tumor-bearing nude mice with blocked and non-blocked receptors, and images were obtained using a micro-SPECT/CT. Whole-body images from three healthy men and two patients with histologically-confirmed prostate cancer (one of them with a previous 68 Ga-PSMA-617scan) were acquired at 1h and 3h after 99m Tc-EDDA/HYNIC-iPSMA administration with radiochemical purities of >98%. In vitro and in vivo studies showed high radiopharmaceutical stability in human serum, specific recognition for PSMA, high tumor uptake (10.22±2.96% ID/g at 1h) with rapid blood clearance and mainly kidney elimination. Preliminary images in patients demonstrated the ability of 99m Tc-EDDA/HYNIC-iPSMA to detect tumors and metastases of

  20. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT

    International Nuclear Information System (INIS)

    Ferro-Flores, Guillermina; Luna-Gutiérrez, Myrna; Ocampo-García, Blanca; Santos-Cuevas, Clara; Azorín-Vega, Erika; Jiménez-Mancilla, Nallely; Orocio-Rodríguez, Emmanuel; Davanzo, Jenny; García-Pérez, Francisco O.

    2017-01-01

    Background: Prostate-specific membrane antigen (PSMA) is highly over-expressed in advanced prostate cancers. 68 Ga-labeled PSMA inhibitors (iPSMA) are currently used for prostate cancer detection by PET imaging. The availability of simple, efficient and reproducible radiolabeling procedures is essential for developing new SPECT radiopharmaceuticals for clinical translation. The aim of this research was to prepare 99m Tc-EDDA/HYNIC-Lys(Nal)-Urea-Glu ( 99m Tc-EDDA/HYNIC-iPSMA) obtained from lyophilized kit formulations and evaluate the in vitro and in vivo radiopharmaceutical binding to prostate cancer cells over-expressing PSMA, as well as the 99m Tc-EDDA/HYNIC-iPSMA normal biodistribution in humans and the preliminary uptake in patients with prostate cancer. Methods: 99m Tc labeling was performed by adding sodium pertechnetate solution and a 0.2 M phosphate buffer (pH 7.0) to a lyophilized formulation containing HYNIC-iPSMA, EDDA, tricine, mannitol and stannous chloride. The radiochemical purity was evaluated by reversed-phase HPLC and ITLC-SG analyses. Stability studies in human serum were performed by size-exclusion HPLC. In vitro cell uptake was tested using prostate cancer cells (LNCaP) with blocked and non-blocked receptors. Biodistribution and tumor uptake were determined in LNCaP tumor-bearing nude mice with blocked and non-blocked receptors, and images were obtained using a micro-SPECT/CT. Whole-body images from three healthy men and two patients with histologically-confirmed prostate cancer (one of them with a previous 68 Ga-PSMA-617scan) were acquired at 1 h and 3 h after 99m Tc-EDDA/HYNIC-iPSMA administration with radiochemical purities of >98%. Results: In vitro and in vivo studies showed high radiopharmaceutical stability in human serum, specific recognition for PSMA, high tumor uptake (10.22 ± 2.96% ID/g at 1 h) with rapid blood clearance and mainly kidney elimination. Preliminary images in patients demonstrated the ability of 99m Tc

  1. 99mTc-RBC subtraction scintigraphy

    International Nuclear Information System (INIS)

    Inagaki, Syoichi; Tonami, Syuichi; Yasui, Masakazu; Kuranishi, Makoto; Sugishita, Kouki; Nakamura, Mamoru

    1994-01-01

    Sequential abdominal scintigrams with 99m Tc-labelled red blood cells (RBC) were subtracted for observing a site of gastrointestinal bleeding and calculating the bleeding rate. This method is technically very easy and can detect the site of bleeding with the minimum rate, as low as 0.2 ml/min., in a phantom experiment. In 23 cases with final diagnosis of gastrointestinal bleeding, conventional non-subtraction scintigraphy detected only 30% (7/23), but subtraction scintigraphy detected 61% (14/23). It was concluded that subtraction scintigraphy had higher sensitivity than conventional scintigraphy for early diagnosing bleeding. A combination of non-subtraction and subtraction scintigraphy is recommended to detect a site of gastrointestinal bleeding in a clinical setting. (author)

  2. Tc-99m-hexakis(t-butylisonitrile)-technetium(I) (Tc-99m-TBI)

    International Nuclear Information System (INIS)

    Angelberger, P.; Dudczak, R.; Jones, A.G.; Lister-James, J.; Wagner-Loffler, M.; Buchheit, O.; Fally, F.

    1986-01-01

    The potassium analog (Tl-201)/sup +/ is widely used in nuclear cardiology but has inferior scintigraphic (80 keV photons), dosimetric and economic properties as compared to Tc-99m. Therefore considerable efforts have been made to develop a Tc-compound that would accumulate in the myocardium in relation to regional blood flow. This study was aimed at optimizing the preparation of Tc-TBI with n.c.a. Tc-99m, analyze and purify the product with HPLC, verify biodistribution in mice and undertake a clinical evaluation

  3. New series of Tc-99m-labeled hepatobiliary tracers: N'-acyl- and N'-sulfonyl ethylenediamine-N,N-diacetic acids

    International Nuclear Information System (INIS)

    Karube, Y.; Kono, A.; Maeda, T.; Ohya, M.; Matsushima, Y.

    1981-01-01

    Various Tc-99m-labeled N'-substituted derivatives of ethylenediamine-N,N-diacetic acid (EDDA) are evaluated as hepatobiliary imaging agents. N-substituted aromatic acyl and aromatic sulfonyl derivatives of EDDA, labeled with Tc-99m, were administered to rabbits and golden hamsters, and the distribution indicated clearance by the hepatobiliary system. N'-aromatic sulfonyl EDDAs were labeled with Tc-99m by the SnCl 2 method with more than 99% yield. Clearance of Tc-99m-p-toluenesulfonyl EDDA from the blood and the liver was as rapid as that of TC-99m N-(2,6-diethylphenylcarbamoylmethyl)iminodiacetic acid (Tc-99m benzenesulfonyl EDDA lowered urinary excretion. It is concluded that the sulfonyl EDDAs provide a fruitful source for Tc-99m-labeled hepatobiliary radiopharmaceuticals

  4. Measurement of lymphatic function with technetium-99m-labelled polyclonal immunoglobulin

    International Nuclear Information System (INIS)

    Svensson, W.; Glass, D.M.; Bradley, D.; Peters, A.M.

    1999-01-01

    A reliable method for measuring lymph flow in physiological units would be valuable, especially in conditions in which it is uncertain whether lymph flow is increased or decreased. The requirements of a radiopharmaceutical for such measurement include stable radionuclide labelling and rapid access to lymphatic vessels following tissue injection but no access to blood vessels. A soluble macromolecule is likely to come closest to meeting these requirements. Technetium-99m- labelled human polyclonal immunoglobulin (HIG) was therefore investigated firstly in comparison with 99m Tc-labelled human serum albumin (HSA) in patients undergoing routine lymphoscintigraphy and secondly with respect to injection site in a group of volunteers with post-mastectomy oedema (PMO). Subcutaneous injection of 99m Tc-HIG into the web space of a distal extremity gave images in which lymphatic vessels were more clearly defined compared with images obtained after injection of 99m Tc-HSA. Lymph nodes were also more clearly defined, suggesting specific retention of HIG, possibly through Fc-mediated binding. Peripheral blood sampling showed a delayed arrival in blood of radioactivity after 99m Tc-HIG compared with 99m Tc-HSA, although ultimately, the blood recovery of 99m Tc-HIG was significantly higher (P 99m Tc-HSA. Clearance rates of radioactivity from the injection site were not sinificantly different, however, between the two agents. In patients with PMO, web space injection of 99m Tc-HIG gave excellent images of normal lymphatic vessels, of lymph nodes and of abnormal lymph drainage such as dermal backflow in swollen arms. In contrast, neither lymphatic vessels nor lymph nodes were visualised after injection into the skin of the dorsum of the distal forearm. Although there was no difference in clearance rates from the injection sites between normal and swollen arms with either agent in PMO, clearance was significantly faster following injection into the web space (0.11% per minute for

  5. Pharmacokinetics of labelled compounds with technetium-99m and samarium-153; Farmacocinetica de compuestos marcados con tecnecio-99m y samario-153

    Energy Technology Data Exchange (ETDEWEB)

    Borda O, L B; Torres L, M N

    1997-07-01

    The purpose of this investigation was to establish the different pharmacokinetics parameters of the main radiopharmaceuticals labeled with technetium-99m and samarium-153. These parameters could be subsequently used as reference to compare other products with the same use. Mathematical models and a computerized pharmacokinetic program were used to this purpose. A biodistribution study in quadruplicate and/or quintuplicate was conducted for each radiopharmaceutical, data was was obtained in injection dose percentages. The biodistribution study involved the injection of a predetermined dose of the radiopharmaceutical into animals (rats or mice), which were subsequently put away at different time intervals, removing the relevant organs. Activity in each organ was read by means of a well-type NaI scintillation counter, data obtained in activity counts was transformed into injection dose percentages. Based on these percentages, the mathematical model was constructed and the pharmacokinetic parameters were obtained using the computerized program Expo 2 v. 1, which is written in C language and works in windows. Analyzing the results obtained, we can conclude that the use of the Expo 2 v. 1 program for a bi compartmental analysis allowed us to obtain reliable pharmacokinetic parameters which describe what happens in the organism when the radiopharmaceutical passes from the central compartment to the peripheral one and vice versa.

  6. Cerebral blood flow imaging by I-123 IMP and Tc-99m HM-PAO

    Energy Technology Data Exchange (ETDEWEB)

    Uno, Koichi; Yoshikawa, Kyosan; Minoshima, Satoshi; Imaseki, Keiko; Arimizu, Noboru; Yamaura, Akira; Uematsu, Sadao

    1988-02-01

    SPECT studies with either N-isopropyl-p-(I-123)iodo- amphetamine (I-123 IMP) or Tc-99m hexamethyl propylene amine oxime (Tc-99m HM-PAO) were cuncurrently performed in 12 patients with brain disorders, comprising cerebral infarction (7), cerebral aneurysm (one), intracranial hemorrhage (3), and subdural hematoma (one). Whereas I-123 IMP was taken up gradually into the brain, the uptake of Tc-99m-HM-PAO in the brain reached the peak immediately after the iv injection, with 90% or more remaining constant by 15 min postinjection. On early SPECT images, a high uptake of I-123 IMP was observed in the lung, and the uptake of Tc-99m HM-PAO was observed as well in the soft tissue of cervical region. In all patients except for one, decreased rCBF was observed in the lesions on both I-123 and Tc-99m SPECT scans. Both of the radiopharmaceuticals were analogous in that decreased blood flow corresponded to cerebral lesions. (Namekawa, K).

  7. Preparation and labelling hydroxyapatite with 223Ra and 99mTc

    International Nuclear Information System (INIS)

    Malkova, E.; Micolova, P.; Vlk, M.; Kozempel, J.; Rabyk, M.

    2015-01-01

    The aim of this study was the preparation, studies and investigation of novel nanoparticles suitable for targeted delivery of 223 Ra and 99 mTc. Preliminary experiments were focused on the synthesis of hydroxyapatite nanoparticles (HANPs) and their affinity to 223 Ra and 99m Tc. Technetium-99m ( 99 mTc, T 1 /2 = 6.0 h) is the most commonly used medical radionuclide for diagnostic procedures. Radium-223 is the first -emitting radionuclide approved for targeted radionuclide therapy. The physical half-life of 223 Ra of 11.4 days is providing sufficient time for the synthesis, distribution and administration of the radiopharmaceutical to patients. HANPs labelling yields with 223 Ra were 95 - 100 % and with 99m Tc were 93 - 94 % depending on the reaction conditions. HANPs were studied on FT-IR (Fourier transform infrared spectroscopy), XRPD (X-Ray Powder Diffraction), DLS (Dynamic Light Scattering), and the sizes of nanoparticles were studied at temperatures 80, 120 and 200 grad C. (authors)

  8. Evaluation of Some Dose Calibration for Measuring of 99mTc

    International Nuclear Information System (INIS)

    Nazaroh; Erni-Juita; Hermawan-Candra

    2001-01-01

    99m Tc is a prime radionuclide in nuclear medicine because of worthwhile in many diagnoses. According to ALARA concept, the lowest risk should be considered in the use of radioactive materials especially for health. Center for development of Radioisotopes and Radiopharmacy-BATAN, Serpong, serves several nuclear medicine departments supplying all their 99m Tc radiopharmaceuticals on a daily basis. It was observed that there was very poor consistency between the assays as determined by P3KRBin and those determined in the various nuclear medicine, using Dose-Calibrator. Investigation has been done to correct measurements result of 99m Tc using several Dose-Calibrators in some hospitals in Java island and the correction factors were vary from 0.91 to 1.16. The same survey done by researcher in Canada using a mock 99m Tc ( 57 Co) and 99m Tc and the correction factors were between 0.74 and 1. Investigation of influences of various environmental conditions on the Calibrator function was also carried out. Influences factors obtained from the survey were vary from 1 to 1.19. (author)

  9. Technetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide

    International Nuclear Information System (INIS)

    Melo, Ivani B.; Buchpiguel, Carlos Alberto; Ueda, Laura T.; Araujo, Elaine B. de; Muramoto, Emiko; Barboza, Marycel F. de; Mengatti, Jair; Silva, Constancia P.G. da

    2008-01-01

    Synthetic somatostatin (SST) analogues have been used in the preparation of receptor-specific radiopharmaceuticals for diagnostic and therapy of neuroendocrine (NE) tumors. 111 In-DTPA-Octreotide (OctreoScan®) has found useful for imaging a range of tumors, including NE cancer, carcinoide and lymphoma. Unfortunately, 111 In is a high-cost cyclotron produced radioisotope with gamma emission not so suitable for scintigraphic images and for dosimetry like 99m Tc. This work studied the labeling conditions with 99m Tc and biological distribution in Swiss mice of two SST analogs (HYNIC-Tyr 3 -Octreotide and HYNICTyr 3 - Octreotate) and compared the biodistribution pattern with 111 In-DTPA-Octreotide. 99 mTc-HYNIC-Tyr 3 - Octreotate ( 99m Tc-HYNIC-TATE) and 99m Tc-HYNIC-Tyr 3 -Octreotide ( 99m Tc-HYNIC-OCT) were produced by labeling conditions using tricine and EDDA as coligands. 111 In-DTPA-Octreotide ( 111 In-DTPA-OCT) was produced by labeling DTPA-Octreotide with 111 InCl 3 (Nordion). Radiochemical purity of labeled preparations was determined by ITLC-SG. Biological distribution studies were performed after injection of radiopharmaceuticals on Swiss mice. Labeling procedures resulted on high radiochemical yield for all three preparations and the labeled products presented high in vitro stability. Biological distribution studies evidenced similar general biodistribution of 99m Tc-labeled peptides when compared with indium-labeled peptide with fast blood clearance and elimination by urinary tract. Kidneys uptake of 99 mTc-HYNIC-TATE are similar to 111 In-DTPA-Octreotide, and both are significantly higher than 99 mTc-HYNIC-OCT. All labeled peptides presented similar uptake on liver, but the retention in time at intestines, particularly at large intestine, was more expressive for 111 In-labeled peptide. The %ID of 99m Tc-HYNIC-OCT and 99m Tc-HYNIC-TATE in organs with high density of SST receptors like pancreas and adrenals were significant and similar to obtained for 111

  10. Design of a formulation for the preparation of 99m Tc-(V)-Dmsa and 186 Re-(V)-Dmsa

    International Nuclear Information System (INIS)

    Marquez L, M.B.

    1998-01-01

    Among the radiopharmaceuticals used for neoplasia, we can find the dimercaptosuccinic acid (Dmsa) labelled with 99m Tc and 186/188 Re. Initially, the 99m Tc-(III)-Dmsa was employed as a renal image agent. Nevertheless, when it is prepared into a basic solution, the 99m Tc-(V)-Dmsa complex is produced in high yield being cumulated by cells with a great metabolic activity. This property makes it a useful radiopharmaceutical for the detection of medullary thyroid carcinoma (MTC), soft-tissue tumors and other head and neck tumors. On the other hand, the renewed interest in β - emitting radionuclides, suggests that the 186 Re-(V)-Dmsa complex could be used as antineoplastic agent in therapy. However, the techniques reported for the preparation of these compounds lack of stability studies and they are still in process of investigation, compromising to continue on the development of the radiopharmaceuticals by introducing new possibilities for better products already known, obtaining in this way, the approximation to the ideal radiopharmaceutical. The objective of this work is to design a freeze dried kit formulation for the instant preparation of 99m Tc-(V)-Dmsa and 186 Re-(V)-Dmsa complexes useful in the diagnostic and therapy of soft-tissue tumors and other head and neck tumors. We obtained a freeze dried stable formulation for the preparation of 99m Tc-(V)-Dmsa kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytical techniques for the determination of the different chemical compounds into the lyophilized kit. On the other hand, we obtained the optimum conditions for preparation of 186 Re-(V)-Dmsa complex in high radiochemical yields (>90%). (Author)

  11. Evaluation of technetium-99m exametazime stabilised with cobalt chloride as a blood flow tracer in focal cerebral ischaemia

    Energy Technology Data Exchange (ETDEWEB)

    Gartshore, G [Wellcome Surgical Inst. and Hugh Fraser Neuroscience Labs., Glasgow Univ. (United Kingdom); Bannan, P [Wellcome Surgical Inst. and Hugh Fraser Neuroscience Labs., Glasgow Univ. (United Kingdom); Patterson, J [Wellcome Surgical Inst. and Hugh Fraser Neuroscience Labs., Glasgow Univ. (United Kingdom); Higley, B [Wellcome Surgical Inst. and Hugh Fraser Neuroscience Labs., Glasgow Univ. (United Kingdom); McCulloch, J [Wellcome Surgical Inst. and Hugh Fraser Neuroscience Labs., Glasgow Univ. (United Kingdom)

    1994-09-01

    A protocol has been devised to effectively extend the limited post-reconstitution shelf life of technetium-99m exametazime as a radiopharmaceutical for imaging cerebral blood flow (CBF) distribution. The potential of [sup 99m]Tc-exametazime stabilised with cobalt chloride for imaging CBF distribution as late as 4 h after reconstitution has been examined in ischaemic and non-ischaemic tissue in halothane-anaesthetised cats. Focal cerebral ischaemia was produced by permanent middle cerebral artery occlusion. The relationship between [sup 99m]Tc-exametazime uptake and retention and CBF (assessed with [[sup 14]C]iodoantipyrine 10 min after first radiopharmaceutical administration) was determined in the same tissue section with double label autoradiography. Over the CBF range 0 - 80 ml 100 g[sup -1] min[sup -1], the uptake of [sup 99m]Tc-exametazime (quantitatively and topographically) was linearly related to CBF irrespective of whether the [sup 99m]Tc-labelled tracer was unstabilised (and administered within 10 min of reconstitution) or was stabilised with cobalt chloride (and administered up to 240 min after reconstitution). For levels of CBF in excess of 80 ml 100 g[sup -1] min[sup -1] the excellent topographical relationship between [sup 99m]Tc-exametazime distribution and CBF is maintained but quantitatively, [sup 99m]Tc-exametazime underestimates CBF to a similar degree in animals receiving stabilised and unstabilised [sup 99m]Tc-exametazime. The presence of the stabiliser, cobalt chloride, extends greatly the period over which [sup 99m]Tc-exametazime can be used after reconstitution to generate images of CBF distribution in normal and ischaemic cerebral tissue. (orig.)

  12. Effect of Radioactivity of Technetium-99m on the Autosterilization Process of non-sterile Tetrofosmin Kits

    Directory of Open Access Journals (Sweden)

    Widyastuti Widyastuti

    2017-03-01

    Full Text Available Technetium-99m labeled radiopharmaceutical is commonly used in nuclear medicines as a diagnostic agent, by mixing the sterile kit with Tc-99m. Manufacturing of kits requires an aseptic facility which need to be well designed and maintained according to cGMP, since mostly kits can not be terminally sterilized. Radiopharmaceuticals as pharmaceuticals containing radionuclide is assumed to have an autosterilization property, but correlation between radioactivity and capability of killing microorganisms has to be studied so far. The aim of this study is to investigate the effect of radioactivity on the autosterilization process of radiopharmaceuticals. The study was carried out by adding Tc-99m of various radioactivity into non-sterile tetrofosmin kits, then the samples were tested for sterility. Sterile tetrofosmin kit and non-sterile kit with no Tc-99m added will be used as a negative control and positive control respectively. The sterility was tested using standard direct inoculation method, by inoculating samples in culture media for both bacteria and fungi and observing qualitatively within 14 days. The results showed that the samples with radioactivity of 1, 3 and 5 mCi changed the clarity of the media to turbid, conformed with the performance of positive controls but samples with radioactivity of 10 mCi and 20 mCi did not change the clarity of the media, conformed with the performance of negative control, indicating neither growth of bacteria nor fungi. It is concluded that Tc-99m behaves as an autosterilizing agent at certain radioactivity. Therefore the preparation of Tc-99m radiopharmaceutical can be considered as terminal sterilization rather than aseptic preparation.

  13. 99mTc labelled peptides for imaging of peripheral receptors

    International Nuclear Information System (INIS)

    Mustanser, J.; Anjum, A.

    2001-01-01

    Several peptides are being used as radiopharmaceuticals for receptor imaging scintigraphy. The peptide receptors are found in the tumours of various sites in the human body. Somatostatin is one of those, which is expressed by a variety of tumours say in brain cortex, medullary carcinoma of thyroid, adrenal glands, pancreas and gut. Therefore neuropeptides based on somatostatin analogues are labelled with different radionuclide, 123 I and 111 In. Efforts are underway to label RC-160 (an analogue of somatostatin) with 99m Tc because of its favourable radiation dosimetry, short half-life, low price, high count rate and better diagnostic efficacy. In this project various methods of labelling RC-160 with different radionuclides 125 I and 99m Tc have been studied in detail. Radioiodination of RC-160 was tried with 125 I using the iodogen method as directed and then with Chloramine T method. Labelling of RC-160 peptide with 99m Tc was done using two different aspects. Direct labelling with 99m Tc and indirect labelling with 99m Tc using double chelating agents. Radiochemical quality control was carried out applying instant thin layer chromatography using ITLC-SG strips in 85% of methanol. Later the HPLC analysis was used for its evaluation. To label RC-160 with 99m Tc the approach of direct labelling was attempted first. 46% labelling could be achieved with 95% of radiochemical purity. The biodistribution of 99m Tc-RC-160 complex in rats has also been studied to determine uptake in various sites of somatostatin receptors. Eventually, attempt was made to synthesize biomolecule by conjugating Boc protected RC-160 with benzoyl MAG-3. As a result 80% of Boc-RC-160 went under conjugation with benzoyl MAG-3. (author)

  14. Evaluation of {sup 99m}Tc-Pheophorbide-a use in infection imaging: A rat model

    Energy Technology Data Exchange (ETDEWEB)

    Ocakoglu, Kasim [Advanced Technologies Research and Application Center, Mersin University, TR 33343 Yenisehir, Mersin (Turkey); Bayrak, Elif; Onursal, Mehmet [Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova 35100, Izmir (Turkey); Yilmaz, Osman [Department of Animal Research Center, Dokuz Eylul University, Izmir (Turkey); Yurt Lambrecht, Fatma, E-mail: fatma.yurt.lambrecht@ege.edu.tr [Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova 35100, Izmir (Turkey); Holzwarth, Alfred R. [Max-Planck-Institut fuer Bioanorganische Chemie, Stiftstrasse 34-36, D-45470, Muelheim an der Ruhr (Germany)

    2011-09-15

    This study aims to prepare {sup 99m}Technetium Pheophorbide-a ({sup 99m}Tc-PH-A) complex and evaluate its efficiency as an infection imaging agent. First, PH-A was obtained from Spirulina maxima algae, and the product compound was confirmed using {sup 1}H NMR and MS (ESI) methods. The PH-A was then labeled with {sup 99m}Tc using the tin chloride method and its biological efficacy as a potential radiotracer for Staphylococcus aureus (S. aureus) infection was evaluated in bacterially infected and sterile inflamed rats. The radiochemical stability of the {sup 99m}Tc-PH-A in human serum was determined by thin-layer radiochromatography (TLRC). The radiochemical purity was 87{+-}3.2% and remained constant at more than 80{+-}0.1% even in serum for 120 min after radiolabeling. These experiments indicated that the ratio of {sup 99m}Tc-PH-A uptake in bacterially infected muscle, as compared to normal muscle, [target/non-target (T/NT)=5.6 at 1 h] was over four times higher than that in sterile inflamed muscle (T/NT=1.29 at 1 h). Disappearance of activity from the kidney and liver indicated that the urinary and hepatobiliary systems were the normal routes of excretion of the complex. {sup 99m}Technetium Pheophorbide prepared with high yield is able to localize well in the bacterially infected muscle of the rats and {sup 99m}Tc-PH-A may be developed as a radiopharmaceutical agent to distinguish infection from inflammation by nuclear imaging.

  15. Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin.

    NARCIS (Netherlands)

    Siaens, R.H.; Rennen, H.J.J.M.; Boerman, O.C.; Dierckx, R.A.; Slegers, G.

    2004-01-01

    The use of (99m)Tc-ciprofloxacin as a tracer for infection and inflammation has been examined and discussed in the literature extensively. Its alleged ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections has led to an intense debate. Other labeled

  16. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.

    Science.gov (United States)

    Płachcińska, Anna; Mikołajczak, Renata; Kozak, Józef; Rzeszutek, Katarzyna; Kuśmierek, Jacek

    2006-01-01

    Aiming at comparison of diagnostic efficacy of 2 radiopharmaceuticals: 99mTc-depreotide (Neospect, Amersham) and 99mTc-EDDA/HYNIC-Tyr3-octreotide (Tektrotyd, Polatom), in differentiation between malignant and benign etiology of solitary pulmonary nodules (SPNs), radionuclide studies with 2 radiotracers were performed in 18 patients. For both radiopharmaceuticals the same acquisition and processing protocols were applied. Studies were acquired with SPECT technique, after administration of 740 MBq of activity. Scintigrams were assessed visually, as: positive (+), equivocal (+/-) and negative (-). Additionally, uptake intensity of both radiotracers in nodules was assessed semiquantitatively, using a tumour-to-background ratio. Verification of scintigraphic results was based in 14 cases upon a pathological examination of tumour samples (histopathology) and in the remaining 4 - on clinical observation and bacteriological studies. Normal scintigrams obtained with both radiopharmaceuticals differed significantly. 99mTc-depreotide was markedly accumulated in spine, sternum, ribs and lungs (mean lung/heart ratio = 2.2). This accumulation was not observed on 99mTc- -EDDA/HYNIC-TOC scintigrams (mean lung/heart ratio = 0.7). In 6 patients a malignant etiology--lung cancer--was revealed (5--adenocarcinoma, 1--squamous cell) and the other 12 cases turned out to be benign (4 hamartomas, 3 tuberculomas, a tuberculous infiltrate, an alien body with inflammatory reaction, a hyperplasia of lymphatic tissue and 2 cases of unknown etiology, from which one had a stable size and the other resolved during a 6 month observation period). In all 6 cases of lung cancer positive results were obtained with both tracers. Moreover, in 2 patients metastases in mediastinum could be observed on scintigrams obtained with both radiopharmaceuticals. From among 12 cases of benign etiology 6 99mTc-depreotide scintigrams were true negative, 1--equivocal and 5--false positive, whereas 6 99m

  17. Biodistribution of 99mTc-ketoconazole in infection initiated by candida albicans, staphylococcus aureus and escherichia coli

    International Nuclear Information System (INIS)

    Rizky Juwita Sugiharti; Iim Halimah; Isa Mahendra; Maula Eka Sriyani

    2016-01-01

    Infectious diseases remain a major health problem and cause of death worldwide, particularly in developing countries. Nuclear medicine imaging, with better sensitivity, offers an attractive option for diagnosis of infections. 99m Tc-ketoconazole was radiolabeled antibiotic which synthesized by labeling ketoconazole with radionuclide technetium-99m. This radiopharmaceutical is expected to be applied for detection of infection in nuclear medicine therefore 99m Tc-ketoconazole must be selectively concentrated in infection sites. Hence, evaluations of 99m Tc-ketoconazole to detect and locate infection caused by some microorganisms in mice have been conducted. The biodistribution study showed accumulation of 99m Tc ketoconazole in infected thigh at 1 hour p.i with target/non target ratio (T/NT) 3.04 for Candida albicans, 1.93 for Staphylococcus aureus and 2.81 for Escherichia coli. This study showed that 99m Tc-ketoconazole is a promising radiopharmaceutical to detect infection rapidly with high sensitivity. (author)

  18. Radiopharmaceuticals For Detection Of Inflammation And Infection

    International Nuclear Information System (INIS)

    Nurlaila, Z.

    2002-01-01

    Feeling of pain in the body could be caused by reaction of inflantation and infection as well. One of the methods could be used to detect the reaction is nuclear technique using radiopharmaceutical as radiotracer. Some radiopharmaceuticals having specific accunulation mechanism to diagnose the presence of inflamations and infections with satisfactory results. Among those radiophannaceuticals are technetium-99m-hexamethylpropileneamine-white blood cell ( 99m Tc-HMPAO-WBC), indium-111-oxine-white blood cell ( 111 In-oksin-WBC). technetium-99m-immunoglobuline G ( 99m Tc-lgG) and technetium-99m-infecton ( 99m Tc-infecton). In visualization using this method. the information of a serial previous medical treatment of the patient should be known, because cer1ain medicament, could influence the biological characteristic of radiopharmaceuticals and hence. a missed diagnosis could be resulted. This review discusses several radiopharmaceuticals for inflamation and infection, diagnoses their accumulation, mechanism in the body. Besides, the radiopharmaceuticals interaction with several drugs are also reviewed

  19. Hospitable radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, M.B.

    1994-01-01

    Two types of hospitalary radiopharmaceutical was given in Nuclear Medicine: the centralized and hospitalary radiopharmaceuticals. The good practice in the use, instrumentation and quality control of radiopharmaceuticals are used in nuclear medicine for diagnostic and therapy diseases

  20. Evaluation by biodistribution of two anti-peptidoglycan aptamers labeled with Technetium-99m for in vivo bacterial infection identification

    International Nuclear Information System (INIS)

    Ferreira, Iêda M.; Lacerda, Camila M.S.; Santos, Sara R.; Andrade, Antero S.R. de; Fernandes, Simone O.; Barros, André B. de; Cardoso, Valbert N.

    2017-01-01

    Nuclear medicine clinics are still awaiting optimal scintigraphic imaging agents capable of discriminating between infection and inflammation, and between fungal and bacterial infections. Aptamers are oligonucleotides that display high affinity and specificity for their molecular targets and are emerging as promising molecules for radiopharmaceuticals development. In the present study, two aptamers for peptidoglycan (termed Antibac1 and Antibac2) were labeled with 99m Tc and evaluated for bacterial infection identification by biodistribution. The direct labeling method with 99m Tc allowed radiolabel yields higher than 90% and the complexes were stable in saline, plasma and cysteine excess. The 99m Tc-Antibac1 in the group infected with S. aureus presented a target/non-target ratio (T/NT) of 2.81 ± 0.67, significantly higher than verified for the 99m Tc-library (control): 1.52 ± 0.07. A radiolabeled library of oligonucleotides with random sequences was used as a control for monitoring nonspecific uptake at the site of infection. In the model with C. albicans infection the T/NT ratio for 99m Tc-Antibac1 was 1.46 ± 0.11, similar that obtained for the 99m Tc-library in the same model: 1.52 ± 0.05. The 99m Tc-Antibac2 in the group infected with S. aureus showed a T/NT ratio of 2.61 ± 0.66, statistically higher than achieved for the 99m Tc-library: 1.52 ± 0.07. In the group infected with C. albicans this ratio for 99m Tc-Antibac2 was 1.75 ± 0.19, also statistically higher in relation to the 99m Tc-library: 1.52 ± 0.05. Both aptamers were effective in identifying bacterial infection foci, but only 99m Tc-Antibac1 showed no cross reactivity for fungal cells. (author)

  1. Tc-99m leucoscintigraphy in surgical patients

    International Nuclear Information System (INIS)

    Durre-e-Sabih

    1990-01-01

    Leucoscintigraphy with Tc-99m-HMPAO is an important diagnostic modality for localizing of the site of infection. It has distinct advantages over gallium 67 and indium-111 labelled leukocytes, in terms of better image quality, less cell activation and the choice of using Technetium instead of In-111. This study was designed to set up the technique in AEMC, Multan Pakistan, to assess the practicality of using the procedure, and to see if the results offered additional clinical information that could affect patient management in our clinical environment. 27 patients were studied using the technique. There were 17 post-surgical patients, 4 post-partal patients and 6 patients who did no fit into the above categories. An accuracy of 81%, sensitivity of 75% and a specificity of 100 % were achieved. The spectrum of clinical presentation was broad and included post-operative infections, intra-abdominal haematoms, brain abscesses, localized peritonitis, sterile and infected intraperitoneal collections, infected pleural effusions and pyrexia of unknown origin. It was concluded that this technique is practicable in our conditions and gives important clinical information. (author)

  2. Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans

    International Nuclear Information System (INIS)

    Knight, Linda C.; Romano, Jan E.; Bright, Lewis T.; Agelan, Alexis; Kantor, Steven; Maurer, Alan H.

    2007-01-01

    Introduction: 99m Tc recombinant bitistatin (rBitistatin) is a radioligand for α IIb β 3 (glycoproteins IIb/IIIa) receptor on platelets and is being developed as a diagnostic radiopharmaceutical for in vivo imaging of acute thrombi and emboli. Prior to the first administration of [ 99m Tc]rBitistatin to human subjects, its biodistribution and effects on platelets were evaluated in animals. This paper reports findings in animal studies in comparison with initial findings in normal human subjects. Methods: [ 99m Tc]rBitistatin was administered to mice, guinea pigs and dogs to assess time-dependent organ distribution, urinary excretion and blood disappearance rates. Blood samples were analyzed to determine radioligand binding to circulating platelets and the extent of plasma protein binding. The effect of [ 99m Tc]rBitistatin on circulating platelet count was determined. These factors were also determined in normal human subjects who received [ 99m Tc]rBitistatin as part of a Phase I clinical trial. Results: The main organs that accumulated [ 99m Tc]rBitistatin were kidneys, liver and spleen in all animal species and humans. The main organs seen on human images were the kidneys and spleen. Liver uptake was fainter, and soft-tissue background was low. [ 99m Tc]rBitistatin bound to circulating platelets in blood, with a higher percentage of binding to platelets in guinea pigs and dogs compared to that in humans. Plasma protein binding was low and of little consequence in view of platelet binding. The main route of excretion was through the urine. [ 99m Tc]rBitistatin did not affect platelet counts in humans or dogs. Conclusions: [ 99m Tc]rBitistatin, when administered at low doses for imaging, has no adverse effects on platelets and has the qualitative biodistribution predicted by animal studies. [ 99m Tc]rBitistatin was found to bind to circulating platelets in humans, suggesting that it will be able to bind to activated platelets in vivo in patients with acute

  3. Labelling, biodistribution and compartmental analysis of N-acetylcysteine labelled with Tc-99m. Comparative investigation with with 99m Tc-MIBI in an in vivo tumoral model

    International Nuclear Information System (INIS)

    Faintuch, Bluma Linkowski

    1997-01-01

    Labelling and biodistribution studies were done with two different ligands, respectively Methoxy isobutyl isonitrile (MIBI) and N-acetylcysteine (NAC), employing Tc-99m as a tracer. The main objective was to assess the pharmacokinetic properties of the second substance, aiming at its possible application in cancer diagnosis. To this purpose an in vivo investigation was done using healthy and tumor-bearing rats with experimental cancer. Images of tumor-bearing rats registered in a scintillation camera indicated that with 99m Tc-MIBI none of the two selected times was adequate for visualization of the cancer mass. In contrast, 99m Tc-NAC permitted clear identification of the humor, four hours after injection. The results have demonstrated that 99m Tc-NAC is a radiopharmaceutical with affinity for cancer tissue and promising for further investigation concerning imaging diagnosis of tumors. (author)

  4. The new 99mTc myocardial perfusion imaging agents: 99mTc-sestamibi and 99mTc-teboroxime

    International Nuclear Information System (INIS)

    Berman, D.S.; Kiat, H.; Maddahi, J.

    1991-01-01

    The two new 99m (99mTc) labeled myocardial perfusion agents, 99mTc-Sestamibi and 99mTc-Teboroxime, are now available for routine clinical application. Both agents allow assessment of ejection fraction by the first-pass technique at rest or during exercise, thus providing additional information not available with thallium-201. 99mTc-Sestamibi has long myocardial residence time, as well as adequate myocardial extraction, providing images of higher count density and superior quality compared with thallium-201. 99mTc-Teboroxime has excellent myocardial uptake characteristics but is cleared very rapidly from the myocardium. Both tracers have shown results similar to those obtained with thallium-201 for detection of coronary artery disease and the assessment of defect reversibility. 99mTc-Sestamibi studies using the rest/stress imaging sequence can be accomplished in approximately 5 hours; studies using dual-isotope imaging (rest thallium-201 and stress 99mTc-Sestamibi injection) can be completed in 1 to 2 hours. Gated stress images can be performed with 99mTc-Sestamibi, providing simultaneous information of myocardial perfusion at stress and resting wall motion or thickening and allowing rapid differentiation of ischemic from infarcted tissue. Because of its slow myocardial clearance and absence of redistribution, 99mTc-Sestamibi allows uncoupling of the time of injection from the time of imaging and thus can be valuable in the evaluation of acute myocardial infarction and outcome of thrombolytic therapy. With 99mTc-Teboroxime, rapid serial studies are feasible. Pharmacologic stress and rest studies with 99mTc-Teboroxime single photon emission computed tomography potentially can be completed in under 30 minutes. 73 references

  5. Process modifications of obtaining Tc-99m by solvent extraction

    International Nuclear Information System (INIS)

    Leon, A.; Verdera, S.

    1978-01-01

    This paper describes a modification in the process to obtaining Tc-99m by the extraction method of solvent from Mo-99 produced by irradiation. Tc-99m is considered an ideal radionuclide for medical and biological applications

  6. Technetium-99m labeled radiodiagnostic agents and method of preparation

    International Nuclear Information System (INIS)

    Molinski, V.J.; Wilczewski, J.A.

    1977-01-01

    A method of preparing improved technetium-99m labeled radiodiagnostic agents by reducing technetium-99m with stannous tartrate is described. Such radiodiagnostic agents are useful in scintigraphic examinations of the bone and lung

  7. Current status of Tc-99m production in Thailand

    International Nuclear Information System (INIS)

    Charoen, Sakda

    2003-01-01

    Technetium-99m is the workhorse of nuclear medicine and currently accounts for over 80% of all in vivo diagnostic procedures. In Thailand, Office of Atomic Energy for Peace (OAEP) had experiences in production of Technetium-99m by solvent extraction process and alternative technology for Technetium-99m generator based on zirconium molybdate and titanium molybdate gel generators were also studied. The paper describes past experiences and future plan of Technetium-99m production in Thailand. (author)

  8. Comparison of liver scintigraphy with sup(99m)Tc-phytate and 198Au-colloid in diffuse hepatic disorders

    International Nuclear Information System (INIS)

    Kamoi, Itsuma; Watanabe, Katsushi; Kawahira, Kenjiro; Nakayama, Chikashi; Higashi, Yoshitaka

    1975-01-01

    sup(99m)Tc-phytate was evaluated as a liver scintigraphic radiopharmaceutical, and the results were compared with those of 198 Au-colloid. Both radionuclides were used on the same day in 55 cases of diffuse hepatic disorders. In 52 of the 55 cases, excellent liver images were obtained with sup(99m)Tc-phytate. Compared with 198 Au-colloid, sup(99m)Tc-phytate was more highly concentrated in the spleen and bone marrow and with higher background radioactivity, although their distributions generally coincided. The known diagnostic criteria for liver scintigraphy with 198 Au-colloid in diffuse hepatic disorders were proven applicable to sup(99m)Tc-phytate. (auth.)

  9. Mismatched uptake of Tc-99m-ECD and Tc-99m-HMPAO in subacute cerebral infarction: Tc-99m-ECD for viability and Tc-99m-HMPAO for flow restoration

    Energy Technology Data Exchange (ETDEWEB)

    Lee, D. S.; Hyun, I. Y.; Kim, S. K. [College of Medicine, Seoul National Univ., Seoul (Korea, Republic of)] [and others

    1997-07-01

    Tc-99m-HMPAO reflects tissue perfusion but Tc-99m-ECD uptake is affected by tissue viability in addition to tissue perfusion which the varied state of cellular retention of Tc-99m-ECD reflects. Luxuriously perfused area on Tc-99m-HMPAO SPECT implies that this cortex was already reperfused either spontaneously or after thrombolysis and that accompanied paralysis of vascular reactivity in those zones warms progressive deterioration. We tried to find out if we can use sequential Tc-99m-ECD/Tc-99m-HMPAO SPECT to reveal cortical perfusion and severity and range of risky areas of cerbral cortex despite reperfusion in sub-acute infarction. In 13 patients (M ; F =7 : 6, mean age 57 (range: 26-84)) with cortical (n=12) and basal ganglia infarction (1), we performed sequential Tc-99m-ECD/Tc-99m-HMPAO SPECT at the same position. At first, 555 MBq of Tc-99m-ECD was injected and imaged and then 1110 MBq of Tc-99m-HMPAO was injected again and imaged with the patients in situ, and the first image (Tc-99m-ECD) and the subtracted image (2nd- 1st : Tc-99m-HMPAO) were compared slice by slice. Study was done from 3 days to 31 days (16{+-}9) after ictus. Tc-99m-ECD uptake was always less than or equal to Tc-99m-HMPAO uptake at the lesion in all cases. Luxury perfusion was prominent in four patients. Mismatched uptake was found in 10 patients. Severity of mismatch showed diverse spectrum and was ranged from total middle cerebral artery territory (1 case) to peripheral thin zones around infarction (2 cases). The other 7 showed intermediate amount of tissues with mismatch , i.e., Tc-99m-ECD defects where Tc-99m-HMPAO uptake is in part increased, normal or decreased. Upon discharge, patients having more uptake with Tc-99m-ECD predicted improvement. Patients having mismatched uptake went dichotomous way. In conclusion, Tc-99m-ECD/Tc-99m-HMPAO sequential SPECT is feasible and reveal both tissue perfusion (Tc-99m-HMPAO ) and discrepant Tc-99m-ECD uptake probably reflecting viability in acute

  10. Comparison study among methodologies of planar chromatography for radiochemical control of technetium-99m

    International Nuclear Information System (INIS)

    Monteiro, Elisiane de Godoy

    2012-01-01

    Radiopharmaceuticals are substances that have radioisotopes in their composition. About 95% of the procedures performed in nuclear medicine use radiopharmaceuticals with diagnostic purposes, and the Lyophilized Reagents (LR) labeled with Technetium-99m ( 99 mTc), obtained from 99 Mo/ 99 mTc generator, are the most one used. Quality Control represents the set of assays to be performed to assure that the product is adequate to its purpose. An important feature to be evaluated in 99m Tc radiopharmaceuticals is the radiochemical purity (% RqP) to quantify free pertechnetate ( 99 mTcO 4 - ) and technetium colloidal (99mTcO 2 ) mainly by paper chromatography (PC), thin layer (TLC) and High Performance Liquid Chromatography (HPLC). The objective of this work was to perform the comparison among the radiochemical control methodologies of LR labeled with 99m Tc, described in the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) and those used by IPEN. 99m TcO 4 - eluate and DISIDA, DMSA, DTPA, EC, ECD, GHA, MIBI, MDP, PIRO, SAH and Sn Coloidal LR were provided by IPEN-CNEN/SP. TLC-cellulose, TLC-SG.TLC-SG reverse phase, HPTLC-cellulose, HPTLC-SG (Merck) and ITLC-SG (Pall Corporation), W1MM, W3MM, W17M e W31ET (Whatman) chromatographic plates were used. The measurement of the radioactivity was done in a Perkin Elmer Cobra D-5002 gamma counter. LR were labeled to obtain 55,0 MBq mL 1 (1,5 mCi mL 1 ) of final radioactive concentration. The % 99m TcO 4 - , % 99m TcO 2 and % RqP were determined up to 4 hour labeling. From 11 LR, only EC and GHA have no radiochemical control methods in USP and EP. In USP and/or EP, DTPA, MDP, PIRO, SAH and Sn Coloidal methods use ITLC-SG; IPEN uses this chromatography plate in DISIDA, EC, ECD, GHA, PIRO, MIBI and SAH. As ITLC-SG had been out of production (recommended in 40, 70 and 41% of the USP, EP and IPEN methodologies, respectively), it was necessary to search alternatives to replace ITLC-SG plate in the radiochemical control

  11. Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole-dipicolylamine-(99m)Tc(CO)3 complex for detecting tumor hypoxia.

    Science.gov (United States)

    Mallia, Madhava B; Mittal, Sweety; Sarma, Haladhar D; Banerjee, Sharmila

    2016-01-01

    Previous studies have clearly demonstrated strong correlation between in vivo distribution and blood clearance of radiopharmaceuticals for the detection of hypoxia. Present study describes an attempt to improve the in vivo distribution of a previously reported 2-nitroimidazole-(99m)Tc(CO)3 complex by tuning its blood clearance pattern through structural modification of the ligand. Herein, a 2-nitroimidazole-dipicolylamine ligand (2-nitroimidazole-DPA) was synthesized in a two-step procedure and radiolabeled with (99m)Tc(CO)3 core. Subsequently, the complex was evaluated in Swiss mice bearing fibrosarcoma tumor. As intended by its design, 2-nitroimidazole-DPA-(99m)Tc(CO)3 complex was more lipophilic than previously reported 2-nitroimidazole-DETA-(99m)Tc(CO)3 complex (DETA-diethylenetriamine) and showed slower blood clearance. Consequently it showed higher tumor uptake than 2-nitroimidazole-DETA-(99m)Tc(CO)3 complex. Significantly, despite structural modifications, other parameters such as the tumor to blood ratio and tumor to muscle ratio of the 2-nitroimidazole-DPA-(99m)Tc(CO)3 complex remained comparable to that of 2-nitroimidazole-DETA-(99m)Tc(CO)3 complex. Present study demonstrates the feasibility of structural modifications for improving in vivo tumor uptake of hypoxia detecting radiopharmaceuticals. This might encourage researchers to improve suboptimal properties of a potential radiopharmaceuticals rather than ignoring it altogether. Copyright © 2015 Elsevier Ltd. All rights reserved.

  12. Is technetium 99m dead or still alive? An outlook to recent developments with special focus on myocardial perfusion imaging

    International Nuclear Information System (INIS)

    Duatti, Adriano

    2012-01-01

    Despite the advances associated with the introduction of PET technology, reasons to consider that SPECT, particularly with 99m Tc radiopharmaceuticals will continue playing an important role in Nuclear Medicine, are presented. The details examined are the following ones. An improvement of the technology SPECT is appreciated with the development of new detection systems and the advantages of the appearance of the hybrid systems SPECT / TAC. The biggest half-life of the main SPECT radionuclides like 123 I and 99m Tc in comparison with PET radionuclides, facilitates its transportation at larger distances, allow the realization of studies with radiopharmaceuticals with different radionuclides in the same patient, and the possibility of the detection of lesions of low tracer accumulation. Finally the main base core for 99m Tc complex formation with different ligands are reviewed, as a background that assure the appearance of new radiopharmaceuticals of practical interest. The oncological and cardiological potential applications are examined with emphasis in these last ones. It is clear that 99m Tc radiopharmacy will continue playing an important role in nuclear medicine. (author)

  13. Role of 99mTc labelled GHA in post treatment evaluation of brain tumours

    International Nuclear Information System (INIS)

    Choudhury, P.

    2003-01-01

    Full text: Introduction: Biochemical investigations have a major role to play in the management of primary brain tumours. It is well known that major biochemical changes occur during cancerous transformation including changes in the energy metabolism of the cell. Changes take place in terms of utilization of glucose and other substrates, protein synthesis and expression of antigens and receptors. Changes also take place in disruption of transport mechanisms across cell membranes and other physiological boundaries like blood brain barrier. In the management of primary brain tumours positron emitting tracers have an undisputed role and the role of cationic tracers like Thallium-201, 99m-Tc MIBI and 99m-Tc tetrofosmin has been cited as an alternative to positron tracers in neuro oncology. It must be borne in mind that the cationic tracers are expensive to procure and facilities for positron emission tomography are not available in most of the developing countries. Tc-99m GHA Brain Imaging: Keeping in view the above, a cheaper alternative for PET radio tracers was evaluated. We have so far conducted more than 100 brain SPECT studies, using Tc-99m Glucoheptonic acid (GHA), in 60 patients of brain tumour, both at the time of their diagnosis, as well as after treatment during the follow-up period. Tc-99m Glucoheptonic acid (GHA) is a chemical glucose analogue. Avid concentration of the radiopharmaceutical was noted in viable tumor tissue in the SPECT images done one hour after injection of 740 MBq of 99m-Tc GHA. This was subsequently confirmed by histopathological examination in patients undergoing re-surgery for residual disease or follow up and clinical correlation in patients under remission. Avid tracer concentration was also well demonstrated in recurrent disease (proven by clinical examination, histopathology and/or magnetic resonance imaging (MRI). No significant tracer uptake was seen in areas of radiation induced necrosis. Non-specific uptake in the tumor bed was

  14. Somatostatin Receptor Scintigraphy (SRS) with 99m-Tc HYNIC-TOC

    International Nuclear Information System (INIS)

    Zarlenga, A.C.; Parma, P.; Arashiro, J.; Castiglia, S.; Obenaus, E.

    2002-01-01

    Background: This compound is a synthetic analogue of somatostatin by conjugating the Hydrazinocotinamide (Hynic) to Tyr 3 -Octreotide (Toc) radiolabeling via quelation with 99m Tc. Purpose: We have analyzed the feasibility in detecting neuroendocrine tumors (NET) by somatostatin receptor with 99m Tc Hynic-Toc. Methods: After comparative studies between 99m Tc Hynic-Toc and 111 In (pentetreotide) with excellent correlation, we have performed 48 scintigrams with 99m Tc Hynic-Toc. 35 patients with suspicions of NET were included (19 women, 16 men. Age range 22-75 y). We have performed planar images at 1,2,24 hs and tomographic images at 150 min after intravenous injection of 740 MBq 99m Tc Hynic-Toc. We compare the results with other diagnosis modalities and /or the histopathological findings after biopsy or surgery. Results: True Positive:17; True Negative:11; False Positive: 4; False Negative:3. Specificity=73.3%; Sensitivity=85%; Accuracy=80%; Not adverse effects were observed. Conclusions: 99m Tc Hynic-Toc is not limited availability of the isotope. It is a suitable radiopharmaceutical for in vivo evaluation to define tumor receptor status, staging, and for identification of patients who may benefit from therapy with somatostatin. The tumor uptake at 24 hs allows a better visualization of abdominal tumor sites. Tc Hynic-Toc is an alternative to 111 In-pentetreotide for imaging somatostatin receptor positive tumors. The study was offered to patients whom the scintigraphy with 111 In-pentetreotide offers a diagnosis alternative with high specificity and accessible cost

  15. Production of 99mTc-anatomy sulfide colloid for lymphoscintigraphy

    International Nuclear Information System (INIS)

    Shabani, G. A.; Hamzeh, H.; Najafi, R.

    2002-01-01

    The lymphatic system provides one of the chief paths for the spread (metastasis) of cancer from one part of body to another. Hodgkin's diseases, lymphocytic leukemia, various metastatic diseases and many lymph ode disorders can be assessed by lymphoscintigraphy. Radionuclide lymphoscintigraphy has been used for many years to define the lymphatic drainage of melanoma. The most common radiopharmaceuticals used for lymphoscintigraphy are 99 mTc-Sc, 99 mTc-antimony sulfide colloid has been chosen between other colloids. For antimony sulfide colloid preparation, hydrogen sulfide gas was passed through D.E. until saturation. Antimony potassium tartrate is then added to the solution to form Sb 2 S 3 ol lide. The colloid was stabilized with P.V.P. Excess H 2 S was removed by bubbling with nitrogen. The preparation was then filtered through a 0.22 μm membrane filter and aliquots containing 1.017 mg Sb 2 S 3 were dispensed into the reaction vials. Labeling was accomplished by adding 99 mTcO 4 and HCl to the vial and then heating it at 100 deg C in boiling water bath for 10 min. The P H was adjust by adding a phosphate buffer. The radiochemical purity of 99 mTc-antimony disulfide colloid by I TLC-S G/normal saline was more than 95 percent. The amount of Sb in reaction vial was 0. 729 mg. The study demonstrated that our formulation of antimony-sulfide which has 0.0486 mg (Sb) in 0.2 ml of 99 mTc-Sb 2 S 3 colloid per patient (total volume after labeling with 99 mTc is 3 ml)

  16. Understanding the in vivo uptake kinetics of a phosphatidylethanolamine-binding agent 99mTc-Duramycin

    International Nuclear Information System (INIS)

    Audi, Said; Li Zhixin; Capacete, Joseph; Liu Yu; Fang, Wei; Shu, Laura G.; Zhao Ming

    2012-01-01

    Introduction: 99m Tc-Duramycin is a peptide-based molecular probe that binds specifically to phosphatidylethanolamine (PE). The goal was to characterize the kinetics of molecular interactions between 99m Tc-Duramycin and the target tissue. Methods: High level of accessible PE is induced in cardiac tissues by myocardial ischemia (30 min) and reperfusion (120 min) in Sprague–Dawley rats. Target binding and biodistribution of 99m Tc-duramycin were captured using SPECT/CT. To quantify the binding kinetics, the presence of radioactivity in ischemic versus normal cardiac tissues was measured by gamma counting at 3, 10, 20, 60 and 180 min after injection. A partially inactivated form of 99m Tc-Duramycin was analyzed in the same fashion. A compartment model was developed to quantify the uptake kinetics of 99m Tc-Duramycin in normal and ischemic myocardial tissue. Results: 99m Tc-duramycin binds avidly to the damaged tissue with a high target-to-background radio. Compartment modeling shows that accessibility of binding sites in myocardial tissue to 99m Tc-Duramycin is not a limiting factor and the rate constant of target binding in the target tissue is at 2.2 ml/nmol/min/g. The number of available binding sites for 99m Tc-Duramycin in ischemic myocardium was estimated at 0.14 nmol/g. Covalent modification of D15 resulted in a 9-fold reduction in binding affinity. Conclusion: 99m Tc-Duramycin accumulates avidly in target tissues in a PE-dependent fashion. Model results reflect an efficient uptake mechanism, consistent with the low molecular weight of the radiopharmaceutical and the relatively high density of available binding sites. These data help better define the imaging utilities of 99m Tc-Duramycin as a novel PE-binding agent.

  17. Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations

    International Nuclear Information System (INIS)

    GRATZ, Stefan; KEMKE, Bendix; KEIZE, Patrik; KAMPEN, Wim U.; LUSTER, Markus; HÖFFKEN, Helmut

    2016-01-01

    The aim of this retrospective study was to compare the targeting of “pure” osteomyelitis (i.e., without surrounding soft tissue infection) by directly 99mTc-labelled complete immunoglobulin G (IgG) monoclonal antibody (MAb) ([99mTc]besilesomab) and by directly 99mTc-labelled fragment antigen-binding (FAb) MAb ([99mTc]sulesomab) in relation to their kinetic fate. A total of 73 patients with “pure” osteomyelitis were examined with [99mTc]besilesomab, (Scintimun®, IBA/CIS bio international, Saclay, France; N.=38) and [99mTc]sulesomab (LeukoScan®, Immunomedics Inc., Morris Plains, NJ, USA; N.=35). Kinetic data were deduced from whole-body and single-photon emission computed tomographic scans, performed 10 minutes to 24 hour p.i. (region-of-interest technique [ROI]). In targeting “pure” osteomyelitis, sensitivities at 1-4 hours were found to be higher for [99mTc]sulesomab (44% and 80% for [99mTc]besilesomab and [99mTc]sulesomab, respectively) but at significantly lower target/background (T/B) ratios than with [99mTc]besilesomab (1.8±0.3 versus 1.4±0.5 for [99mTc]besilesomab and [99mTc]sulesomab respectively; P<0.01). With [99mTc]besilesomab, there was a continuous osteomyelitis uptake over 24 hours, whereas with [99mTc]sulesomab, the maximal uptake occurred mostly within 1-4 hours, with subsequent clearance being slower for antigen-bound activity than for nonspecific background. Hence, diagnosis was possible mostly after 4h with [99mTc]sulesomab but often not before 24 hours with [99mTc]besilesomab, the later increasing significantly (P<0.01) in sensitivity (87% and 84% for [99mTc]besilesomab and [99mTc]sulesomab, respectively). These results show that the higher sensitivity of [99mTc]sulesomab in osteomyelitis targeting at earlier p.i. times does not rely on an increased antibody uptake but on a more rapid clearance of nonspecific background activity due to faster metabolism and excretion. Intact [99mTc]besilesomab show a slow, continuous uptake

  18. In vivo regional quantitation of intrathoracic /sup 99m/Tc using SPECT: concise communication

    International Nuclear Information System (INIS)

    Osborne, D.; Jaszczak, R.; Coleman, R.E.; Greer, K.; Lischko, M.

    1982-01-01

    A whole-body single-photon emission computed tomographic system (SPECT) was used to quantitate the activities of a series of /sup 99m/Tc point sources in the dog's thorax and to evaluate attenuation of a uniform esophageal line source containing a known concentration of /sup 99m/Tc. A first-order attenuation correction and an empirically derived attenuation coefficient of 0.09 cm-1 were used in the SPECT analyses of the intrathoracic point sources. The relationship between SPECT measurements of multiple point-source activities and the same sources measured in air was linear over a range of 100 to 1000 muCi (slope 1.08; R2 coefficient of determination 0.97). These data are sufficiently accurate to allow an estimate of the regional activity of radiopharmaceutical in the dog's thorax and justify their use in experimental quantitation of regional pulmonary perfusion

  19. Effects of concurrent drug therapy on technetium /sup 99m/Tc gluceptate biodistribution

    International Nuclear Information System (INIS)

    Hinkle, G.H.; Basmadjian, G.P.; Peek, C.; Barker, K.K.; Ice, R.D.

    1982-01-01

    Drug interactions with /sup 99m/Tc gluceptate resulting in altered biodistribution were studied using chart review and animal tests. Charts of nine patients who had abnormal gallbladder uptake of technetium /sup 99m/Tc gluceptate during a two-year period were reviewed to obtain data such as concurrent drug therapy, primary diagnosis, and laboratory values. Adult New Zealand white rabbits were then used for testing the biodistribution of technetium /sup 99m/Tc gluceptate when administered concurrently with possibly interacting drugs identified in the chart review--penicillamine, penicillin G potassium, penicillin V potassium, acetaminophen, and trimethoprim-sulfamethoxazole. Chart review revealed no conclusive patterns of altered biodistribution associated with other factors. The data did suggest the possibility that the five drugs listed above might cause increased hepatobiliary clearance of the radiopharmaceutical. Animal tests showed that i.v. penicillamine caused substantial distribution of radioactivity into the gallbladder and small bowel. Minimally increased gallbladder radioactivity occurred when oral acetaminophen and trimethoprim-sulfamethoxazole were administered concurrently. Oral and i.v. penicillins did not increase gallbladder activity. Penicillamine may cause substantial alteration of the biodistribution of technetium /sup 99m/Tc gluceptate

  20. Exploring the Potential of (99m)Tc(CO)3-Labeled Triazolyl Peptides for Tumor Diagnosis.

    Science.gov (United States)

    Gaonkar, Raghuvir H; Ganguly, Soumya; Baishya, Rinku; Dewanjee, Saikat; Sinha, Samarendu; Gupta, Amit; Ganguly, Shantanu; Debnath, Mita C

    2016-04-01

    In recent years the authors have reported on (99m)Tc(CO)3-labeled peptides that serve as carriers for biomolecules or radiopharmaceuticals to the tumors. In continuation of that work they report the synthesis of a pentapeptide (Met-Phe-Phe-Gly-His; pep-1), a hexapeptide (Met-Phe-Phe-Asp-Gly-His; pep-2), and a tetrapeptide (Asp-Gly-Arg-His; pep-3) and the attachment of 3-amino-1,2,4-triazole to the β carboxylic function of the aspartic acid unit of pep-2 and pep-3. The pharmacophores were radiolabeled in high yields with [(99m)Tc(CO)3(H2O)3](+) metal aqua ion, characterized for their stability in serum and saline, as well as in His solution, and found to be substantially stable. B16F10 cell line binding studies showed favorable uptake and internalization. In vivo behavior of the radiolabeled triazolyl peptides was assessed in mice bearing induced tumor. The (99m)Tc(CO)3-triazolyl pep-3 demonstrated rapid urinary clearance and comparatively better tumor uptake. Imaging studies showed visualization of the tumor using (99m)Tc(CO)3-triazolyl pep-3, but due to high abdominal background, low delineation occurred. Based on the results further experiments will be carried out for targeting tumor with triazolyl peptides.

  1. Effects of broccoli extract on biodistribution and labeling blood components with 99mTc-GH

    International Nuclear Information System (INIS)

    Cekic, Betul; Muftuler, Fazilet Zumrut Biber; Kilcar, Ayfer Yurt; Ichedef, Cigdem; Unak, Perihan

    2011-01-01

    Purpose: people consume vegetables without the knowledge of the side effects of the biological and chemical contents and interactions between radiopharmaceuticals and herbal extract. To this end, current study is focused on the effects of broccoli extract on biodistribution of radiolabeled glucoheptonate ( 99m Tc-GH) and radiolabeling of blood components. Methods: GH was labeled with 99m Tc. Quality control studies were done utilizing TLC method. Biodistribution studies were performed on male rats which were treated via gavage with either broccoli extract or SF as control group for 15 days. Blood samples were withdrawn from rats' heart. Radiolabeling of blood constituents performed incubating with GH, SnCl 2 and 99m Tc. Results: radiochemical yield of 99m Tc-GH is 98.46±1.48 % (n=8). Biodistribution studies have shown that according to the control, the treated group with broccoli has approximately 10 times less uptake in kidney. The percentage of the radioactivity ratios of the blood components is found to be same in both groups. Conclusions: although there is no considerable effect on the radiolabeling of blood components, there is an outstanding change on the biodistribution studies especially on kidneys. The knowledge of this change on kidney uptake may contribute to reduce the risk of misdiagnosis and/or repetition of the examinations in Nuclear Medicine. (author)

  2. Specifications and Quality of Technetium99m Produced diopharmaceuticals According to Good Manufacturing Practice Regulations

    International Nuclear Information System (INIS)

    Abudaia, Jamal; Ben Othman, Monji H.; Maatoug, Maatoug A.; Maatoug, M. Omar

    2003-01-01

    A Technological revolution has occurred in the last two decades of this century in field of Cold Kits preparations processed by Lyophilization technique (A drying process while frozen) which are labeled afterwards with Technetium-99m radionuclide. Such materials are intended to be used as Radiopharmaceutical probes in nuclear medicine for the diagnosis of dynamic and static conditions of organs, and therefore; uncovering of diseases and syndromes targeting humans. Preferability and the advantages of such kits labeled with Technetium-99m radionuclide over other types of radiopharmaceuticals is attributed to the unique physical properties of the radionuclide including its short half life of 6.02 hours, low photon energy of 140 keV, lacking of alpha and beta particles which are usually exposing patients to have additional exposed doses. Moreover, simplicity in obtaining such radionuclide in form portable generators containing the mother radionuclide Molybdenum - 99 (i.e. solvent extraction generators or adsorption column chromatographic generators) for-on-the- spot-labeling, and the ability of formulating the cold kits as chemical complexes located at different organs of human body. Those lyophilized kits intended for radiopharmaceutical preparations labeled with Technetium - 99m radionuclide must stand for quality assurance standards and assessments for the sake of safety, efficiency, apyrogenecity, radiochemical purity, in- vivo stability and suitability for the endeavor planed for. Therefore, in order to control and optimize those considerations, implementations of the so-called GOOD MANUFACTURING PRACTICE composed of regulations and constitutional laws related to the process of preparation and final produced preparation must take place.(author)

  3. Development of a formulation for the preparation of 99m Tc-Ida-bis-Biotin complex

    International Nuclear Information System (INIS)

    Gutierrez B, L.C.

    2000-01-01

    The radiopharmaceuticals of diagnostic use incorporate the radioisotope to an organic or inorganic molecule which goes selectively to the interest organ, to an a physiologic or metabolic process of the body with a simple and quantitatively interpretable kinetics. The 99m Tc occupies 80% from total of the studies realized in the world by the optimum combination of physical half-life (6 h), radionuclide quantity (ng) and high energy emission which allows to obtain results with the greatest information. Actually, in Nuclear Medicine, the research strategies are directed to the use of 'premarkers systems' based in the antibody administration, separated from radionuclide through the use of the avidin/biotin system. According to these considerations it was developed the 99m Tc-IDA-bis-Biotine complex as a new radiopharmaceutical which improves the diagnostic image of infectious core and tumorals. The IDA-biotin compound was synthesised and characterized by its melting point, IR spectroscopy, NMR, MS, UV and High-resolution liquid chromatography (HRLC). With base in an experimental factorial design those variables were established which influence in the radiochemical purity of the radiopharmaceutical which allowed to determine the reaction conditions, pH 9 at environmental temperature (22 Celsius degrees) and the optimum concentrations of the formulation components. IDA-biotine 1.0 mg, stannous chloride 0.1 mg and gluconate 15 mg as weak binding linking were realized to the lyophilized product quality control tests like: stability and radiochemical purity. The analytical techniques used UV spectrophotometry and HRLC were validated. The studies of biodistribution of the 99m Tc-Ida-bis-biotin complex were realized in healthy laboratory animals, showing stability 'In vivo' with renal purification. (Author)

  4. Development of 99mTc-ethyl cysteinate dimer (Neurolite) for imaging brain blood flow in stroke and other disorders

    International Nuclear Information System (INIS)

    Liteplo, M.P.

    1992-01-01

    Compounds labeled with 99m Tc are widely used for imaging in diagnostic medicine to provide information on physiological functions of the body not obtainable with other imaging techniques that give primarily anatomical information, such as X-ray and magnetic resonance imaging. These radiopharmaceuticals are typically injected intravenously and allowed to distribute in the body; the patient is then imaged using a scintillation gamma camera. For example, in patients suspected of coronary artery disease, 99m Tc-Sestamibi (Cardiolite reg-sign) is injected into the blood stream during a stress test and is rapidly extracted by the heart muscle in proportion to its regional blood supply. The resulting images of the heart clearly distinguish areas of normal heart muscle form areas where the blood supply is compromised by coronary artery disease. In recent years, there has been considerable interest in the application of 99m Tc compounds to the diagnosis of brain diseases and disorders. This paper describes the development of 99m Tc-ethyl cysteinate dimer ( 99m Tc-ECD, Neurolite reg-sign) as a radiopharmaceutical for imaging the blood supply to the brain in patients with stroke or head trauma. In research, this agent is also useful in studying the effect of sensory stimuli, therapeutic drugs, and drugs of abuse on brain blood flow

  5. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules

    International Nuclear Information System (INIS)

    Plachcinska, A.; Kusmierek, J.; Mikolajczak, R.; Kozak, J.; Rzeszutek, K.

    2006-01-01

    Aiming at comparison of diagnostic efficacy of 2 radiopharmaceuticals: 99m Tc-depreotide (Neospect, Amersham) and 99m Tc-EDDA/HYNIC-Tyr3-octreotide (Tektrotyd, Polatom), in differentiation between malignant and benign etiology of solitary pulmonary nodules (SPNs), radionuclide studies with 2 radiotracers were performed in 18 patients. For both radiopharmaceuticals the same acquisition and processing protocols were applied. Studies were acquired with SPECT technique, after administration of 740 MBq of activity. Scintigrams were assessed visually, as: positive (+), equivocal (±) and negative (-). Additionally, uptake intensity of both radiotracers in nodules was assessed semiquantitatively, using a tumour-to-background ratio. Verification of scintigraphic results was based in 14 cases upon a pathological examination of tumour samples (histopathology) and in the remaining 4 - on clinical observation and bacteriological studies. Normal scintigrams obtained with both diopharmaceuticals differed significantly. 99m Tc-depreotide was markedly accumulated in spine, sternum, ribs and lungs (mean lung/heart ratio = 2.2). This accumulation was not observed on 99m Tc- -EDDA/HYNIC-TOC scintigrams (mean lung/heart ratio = 0.7). In 6 patients a malignant etiology - lung cancer - was revealed (5 - adenocarcinoma, 1 - squamous cell) and the other 12 cases turned out to be benign (4 hamartomas, 3 tuberculomas, a tuberculous infiltrate, an alien body with inflammatory reaction, a hyperplasia of lymphatic tissue and 2 cases of unknown etiology, from which one had a stable size and the other resolved during a 6 month observation period). In all 6 cases of lung cancer positive results were obtained with both tracers. Moreover, in 2 patients metastases in mediastinum could be observed on scintigrams obtained with both radiopharmaceuticals. From among 12 cases of benign etiology 6 99m Tc-depreotide scintigrams were true negative, 1 - equivocal and 5 - false positive, whereas 6 99m Tc

  6. 99mTc-UBI Biokinetics: A Specific Peptide for Infection Detection

    Science.gov (United States)

    Rodríguez-Cortés, J.; Meléndez-Alafort, L.; Herrera-Rodríguez, R.; Ferro-Flores, G.; Mitsoura, E.; Martínez-Duncker, C.

    2003-09-01

    Recently, antimicrobial peptides have been proposed as new agents to distinguish between bacterial infections and sterile inflammatory processes. Based on these considerations, Ubiquicidin peptide 29-41 (UBI) has been labeled with 99mTc using a new direct method showing a radiochemical purity > 97 %, high stability in human serum, and low protein binding. In addition 99mTc-UBI showed a specific in vitro and in vivo binding to bacteria. However its biokinetic parameters have not been evaluated since it is one of the new generation radiopharmaceuticals based on peptide structures. Therefore the aim of this project was to establish the biokinetic model for 99mTc-UBI. An activity from 74 to 148 MBq was injected to patients with bone infection and 5 whole body scans were taken at 1, 30, 120, 240 min and 24 h after radiopharmaceutical administration, with a dual head scanner. Urine was collected for 24 h. An antropomorphic phantom was previously used to calculate the effect of attenuation and scattered radiation on the gamma camera acquisition images. ROIs of the selected organs in patients (kidney, liver, heart, bone, soft tissue and lesion) were drawn, and attenuation and scatter corrected. The % urine elimination at 24 h and time integrated ROIs (cpm/pixel/ROIs) were used to obtain the residence time (τ) in each tissue and to establish the biokinetic model. Pharmacokinetic data show that blood clearance is biexponential with a mean residence time in the central compartment of 0.52 h. The images showed non-accumulation in metabolic organs. More than 75 % of the injected activity was eliminated by renal clearance 4 h after 99mTc-UBI administration. The mean radiation dose calculated according to the MIRD formalism was 0.130 mGy/MBq for kidney and the effective dose was 4.29 × 10-3 mSv/MBq.

  7. Preparation, radiochemical purity control and stability of 99mTc-mertiatide (Mag-3)

    International Nuclear Information System (INIS)

    Van Hemert, F.J.; Schimmel, K.J.M.; Van Eck-Smit, B.L.F.; Van Lenthe, H.

    2005-01-01

    Scintigraphic image analysis of 99m Tc-mertiatide (Mag-3, mercaptoacetyltriglycine) clearance provides the determination of the blood flow, the tubular transit time and the excretion as well from both kidneys. Radiopharmaceutical routine recommends a radiochemical purity control before administration of the product to a patient. The main objective of this study is to develop a Mag-3 labeling procedure that fits better than the previous one in our daily routine production of radiopharmaceuticals. Increasing proportions of 99m Tc-Mag-3 were measured during the heating and cooling steps of the Mag-3 labeling procedure. High performance liquid chromatography (HPLC) analysis was used to confirm the results of a rapid radiochemical quality control assay on standard instant thin-layer chromatography-silica gel (ITLC-SG) paper. The reconstitution time takes 20-25 minutes from the harvest of pertechnetate to a ready-for-use calibrated patient syringe. The HPLC profile of 99m Tc-Mag-3 including its minor impurities remains unchanged for 24-48 hours after reconstitution. The application of a programmable Peltier-directed device for heating/cooling provides a better control of the temperature course. The procedure proposed fully meets the labeling criteria recommended by the supplier and can be performed with a minimum of attention within a time-span that we formerly needed for solely the radiochemical purity control assay. Moreover, 99m Tc-Mag-3 prepared in this way seems to be considerably more stable than mentioned in the manufacturer's instructions. (author)

  8. Comparisons of 131I, 201Tl and 99mTc activity measurements in activimeters

    International Nuclear Information System (INIS)

    Oropesa Verdecia, Pilar; Hernandez Rivero, Aerulio T.; Serra Aguila, Rolando A.; Martinez Herrera, Ernesto; Varela Corona, Consuelo

    2003-01-01

    The correct administration to a patient of the a priori established activity of the radiopharmaceutical is an important factor to ensure the confidence in the diagnosis or the therapy efficiency, keeping at the same time the human exposure as low as possible. National comparisons for the 131I, 201Tl and 99mTc activity measurements in activimeters have been organized for the first time with the aim of obtaining information about the quality of the administration of radiopharmaceuticals. In the comparison run participated ten Cuban Nuclear Medicine Departments and the laboratories involved in the production of that kind of compounds. The comparison results, shown in this paper, have facilitated the identification of the problems and to initiate preventive actions. Furthermore, these results reflect the need of establishing Quality Systems in Nuclear Medicine in Cuba

  9. Synthesis and quality control of sup(99m)Tc-p-butyl IDA

    International Nuclear Information System (INIS)

    Zmbova, B.; Konstantinovska-Djokic, D.; Tadzer, I.

    1985-01-01

    A procedure is described for synthesis of p-butyl IDA and for identification of the product by i.r. and NMR spectroscopy and by chemical analysis. A method for preparing this compound by ''instant'' technique and for its labelling with sup(99m)Tc is also given, as well as a procedure for control of the chemical and biological properties of the radiopharmaceutical. Radiochemical study shows a high labelling yield of 95%. Investigation of the biodistribution proves that this preparation is a good hepatobiliary reagent, suitable for use in investigation of the liver functions and for quantitative visualization of the hepatobiliary system. (author)

  10. Preparation of99mTc - dextran-500 for use in lymphoscintigraphy

    International Nuclear Information System (INIS)

    Hamada, E.S.; Muramoto, E.; Pereira, N.P.S. de; Brito, R.H.; Silva, C.P.G. da.

    1990-03-01

    This paper reported the preparation of lyophilized kit Dextran-500 for labelling with 99m Tc used in Nuclear Medicine as a lymphoscintigraphic agent. Each vial contains 100 mg Dextran-500 and 1,5 mg stannous chloride. The radiopharmaceutical was checked by ITLC, and the radiochemical purity and stability were determined. The studies of biological distribution were made in Wistar rats and the clinical evaluation in men was realized. Our results permited to incorporate Dextran-500 formulation as an ideal agent for routine use in lymphoscintigraphic. (author) [pt

  11. Scintigraphic imaging of Staphylococcus aureus infection using 99mTc radiolabeled aptamers.

    Science.gov (United States)

    Santos, Sara Roberta Dos; de Sousa Lacerda, Camila Maria; Ferreira, Iêda Mendes; de Barros, André Luís Branco; Fernandes, Simone Odília; Cardoso, Valbert Nascimento; de Andrade, Antero Silva Ribeiro

    2017-10-01

    Staphylococcus aureus is a specie of great medical importance associated with many infections as bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device related infections. Early identification of infectious foci is crucial for successful treatment. Scintigraphy could contribute to this purpose since specific radiotracers were available. Aptamers due to their high specificity have great potential for radiopharmaceuticals development. In the present study scintigraphic images of S. aureus infectious foci were obtained using specific S. aureus aptamers radiolabeled with 99m Tc. Copyright © 2017 Elsevier Ltd. All rights reserved.

  12. Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative

    International Nuclear Information System (INIS)

    Lin Jianguo; Qiu Ling; Cheng Wen; Luo Shineng; Ye Wanzhong

    2011-01-01

    Introduction: To enable imaging at an earlier time after injection, a radiopharmaceutical with higher affinity for bone, larger ratio of bone-to-soft tissue uptake and more rapid clearance from blood is required. The nature of diphosphonic acid is a key factor to determine the advantages of the radiopharmaceuticals. The purpose of this study is to optimize the linker chain between the imidazolyl and geminal diphosphonate group in the zoledronic acid (ZL) to develop novel single photon emission computed tomography (SPECT) bone imaging agent. Methods: A novel ZL derivative, 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diyldiphosphonic acid (IPrDP), was successfully prepared and labeled with 99m Tc in a high labeling yield. Biodistribution of 99m Tc-IPrDP and 99m Tc-ZL in normal mice were studied and compared. SPECT bone scanning was performed on the rabbit and a series of dynamic and static images were recorded by Philips SKY Light emission computed tomography. Results: In the biodistribution studies, 99m Tc-IPrDP exhibits significant advantages on the bone resorption and the clearance from soft tissues compared with 99m Tc-ZL. Kinetics of blood clearance in mice showed that T 1/2α and T 1/2β of 99m Tc-IPrDP were 1.47 min and 46.47 min, while those of 99m Tc-ZL were 2.28 and 52.63 min respectively. Excellent images of the rabbit skeleton can be quickly obtained for 99m Tc-IPrDP, which was faster than 99m Tc-ZL and the clinically widely used bone imaging agent 99m Tc-MDP (technetium-99m labeled with methylenediphosphonate). Conclusions: 99m Tc-IPrDP possesses excellent characteristics for the potential application as a novel bone scanning agent.

  13. Bacterial infection identification by an anti-peptidoglycan aptamer labeled with Technetium-99m

    Energy Technology Data Exchange (ETDEWEB)

    Andrade, Antero Silva Ribeiro; Ferreira, Iêda Mendes [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte, MG (Brazil); Barros, Andre Luis Branco de; Cardoso, Valbert Nascimento [Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG (Brazil)

    2017-07-01

    Full text: Introduction: A variety of radiopharmaceuticals is used to detect infection, but long-term clinical use has shown that the majority of them cannot distinguish between inflammation and infection. Nuclear medicine clinics are still awaiting the optimal scintigraphic imaging agents capable of discriminating between infection and inflammation, and between fungal and bacterial infections. Aptamers are oligonucleotides that display high affinity and specificity for their molecular targets and are emerging as promising molecules for radiopharmaceuticals development. Material and Methods: An aptamer for the peptidoglycan (main constituent of bacterial cell walls) termed Antibac1 was selected in a previous work. In the present study, this aptamer were labeled with {sup 99m}Tc and evaluated for bacterial infections identification by scintigraphy. All protocols were approved by the local Ethics Committee for Animal Experimentation of the Federal University of Minas Gerais (CETEA / UFMG), Protocol number 108/2014. Labeling with {sup 99m}Tc was performed by the direct method and the complex stability was evaluated in saline, plasma and presence of cysteine. The biodistribution and scintigraphic imaging studies with the {sup 99m}Tc-Antibac1 were carried out in two distinct experimental infection models: Swiss mice infected in the right thigh with Staphylococcus aureus or Candida albicans. {sup 99m}Tc radiolabeled library, consisting of oligonucleotides with random sequences, was used as a control in both experimental models. The direct radiolabeling allowed radiolabel yields above 90%. Results: A high complex stability was obtained in saline solution and plasma, but 51% of transchelation was verified after 24 h in the presence of cysteine. Scintigraphic images of S. aureus infected mice that received the {sup 99m}Tc-Antibac1 showed target to non-target ratios of 4.7 ± 0.90 and 4.6 ± 0.10 at 1.5 and 3.0 h, respectively. These values were statistically higher than

  14. Bacterial infection identification by an anti-peptidoglycan aptamer labeled with Technetium-99m

    International Nuclear Information System (INIS)

    Andrade, Antero Silva Ribeiro; Ferreira, Iêda Mendes; Barros, Andre Luis Branco de; Cardoso, Valbert Nascimento

    2017-01-01

    Full text: Introduction: A variety of radiopharmaceuticals is used to detect infection, but long-term clinical use has shown that the majority of them cannot distinguish between inflammation and infection. Nuclear medicine clinics are still awaiting the optimal scintigraphic imaging agents capable of discriminating between infection and inflammation, and between fungal and bacterial infections. Aptamers are oligonucleotides that display high affinity and specificity for their molecular targets and are emerging as promising molecules for radiopharmaceuticals development. Material and Methods: An aptamer for the peptidoglycan (main constituent of bacterial cell walls) termed Antibac1 was selected in a previous work. In the present study, this aptamer were labeled with 99m Tc and evaluated for bacterial infections identification by scintigraphy. All protocols were approved by the local Ethics Committee for Animal Experimentation of the Federal University of Minas Gerais (CETEA / UFMG), Protocol number 108/2014. Labeling with 99m Tc was performed by the direct method and the complex stability was evaluated in saline, plasma and presence of cysteine. The biodistribution and scintigraphic imaging studies with the 99m Tc-Antibac1 were carried out in two distinct experimental infection models: Swiss mice infected in the right thigh with Staphylococcus aureus or Candida albicans. 99m Tc radiolabeled library, consisting of oligonucleotides with random sequences, was used as a control in both experimental models. The direct radiolabeling allowed radiolabel yields above 90%. Results: A high complex stability was obtained in saline solution and plasma, but 51% of transchelation was verified after 24 h in the presence of cysteine. Scintigraphic images of S. aureus infected mice that received the 99m Tc-Antibac1 showed target to non-target ratios of 4.7 ± 0.90 and 4.6 ± 0.10 at 1.5 and 3.0 h, respectively. These values were statistically higher than found for the 99m Tc

  15. Accumulation of Tc-99m-MIBI and Tc-99m-tetrofosmin in tumor cells. Uptake and washout studies

    International Nuclear Information System (INIS)

    Rodrigues, M.; Aghajanian, A.A.; Sinzinger, H.; Kalinowska, W.; Zielinski, C.

    2002-01-01

    Aim: To investigate in-vitro the uptake and washout of Tc-99m-MIBI and Tc-99m-tetrofosmin in human breast adenocarcinoma and soft tissue sarcoma cell lines. Methods: The uptake of Tc-99m-MIBI and Tc-99m-tetrofosmin (at 37 0 C, 10, 30 and 60 minutes after incubation with 7.4x10E5 Bq each tracer) was investigated in breast adenocarcinoma MCF-7 and SK-BR-3 cells, synovial sarcoma SW 982 cells and chondrosarcoma SW 1353 cells (concentration of 1x10E6 cells/ml incubation medium). Tracer uptake in cells incubated with ouabain (Na/K-ATPase pump inhibitor; 100 μM and 1mM; 15 and 30 minutes), nigericin (increases mitochondrial potential and disrupts cell membrane potential; 5 and 50 μg/ml; 15 minutes) and carbonyl cyanide m-chlorophenylhydrazone (CCCP) (depolarizes mitochondrial membrane; 10 and 100 μM; 30 minutes) was compared to that in cells without incubation with chemical agents (control cells). The washout (at 37 0 C, 10-60 minutes, 30 and 60 minutes after tracer incubation) of Tc-99m-MIBI and Tc-99m-tetrofosmin was studied in MCF-7 cells, SK-BR-3 cells , SW 1353 cells and fibrosarcoma SW 684 cells. Results: Cellular tracer uptake decreased with ouabain (decrease of Tc-99m-tetrofosmin > Tc-99m-MIBI in SK-BR-3 cells and SW 982 cells) and increased with nigericin (increase of Tc-99m-MIBI > Tc-99m-tetrofosmin in all cells) as compared to the uptake in control cells. With CCCP, decrease of Tc-99m-MIBI uptake in cells preincubated with nigericin was higher than that in cells under basal conditions, whereas a similar decrease of Tc-99m-tetrofosmin uptake in these two group of cells was found. Washout of Tc-99m-MIBI from all cells was lower than that of Tc-99m-tetrofosmin. No significant difference in cell-associated activity of both tracers was found between washout after 30 minutes and that after 60 minutes of incubation, in all cells. Washout of Tc-99m-MIBI from SK-BR-3 cells Tc-99m-tetrofosmin) and Na/K-ATPase pump (Tc-99m-tetrofosmin > Tc-99m-MIBI). Tc-99m-MIBI and

  16. A study of core electron binding energies in technetium-99m complexes by internal conversion electron spectroscopy

    International Nuclear Information System (INIS)

    Burke, J.F.; Archer, C.M.; Wei Chiu, K.; Latham, I.A.; Egdell, R.G.

    1991-01-01

    Core electron binding energies in a series of 99m Tc complexes have been studied by internal conversion electron spectroscopy (ICES) in a conventional x-ray photoelectron spectrometer. In both 3d and 3p regions, a chemical shift of about 1 eV is observed per unit increase in oxidation state. The role of ICES in characterizing radiopharmaceutical agents is illustrated with studies of some novel 99m Tc-phosphine complexes that have been developed for myocardial perfusion imaging. (author)

  17. Simultaneous /sup 99m/Tc-p-butyl-IDA and 131I-rose bengal scintigraphy in neonatal jaundice

    International Nuclear Information System (INIS)

    Collier, B.D.; Treves, S.; Davis, M.A.; Heyman, S.; Subramanian, G.; McAfee, J.G.

    1980-01-01

    Eight neonates with jaundice were studied simultaneously with /sup 99m/Tc-p-butyl-IDA and 131 I-rose bengal. Due to physical decay, /sup 99m/Tc-p-butyl-IDA failed to demonstrate delayed excretion through the patent extrahepatic biliary tract in 3 of 5 patients with concomitant hepatitis; 131 I-rose bengal showed small-bowel activity in all 5. Neither agent demonstrated small-bowel activity in 3 neonates with extrahepatic biliary atresia. Based on this clinical trial, 131 I-rose bengal remains the radiopharmaceutical of choice for distinguishing between hepatitis and biliary atresia in these patients

  18. Diffuse Pulmonary Uptake of Tc-99m Methylene Diphosphonate in a Patient with Non-tuberculosis Mycobacterial Infection

    International Nuclear Information System (INIS)

    Kwon, Hyun Woo; Chung, June Key; Lee, Dong Soo; Ab-Aziz, Aini

    2010-01-01

    Extra-osseous uptake of bone-seeking radiopharmaceuticals has been reported at various sites and it is known to be induced by various causes. Diffuse pulmonary infection, such as tuberculosis, can be a cause of lung uptake of bone-scan agent. Here we report on a patient with non-tuberculosis mycobacterial infection (NTM) who demonstrated diffuse pulmonary uptake on Tc-99m MDP bone scan. After medical treatment for NTM, the patient's lung lesions improved. Estra skeletal lung Tc-99m MDP uptake on bone scan may suggest lung parenchymal damage associated with disease activity.

  19. Diffuse Pulmonary Uptake of Tc-99m Methylene Diphosphonate in a Patient with Non-tuberculosis Mycobacterial Infection

    Energy Technology Data Exchange (ETDEWEB)

    Kwon, Hyun Woo; Chung, June Key; Lee, Dong Soo [Seoul National University College of Medicine, Seoul (Korea, Republic of); Ab-Aziz, Aini [University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, (Morocco)

    2010-06-15

    Extra-osseous uptake of bone-seeking radiopharmaceuticals has been reported at various sites and it is known to be induced by various causes. Diffuse pulmonary infection, such as tuberculosis, can be a cause of lung uptake of bone-scan agent. Here we report on a patient with non-tuberculosis mycobacterial infection (NTM) who demonstrated diffuse pulmonary uptake on Tc-99m MDP bone scan. After medical treatment for NTM, the patient's lung lesions improved. Estra skeletal lung Tc-99m MDP uptake on bone scan may suggest lung parenchymal damage associated with disease activity.

  20. Comparison of sup(99m)Tc-MDP to sup(99m)Tc-pertechnetate by computerized quantitative joint scintigraphy

    International Nuclear Information System (INIS)

    Rekonen, A.; Moettoenen, T.; Oka, M.

    1982-01-01

    99mTc-pertechnetate was compared to 99mTc-MDP in joint pairs with asymmetric arthritis. Markedly elevated joint activity ratios (inflamed/uninflamed joint) were measured in all the joint pairs studied. In the joints affected by reactive arthritis and without roentgenologic changes the mean joint activity was the same with both tracers. A very high activity ratio with 99mTc-MDP was found in septic arthritis. In rheumatoid arthritis the sensitivity of 99mTc-MDP as an indicator of active arthritis seemed to be better than that of 99mTc-pertechnetate. Even in joints without erosions in roentgenograms the joint activity ratios were markedly elevated with 99mTc-MDP. This suggests, that high activity in 99mTc-MDP scanning might be prognostic of erosive joint changes. In this work a profile curve was used for quantitation differences between joints

  1. Pharmacokinetics of labelled compounds with technetium-99m and samarium-153

    International Nuclear Information System (INIS)

    Borda O, L.B.; Torres L, M.N.

    1997-01-01

    The purpose of this investigation was to establish the different pharmacokinetics parameters of the main radiopharmaceuticals labeled with technetium-99m and samarium-153. These parameters could be subsequently used as reference to compare other products with the same use. Mathematical models and a computerized pharmacokinetic program were used to this purpose. A biodistribution study in quadruplicate and/or quintuplicate was conducted for each radiopharmaceutical, data was was obtained in injection dose percentages. The biodistribution study involved the injection of a predetermined dose of the radiopharmaceutical into animals (rats or mice), which were subsequently put away at different time intervals, removing the relevant organs. Activity in each organ was read by means of a well-type NaI scintillation counter, data obtained in activity counts was transformed into injection dose percentages. Based on these percentages, the mathematical model was constructed and the pharmacokinetic parameters were obtained using the computerized program Expo 2 v. 1, which is written in C language and works in windows. Analyzing the results obtained, we can conclude that the use of the Expo 2 v. 1 program for a bi compartmental analysis allowed us to obtain reliable pharmacokinetic parameters which describe what happens in the organism when the radiopharmaceutical passes from the central compartment to the peripheral one and vice versa

  2. Studies of techniques for the post-elution concentration of 99mTc obtained from gel type 99Mo/99mTc generators

    International Nuclear Information System (INIS)

    Suzuki, Katia Noriko

    2009-01-01

    On average 80% of the radiopharmaceuticals used in Nuclear Medicine are labeled with 99 mTc due to its physical properties and easy attainment through of 99 Mo/ 99 mTc generators. The Directory of Radiopharmacy (DIRF) of IPEN-CNEN/SP developed a gel type chromatographic generator of MoZr with 99 Mo produced by 98 Mo(n,γ) 99 Mo reaction that occurs at the IEA-R1 Nuclear Reactor. The gel is composed of zirconium molybdate with elution volume of 12 mL with an activity of 11100 MBq (300 mCi) producing a radioactive concentration of 925 MBq (25 mCi)/mL. The fission generator gives a higher radioactive concentration around 1850 MBq (50 mCi)/mL. The aim of this work is to study a system of post-elution concentration of 99 mTc for the attainment of a high enough radioactive concentration to meet the demands of the market, with a proved quality. Two types of systems of post-elution concentration were developed: the single and the tandem. The most appropriate system for the gel generator of 99 Mo/ 99 mTc, being at the same time sterile and vacuum automated, was the tandem system using Dionex 2.5 cc/QMA cartridges. The gel generator is eluted with 10 mL of solution of 0.1% NaCl and the pertechnetate anion is retained in the QMA cartridge and further eluted with 4 mL of saline. The process takes no more than 30 minutes. The elution efficiency of the system of concentration was 90 %. At the beginning of 2009 a global crisis in the supply of 99 Mo took place making it necessary the development of alternative technologies for the production of 99 Mo/ 99 mTc generators using fission produced 99 Mo and the development of an appropriate method to extend the useful life of this generator. The results of this study showed that the same system developed for the post- concentration of the gel generator can be employed for the fission generator, using the tandem system, giving a concentration factor of 3 for the elution of 99 mTc. (author)

  3. 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo

    International Nuclear Information System (INIS)

    Bernard, Bert F.; Krenning, Eric P.; Breeman, Wout A. P.; Ensing, Geert; Benjamins, Harry; Bakker, Willem H.; Visser, Theo J.; Jong, Marion de

    1998-01-01

    The aim of this study was to compare uptake of 99m Tc-MIBI, 99m Tc-tetrofosmin and 99m Tc-Q12 in vitro and biodistribution in vivo in rats. In vitro, uptake decreased in the order MIBI→tetrofosmin→Q12. Uptake of MIBI and tetrofosmin, but not of Q12, in cultured tumor cells was dependent on the plasma membrane and mitochondrial potential. In vivo, heart uptake of all three compounds was high and stable. Tumor uptake decreased in the order MIBI→Q12→tetrofosmin and the tumor/blood ratio in the order MIBI→tetrofosmin→Q12

  4. A system for routine production of 99mTc by thermal separation technique

    International Nuclear Information System (INIS)

    Sahm, U.; Helus, F.; Krauss, O.; Baier-Borst, W.

    1976-01-01

    Technetium-99m is one of the most widely used radionuclides in diagnostic medicine, and it is a general opinion that 99m Tc and the radiopharmaceuticals obtained from it will be used for a long time. 99m Tc has convenient physical and biological parameters for clinical applications. 99m Tc is formed by the beta decay from its 99 Mo parent. 99 Mo is produced by neutron irradiation of natural Mo or enriched 98 Mo, or as a fission product of 235 U. A third approach is cyclotron production of 99 Mo by proton bombardment of enriched 100 Mo over 100 Mo(p,pn) 99 Mo reaction. The most common method of separating 99m Tc from its 99 Mo parent is the elution of 99m Tc with normal saline from an aluminum oxide column containing adsorbed 99 Mo. The second method is solvent extraction using methylethylketon. The sublimation method is based on different volatility of MoO 3 and Tc 2 O 7 . Previously the development of a practical sublimation generator has been studied and some of them have been used routinely. As a reactor and cyclotron owner we have examined the possibility of producing our own 99m Tc with the aim of being independent from supplier and transportation problems. We have studied the separation of 99m Tc with the aim of being independent from supplier and transportation problems. We have studied the separation of 99m Tc from MoO 3 by complete distillation of gram amounts of natural MoO 3 or enriched 98 MoO 3 irradiated in reactor. The principle of the described method is based on the complete evaporation of MoO 3 and Tc 2 O 7 oxides and its following fractionated condensation. To realize this idea, two different generator systems for repeated multiple separation were developed and studied. The first based on using a two-oven technique. A quartz apparatus is placed in two ovens which are situated side by side and heated to different temperatures. Sweeping gas carries irradiated 99 MoO 3 from a middle part of the first oven heated to a higher temperature (1100 deg. C

  5. Utility of the dimercapto succinic acid pentavalent (99m Tc- DMSA V) in the diagnostic of secondary bone leisure at metastasis of diverse primary tumours. Preliminary study

    International Nuclear Information System (INIS)

    Ortega L, N.; Pichardo R, P.A.; Marquez H, A.

    2005-01-01

    The more used method in the diagnosis of secondary bone lesions to become cancerous it is by means of having derived of phosphates like it is the 99m Tc- MDP. The reason of acquiring searching with the radiopharmaceutical 99m Tc- DMSA V is with the purpose to find other bone lesions that are not visualized with the gammagraphy with diphosphonate and therefore to increase the specificity of the study. (Author)

  6. 99mTc-O2S4: a new generation hepatobiliary imaging agent

    International Nuclear Information System (INIS)

    Babbar, A.K.; Mathur, R.; Katiyar, N.; Dutta, M.; Flora; Mishra, A.K.; Yadav, A.

    2010-01-01

    Full text: Hepatobiliary imaging radionuclide - 99m Tc-Mebrofenin is indicated as a hepatobiliary imaging agent for the evaluation of hepatobiliary tract patency to differentiate jaundice resulting from hepatocellular causes from jaundice resulting from partial or complete biliary obstruction; to differentiate extrahepatic biliary atresia from neonatal hepatitis; to detect cystic duct obstruction associated with acute cholecystitis; and to detect bile leaks. Also, 99m Tc-Mebrofenin may be useful to detect intrahepatic cholestasis and to distinguish it from other hepatobiliary diseases, which involve hepatocyte damage. However, the Mebrofenin kit has to be obtained at an exorbitant cost and there was need to develop an indigenous kit that was readily available and could give similar results. For the first time in India, a derivative of DMSA developed by DRDE, Gwalior and modified at INMAS, Delhi to adopt early transition metals, was successfully labelled with 99m Tc (LE>99%). The reaction conditions were optimized after studying the effects of amount of SnCl 2 , pH of the reaction and effect of incubation time. The labelled product 99m Tc-O 2 S 4 , was characterized by ITLC-SG using acetone and saline. The complex was found to be fairly stable at room temperature and showed>95% plasma protein binding. The biodistribution studies showed that after intravenous administration, there was immediate accumulation of radioactivity in liver, the activity kept on increasing in gall bladder with time and thereafter the radioactivity moved to common bile duct (CBD) and small intestines. No significant radioactivity was found in kidneys and blood. Clear visualization of the gallbladder and intestines, within 15 to 45 minutes of administration of 99m Tc-O 2 S 4 in normal rabbit, demonstrates hepatobiliary tract patency of the newly developed radiotracer. The dynamic and static images showed that the newly developed radiopharmaceutical 99m Tc-O 2 S 4 has full potential in studying

  7. A review of sup(99m)Tc generator technology

    International Nuclear Information System (INIS)

    Molinski, V.J.

    1982-01-01

    The sup(99m)Tc generator has found widespread use because it is ideally suited for scintigraphy. The preparation of sup(99m)Tc generators using alumina and other ion exchange systems is described. Other methods of separating 99 Mo and sup(99m)Tc, such as solvent extraction and sublimation, are also discussed. Some of the problems associated with the alumina column type sup(99m)Tc generator are listed with possible causes and solutions to their problems. The current biomedical applications of the sup(99m)Tc radioisotope are the basis of a $100 million nuclear medicine business. The importance of the sup(99m)Tc generator makes it imperative that we understand and solve the problems associated with its manufacture. (author)

  8. Quality assurance of Mo-99/Tc-99m radionuclide generators

    Science.gov (United States)

    Uzunov, Nikolay; Yordanova, Galina; Salim, Seniha; Stancheva, Natalya; Mineva, Vanya; Meléndez-Alafort, Laura; Rosato, Antonio

    2018-03-01

    Gamma-ray spectrometry analyses of the radionuclide content of eluate from two Mo-99/Tc-99m radionuclide generators POLTECHNET have been performed. The relative activities of 99Mo 103Ru and 131I radioisotopes with respect to the activity of 99mTc at different time intervals after the primary pertechnetate elution of the generators have been analyzed. The relative activities of the isotopes were determined and compared to the radionuclidic purity requirements for 99mTc.

  9. Preoperative localization of parathyroid carcinoma using Tc-99m MIBI.

    Science.gov (United States)

    Kitapçi, M T; Tastekin, G; Turgut, M; Caner, B; Kars, A; Barista, I; Bekdik, C

    1993-03-01

    A patient with parathyroid cancer is presented who underwent Tc-99m MIBI scintigraphy. The Tc-99m MIBI image demonstrated increased accumulation of activity at the lower pole of the left thyroid lobe which was later confirmed as a parathyroid cancer. Uptake by parathyroid cancer must be kept in mind as a cause of increased Tc-99m MIBI accumulation when a disease is in question in the thyroid or parathyroid gland.

  10. Achalasia diagnosed by 99mTc pertechnetate scintigraphy

    International Nuclear Information System (INIS)

    Mikosch, P.; Gallowitsch, H.J.; Kresnik, E.; Lind, P.

    1997-01-01

    A 73-year-old patient presented a 99m Tc scintiscan with a focal tracer accumulation left and caudal of the thyroid gland. Further investigations with sonography, CT, esophagoscopy and barium swallow provided the diagnosis of achalasia as the reason for focal 99m Tc retention caudal of the thyroid gland. Explanation for 99m Tc accumulation within the esophagus may be the nonspecific accumulation of 99m Tc not only in the thyroid gland but also in the salivary glands. Excretion of the tracer follows with the saliva. Structural and motor disorders of the esophagus can thus lead to focal tracer retention within the esophagus simulating thyroid tissue. (orig.) [de

  11. Radiolabeling, quality control and radiochemical purity assessment of 99mTc-HYNIC-TOC

    International Nuclear Information System (INIS)

    Melero, Laura T.U.H.; Araujo, Elaine B.; Mengatti, Jair

    2009-01-01

    Somatostatine receptors are widely expressed by several tumors, especially of the neuroendocrine origin. In vivo images of these tumors using radiolabeled somatostatine analogues became a useful clinical tool in oncology. The aim of this work was the radiolabeling of the somatostatine analogue HYNIC-TOC with 99mTc as well as the evaluation of the radiochemical stability and quality control of labeled complex. 99mTc-HYNIC-TOC was produced by labeling conditions using 20 μg of peptide, 20 mg of tricine and 10 mg of EDDA as coligands, 1110 MBq of 99mTc (99Mo-99mTc IPEN-TEC generator) and 15 μg of SnCl 2 .2H 2 O. The reaction proceeds for 10 minutes at boiling water bath. Radiochemical purity of labeled preparation was evaluated by different chromatographic systems: ITLC-SG in methanol:ammonium acetate (1:1); TLC-SG in sodium citrate buffer 0.1 N pH 5.0 and methylethylketone, and HPLC employing column C-18, 5 μm, 4.6 mm x 250 mm, UV (220 nm), radioactivity detectors, 1 mL/minute flow of acetonitrile and trifluoroacetic acid solution 0.1 %. Labeled compound has been found radiochemically stable for 5 hours and radiochemical purity was higher than 90 %. The thin layer chromatographic systems enabled the separation of radiochemical species presented in the labeled mixture as well as HPLC system. The labeling procedure studied resulted in high radiochemical yield and easy preparation. Future works include the preparation of a lyophilized reagent to make feasible the preparation of 99mTc-HYNIC-TOC at nuclear medicine services in order to study the clinical potential of the radiopharmaceutical in diagnostic and staging of neuroendocrine tumors. (author)

  12. Radiolabeling, quality control and radiochemical purity assessment of {sup 99m}Tc-HYNIC-TOC

    Energy Technology Data Exchange (ETDEWEB)

    Melero, Laura T.U.H.; Araujo, Elaine B.; Mengatti, Jair [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

    2009-07-01

    Somatostatine receptors are widely expressed by several tumors, especially of the neuroendocrine origin. In vivo images of these tumors using radiolabeled somatostatine analogues became a useful clinical tool in oncology. The aim of this work was the radiolabeling of the somatostatine analogue HYNIC-TOC with 99mTc as well as the evaluation of the radiochemical stability and quality control of labeled complex. 99mTc-HYNIC-TOC was produced by labeling conditions using 20 {mu}g of peptide, 20 mg of tricine and 10 mg of EDDA as coligands, 1110 MBq of 99mTc (99Mo-99mTc IPEN-TEC generator) and 15 {mu}g of SnCl{sub 2}.2H{sub 2}O. The reaction proceeds for 10 minutes at boiling water bath. Radiochemical purity of labeled preparation was evaluated by different chromatographic systems: ITLC-SG in methanol:ammonium acetate (1:1); TLC-SG in sodium citrate buffer 0.1 N pH 5.0 and methylethylketone, and HPLC employing column C-18, 5 {mu}m, 4.6 mm x 250 mm, UV (220 nm), radioactivity detectors, 1 mL/minute flow of acetonitrile and trifluoroacetic acid solution 0.1 %. Labeled compound has been found radiochemically stable for 5 hours and radiochemical purity was higher than 90 %. The thin layer chromatographic systems enabled the separation of radiochemical species presented in the labeled mixture as well as HPLC system. The labeling procedure studied resulted in high radiochemical yield and easy preparation. Future works include the preparation of a lyophilized reagent to make feasible the preparation of 99mTc-HYNIC-TOC at nuclear medicine services in order to study the clinical potential of the radiopharmaceutical in diagnostic and staging of neuroendocrine tumors. (author)

  13. On-site preparation of technetium-99m labeled human serum albumin for clinical application

    International Nuclear Information System (INIS)

    Wang Yuhfeng; Chuang Meihua; Cham Thauming; Chung Meiing; Chiu Jainnshiun

    2007-01-01

    Technetium-99m labeled human serum albumin (Tc-99m HSA) is an important radiopharmaceutical for clinical applications, such as cardiac function tests or protein-losing gastroenteropathy assessment. However, because of transfusion-induced infectious diseases, the safety of serum products is a serious concern. In this context, serum products acquired from patients themselves are the most ideal tracer. However, the development of rapid separation and easy clinical labeling methods is not yet well established. Under such situation, products from the same ethnic group or country are now recommended by the World Health Organization as an alternative preparation. This article describes the on-site preparation of Tc-99m HSA from locally supplied serum products. Different formulations were prepared and the labeling efficiency and stability were examined. Radio-labeling efficiencies were more than 90% in all preparation protocols, except for one that omitted the stannous solution. The most cost-effective protocol contained HSA 0.1 mg, treated with stannous fluoride 0.2 mg, and mixed with Tc-99m pertechnetate 30 mCi. A biodistribution study was performed in rats using a gamma camera immediately after intravenous administration of radiolabeled HSA. Tissue/organ uptake was obtained by measuring the radioactivity in organs after sacrificing the rats at timed intervals. The biologic half-life was about 32 min, determined from sequential venous blood collections. These data indicate that our preparation of Tc-99m HSA is useful and potentially applicable clinically. In addition, this on-site preparation provides the possibility of labeling a patient's own serum for subsequent clinical application. (author)

  14. Technical problems associated with the production of technetium Tc 99m tin(II) pyrophosphate kits

    International Nuclear Information System (INIS)

    Kowalsky, R.J.; Dalton, D.R.

    1981-01-01

    The amount of tin(II) required for adequate reduction, complexation, and stability of technetium Tc 99m pertechnetate in radiopharmaceutical kits, and methods of preventing the loss of tin(II) during formulation of these lyophilized kits are investigated. Tin(II) loss from stannous chloride solutions was studied under several conditions, including room air versus nitrogen atmospheres, during vial filling in a laminar-flow hood with samples frozen on dry ice versus samples at room temperature, during lyophilization, and during storage under refrigerated, ambient, and elevated temperatures. Various amounts of stannous chloride, ranging from 5 to 1000 microgram/ml, were used in formulating sodium pertechnetate Tc 99m kits containing 100 mCi technetium Tc 99m and 0.4 microgram total technetium. Samples were removed at various times; hydrolyzed technetium, pertechnetate, and technetium Tc 99m pyrophosphate were isolated on instant thin-layer chromatography-silica gel and quantified with a scintillation counter. The time necessary to deoxygenate distilled water by nitrogen purging was measured. Several sources of stannous chloride were assayed for tin(II) content. Tin(II) loss occurs rapidly in solution (15% in one hour) unless continuously protected with nitrogen, and during vial filling in a laminar-flow hood unless frozen with dry ice. No substantial loss of tin(II) was detected during lyophilization or during storage of lyophilized product at any of the three temperatures. A minimum of 400 microgram tin(II) was required to provide 90% technetium Tc 99m pyrophosphate at six hours after preparation. Adequate deoxygenation of small quantities (450 ml) of water was accomplished in less than one hour. Some stannous chloride salts were highly oxidized in the dry state, and only high-purity elemental tin wire gave acceptable yields of tin

  15. Evaluation of radionuclide calibrator performance with Tc-99m and I-123 in nuclear medicine centers

    International Nuclear Information System (INIS)

    Ahn, Ji Young; Kim, Gwe Ya; Yang, Hyun Kyu; Lim, Chun Il; Lee, Hyun Koo; Kim, Byung Tae; Jeong, Hee Kyo

    2004-01-01

    To minimize unnecessary radiation dose to patients, it is important to ensure that the radiopharmaceutical administered is accurately measured. Tc-99m is one of the popular radionuclide used in nuclear medicine and I-123 is also used widely in nuclear medicine. To investigate the level of measurement performance and to provide the participants with a traceable standard to check and review their calibration factors for these particular radionuclides, Korean Food and Drug Administration (KFDA) as a national secondary standard dosimetry laboratory conducted comparison program for Tc-99m and I-123 in nuclear medicine centers. 72 nuclear medicine centers (78 calibrators) participated in the comparison program for Tc-99m in 2003 and 37 centers (41 calibrators) for I-123 in 2004. For a comparison, Tc-99m and I-12